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1. One of the most important international treaties that Iraq is not 
part of is the TRIPS agreement. Iraq is not one of the members of 
WTO, but it is in the process and right now is in the list of observer 
governments. In the same way Iraq is not a member of the most 
treaties and unions under WIPO except for Paris Convention (1976) 
and WIPO Convention (1976). However, it is the TRIPS agreement 
that provides for the wide range of protections of intellectual property 
rights. Therefore, it is the purpose of this research to analyse all 
possibilities of implementing the TRIPS agreement, especially in the 
area of patent by the Iraqi government. 
Therefore, the key hypothesis of this research is that Iraq should 
implement a law that fulfils the requirements of the TRIPS Agreement 
and at the same time include all the legal flexibilities that help to 
develop the country with minimum costs and sacrifices. For this 
reason, the main question that this research asks is whether the CPA 
Order No. 81 after its dramatical amendments has achieved this goal. 
The main objective of this research is to examine and analyse the 
original Iraqi Patent and Industrial Design Law No. 65 of 1970 (The 
Patent Laws only) in comparison to the amendments in particular the 
CPA Order No. 81, then compare these with the provisions of the 
TRIPS Agreement in order to find out the confirmations and 
contradictions among them.  
 
The main results achieved are summarized below: 
 
2. TRIPS Agreement is one of the most important agreement 
which have standardized the intellectual property protection by stating 
the minimum requirement. There are other international conventions 
which were established long before the TRIPS Agreement such as 
Paris and Berne Conventions. Nevertheless, colonial countries 
exercised pressures and drove their colonies and foreign possessions 
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into the Berne Convention through its Article 19. Therefore, many 
least developed and developing countries joined the Berne Convention 
without their free will, and even the new independent countries that 
did not have any economic and cultural experience joined the 
convention based on their colonial countries.  
Other developing countries that tried to enact national laws in 
their own interest were opposed by developed countries and their 
companies. The reason was that many of the developing countries in 
their national laws provided for little protection, for example in the 
area of pharmaceuticals.    
Before the TRIPS Agreement, the countries around the world 
were unhappy about the existing conventions and agreements that 
regulate intellectual property rights and were trying to amend them. 
The reason was that the developing countries were always trying for 
better regulations that allow them to access to foreign technologies 
and developed countries were condemning them for lacking 
enforcement mechanism and not being able to sanction the non-
compliance countries effectively.  
In order for the United States of America to be able to enforce its 
interest in the new agreement that regulate the intellectual property 
rights, it chose the GATT forum as it has strong position in the GATT. 
This was a new step because up to that moment intellectual property 
rights were looked at as an obstacle to free trade. Within GATT the 
developed countries could establish a single agreement that 
incorporate all intellectual property rights. The developing countries 
did not have a choice except to accept the TRIPS Agreement with the 
hope to benefit from GATT (WTO) over all. 
Nevertheless, the United States of America used its entities such 
as the Office of the United States Trade Representative (USTR) and 
the United States International Trade Commission (ITC). These 
entities provided necessary information to government and enforced 
the requests of congress and interest groups. USTR has taken many 
actions under section 301 and special 301 of the Trade Act 1974 such 
as imposing trade sanctions on foreign countries, impose duties on 
their goods or threat of using unilateral retaliation if not reforming 
their intellectual property practices. USTR’s pressured developing 
Summary 
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countries such as Chile and Indonesia, and also pressured developed 
countries such as Japan. Another advantage of United States of 
America that had over other countries during the negotiation process 
at GATT was continuously receiving information from associations 
such as International Intellectual Property Alliance (IIPA) and 
Business Software Alliance (BSA), in which thousands of companies 
were their member. Accepting high standard of protection refused by 
the developing countries (in Group Ten) as it was not in their best 
interests and resisted the GATT forum, but they did not succeed due 
to economic threatening and political pressures from the United States 
and eventually the TRIPS Agreement came into existence.  
 
3. The main purposes and objectives of the TRIPS Agreement 
that can be inferred from the Preamble are; presentation of intellectual 
property protection in a manner that reduce distortions and 
impediments to international trade; and recognition of intellectual 
property rights as private rights so that can be protected against any 
arbitrary and unjust acts of governments. Creating connection between 
intellectual property protection and international trade was due to the 
attempts of the United States and its big corporations so that insert 
intellectual property protection into the Uruguay round as it is an 
important principle of the WTO Agreement as well. Though, the 
Preamble of the TRIPS Agreement has no legal power as any other 
Articles of the Agreement, nevertheless, it is very useful in clarifying 
the ambiguity of the Articles and helpful in interpreting them.  
Article 1 of the TRIPS Agreement provides for the nature and 
scope of the Agreement by stating the TRIPS Agreement is not self-
executing and the minimum standard of protection provided for have 
to be given effect by the member countries in their own jurisdictions. 
The TRIPS Agreement does not state any procedures on how this 
process to be carried out, therefore this may cause problems for the 
developing countries as it requires reform in many domestic 
legislations. Even though the member countries are given freedom to 
choose the best method of implementation, but they have to prove that 
it was the best method available at the time. However, the TRIPS 
Agreement provides for opportunity for the member countries to 
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implement more extensive protection than what provided for by the 
Agreement. Article 1 also determines the scope of the TRIPS 
Agreement by including all categories that are stated in section 1 to 7 
of Part II of the TRIPS Agreement within the term of ‘intellectual 
property’.   
Article 7 of the TRIPS Agreement states the objectives of the 
Agreement by emphasizing that the TRIPS Agreement should have 
positive effects on progressing technological and economic 
development and social welfare of the developing countries. This was 
proposed by developing countries so that the TRIPS Agreement 
should not be in favour of the developing countries only through high 
standard of protection. If this objective is not achieved the developing 
countries have right to object the exclusive rights of the right holders. 
It is also the objective of the TRIPS Agreement that in all types of 
intellectual property rights the balance of rights and obligations has to 
be kept, and the interest of the right holders and users have to be 
balanced. Even though this objective inserted on the request of the 
developing countries, but nevertheless, the balance between rights and 
obligations considered superseding objective of the WTO system.  
The important principles of the TRIPS Agreement can be found in 
Article 8. According to this Article member countries are allowed to 
adopt measures ‘to protect public health and nutrition, and to promote 
the public interest in sectors of vital importance to their socio-
economic and technological development’. These measures can be 
taken from the provisions of the TRIPS Agreement such as exceptions 
to exclusive rights and compulsory licences, or other measures that 
have no base in the TRIPS Agreement but consistent with the 
provisions of the Agreement. Promoting public interest can include 
many areas and the member countries are allowed to determine their 
own sectors of vital importance. Therefore, the member countries in 
general, and the developing countries have great chance of adopting 
measures that benefit their societies by preventing abuse of 
intellectual property rights by the right holders, practices which 
unreasonably restrain trade or practices which have adverse effect on 




4. Patent Law No. 61 of 1935 was enacted during the Kingdom of 
Iraq. However, this law regulated the law of patent in a very basic 
manner such as having a simple and plain definition of invention that 
includes mere discovery. Besides that, it excludes some areas from 
patentability for example pharmaceutical formulations and medicines 
which made it to the next Law No. 65 of 1970. Law No. 61 of 1935 
granted patent to an invention without making any investigation of the 
usefulness, correctness, truthfulness or correctness of its data or 
compare the data with the invention that submitted for patent to make 
sure it matches the invention. The law also stated that the government 
will not guarantee any of these matters. Even though this law went 
through a few amendments by law No. 64 of 1940, law No. 27 of 
1949 and the last amendment was during the Republic of Iraq by law 
No. 210 of 1968.  
After all these amendments the law No. 61 of 1935 was not up to 
the standard of protection of intellectual property rights. Therefore, 
Patent and Industrial Design Law No. 65 of 1970 for the first time 
enacted during the Republic of Iraq to repeal the law No. 61 of 1935. 
The new law also has undergone few amendments in order to keep 
with the international standard of protection. The most important of 
those amendments were by law No. 28 of 1999 and CPA Order No. 
81. The CPA has issued many regulations, memoranda, public notices 
and orders, in order to rebuild a strong Iraq economically and establish 
justice after the long run of dictatorship. Through Order No. 81 the 
CPA has changed the title of the law No. 65 of 1970 to ‘Patent, 
Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law’. This Order has added a few more chapter to the 
original law including a chapter on ‘Protection of New Varieties of 
Plants’. The Order made 22 amendments on the first chapter (Patent), 
in which some of them were simple amendments while some other 
repealed the whole section and replaced them with new ones.  
 
5. The term ‘invention’ in the original law No. 65 of 1970 and its 
amendments has gone through some changes. The law defined the 
invention in section 1.4 as ‘every new innovation that industrially 
exploitable whether relates to new industrial products or innovative 
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methods and means or both of them together’. This definition included 
and could be used to identify the major important criteria of 
patentability because the law did not state the criteria of patentability 
in other sections of the law. Then the law No. 28 of 1999 added the 
words of (achieve some specific development). Even though all the 
traditional criteria of patentability could be found in this definition, 
but still the CPA Order No. 81 repealed this definition and introduced 
another one. The new definition contains all the elements of the old 
one but changed the words. After examining relevant factors, this 
thesis argues that since the TRIPS Agreement does no define the term 
‘invention’ and it is left for the member countries to define them in the 
best way that suit their legal system, therefore, one can say that the 
both of the definitions are in compliance with the requirement of the 
TRIPS Agreement.  
The thesis furthermore examines the original law No. 65 of 1970, 
in which section 2 states that ‘Patents of invention shall be granted 
according to the provisions of this Law’. However, the CPA Order 
No. 81 repealed this section and replaced it with new section to 
include all the criteria of patentability in much clear and similar 
manner to the TRIPS Agreement. The new section 2 states that 
‘Patents of invention shall be granted pursuant to the provisions of this 
Law for each invention that is industrially applicable, novel and 
involves an inventive step, either concerning new industrial products, 
new industrial methods, or new application of known industrial 
methods’. This is clearly an improvement to the Iraqi patent law that 
eliminate any doubts in non-compliance to the TRIPS Agreement. 
 
6. Exclusion from patentability is another important principle that 
the TRIPS Agreement which will be another important topic of the 
thesis to cover. Both subparagraphs of number 2 and 3 of article 27 
provide options for the member countries to exclude some areas from 
patentability. Article 27.2 provides that the member countries may 
exclude any invention that its exploitation in the territory of a member 
country goes against ordre public and morality. Including these two 
types of exclusion was based on the proposals by the EEC, Japan and 
developing countries, because it was common to exclude invention on 
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these bases by the member countries and other international 
conventions long before the TRIPS Agreement. However, the TRIPS 
Agreement does not provide for definition of these terms. In this 
context, the researcher argues that the member countries are free to 
determine what situations lead to arise the implementation of these 
exclusions.  
Ordre public can be determined by referring to some situations 
such as riots and public disorder. Nevertheless, member countries are 
free to apply the ordre public to new situations that do not have prior 
application and not known at international level. It can be applied if 
the commercial exploitation of the invention endangers the structure 
of civil society or simply disharmonize the livelihood of individuals to 
live in peace and security. The term morality in the TRIPS Agreement 
is referring to public morality and not individual morality. Article 
XX(a) of GATT of 1947 under the general exception refers to ‘public 
moral’. Hence, the researcher suggests that if the commercial 
exploitation of an invention in the territory of a member country 
caused collective immorality or has negative effect on the morality of 
the community at large, then that member country is allowed to 
exclude such invention from patentability.   
To compare the above matter with the original Iraqi patent law 
No. 65 of 1970, section 3.1 provides for exclusions of ‘Inventions in 
which their exploitations cause breaches of public moral or ordre 
public or contradict the public interest’. The term exploitation refers to 
exploitation in any ‘fields of work related to industry, agriculture, 
profession, and services in broader understanding’. Here in same way 
of the TRIPS Agreement, the Iraqi patent law provides for exclusion 
base on public moral and ordre public. These exclusions are very 
important of Iraqi society because of ethnic and religious diversity of 
Iraq. However, this provision provides for one more base of exclusion 
which is public interest. Public interest is much wider concept than the 
ordre public and public moral, as it can include these two concepts 
and more. It has not been used by Article 27.2 of the TRIPS 
Agreement. Nevertheless, the protection of public interest is allowed 
under Article 8.1 which allow the member countries to take measures 
to promote their ‘public interest in sectors of vital importance to their 
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socio-economic and technological development’. Therefore, the 
researcher suggests that the Iraqi patent law is in compliance with the 
TRIPS Agreement. From the silence of the CPA Order No. 81 on this 
issue by not repealing or amending this section it can be inferred that 
the CPA was of the opinion that this section does not violate the 
provisions and principles of the TRIPS Agreement. 
 
7. Subsequently, the thesis turns into another relevant topic which 
is covered by Article 27.3 (a) of the TRIPS Agreement. This provision 
states that the member countries may exclude from patentability the 
‘diagnostic, therapeutic and surgical methods for the treatment of 
humans or animals’. Therefore, methods of treatment of humans and 
animals are excluded from patentability. This exclusion cannot be 
extended to products and process that are part of humans and animals 
treatments. Many countries around the world have excluded such 
methods and some countries have excluded methods of treatment from 
patentability base on the lack of industrial applicability. On the other 
hand, some developed countries such as Australia, New Zealand and 
United States of America are allowing these methods to be patented as 
long as they satisfy the criteria of patentability.   
In comparison the Iraqi patent law No. 65 of 1970 does not 
contain any provision in regard of the method of treatment of humans 
and animals to exclude them from patentability. This silence can be 
interpreted so that these methods are patentable as a general rule. 
None of the amendments that passed on added regulation in this 
regard. The CPA Order No. 81 repealed and amended many 
provisions of the law No. 65 of 1970 but kept silence on this issue. 
Maybe it is due to the fact that in the United States of America method 
of treatment is patentable. Therefore, the CPA in this issue followed 
the United States patent law rather than using the option of exclusion 
stated in the TRIPS Agreement, which supposed to enhance the Iraqi 
patent law to the international standard (TRIPS Agreement).   
 
8. The TRIPS Agreement has been blamed for allowing patenting 
medicines and drugs which caused rising of prices of medicines 
beyond capacity of least developed and developing countries. These 
Summary 
25 
countries relying on generic drugs to solve their public health crises 
but once they joined the TRIPS Agreement they will not be allowed to 
do so any more, and the problem is that these countries are not able to 
access patented drugs due to their high prices. The effort of these 
countries led to the adoption of the Doha Declaration on the TRIPS 
Agreement and Public Health (14 November 2001). The Doha 
Declaration addresses the issue of public health and tries to find 
solutions for the developing countries to solve their public health 
issues. This declaration emphasizes that the TRIPS Agreement should 
not prevent member countries from adopting necessary measures to 
protect their public health and requested the General Council to find a 
solution for those member countries that cannot benefit from the 
compulsory licence due to insufficient or no manufacturing capacities 
in the pharmaceutical sectors. Nevertheless, the CPA Order No. 81 did 
not add any provision in this regard to help Iraq to have access to 
inexpensive medicines to support public health in crises, or to take 
necessary measures to protect Iraqi public health.   
 
9. Next, due to the importance of plants and saving seeds, there 
are many international conventions and agreements that regulate this 
issue, such as UPOV Convention, TRIPS Agreement, International 
Treaty on Plant Genetic Resources for Food and Agriculture and 
CBD. UPOV Convention is one of the important convention in this 
area especially after the TRIPS Agreement requested all member 
countries to protect plant varieties whether through a patent or sui 
generis system.  
Interestingly, Article 27.3 (b) of the TRIPS Agreement provides 
for excluding plants and animals from patentability. Nevertheless, this 
provision requires that the member countries provide for some form of 
protection of plant varieties through patent, an effective sui generis 
system or any combination of thereof. This causes problem for the 
developing countries because many of them never had any form of 
protection of plant varieties. This protection will have huge impact on 
their farming practices in the area of saving seeds, genetic diversity 
and food security. As societies in these countries still farm on the 
traditional way of saving seeds for next year planting and exchange 
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good seeds among themselves. Iraq is one of the developing countries 
that have great fertile land, but due to the uninterrupted wars, majority 
of its agricultural land and bank seed has been destroyed.   
In comparison, the original Iraqi patent law No. 65 of 1970, does 
not have any regulations pertinent to the protection of animals and 
plants or excluding them from patentability. nevertheless, after the 
invasion of Iraq the CPA Order No. 81 added chapter Threequater for 
protection of plant varieties. Most of the provisions of this new 
chapter have been taken from the UPOV Convention of 1991. For 
example, the definition of plant varieties is the same definition of the 
UPOV Convention and all the criteria of registration of plant varieties 
are same as those of the UPOV Convention which they have to be 
novel, distinctive, uniform, and stable.  
However, in 2013 a new law enacted under the title of 
‘Registration, Accreditation and Protection of Agricultural Varieties’ 
Law No. 15 of 2013. This new law repealed and replaced chapter 
Threequater.  
The CPA Order No. 81 prevented re-using of seeds of protected 
varieties, however, the new law No. 15 of 2013 introduced new 
exception which is called ‘Optional Exception’ which exists under the 
UPOV Convention, but the CPA Order No. 81 did not introduce it to 
chapter Threequater. The optional exception allows for re-using the 
seeds of protected varieties that obtained by planting on the farmer’s 
holdings. The new law also included some more exceptions than the 
CPA Order No. 81 which are on favour of farmers.      
  
10. Article 28 of the TRIPS Agreement states certain rights to the 
patent holder. However, the rights conferred are in the form of negative 
rights in which the patent owner has rights to prevent others, for the 
period of 20 years from the filing date according to Article 33 of the 
TRIPS Agreement, in cases where the subject matter of the patent is 
product, from making, using, offering for sale, selling, or importing for 
these purposes that product, as it is stated in Article 28.1 lit. (a). In cases 
where the subject matter of the patent is process, as it is stated by 
Article 28.1 lit. (b), the patent owner has exclusive rights to prevent 
others to use his process without his consent. Also, when the products 
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are obtained directly his process he has rights to prevent others from 
using, offering for sale, selling, or importing for these purposes.  
Furthermore, Article 34 has empowered the judicial authorities of 
the member countries to reverse the burden of proof where there is no 
enough evidence that the products are manufactured by the patented 
process. Naturally it is difficult for the patent owner to proof that his 
patented process is used for manufacturing products that are identical 
to products that can be manufactured by his process. In these cases, 
the owner of such identical products has to show that the patented 
process is not used. Nevertheless, the interest of alleged infringer has 
to be protected by the courts. Because he may has used different 
process and want to keep his process secret.      
Article 28.2 also has granted the rights to assign, or transfer by 
succession the patent and to conclude licensing contracts. Even though 
this article has granted such rights, but it has to be beard in mind that 
the TRIPS Agreement has allowed the member countries to grant 
compulsory licence without the consent or against the wishes of the 
patent owner according to Article 31 and 31bis.  
As for the Iraqi patent law, section 12 of the original law No. 65 
of 1970 referred to rights conferred in a general manner by stating that 
the patent owner has exclusive right to exploit his invention by all 
legal means. However, the CPA Order No. 81 repealed this section 
and replaced with another section that have two subsections very 
similar to Article 28.1, in which the first subsection dedicated for 
patented products and the other to patented processes.   
 
11. Even though the patent grants exclusive right to the patent 
owners, however, countries around the world have set limitations on 
this exclusive right by providing certain exceptions. In this regard the 
TRIPS Agreement has provided some exceptions. The first of type of 
exception can be found in Article 30 of the TRIPS Agreement. This 
Article gives chance to member countries to provide in their domestic 
legislations some exceptions to the exclusive rights conferred by a 
patent. There are some possible exceptions that can be adopted by 
member countries according to Article 30 of the TRIPS Agreement, 
such as research and experimentation exception, early working (bolar) 
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exception, individual prescriptions exception, prior use exception and 
parallel imports exception.  
Last but not least, the TRIPS Agreement also provides for another 
type of exception which is called compulsory licence. Article 31 
provides for this principle under the name of ‘other use without 
authorization of the right holder’. This is involuntarily licence in 
which the patent holder has no choice because the licence is enforced 
on him. This licence can be authorized by the governments on the 
grounds of national emergency, anti-competitive practices, public 
non-commercial use and dependent patents. However, whenever the 
member countries have fulfilled the conditions that are stated in 
Article 31, they can authorize compulsory licence on other grounds as 
well. However, some of the conditions in Article 31 cannot be 
fulfilled by the least developed and developing countries due to their 
underdeveloped technologies. Therefore, after great debate and long 
process Article 31bis came into existence. 
Article 31bis is the first amendment since the TRIPS Agreement’s 
enforcement. It was amended on 6 December 2005 and entered into 
force on 23 January 2017. The main purpose of this Article is to allow 
member countries to have better and easier access to health products 
through special compulsory licences. Compulsory licence under 
Article 31 requires that the granting of a compulsory licence has to be 
predominantly for the supply of domestic market. Therefore, under 
Article 31 it is not allowed to export majority of products 
manufactured under the compulsory licence. However, according to 
the new Article 31bis member countries are allowed to grant 
compulsory licence for the purposes of production of pharmaceutical 
products and export them to other member countries. Article 31bis 
also prevents the double payment of remuneration to the patent owner 
by both importing and exporting member countries. In this case only 
the exporting country is required to pay an adequate remuneration and 
the importing country is not require paying the remuneration when 
grants the compulsory licence for the same pharmaceutical products of 
the exporting country.  
The Iraqi patent law No. 65 of 1970 does not provide for any 
types of exceptions that allowed under Article 30 of the TRIPS 
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Agreement. Even though the CPA was well aware of the provisions of 
the TRIPS Agreement but did not add any similar exceptions to the 
Iraqi patent law. However, the original law No. 65 of 1970 provides 
some provisions in regard of granting compulsory licence. 
Nevertheless, all these provisions were amended by the CPA Order 
No. 81. This order has included almost all the conditions that are 
stated in the TRIPS Agreement for granting compulsory licence. On 
the other hand, repealed some flexibilities of compulsory licence that 
were in favour of Iraq, such as granting compulsory licence when the 
exploitation corresponds to the needs of Iraq. Thus, the thesis argues 
that the CPA Order No. 81 also did not add any provisions in regard 
of granting special compulsory licence for the purpose of 
pharmaceutical products.   
 
12. It can be concluded that the original law No. 65 of 1970 needs 
another amendment in order to be incompliance in a better way with 
the TRIPS Agreement and suits the development of the country and its 
people. Some of the important recommendations can be summarized 
as follows. 
a) Provision that exclude method of treatment from patentability 
is existing in laws of many member countries. Therefore, a new 
provision should be added to this law according to the option 
established in Article 27.3 (a) of the TRIPS Agreement that can be 
read as ‘patent shall not be granted in diagnostic, therapeutic and 
surgical methods for the treatment of humans or animals’. Similar 
provision is necessary so that the underdeveloped country of Iraq 
benefit from this exclusion.  
b) Furthermore, Article 27.3 (b) of the TRIPS Agreement orders 
the member countries to provide for protection of plant varieties. In 
this regard the law No. 15 of 2013 is a sui generis system that 
provides for protection of plant varieties. However, this law reduced 
the period of protection and failed to take advantages of the UPOV 
Convention. For this reason, this thesis recommends an amendment on 
this law so that be incompliance with the TRIPS Agreement and 
provide for all the advantages that are stated in the UPOV Convention.  
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c) The researcher also recommends that another provision should 
be added to the Iraqi patent law in order to provide for exceptions that 
allowed under Article 30 of the TRIPS Agreement. The CPA Order 
No. 81 failed to act in best interest of Iraq and did not include 
exceptions such as parallel imports, prior use exceptions, individual 
prescriptions, early working (bolar exception), and research and 
experimentation exception, which are allowed to be implemented in 
domestic legislations of the member countries under Article 30.   
d) In addition, the original law No. 65 of 1970 does not have any 
provision similar to Article 34 of the TRIPS Agreement that reverse 
the burden of proof in cases involve production of identical products 
of the patented process. Since the CPA Order No. 81 failed to include 
such provision, therefore, this thesis recommend such provision to be 
included in the Iraqi patent law so that the patent owners of patented 
processes enjoy better protection.  
e) Lastly, this thesis recommends an amendment to the original 
patent law No. 65 of 1970 in order to include provisions in order to 
give effect to Article 31bis of the TRIPS Agreement. According to 
Article 31bis exporting member countries are allowed to grant a 
compulsory licence so that majority or all of the productions under 
such licence be exported to outside the country. The importing 
member countries of such productions are exempted from paying 
adequate remuneration to the patent owner while granting compulsory 
licence to the same products. Subsequently, Iraq as an importing 
member country that does not have sufficient manufacturing 
capacities will be able to grant compulsory licences for importing 
medicines from other member countries that produce such medicines 




1. Uno de los tratados internacionales más importantes del que 
Iraq no forma parte es el Acuerdo sobre los Aspectos de los Derechos 
de Propiedad Intelectual relacionados con el Comercio (ADPIC o 
TRIPS en sus iniciales inglesas). Iraq no es miembro de la 
Organización Mundial del Comercio (OMC), pero está en proceso de 
adhesión y en este momento está en la lista de gobiernos 
observadores. Del mismo modo, Iraq tampoco es miembro de la 
mayoría de los tratados y uniones de la OMPI, a excepción del 
Convenio de París (1976) y del Convenio de la OMPI (1976). Sin 
embargo, es el acuerdo ADPIC el que brinda una mayor protección de 
los derechos de propiedad industrial e intelectual.  
El objetivo de esta tesis doctoral es analizar todas las 
posibilidades de implementación del Acuerdo ADPIC por parte del 
gobierno iraquí, especialmente en el ámbito de las patentes. Por lo 
tanto, la hipótesis clave de esta investigación es que Iraq debería 
implementar una ley que cumpla con los requisitos del Acuerdo sobre 
los ADPIC y, al mismo tiempo, incluir todas las flexibilidades legales 
que ayuden a desarrollar el país con el mínimo de costes y sacrificios. 
 El objetivo principal de esta investigación es examinar y analizar 
la regulación sobre las patentes contenida en la Ley iraquí de Patentes 
y Diseño Industrial n.º. 65 de 1970, tanto en su versión inicial como 
en sus modificaciones posteriores [en especial la realizada por la 
Orden n.º 81 de la Autoridad Provisional de la Coalición (CPA)], y 
compararla con las disposiciones del Acuerdo sobre los ADPIC a fin 
de conocer las coincidencias y contradicciones entre estos textos 
legales.  
 
Se resumen a continuación los principales resultados alcanzados. 
 
2. El Acuerdo sobre los ADPIC es uno de los acuerdos 
internacionales más importantes de entre los que han estandarizado la 
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protección de los derechos de propiedad industrial e intelectual 
exigiendo una tutela mínima. Con anterioridad al Acuerdo ADPIC se 
concertaron otros tratados internacionales, como las convenciones de 
París y Berna, a las cuales se sumaron muchos países menos 
desarrollados y países en vías de desarrollo, a los que faltaba la 
adecuada experiencia económica y cultural, pero que lo hicieron por la 
presión de los países coloniales. Así sucedió, por ejemplo, con el 
Convenio de Berna, al que muchos países se adhirieron por medio de 
su artículo 19 en contra de su libre voluntad.  
En ese contexto, los países en desarrollo que intentaron promulgar 
leyes nacionales que atendían a sus intereses nacionales se 
encontraron con la oposición de los países desarrollados y sus 
empresas, porque estos países en desarrollo ofrecían en sus 
legislaciones nacionales un reducido nivel de protección de los 
derechos de propiedad industrial e intelectual, por ejemplo, en el 
ámbito de los productos farmacéuticos.   
En consecuencia, en el período anterior a la celebración del 
Acuerdo ADPIC, distintos países a lo largo del mundo estaban 
insatisfechos con los convenios y acuerdos existentes en materia de 
propiedad industrial e intelectual e intentaron modificarlos. Los países 
en vías desarrollo pretendían una mejor regulación que le permitiera 
acceder a tecnologías extranjeras, mientras que los países 
desarrollados les imputaban una falta de mecanismos de defensa y 
aplicación de dichos derechos, sin que pudiesen sancionar 
efectivamente a esos países por no cumplimiento. 
Para poder hacer valer sus intereses en el nuevo acuerdo que 
regula los derechos de propiedad industrial e intelectual, Estados 
Unidos de América eligió el foro del GATT, donde ya tenía una 
posición fuerte. Este fue un paso novedoso porque hasta ese momento 
los derechos de propiedad industrial e intelectual se consideraban un 
obstáculo para el libre comercio. Dentro del GATT, los países 
desarrollados pudieron establecer un acuerdo único que incorporase 
todos los derechos de propiedad industrial e intelectual. Y los países 
en desarrollo no tuvieron otra opción que aceptar el Acuerdo sobre los 
ADPIC con la esperanza de beneficiarse del GATT (OMC). 
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Los Estados Unidos de América utilizaron sus entidades, tales 
como la Oficina del Representante de Comercio de los Estados Unidos 
(Office of the United States Trade Representative, USTR) y la 
Comisión de Comercio Internacional (United States International 
Trade Commission, ITC). Estas entidades proporcionaron la 
información necesaria al gobierno y aplicaron las peticiones del 
congreso y los grupos de presión. La USTR adoptó distintas medidas 
en virtud de la sección 301 y 301 de la Ley de Comercio de 1974, 
como imponer sanciones comerciales a países extranjeros, imponer 
aranceles a sus productos o amenazar con utilizar represalias 
unilaterales si no modificaban sus prácticas de propiedad intelectual. 
Entre los países presionados por la USTR se encuentran países en 
desarrollo como Chile e Indonesia, y también países desarrollados 
como Japón. Asimismo, otra ventaja de los Estados Unidos de 
América durante el proceso de negociación en el GATT fue recibir 
continuamente información de asociaciones como la Alianza 
Internacional de la Propiedad Intelectual [International Intellectual 
Property Alliance (IIPA)] y la Alianza de Software Empresarial 
(Business Software Alliance, BSA), integradas por miles de 
compañías. Finalmente, los países en desarrollo tuvieron que aceptar 
los altos niveles de protección de la propiedad industrial e intelectual 
(que inicialmente rechazaron en el Grupo 10), debido a amenazas 
económicas y presiones políticas de los Estados Unidos, y el Acuerdo 
sobre los ADPIC se convirtió en una realidad.  
 
3. Los principales propósitos y objetivos del Acuerdo sobre los 
ADPIC pueden inferirse ya del Preámbulo y son la protección de la 
propiedad intelectual (término con el que se engloban tanto los 
derechos de propiedad industrial como los del propiedad intelectual en 
sentido estricto) de manera que se reduzcan las distorsiones y los 
obstáculos al comercio internacional; y el reconocimiento de los 
derechos de propiedad intelectual como derechos privados para que 
puedan protegerse contra actos arbitrarios e injustos de los gobiernos. 
La conexión entre la protección de la propiedad intelectual y el 
comercio internacional se debió a los intentos de los Estados Unidos y 
sus grandes empresas de insertar la protección de la propiedad 
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intelectual en la Ronda de Uruguay, ya que también es un principio 
importante del Acuerdo sobre la OMC. Con todo, aunque es de gran 
utilidad a los efectos interpretativos, el Preámbulo del Acuerdo sobre 
los ADPIC no tiene un valor jurídico equiparable al de los artículos 
del Acuerdo.  
El artículo 1 del Acuerdo sobre los ADPIC establece la naturaleza 
y el alcance de las obligaciones del Acuerdo, disponiendo que no es 
de aplicación automática y que los miembros respetarán en sus 
legislaciones el nivel mínimo de protección previsto. El Acuerdo 
sobre los ADPIC no establece ningún método para que los miembros 
apliquen sus disposiciones en el marco de su propio sistema y práctica 
jurídicos, lo que puede causar problemas para los países en desarrollo, 
cuyas legislaciones nacionales deberán ser reformadas. En todo caso, 
aunque los países miembros tienen libertad para elegir el mejor 
método de implementación, deben demostrar que fue el mejor método 
disponible en ese momento. Por lo demás, el Acuerdo sobre los 
ADPIC permite que los países miembros implementen una protección 
más amplia que la prevista en el Acuerdo. El artículo 1 también 
determina el alcance del Acuerdo sobre los ADPIC al incluir todas las 
categorías que figuran en las secciones 1 a 7 de la Parte II del Acuerdo 
sobre los ADPIC dentro del término de «propiedad intelectual». 
El artículo 7 del Acuerdo sobre los ADPIC establece los objetivos 
del Acuerdo al hacer hincapié en que éste deberá tener efectos 
positivos en la promoción de la innovación tecnológica y el bienestar 
social y económico de los países en desarrollo. Esta disposición fue 
propuesta por los países en desarrollo para que el Acuerdo no 
beneficiase únicamente a los países desarrollados estableciendo un 
estándar elevado de protección.  Si no se logra este objetivo, los países 
en desarrollo tienen derecho a oponerse a los derechos exclusivos de 
los titulares de los derechos. Asimismo, otro objetivo del Acuerdo es 
que en todos los tipos de derechos de propiedad intelectual se 
mantenga el equilibrio de derechos y obligaciones, equilibrando el 
interés de los titulares de derechos y los usuarios. Aunque este 
objetivo también se insertó a petición de los países en desarrollo, el 
equilibrio entre los derechos y obligaciones es considerado un 
objetivo general del sistema de la OMC. 
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Por su parte, los principios del Acuerdo sobre los ADPIC se 
recogen en su artículo 8. De conformidad con este artículo, los países 
miembros pueden adoptar medidas «para proteger la salud pública y la 
nutrición de la población, o para promover el interés público en 
sectores de importancia vital para su desarrollo socioeconómico y 
tecnológico». Estas medidas pueden consistir en medidas 
expresamente recogidas en el Acuerdo sobre los ADPIC, como las 
excepciones a los derechos exclusivos y las licencias obligatorias, o en 
otras medidas que no se recogen expresamente en el Acuerdo pero que 
son coherentes con sus disposiciones. En este sentido, la promoción 
del interés público puede incluir muchas áreas y los países miembros 
pueden determinar sus propios sectores de vital importancia. Por lo 
tanto, los países miembros en general, y los países en desarrollo en 
particular, tienen grandes posibilidades de adoptar medidas que 
beneficien a sus sociedades, previniendo el abuso de los derechos de 
propiedad intelectual por parte de sus titulares, las prácticas que 
restrinjan injustificadamente el comercio o las prácticas que tienen un 
efecto negativo en la transferencia internacional de tecnología. 
 
4. La Ley iraquí de Patentes n.º 61 de 1935 se promulgó durante 
el Reino de Iraq. Sin embargo, esta ley regulaba las patentes de una 
manera muy básica, hasta el punto de contener una definición de 
invención que incluía los meros descubrimientos. Además, establecía 
determinadas prohibiciones de patentabilidad, como las referentes a 
las fórmulas farmacéuticas y los medicamentos, prohibiciones que 
llegaron hasta la siguiente Ley n.º 65 de 1970. Por lo demás, de 
acuerdo con la Ley n.º 61 de 1935 las patentes se concedían sin 
realizar ningún tipo de examen sobre la utilidad, corrección, veracidad 
o la exactitud de los datos y sin comparar los datos suministrados con 
la invención para la que se solicitaba la patente. De hecho, la ley 
declaraba expresamente que el Gobierno no garantizaba ninguno de 
estos extremos. Esta ley fue sometida a algunas enmiendas por la ley 
n.º 64 de 1940 y la ley n.º 27 de 1949. Y la última modificación tuvo 
lugar durante la República del Iraq por medio la ley n.º 210 de 1968. 
Aún después de todas estas enmiendas, la ley n.º 61 de 1935 no 
estaba a la altura del nivel de protección de los derechos de propiedad 
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intelectual. Esto hizo que fuese derogada por la Ley de Patentes y 
Diseño Industrial n.º 65 de 1970, promulgada durante la República del 
Iraq, nueva ley que también ha sido objeto de algunas modificaciones 
posteriores para cumplir con el estándar internacional de protección. 
Los más importantes de esos cambios fueron los realizados por la Ley 
n.º 28 de 1999 y por la Orden n.º 81 de la Autoridad Provisional de la 
Coalición (CPA).  
La CPA aprobó numerosas reglamentaciones, memorandos, 
avisos públicos y órdenes para reconstruir económicamente a Iraq y 
establecer justicia después del largo período de dictadura. A través de 
la Orden n.º 81, la CPA cambió el título de la ley n.º 65 de 1970, que 
pasó a denominarse Ley de «patentes, diseño industrial, secreto 
empresarial, topografías de productos semiconductores y de 
variedades vegetales». Además, la Orden añadió algunos capítulos 
nuevos a la ley original, incluido un capítulo sobre «Protección de 
nuevas variedades vegetales», e hizo 22 enmiendas en el primer 
capítulo (Patentes), algunas de las cuales fueron simples 
modificaciones menores mientras que otras implicaron la derogación 
de secciones y la sustitución por otras nuevas.  
 
5. La definición del término «invención» contenida en la ley 
original n.º 65 de 1970 y sus enmiendas ha sufrido algunos cambios. 
La ley definía la invención en la sección 1.4 como «toda innovación 
nueva susceptible de aplicación industrial, consistente en nuevos 
productos industriales, métodos o medios innovadores, o en ambos 
tipos de innovación». Por lo tanto, esta definición incluía y podría 
utilizarse para identificar los principales requisitos de patentabilidad, 
porque la ley no los establecía en otras secciones. Posteriormente, la 
ley n.º 28 de 1999 agregó la referencia a la necesidad de lograr algún 
desarrollo específico. A pesar de que todos los requisitos tradicionales 
de patentabilidad se podían encontrar en esta definición, la Orden de 
CPA n.º 81 derogó dicha definición e introdujo otra que contiene 
todos los elementos del antiguo texto legal, pero cambiando las 
palabras utilizadas.  
Después de examinar los factores relevantes, en esta tesis sea 
argumenta que, dado que el Acuerdo sobre los ADPIC no define el 
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término «invención» y se permite que los países miembros lo definan 
de la mejor manera que se adapte a su sistema legal, se puede concluir 
que ambas definiciones respetan en este punto el Acuerdo sobre los 
ADPIC. 
La presente tesis también examina los requisitos de 
patentabilidad. La ley n.º 65 de 1970, en su versión inicial, establecía 
en su sección 2 que «las patentes de invención se otorgarán de acuerdo 
con las disposiciones de esta Ley». Sin embargo, la Orden n.º 81 de la 
CPA derogó dicha sección y la reemplazó por otra para incluir todos 
los criterios de patentabilidad de una manera muy clara y similar al 
Acuerdo sobre los ADPIC. Así, la nueva sección 2 establece que «las 
patentes de invención se otorgarán de conformidad con las 
disposiciones de esta Ley para cada invención susceptible de 
aplicación industrial, novedosa y que implique una actividad 
inventiva, ya sea en relación con nuevos productos industriales, 
nuevos métodos industriales o una nueva aplicación de métodos 
industriales ya conocidos». Se trata, claramente, de una mejora de la 
ley iraquí de patentes que elimina cualquier duda sobre la coincidencia 
con lo dispuesto en el Acuerdo sobre los ADPIC. 
 
6. Las exclusiones de patentabilidad constituyen otro de los 
principios importantes del Acuerdo sobre los ADPIC y es, en 
consecuencia, otro de los temas examinados con detalle en la presente 
tesis doctoral. 
Los dos subpárrafos de los números 2 y 3 del artículo 27 del 
Acuerdo permiten que los países miembros establezcan algunas 
exclusiones de patentabilidad. El artículo 27.2 dispone que los países 
miembros podrán excluir de la patentabilidad las invenciones cuya 
explotación comercial en su territorio deba impedirse necesariamente 
para proteger el orden público o la moralidad. La inclusión de estos 
dos tipos de exclusión obedeció a las propuestas de la CEE, Japón y 
los países en desarrollo, porque era común la existencia de este tipo de 
exclusiones en los países miembros, al amparo de otros convenios 
internacionales anteriores al Acuerdo sobre los ADPIC. Sin embargo, 
el Acuerdo sobre los ADPIC no prevé la definición de estos términos. 
Y en este contexto, en la tesis se argumenta que los países miembros 
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son libres de determinar qué situaciones conducen a la 
implementación de estas exclusiones. 
Así, el orden público se puede delimitar por referencia a algunas 
situaciones como disturbios y desordenes públicos. Sin embargo, los 
países miembros son libres de aplicar el orden público a situaciones 
nuevas que no tienen aplicación previa y no se conocen a nivel 
internacional. Así, se puede aplicar si la explotación comercial de la 
invención pone en peligro la estructura de la sociedad civil o 
simplemente afecta a las condiciones de las personas para vivir en paz 
y seguridad.  
Por su parte, el término moralidad en el Acuerdo sobre los 
ADPIC se refiere a la moral pública y no a la moral individual. De 
hecho, el apartado a) del artículo XX del GATT de 1947 se refiere a la 
«moral pública». En este sentido, en la tesis se sugiere que, si la 
explotación comercial de una invención en el territorio de un país 
miembro provoca inmoralidad colectiva o tiene un efecto negativo 
sobre la moralidad de la comunidad en general, entonces ese país 
miembro puede excluir dicha invención de la patentabilidad. 
Analizando esta cuestión en la legislación nacional iraquí, se 
constata que en la ley de patentes iraquí n.º 65 de 1970, la sección 3.1 
excluye la patentabilidad de las «invenciones cuya explotación viola 
la moral o el orden públicos o contradice el interés público». El 
término explotación se refiere a la explotación en cualquier «campo de 
trabajo relacionado con la industria, la agricultura, la profesión y los 
servicios en sentido amplio». En este punto, de la misma manera que 
el Acuerdo sobre los ADPIC, la ley iraquí de patentes utiliza la moral 
pública y el orden público como base para la exclusión de la 
patentabilidad. Y estas exclusiones son muy importantes para la 
sociedad iraquí debido a la diversidad étnica y religiosa del país. Pero 
además esta disposición añade un motivo adicional para la exclusión 
de la patentabilidad, a saber: que la invención sea contraria al interés 
público, el cual es un concepto mucho más amplio que el de orden 
público y moral pública, ya que puede incluir más elementos además 
de esos.  
El artículo 27.2 del Acuerdo sobre los ADPIC no alude al «interés 
público». Sin embargo, la protección del interés público está permitida 
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por el artículo 8.1, que faculta a los países miembros para tomar 
medidas para promover su «interés público en sectores de importancia 
vital para su desarrollo socioeconómico y tecnológico». Por lo tanto, 
en la tesis se concluye que la ley iraquí de patentes cumple con el 
Acuerdo sobre los ADPIC. Del silencio de la Orden n.º 81 sobre esta 
cuestión, al no derogar ni modificar esta sección, se puede inferir que 
la CPA consideró que esta sección no viola las disposiciones y 
principios del Acuerdo sobre los ADPIC. 
 
7. Posteriormente, la tesis analiza otro tema relevante, regulado 
por el artículo 27.3 (a) del Acuerdo sobre los ADPIC; a saber: la 
posibilidad de excluir la patentabilidad de «los métodos de 
diagnóstico, terapéuticos y quirúrgicos para el tratamiento de personas 
o animales»; exclusión que no se puede extender a los productos y 
procesos que son parte de los tratamientos de humanos y animales.  
Muchos países de todo el mundo han excluido tales métodos, 
algunos basándose en la falta de aplicación industrial. En cambio, 
otros países desarrollados como Australia, Nueva Zelanda y los 
Estados Unidos de América permiten que estos métodos sean 
patentados siempre que satisfagan los criterios de patentabilidad. 
Por su parte, la ley de patentes iraquí n.º 65 de 1970 no contiene 
ninguna disposición excluyendo la patentabilidad de este tipo de 
métodos, lo cual puede interpretarse en el sentido de que estos 
métodos son, como regla general, patentables. A este respecto, 
ninguna de las modificaciones posteriores de la ley introdujo cambios 
en este punto. La Orden n.º 81 de la CPA derogó y enmendó muchas 
disposiciones de la ley n.º 65 de 1970, pero guardó silencio sobre este 
tema. Tal vez se deba al hecho de que en los Estados Unidos de 
América el método de tratamiento es patentable. Por lo tanto, la CPA 
en esta cuestión siguió la ley de patentes de los Estados Unidos en 
lugar de acoger la posibilidad establecida en el Acuerdo ADPIC de 
excluir la patentabilidad de estos métodos. 
 
8. Una de las críticas que se ha formulado contra el Acuerdo sobre los 
ADPIC es que permite la concesión de patentes sobre medicamentos, 
originando el aumento de su precio por encima de la capacidad de los 
SAMAN ABDULRAHMAN ALI 
40 
países menos adelantados y en desarrollo. Estos países dependen de 
medicamentos genéricos para resolver sus crisis de salud pública, pero 
una vez que ratifican al Acuerdo sobre los ADPIC ya no pueden 
hacerlo, y el problema es que estos países no pueden acceder a 
medicamentos patentados debido a sus altos precios. El esfuerzo de 
estos países condujo a la adopción de la Declaración de Doha sobre el 
Acuerdo sobre los ADPIC y la Salud Pública (14 de noviembre de 
2001). La Declaración de Doha aborda el problema de la salud pública 
e intenta encontrar soluciones para que los países en desarrollo 
resuelvan sus problemas de salud pública. Esta declaración enfatiza 
que el Acuerdo ADPIC no debe impedir que los países miembros 
adopten medidas necesarias para proteger su salud pública y en ella se 
solicita al Consejo General que encuentre una solución para aquellos 
países miembros que no pueden beneficiarse de la licencia obligatoria 
debido a capacidades de fabricación insuficientes o inexistentes en el 
país en el sector farmacéutico.  
Sin embargo, la Orden n.º 81 de la CPA no añadió ninguna 
disposición a este respecto para ayudar a Iraq a tener acceso a 
medicinas de bajo costo para apoyar la salud pública en crisis o para 
tomar las medidas necesarias para proteger la salud pública iraquí. 
 
9. Por otra parte, debido a la importancia de las plantas y a la 
práctica de los agricultores consistente en conservar semillas de su 
propia producción para proceder a sembrarlas en el siguiente ciclo de 
cultivo, existen muchos convenios y acuerdos internacionales que 
regulan esta cuestión, como el Convenio de la UPOV (Convenio 
internacional para la protección de las obtenciones vegetales, firmado 
en París el 2 de diciembre de 1961 y posteriormente modificado por 
las Actas de 10 de noviembre de 1972, 23 de octubre de 1978 y 19 de 
marzo de 1991), el Acuerdo sobre los ADPIC, el Tratado internacional 
sobre los recursos fitogenéticos para la alimentación y la agricultura y 
el Convenio sobre la Diversidad Biológica, hecho en Río de Janeiro el 
5 de junio de 1992. El Convenio de la UPOV es uno de los convenios 
importantes en esta área, especialmente después de que el Acuerdo 
sobre los ADPIC haya establecido que los Miembros otorgarán 
protección a todas las obtenciones vegetales mediante patentes, 
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mediante un sistema eficaz sui generis o mediante una combinación 
de aquéllas y éste. 
En efecto, el artículo 27.3 (b) del Acuerdo sobre los ADPIC 
permite la exclusión de la patentabilidad de las plantas y animales. Sin 
embargo, esta disposición requiere que los países miembros 
proporcionen alguna forma de protección a las obtenciones vegetales a 
través de patentes, un sistema sui generis efectivo o cualquier 
combinación de los mismos. Esto causa un problema para los países 
en desarrollo, porque muchos de ellos nunca tuvieron ninguna forma 
de protección de variedades vegetales, y la previsión de la protección 
tendrá un gran impacto en las prácticas agrícolas de conservación de 
semillas para proceder a sembrarlas en el siguiente ciclo de cultivo, así 
como en la diversidad genética y seguridad alimentaria. Porque, en 
efecto, los agricultores en estos países todavía cultivan en la forma 
tradicional de guardar semillas para el próximo año, plantando e 
intercambiando buenas semillas entre ellos. Además, Iraq es uno país 
en desarrollo que tiene una gran tierra fértil, pero debido a las guerras 
ininterrumpidas, la mayoría de sus tierras agrícolas y bancos de 
semillas han sido destruidos.  
La ley de patentes iraquí n.º 65 de 1970 no contiene, en su versión 
inicial, ninguna referencia a la protección de animales y plantas ni a la 
exclusión de su patentabilidad. Sin embargo, después de la invasión de 
Iraq, la Orden n.º 81 de la CPA añadió el capítulo tresquater para la 
protección de variedades vegetales. La mayoría de las disposiciones 
de este nuevo capítulo se tomaron del Convenio de la UPOV de 1991. 
Por ejemplo, la definición de variedad vegetal es la misma definición 
del Convenio de la UPOV y todos los requisitos para la protección de 
las variedades vegetales son los de la UPOV (novedad, distinción, 
uniformidad y estabilidad). 
 Sin embargo, en 2013 se promulgó una nueva ley bajo el título de 
«Ley de Registro, Acreditación y Protección de Variedades 
Agrícolas», Ley n.º 15 de 2013, que derogó y reemplazó el 
mencionado capítulo tresquater. 
La Orden n.º 81 de la CPA impidió la reutilización de semillas de 
variedades protegidas. Pero la nueva ley n.º 15 de 2013 introdujo la 
excepción opcional recogida en el Convenio de la UPOV que permite 
SAMAN ABDULRAHMAN ALI 
42 
al agricultor reutilizar las semillas de variedades protegidas obtenidas 
mediante la plantación en sus explotaciones. Además, la nueva ley 
también incluyó algunas excepciones más que no figuraban en la 
Orden n.º 81 de CPA, nuevas excepciones con las que se pretende 
favorecer a los agricultores.  
 
10. El artículo 28 del Acuerdo sobre los ADPIC se refiere a los 
derechos conferidos por una patente. Se trata de una serie de 
facultades negativas en virtud de las cuales el titular de la patente 
puede impedir a terceros determinadas actuaciones, durante el período 
de duración de la patente (como mínimo 20 años contados desde la 
fecha de presentación de la solicitud, según el artículo 33 del 
Acuerdo).  Cuando se trata de una patente de producto, el titular tiene 
el derecho de impedir que terceros, sin su consentimiento, realicen 
actos de fabricación, uso, oferta para la venta, venta o importación 
para estos fines del producto objeto de la patente (art. 28.1 a). Y 
cuando la patente es de procedimiento, el titular tiene el derecho de 
impedir que terceros, sin su consentimiento, realicen el acto de 
utilización del procedimiento y los actos de uso, oferta para la venta, 
venta o importación para estos fines de, por lo menos, el producto 
obtenido directamente por medio de dicho procedimiento (art. 28.1 b). 
Además, el artículo 34 del Acuerdo ADPIC ha facultado a las 
autoridades judiciales de los países miembros para invertir la carga de 
la prueba cuando no hay pruebas suficientes de que los productos han 
sido fabricados mediante el procedimiento patentado. Naturalmente, 
es difícil para el titular de la patente probar que su procedimiento 
patentado se utiliza para fabricar productos que son idénticos a los 
productos que pueden fabricarse mediante su procedimiento. En estos 
casos, el propietario de tales productos idénticos debe mostrar que no 
ha utilizado el procedimiento patentado. Sin embargo, el interés del 
presunto infractor debe ser protegido por los tribunales. Porque puede 
haber usado un procedimiento diferente y querer mantenerlo en 
secreto. 
El artículo 28.2 también dispone que los titulares de patentes 
tendrán el derecho de cederlas o transferirlas por sucesión y de 
concertar contratos de licencia. No obstante, aunque este artículo ha 
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otorgado tales derechos, debe tenerse en cuenta que el Acuerdo sobre 
los ADPIC ha permitido a los países miembros otorgar licencias 
obligatorias sin el consentimiento o contra los deseos del titular de la 
patente de conformidad con los artículos 31 y 31 bis. 
En cuanto a la ley de patentes iraquí, el artículo 12 de la ley n. º 
65 de 1970, en su versión inicial, se refería a los derechos conferidos 
de manera general al establecer que el titular de la patente tiene el 
derecho exclusivo de explotar su invención por todos los medios 
legales. Sin embargo, la Orden n.º 81 de la CPA derogó esta sección y 
la reemplazó por otra que tiene dos subsecciones muy similares al 
artículo 28.1 del ADPIC, la primera dedicada a las patentes de 
producto y la segunda a las de procedimiento.  
 
11. A pesar de que la patente otorga derechos exclusivos a su 
titular, los países de todo el mundo han establecido limitaciones o 
excepciones a este derecho exclusivo. Y a este respecto, el Acuerdo 
sobre los ADPIC también prevé algunas excepciones.  
El primer tipo de excepciones se recogen en el artículo 30 del 
Acuerdo, según el cual los miembros podrán prever excepciones 
limitadas de los derechos exclusivos conferidos por una patente, a 
condición de que tales excepciones no atenten de manera injustificable 
contra la explotación normal de la patente ni causen un perjuicio 
injustificado a los legítimos intereses del titular de la patente, teniendo 
en cuenta los intereses legítimos de terceros. Encajan aquí 
excepciones como la excepción de investigación y experimentación, la 
cláusula Bolar, la excepción referida a la preparación de 
medicamentos realizada en farmacias extemporáneamente y por 
unidad de ejecución de una receta médica, la excepción de uso 
anterior o la excepción de importación paralela. 
Por último, pero no menos importante, el Acuerdo sobre los 
ADPIC también prevé la licencia obligatoria, que constituye otra 
limitación del derecho de patente. El artículo 31 establece este 
principio bajo el nombre de «otro uso sin autorización del titular del 
derecho». Se trata de una licencia que se le impone al titular de la 
patente y que puede ser establecida por los gobiernos por motivos de 
emergencia nacional, para poner fin a prácticas anticompetitivas, para 
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permitir un uso público no comercial, para permitir la explotación de 
patentes dependientes, o por otros motivos, siempre que los países 
miembros cumplan las condiciones establecidas en el artículo 31 del 
ADPIC.  
Sin embargo, algunas de las condiciones del artículo 31 no 
pueden ser cumplidas por los países menos desarrollados y en 
desarrollo debido a sus tecnologías subdesarrolladas. Por lo tanto, 
después de un gran debate y un largo proceso, el 6 de diciembre de 
2005 se introdujo en el Acuerdo ADPIC un nuevo artículo 31 bis, que 
entró en vigor el 23 de enero de 2017 y que supuso la primera 
modificación del Acuerdo. El objetivo principal de este artículo es 
permitir a los países miembros tener un mejor y más fácil acceso a los 
productos de salud a través de licencias obligatorias especiales.  
La licencia obligatoria a la que se refiere el artículo 31 del ADPIC 
requiere que la concesión de la licencia obligatoria tenga que ser 
predominantemente para el suministro del mercado interno, lo cual 
impide exportar la mayoría de los productos fabricados con la licencia 
obligatoria. Sin embargo, según el nuevo artículo 31 bis, los países 
miembros pueden otorgar licencias obligatorias para la producción de 
productos farmacéuticos destinados a ser exportarlos a otros países 
miembros, lo cual va a permitir la fabricación bajo licencia obligatoria 
en países desarrollados de fármacos con los que se pretende atender 
las necesidades de salud pública de los países en desarrollo. Además, 
el artículo 31 bis también impide el doble pago de la remuneración al 
titular de la patente por parte de los países miembros importadores y 
exportadores. En este caso, solo el país exportador debe pagar una 
remuneración adecuada y el país importador no está obligado a pagar 
la remuneración cuando concede la licencia obligatoria para los 
mismos productos farmacéuticos del país exportador. 
La Ley iraquí de patentes n.º 65 de 1970 no prevé ningún tipo de 
excepción de las que encajan en el artículo 30 del Acuerdo sobre los 
ADPIC. Aunque la CPA conocía bien las disposiciones del Acuerdo 
sobre los ADPIC, no añadió ninguna excepción similar en la ley de 
patentes iraquí. Sin embargo, la ley iraquí n.º 65 de 1970, en su 
versión original, proporcionaba algunas disposiciones con respecto a 
la concesión de licencias obligatorias, disposiciones que fueron 
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modificadas por la Orden n.º 81 de la CPA, en la que se incluyen casi 
todas las condiciones que se establecen en el Acuerdo sobre los 
ADPIC para la concesión de licencias obligatorias. Por otro lado, la 
citada Orden n. 81 de la CPA también derogó algunas flexibilidades 
de la licencia obligatoria que favorecían a Iraq, como la concesión de 
licencias obligatorias cuando la explotación corresponde a las 
necesidades de Iraq. Por lo tanto, se concluye que la Orden n.º 81 de la 
CPA tampoco añadió ninguna disposición con respecto a la concesión 
de una licencia obligatoria especial para los productos farmacéuticos. 
 
12. La conclusión general que se extrae en la tesis es que la ley 
iraquí n. 65 de 1970 necesita ser modificada para adaptarla 
plenamente a lo dispuesto en el Acuerdo sobre los ADPIC, así como 
para adecuarla al desarrollo del país y de su población. Algunas de las 
principales conclusiones alcanzadas en la tesis se pueden resumir del 
siguiente modo: 
a) Al igual que sucede en la legislación de otros muchos países, 
debe incluirse en la legislación iraquí una disposición, al amparo del 
artículo 27.3 (a) del Acuerdo sobre los ADPIC, que disponga que «no 
se concederán patentes sobre métodos de diagnóstico, terapéuticos y 
quirúrgicos para el tratamiento de personas o animales». Se necesita 
una disposición similar para que un país subdesarrollado como es Iraq 
se beneficie de esta exclusión. 
b) El artículo 27.3 (b) del Acuerdo sobre los ADPIC ordena a los 
países miembros prever la protección de las obtenciones vegetales. Y 
en este sentido, la ley n.º 15 de 2013 es un sistema sui generis que 
brinda protección a las variedades vegetales. Sin embargo, esta ley 
redujo el período de protección y no aprovechó las ventajas del 
Convenio de la UPOV. Por esta razón, en esta tesis se recomienda una 
modificación de ley para que, a la par que se respeta el Acuerdo sobre 
los ADPIC, se recojan todas las ventajas que se establecen en el 
Convenio de la UPOV. 
c) El investigador también recomienda que se agregue una 
disposición a la ley iraquí de patentes para prever las excepciones 
permitidas en virtud del artículo 30 del Acuerdo sobre los ADPIC. La 
Orden n.º 81 de la CPA no actuó en interés de Iraq y no incluyó 
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excepciones como la excepción de importación paralela, la excepción 
de uso anterior, la excepción referida a la preparación de 
medicamentos realizada en farmacias extemporáneamente y por 
unidad de ejecución de una receta médica, la cláusula Bolar o la 
excepción de investigación y experimentación, que pueden aplicarse 
en las legislaciones nacionales de los países miembros de conformidad 
con el artículo 30 del ADPIC.  
d) La Ley iraquí de patentes n.º 65 de 1970 no contiene ninguna 
disposición similar al artículo 34 del Acuerdo sobre los ADPIC que 
invierta la carga de la prueba en los casos relacionados con la eventual 
infracción de patentes de procedimiento. Dado que la Orden n.º 81 de 
la CPA no incluyó dicha disposición, en esta tesis se recomienda que 
dicha disposición se incluya en la ley de patentes iraquí para que los 
titulares de patentes de procedimiento gocen de una mejor protección. 
e) Por último, esta tesis recomienda modificar la ley iraquí de 
patentes n.º 65 de 1970 para incluir disposiciones que den efecto al 
artículo 3 1bis del Acuerdo sobre los ADPIC. De conformidad con el 
artículo 31 bis, los países exportadores pueden otorgar licencias 
obligatorias, de modo que la mayoría o la totalidad de las 
producciones con esa licencia se exporten fuera del país. Los países 
miembros importadores de tales producciones están exentos de pagar 
una remuneración adecuada al titular de la patente mientras otorgan 
una licencia obligatoria a los mismos productos. En consecuencia, tras 
esta reforma Iraq, como país miembro importador que carece de 
capacidad de fabricación suficiente, podrá otorgar licencias 
obligatorias para importar medicamentos de otros países miembros 




1 INTRODUCTION  
Iraq, as one of the developing countries, needs to improve its 
standard in the area of international trade in general, and in the area of 
intellectual property rights in particular. In order for Iraq to have good 
relationship with other countries of international community, it has to 
respect their rights and possessions. This can be achieved through 
enacting rules and regulations that are in interest of both Iraq and 
international communities. The original Iraqi Patent and Industrial 
Design Law No. 65 of 1970 consisted of 54 sections, in which only 
the first 35 sections were dedicated to patent law and the rest were 
dedicated to industrial design law. However, four amendments were 
passed on this law and the most important is by CPA Order No. 81/26 
April 2004 which was passed after the invasion of Iraq. The Coalition 
Provisional Authority lead by USA amended this law intensely by 
even adding some extra areas and changed the name of the law to 
(Patents, industrial design, undisclosed information, integrated circuits 
and plant variety Law). This law intended to enhance the original Law 
to international standard especially to the TRIPS Agreement as it is 
stated in the Preamble of the CPA Order No. 81. The reason is that 
Iraq wanted to join the WTO and currently it is in the accession 
process. Therefore, one can say that Iraqi patent law is still in the 
process of developing in order to meet the minimum standard of 
protection that required by the TRIPS Agreement.       
Although Iraq is one of the developing countries that has great 
natural resources in particular oil, yet, it has the potential to be an 
agricultural country if the fertile soil utilized properly it can secure 
food production for its national demand or even more. Iraq was rich in 
human resources as well, however, due to many consecutive wars with 
Iran, Kuwait, Coalition States lead by United States of America and 
currently war with terror, the number of skilled human resources 
decreased significantly due to death or migration. Therefore, the 
country needs proper and suitable laws to help to elevate the country 
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to the status it deserves. A law that help the country to access 
necessary technology to build a technological country that be able to 
rely on itself for every type of production including medical products. 
A technology for rebuilding agricultural sector so that it can secure 
food production for the need of the whole country instead of relying 
on importation. 
Right now, Iraq is considered to be developing rapidly 
commercially, therefore, it is necessary to import all kinds of 
equipment, materials and products without knowing their IP rights and 
being able to respect these rights. There may be many reasons for this; 
however, one of the reasons is due to Iraq’s nonparticipation in the 
international conventions and treaties that related to IPR. One of the 
most important international treaties that Iraq is not part of is the 
TRIPS agreement. Iraq is not one of the members of WTO, but it is in 
the process and right now is in the list of observer governments. In the 
same way Iraq is not a member of the most treaties and unions under 
WIPO except for Paris Convention (1976) and WIPO Convention 
(1976). However, it is the TRIPS agreement that provides for the wide 
range of protections of intellectual property rights. Therefore, it is the 
purpose of this research to analyse all possibilities of implementing 
the TRIPS agreement, especially in the area of patent by the Iraqi 
government. 
Therefore, the key hypothesis of this research is that Iraq should 
implement a law that fulfils the requirements of the TRIPS Agreement 
and at the same time include all the legal flexibilities that help to 
develop the country with minimum costs and sacrifices. For this 
reason, the main question that this research asks is whether the CPA 
Order No. 81 after its dramatical amendments has achieved this goal. 
The TRIPS Agreement is not the first international agreement in 
the area of intellectual property rights, other international conventions 
such as the Paris Convention and the Berne Convention existed long 
before the TRIPS Agreement. However, the developed countries and 
in particular the United States of America, were not happy with the 
outcome of these international conventions. Therefore, their effort was 
to establish a strong international agreement that be able to reduce 
distortions and impediments to international trades and can take the 
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member countries accountable of their breaches of the agreement. 
Nevertheless, the developing countries created their own frontier with 
the aim of inserting some provisions in their own interest. The 
enforcement of the TRIPS Agreement should be for the mutual 
advantages of both producers and users in the same time and balance 
of rights and obligations should be kept at all the times. Developing 
countries have right to protect their public health and public interest 
within the scope of the TRIPS Agreement, as long as the minimum 
standard which is required by the TRIPS Agreement is implemented.  
Patent law is very important for the development of society as it 
will grant exclusive right to the patent owners. Patent owner will 
receive exclusive right to use, make and exploit his invention so that 
gain economic profit. This is an incentive for every inventors and 
government will guarantee patentee’s rights. In return his invention 
will be disclosed to public to study and research, and even after the 
expiry of the patent everyone will be able to use the invention for 
economic benefits as will.  
In order for a patent to be granted to an invention, it should have 
some requirements. Even though the TRIPS Agreement does not 
define the term invention nevertheless it states the traditional 
requirements of patentability which they are novelty, inventive step 
and industrial applicability. Therefore, this research will discuss the 
requirements of patentability of the original Iraqi patent law No. 65 of 
1970 and its amendment of the CPA Order No. 81, in order to see 
whether the amendment has brought the Iraqi patent law closer to the 
TRIPS Agreement or not. Whether such amendments were necessary 
or not.  
The TRIPS Agreement provides some exclusions from 
patentability. This is one of the most important area for the developing 
countries. Article 27.2 of the TRIPS Agreement provides an option 
that the member countries can exclude inventions from patentability, 
if the exploitation of such inventions goes against the principles of 
public ordre and morality. The TRIPS Agreement does not define any 
such principles and left for member countries to define them and 
implement them. However, if exploitation of any invention endangers 
the structure of civil society and its institutions, or negatively affect 
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the community’s immorality then member countries are allowed to 
exercise its rights under this provision of the TRIPS Agreement and 
exclude such invention from patentability. therefore, this research will 
discuss in detail these exclusions and the relevant provisions under the 
original Iraqi patent law and its amendment by the CPA Order No.81.   
The TRIPS Agreement also provides another option for excluding 
from patentability that relate to method of treatment which they are 
the diagnostic, therapeutic and surgical methods for treatment of 
humans or animals. The research will examine this provision in order 
to find out what can be excluded from patentability. Positions of 
member countries on this type of exclusion will be analysed even 
before the existence of this provision and position of those member 
countries that allow patenting such methods of treatment. Then 
position of Iraqi patent law and CPA Order will be analysed as well.  
Access to medicines and fulfilling the public health needs are 
always one of the problems of the least developed and developing 
countries. The sources of these medicines are usually the developed 
countries and their higher prices has always been problem for poor 
countries especially with the higher standard of protection of the 
TRIPS Agreement. Because it will prevent the least developed and 
developing countries from having access to generic drugs. 
Notwithstanding, the fact the higher standard of protection will help 
the pharmaceutical companies to make better profits and in return this 
encourage them to conduct expensive research and development for 
discovering new medicines. Eventually, the least developed and 
developing countries attempt to balance the result of the Uruguay 
Round, led to the adoption of the Doha Declaration on the TRIPS 
Agreement and Public Health (14 November 2001). This declaration 
to acknowledge the problem of these countries and emphasizes that 
the TRIPS Agreement should not be an obstacle in solving their public 
health problems. Therefore, this research will discuss the Doha 
Declaration in detail to find out to what extend it has solved the public 
health concerns and access to medicines by the member countries, and 
the Iraqi patent law position will be discussed as well. 
The TRIPS Agreement also provides for exclusion from 
patentability of plants and animals. This is another important area of 
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exclusion; however, the TRIPS Agreement require from the member 
countries to provide for the protection of plant varieties. This 
protection can be through a patent or an effective sui generis system 
or both of them. The research has discussed this area of exclusion in 
detail with reference to some other important international agreements 
that have regulated the protection of plant varieties including saving 
seeds. Iraq has vast area of fertile land that can be used for agriculture. 
Therefore, providing protection of plant varieties and seeds will affect 
the farmers significantly. The Iraqi laws in this regard will be 
examined and analysed with reference to the amendments as well.     
The last part of the research will focus on the exceptions to 
exclusive rights of patent owners in the TRIPS Agreement and Iraqi 
patent law. The TRIPS Agreement states that member countries have 
right to provide for limited exceptions to right conferred, without 
naming any type of exceptions. However, long before the TRIPS 
Agreement countries around the world were used to limit the 
exclusive rights of the patent holders by introducing some important 
exceptions according to their needs. By not naming specific type of 
exception the TRIPS Agreement offers flexibilities to the member 
countries to include the exceptions in their domestic law that best 
serve circumstances. However, the conditions in the TRIPS 
Agreement have to be abide by the member countries.   
Beside the above exception, the TRIPS Agreement provides for 
another type of exception which names it ‘Other Use Without 
Authorization of the Right Holder’, as commonly known as 
(Compulsory licence). compulsory licence is very powerful tool at the 
hand of the local authorities to rectify any unbalanced circumstances 
created due to the exclusive rights of the patent owners. This type of 
licence imposed on the right holders without their consent. Therefore, 
the TRIPS Agreement has states a list of conditions and restrictions 
that have to be followed before any member countries be able to grant 
a compulsory licence under the TRIPS Agreement. The research will 
examine and analyse in detail the conditions and circumstances in 
which this exception can be applied in.  
However, due to the strict conditions for applying the compulsory 
licence, that made many member countries especially the least 
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developed and developing countries unable to utilise the compulsory 
licence to supply the needs medicines for themselves. This eventually 
leads to an amendment to the TRIPS Agreement and introducing 
special compulsory licence for the purpose supplying pharmaceutical 
products for the need of the member countries. The research will 
discuss this new compulsory licence in detail and explain the 
situations that can be applied on.  
The original Iraqi patent law provided for compulsory licence. 
However, the amendment of the CPA Order No. 81 replaced all the 
provisions that related to compulsory licence. the research will 
examine all the provisions of the of the Iraqi patent law before the 
amendment and after the amendment by the CPA and analyse the 





The main objective of this research is to examine and analyse the 
original Iraqi Patent and Industrial Design Law No. 65 of 1970 (The 
Patent Laws only) in comparison to the amendments in particular the 
CPA Order No. 81, then compare these with the provisions of the 
TRIPS Agreement in order to find out the confirmations and 
contradictions among them.  
Apart from the above main objective, there is a significant 
number of other objectives as follows:  
First: To find out whether the TRIPS Agreement established on 
bases of fair negotiations and without any coercion from the powerful 
developed countries and their companies such as big pharmaceutical 
companies.   
Second: Analyse and examine the nature, scope, purposes, 
objectives and principles of the TRIPS Agreement in order for the 
member countries (least developed, developing and developed 
countries, and particularly the Iraqi law makers) have clear vision on 
how to deal with the TRIPS Agreement and be able to benefit from it. 
Third: Examine the historical development of the Iraqi patent law 
and assess the requirement of patentability under the original Iraqi 
patent law and its amendments to find out to what extend compatible 
with the requirement of patentability under the TRIPS Agreement. 
Fourth: Analyse the provisions of the TRIPS Agreement that 
provide for exceptions and exclusion from patentability and compare 
them to the Iraqi patent law and its amendments made by the CPA 
Order No. 81 in order to find compatibility among them, and to find 






The thesis methodology is comprised of legal comparative and 
analytical approaches to all existing significant provisions of the Iraqi 
patent law before and after amendments among themselves and in 
comparison, to the provisions of the TRIPS Agreement. The 
justification for the research analyses is to identify the reasons behind 
the existence of the TRIPS Agreement and the negotiations that 
occurred between the developed and developing countries. Analysing 
the process of standardizing the minimum protection of patent rights 
before the TRIPS Agreement and tactics used by the each developed 
and developing countries to gain most out of the TRIPS Agreement 
and reasons made the developing countries to accept the TRIPS 
Agreement.  
The research compares and analyses the provisions of the original 
Iraqi patent law with the amendments that followed by the CPA. In 
this way the research will be able to arrive to conclusion whether the 
progresses and amendments were made for the benefits of Iraq as a 
country. For arriving at this conclusion, examining the history of 
creating the TRIPS Agreement and the provisions of this agreement is 
necessary. Comparing the original Iraqi patent law and CPA Order 
No. 81 of the provisions of the TRIPS Agreement will be the best way 
to find discrepancies among them and a good attempt to make 
harmonization among them.     






















1 TRIPS HISTORY, BACKGROUND, 
NEGOTIATION: DEVELOPED 
AND DEVELOPING COUNTRIES 
STAND DURING NEGOTIATIONS. 
 
1.1 INTRODUCTION  
The agreement of Trade-Related Aspects of Intellectual Property 
Rights TRIPS (hereinafter the “TRIPS Agreement”) is considered as 
one of the most important and popular agreement on standardizing 
Intellectual Property Law, as most of the countries in the world are 
either members or trying and in the process of accession.  The TRIPS 
Agreement is the result of Ministerial Conference in Marrakesh on 15 
April 1994, signed by the General Agreement on Tariffs and Trade 
(hereinafter the “GATT”) contracting parties as an annex to the World 
Trade Organization (hereinafter the “WTO”) Agreement.
1
 
The process of standardizing intellectual property protection is 
not new, and its starting point can be traced back to the colonization 
period.
2
 During the colonization period, this process was done by 
force with the aim of prioritizing the interests of colonial countries. 
Most of the colonial countries transferred their intellectual property 
laws into their colonies without their consent. For example, British 
copy right law applied in Malaysia, Spanish patent law enforced in 
Philippines and Korean patent law replaced by Japanese patent law.
3
 
                                                 
1 Nuno Pires de Carvalho, The TRIPS Regime of Patents and Test Data, Fourth edition 
(Alphen aan den Rijn, The Netherlands: Kluwer Law International, 2014), p. 1. 
2 Emir Aly Crowne, ‘Fishing TRIPS: A Look at the History of the Agreement on Trade-
Related Aspects of Intellectual Property’, Creighton International and Comparative Law 
Journal, 2 (2011), 77, p. 77. 
3 Peter Drahos, ‘Developing Countries and International Intellectual Property Standard-
Setting’, The Journal of World Intellectual Property, 5.5 (2002), 765–89, p. 766-67. 
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These clearly explain that most of the current developing countries 
had little option of exercising rights over their intellectual property 
protection standards.  
The Paris Convention for the Protection of Industrial Property of 
March 20, 1883 (hereinafter the Paris Convention) and the Berne 
Convention for the Protection of Literary and Artistic Works of 
September 9, 1886 (hereinafter the Berne Convention) long before the 
TRIPS agreement dealt with the international intellectual property 
rights. The latter one particularly came to existence as an international 
convention to protect the interests of exporters. The major colonial 
countries brought their colonies and foreign possessions into the 
convention according to Article 19 of the Berne Act. The Article 
clearly stated that colonial powers has right to act on behalf of their 
colonies and accede them to the Convention. Most of the current 
developing and least developing countries dragged into Berne 
Convention without their freewill and in fact many of them never had 
a chance of deciding on the setting of intellectual property standards. 
Even afterwards, some of the newly independent countries were 
inexperienced economically and culturally that necessitated them to 
completely rely on their mother countries.
4
 In other words they 
followed the system that chosen by the developed countries and 
accepted standards that were in the best interest of the developed 
countries.  
Other developing countries that tried to establish some standards 
for the cause of their own national interests were opposed by the 
developed countries, because many of them passed national law that 
gave little protection, for example in the area of pharmaceuticals. 
These developing countries were not doing something new, in fact 
they were following the footsteps of current developed states.
5
 A 
study shows that developed countries’ members of the Paris 
Convention excluded from protection some areas that were not in their 
                                                 
4 Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’, 
pp. 766–67. 
5 Abdulqawi A. Yusuf, ‘TRIPS: Background, Principles and General Provisions’, in 
Intellectual Property and International Trade: The TRIPs Agreement, ed. by Carlos María 
Correa and Abdulqawi A. Yusuf, 2nd ed (Austin : Alphen aan den Rijn, Netherlands: 
Wolters Kluwer Law & Business ; Kluwer Law International, 2008), p. 4. 




 However, this trend of conflict between developed and 
developing were not new, because always underdeveloped countries 
that are in the process of industrialization have given little protection 
rights in order to reach its goal easily and with minimum cost. It has 
been admitted by United States Congress that in early stages of 
development, the United States refused to respect international 
intellectual property rights because by freely accessing to foreign 
works could forward its economy and society.
7
   
1.2 REASONS BEHIND THE EXISTENCE OF THE TRIPS 
AGREEMENT    
Prior to the existing of the TRIPS Agreement many attempts were 
made by both developed and developing countries to revise the 
international standards of intellectual property rights. In many 
occasions developing countries questioned the international standards 
of intellectual property rights in particular the Paris Convention and 
the Berne Convention.
8
 These questions were an attempt to modify the 
regulations so that they will satisfy their needs. As latecomers the 
developing countries tried to amend and update the conventions so 
that they have better access to foreign technologies, but they were 
unsuccessful. On the other hand, these conventions were described as 
teeth less conventions by developed countries, because they lacked the 
enforcement mechanisms and could not effectively sanction the non-
compliance parties. Dispute under the Paris Convention had to be 
settle by International Court of Justice (hereinafter the “ICJ”) and the 
decision of the ICJ was not enforceable unless the countries 
voluntarily cooperated. Both the developed and developing countries 
pursued different directions with different agendas.
9
  
                                                 
6 Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’, 
p. 768. 
7 Yusuf, p. 4. 
8 Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’, 
p. 768. 
9 Crowne, pp. 78–79; Srividhya Ragavan, Patent and Trade Disparities in Developing 
Countries (OUP USA, 2012), p. 65. 
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In the same way the developed countries were unhappy about the 
international standards protection, as they were aiming for stronger 
protection and realized that such protection cannot be achieved by 
World Intellectual Property Organization (hereinafter the “WIPO”) 
and other forums like the United Nations Conference on Trade and 
Development (hereinafter the “UNCTAD”) and the United Nations 
Educational, Scientific and Cultural Organization (hereinafter the 
“UNESCO”) because its position in these forums is weak and can 
easily be defeated by developing countries.
10
 United States’ failed 
attempts lead to think about shifting to a forum where it is the 
strongest influential party and can impose its interest without effective 
opposition. This forum was the GATT forum. This made United 
States to think again and propose that the issue of intellectual property 
protection has to be considered as an issue of multilateral trade 
negotiation.
11
 Since developing countries were not sympathetic to the 
United States intellectual property needs, it had no choice but to create 
a link between international trade regime and enforcement of 
intellectual property standards so that be able to stop free riding and 
‘rebalance the equation’.
12
 In fact up to that moment intellectual 
property rights were looked at as an obstacle to free trade, but due to 
the United States and United States big businesses, the contracting 
parties to the GATT meeting in Punta del Este (Uruguay) agreed that 
in the next round (which is known as Uruguay Round) to include trade 
related aspects of intellectual property rights as a subject for 
negotiations.
13
 This process was not sudden but it was planned long 
before Uruguay Round. Some attempts were made during the Tokyo 
Round on the issue of trade in counterfeit goods which was led by the 
Levi Strauss Corporation, even though the attempt was unsuccessful 
to frame the intellectual property rights a trade related issue, but it was 
                                                 
10 Crowne, p. 79. 
11 Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’, 
p. 769. 
12 Peter Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION: The Story of TRIPS 
at the GATT’, Prometheus, 13.1 (1995), 6–19 (p. 8). 
13 Crowne, p. 79. 




 This followed by creating the Group of Expert on 
Trade on Counterfeit Goods by contracting parties at their Fourth 
Session in 1984. The Group was of the opinion that joint action was 
necessary, but some countries were against producing additional 
norms and standards and others were of the belief that WIPO was a 
better forum for dealing with these issues and not GATT.
15
 However, 
there are other reasons that encouraged developed countries to push 
for GATT. One of the reasons was that they can incorporate all 
intellectual property rights into a single document and any country 
wants to benefit from WTO has to ratify this single document (the 
TRIPS Agreement) as well.
16
 Even though the developing countries 
were aware that TRIPS was a loss but they were of the opinion that 
joining WTO will be beneficial overall.
17
 GATT was considered to be 
a place where contracts and pacts were freely traded rather than 
concentration on free trades.
18
 Another strong reason that led the 
developed countries to prefer GATT over WIPO was that the former 
had a well-established enforcement and dispute settlement 
mechanisms.
19
 Another reason for chosen GATT by United States as a 
forum for intellectual property was that the GATT’s background and 
dealings with the developing countries was not perfect as supposed to 
be. The representatives of developing countries were not existed 
continuously during the process of creating the TRIPS Agreement and 
during drafting the (Framework of Understanding) and setting the 
foundations of the final agreement they were left out.
20
    
                                                 
14 Graham Dutfield, Intellectual Property Rights and the Life Science Industries: A Twentieth 
Century History, Globalization and Law (Aldershot, Hampshire, England ; Burlington, 
VT: Ashgate, 2003), p. 197. 
15 Daniel J. Gervais, The TRIPS Agreement: Drafting History and Analysis, 3rd ed (London: 
Sweet & Maxwell, 2008), pp. 8–9. 
16 Crowne, pp. 79–80. 
17 Dutfield, p. 197. 
18 Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION’, p. 13. 
19 Dutfield, p. 199. 
20 Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’, 
p. 770. 
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1.3 STEPS TAKEN BY DEVELOPED COUNTRIES (UNITED STATES OF 
AMERICA IN PARTICULAR): 
United States government had a great role in the actual existence 
of the TRIPS Agreement. Alone with all the powers it had could 
persuade more than 100 countries that they should pay more for the 
importation of information.
21
 The United States government was 
backing up the interest groups especially those of pharmaceuticals and 
brand name goods on one side and other various high technology 
sectors on the other. Fears spread wide that the United States economy 
was declining and weakening. Base on this pessimism among political 
elites led the United States government think that this is highly due to 
intellectual property piracy by other countries.
22
 Many American big 
corporations like IBM, Pfizer and Microsoft which largely relying on 
intellectual property assets, were worried about losing profits due to 
piracy.
23
 Data collected by the United States International Trade 
Commission (hereinafter the “ITC”) showed that United States 
corporations losing some US$ 50 billion a year due to weak 
intellectual property protection abroad.
24
 Furthermore, some 
developing countries were emerging as potential regional economic 
power such as Brazil and India. While United States looking at their 
developing as a threat and unfriendly economic rivals.
25
 Long before 
the Punta del Este Ministerial Conference, both of the patent and 
copyright interest groups were of the opinion that strong and 
enforceable intellectual property protection is necessary. Patent 
industries wanted to achieve this through multilateral approach with 
the aim of globalizing United States standards of intellectual property 
protection. On the other hand, the copy right industries were 
concerned more with their level of enforcement. But before the 
                                                 
21 Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION’,p. 7. 
22 Dutfield, p. 199. 
23 Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION’, p. 7. 
24 Adronico O Adede, ‘Origins and History of the TRIPS Negotiations’, in Trading in 
Knowledge: Development Perspectives on TRIPS, Trade, and Sustainability, ed. by 
Christophe Bellmann, Graham Dutfield, and Ricardo Meléndez-Ortiz (Earthscan, 2003), p. 
24. 
25 Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION’, p. 7. 
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Conference both parties agreed that their approaches were 
complementary.
26
       
There are two main entities that had great influence on the United 
States government decision on preferring strong and high standard of 
intellectual property rights. The first and most important of these 
entities is the Office of the United States Trade Representative 
(hereinafter the “USTR”). USTR was created by Congress and placed 
in the Executive Office of the President to coordinate trade policy, but 
in reality, it was a means through which the Congress and interest 
groups put pressure on the Executive to incorporate their interests in 
the country’s international trade policy. The other entity was the 
United States ITC. ITC aimed at providing trade expertise to both 
branches of government (Legislative and Executive) by identifying the 
effects of imports on US industries and actions necessary to be taken 
against ‘unfair trade practice’ including intellectual property piracy. 
The interests of other developed countries were similar to those of 
United States. Therefore, it was easy for United States to acquire 
support of European Union, Japan, Canada and other developed 
countries. However, before receiving such support, United States 
through major multinational corporations established Intellectual 
Property Committee (hereinafter the “IPC”) in 1986. IPC did its best 
to gather supports of European and Japanese governments and 
businesses. IPC could with help from other local and international 
business and trade association turn the issue of intellectual property 
into a trade related issue in a package and eventually developed into 
the TRIPS agreement. 
27
 However, developing countries resisted this 
attempt and United States had to deal with opposition in its own way. 
Since the United States can be considered as a mastermind of 
existence of the TRIPS agreement and mostly will be beneficial for 
the United States, it was the United States that strongly opposed all 
the resistance. Dealing with sovereign states was not easy for the 
United States because they had rights under previous international 
conventions to regulate laws with lower protection from what United 
States wishes for. Some of these countries were not culturally ready to 
                                                 
26 Dutfield, p. 201. 
27 Crowne, pp. 81–83. 
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accept intellectual property and some looked at it as a new form of 
decolonization or economic imperialism.
28
         
As has already been said, one of the main countries that 
contributed to the existence of TRIPS Agreement and strongly 
repulsed any resistance against creation of the TRIPS was United 
States of America. The United States had taken some measures to 
ensure that nations and in particular developing nations would follow 
the standards that USA prefers. IPC adopted a strategy of dialogue to 
divide between the developing countries. In 1988 a delegation from 
IPC visited newly industrialized countries like Korea, Hong Kong and 
Singapore, with the intention separate them from India and Brazil by 
persuading them that their issues and interests are not same as of India 
and Brazil. The IPC delegation also visited ASEANS with the 
intention to persuade them that India and Brazil are not suitable 




The origin of the Office of the United States Trade Representative 
(USTR) goes back to the time of President Kennedy. During his time 
and under the Trade Expansion Act of 1962, Congress requested the 
President to create a Special Representative for Trade Negotiations to 
conduct United States trade negotiation, which up to that time it was 
the responsibility of the Department of State.
30
 In the beginning the 
office was called Special Trade Representative (hereinafter the 
“STR”), but later on according to section 1 (a) of the Reorganization 
Plan No. 3 of 1979, the office renamed as the Office of the United 
States Trade Representative (USTR). Reorganization Plan No. 3 of 
1979 broadened USTR responsibilities. The primary responsibilities 
of USTR as stated in Section 1 (b) (1) are developing and coordinating 
the implementation of United States international trade policy, 
including commodity matters and direct investment policy and 
overseeing negotiations with other countries. USTR serve as the 
principal advisor to the President on international trade policy and on 
                                                 
28 Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION’, p. 9. 
29 Peter Drahos and John Braithwaite, Information Feudalism: Who Owns the Knowledge 
Economy? (London: Earthscan, 2002), p. 129. 
30 https://ustr.gov/about-us/history. Seen on 03/11/2016 
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the impact of other policies of the United States Government on 
international trade.  
Even though there are other committees and groups such as Trade 
Policy Staff Committee (hereinafter the “TPSC”) and Trade policy 
Review Group (hereinafter the “TPRG”), however it is the USTR that 
dominates the bureaucratic process and it is all due to USTR’s 
primary responsibility for trade policy formation and implementation. 
Most of the actions by USTR, among others are under Section 301 of 
Trade Act 1974 regarding unfair foreign trade practices and Section 
182 (which is called special 301 and introduced in 1988 amendments) 
on intellectual property rights.
31
 These new laws were come into 
existing in order for United States prepare itself for world domination 
of intellectual property and enforce its own interests by coercing other 
sovereign states.
32
 This is no different from what the British 
government had done when it had dominant power. For example, 
when its trade monopoly ended with china, the British government 
pressured by Lancashire manufacturers, ship owners and other 
commercial interests to extend the monopoly through whatever means 
is necessary. Eventually through using military power the monopoly 
further extended while the Chinese government agreed to more trade 
agreements. Then after a while further agreement enforced on china, 
but this time British government aided by the French.
33
        
Section 301 is the first section under Title III, Chapter 1 of the 
Trade Act of 1974. Title III specialised for relief from unfair trade 
practices and its chapter one dedicated to enforcement of rights of 
United States and responses to certain foreign trade practices. The first 
section which is Section 301 titled ‘Actions by United States Trade 
Representative’. Originally Section 301 enacted to give the President 
the huge flexible power to solve trade disputes and also enhanced the 
President’s authority to impose sanctions unilaterally without 
observing international obligations. However, currently this 
responsibility transferred to USTR and it has final decision in cases 
                                                 
31 Marcus Noland, ‘Chasing Phantoms: The Political Economy of USTR’, International 
Organization, 51.3 (1997), 365–87 (p. 367). 
32 Drahos, ‘GLOBAL PROPERTY RIGHTS IN INFORMATION’, p. 9. 
33 Edward Goldsmith, ‘The Uruguay Round: Gunboat Diplomacy by Another Name’, 
Ecologist, 1990, 202–4 (p. 202-203). 
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Section 301 is not directly related to intellectual property rights 
but gives great power to USTR to take actions, and in fact it is 
mandatory action when “the rights of the United States under any 
trade agreement are being denied or an act, policy, or practice of a 
foreign country (i) violates, or is inconsistent with, the provisions of, 
or otherwise denies benefits to the United States under, any trade 
agreement, or (ii) is unjustifiable and burdens or restricts United 
States commerce”.
35
 Section 301 specified the authority that USTR 
has, which in reality is a very broad that includes suspension, 
withdrawal or prevention of benefits from trade agreements. 
Furthermore USTR has authority to impose duties or other import 
restrictions on the goods.
36
 Also, USTR has the right to take 
discretionary action when (1) an act, policy, or practice of a foreign 
country is unreasonable or discriminatory and burdens or restricts 
United States commerce, and (2) action by the United States is 
appropriate.
37
 Therefore, USTR has authority to take action and 
impose trade sanction and punish foreign countries and Section 301 
has given United States unilateral power to punish any foreign 
countries that threaten American interests, whether United States has 
bilateral or multilateral agreements with these foreign countries or 
simply their actions considered unreasonable, unjustifiable or 
discriminatory that restrict or burden the United States trade.
38
 Even 
though section 301 interpreted in such a way as to be applied to all 
kind of trade practice including trades related to intellectual property. 
However, to further strengthen the protection of United States 
intellectual property trades Special 301 added to the Trade Act of 
1974 in 1988. Special 301 particularly designed to protect the 
intellectual property rights.  
                                                 
34 A. Lynne Puckett and William L. Reynolds, ‘Rules, Sanctions and Enforcement under 
Section 301: At Odds with the WTO?’, The American Journal of International Law, 90.4 
(1996), 675–89 (pp. 676–77). 
35 Section 301 (a)(1)(A) &(B) Trade Act of 1974 
36 Section 301 (c)(1)(A) &(B) Trade Act of 1974 
37 Section 301 (b) Trade Act of 1974 
38 Puckett and Reynolds, p. 675. 
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The title of special 301 (section 182) of Trade Act of 1974 reads 
as “Identification of Countries That Deny Adequate Protection, Or 
Market Access, For Intellectual Property Rights”. The main purpose 
of the Special 301 as can be understood from the title is to promote the 
adequate and effective protection of intellectual property rights in 
foreign countries. This can be achieved by Special 301 (section 182) 
through using a foreseeable threat of unilateral retaliation by the 
United States to induce trading partners to reform their intellectual 
property practices.
39
 This retaliation was the result of the reality as 
stated by the United States International Trade Commission that in 
1986 alone United States companies lost between $43 and $61 billion 
due to the piracy practices abroad. The President and the Congress 
were firmly committed and ready to do everything to adequately 
protect intellectual property rights through international trade 
negotiations and revisions to the United States trade laws.
40
 Protecting 
the United States businesses and interests and satisfying the policies of 
both the president and the Congress were the reasons of enacting and 
designing the Special 301 in its current form. Base on this 
determination, Special 301 requires the USTR that within 30 days 
after submission of a report of (National Trade Estimate) to the 
President, the Committee on Finance of the Senate, and appropriate 
committees of the House of Representative,
41
 to identify those foreign 
countries that ‘deny adequate and effective protection of intellectual 
property rights, or deny fair and equitable market access to United 
States persons that rely upon intellectual property protection’.
42
 
Furthermore USTR can identify some foreign countries as ‘priority 
foreign countries’. However, some stipulations are stated in Special 
301 (section 182 of the Trade Act 1974) in those countries in order 
USTR be able to list as priority foreign countries, such as if they ‘have 
the most onerous or egregious acts, policies, or practices that (i) deny 
adequate and effective intellectual property rights, or (ii) deny fair and 
equitable market access to United States persons that relay upon 
                                                 
39 Judith H. Bello and Alan F. Holmer, ‘Special 301: Its Requirements, Implementation, and 
Significance’, Fordham International Law Journal, 13 (1989), 259 (p. 259). 
40 Bello and Holmer, p. 260. 
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 Special 301 does not stop here but 
further authorised USTR to put any states in priority foreign countries 
‘whose acts, policies or practices described in subparagraph (A) have 
the greatest adverse impact (actual or potential) on the relevant United 
States products, and that are not (i) entering into good faith 
negotiations, or (ii) making significant progress in bilateral or 
multilateral negotiations, to provide adequate and effective protection 
of intellectual property rights’.
44
  
Special 301 enacted exclusively to protect the intellectual 
property rights of United States companies and businesses in foreign 
countries. It gives a great authority to USTR to investigate in a very 
short time, much faster than investigation conducted according to 
normal section 301.
45
 USTR admitted that Special 301 has great 
impact on changing acts and policies of intellectual property rights of 
foreign countries. For example, during 1989, People’s Republic of 
China and Taiwan committed and agreed to amend their copyright 
laws that bring them into line with what is acceptable intellectual 
property rights according to the United States. Colombia also changes 
its policy regarding permission problems of motion picture and Saudi 
Arabia enacted a new patent law entirely. USTR also admitted that 
both Chile and Indonesia yield to the proposed patent law 
amendments or anew patent law including increased protection for 
pharmaceuticals. But still USTR was not satisfied and believed that 
during Uruguay Round none of the United States trading partner 
happy with the intellectual property standards proposed by U.S.
46
  
USTR did not stop by targeting developing countries only, but 
rather USTR used section 301 to put pressure on a developed country 
such as Japan in order to direct its intellectual property protection 
standards to the same of those of United States. Japanese market in 
United States was blooming and creating bad image to the United 
States economic capabilities. Therefore, public was made to 
understand that it is the United States ideas and knowledge that have 
                                                 
43 Special 301(Section 182) (b)(1)(A) Trade Act of 1974 
44 Special 301(Section 182) (b)(1)(B) & (C) Trade Act of 1974  
45 Bello and Holmer, p. 263. 
46 Bello and Holmer, pp. 265–66. 
Trips history, background, negotiation: developed and developing countries stand during negotiations 
73 
been stolen by the Japanese.
47
 Eventually, the United States 
government worked on this point and in 1984 the United States trade 
officials put pressure on Japan’s Ministry of International Trade and 
Industry to give up its proposals for a sui generis  form of protection 
for computer software.
48
 This may be the reasons why Japan stayed 




Even though section 301 and special 301 had a great role in 
assisting USTR in performing its task, but without reports and data 
from intellectual property lobbies such as International Intellectual 
Property Alliance (hereinafter the “IIPA”) and Business Software 
Alliance (hereinafter the “BSA”), USTR could not perform its duty. 
Thousands of companies are gathered to create these associations and 
they were active in countries all over the world and continuously 
feeding information to USTR. With the help of all these big 
corporations, USTR was capable of persuading ample number of 
countries, majority of them were developing countries, to enact or 
amend their intellectual property laws so that satisfy United States 
needs.
50
   
This clearly helped and put United States in advantageous 
position comparing to other countries while negotiating and 
submitting its idea at GATT. But this was not enough as some 
developed countries priority was not inclusion of intellectual property 
into the trade domain, i.e. to be part of GATT.  Therefore, United 
States had to do its best to influence its alliance within the developed 
countries and started with the most distinct group which was Quad 
group. Quad group was one of the essential groups which had great 
influence on TRIPS negotiations. Quad consisted of the United States, 
the European Community (hereinafter the “EC”), Japan and Canada. 
Sometimes the group extended to include Switzerland and Australia, 
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The intellectual Property Committee (IPC) had a great task of 
persuading the member states of Quad to have consensus plan and 
strategy while entering negotiation during GATT meetings and 
eventually overcome resistance that comes from the developing 
countries. United States was well prepared and informed. All the 
United States intellectual property associations and committees were 
continuously advising the negotiation delegation. The United States 
negotiators in comparison to other countries negotiators had gained an 
advanced expertise during bilateral and North American Free Trade 
Agreement (hereinafter the “NAFTA”). Even it was the first time for 
the GATT Secretariat to deal with the intellectual property and above 
all it was a surprise topic to be discussed in the round and other 
countries were unprepared as it was last minute inclusion,
52
 and 
considered as a very small issue in an overloaded busy agenda of the 
Uruguay Round, and it was not certain whether such a controversial 
issue will make it to the end of the round.
53
  
However, it cannot simply accept the notion that developing 
countries surrender to United States will without any resistance. In 
fact, some developing countries resisted on the issue of intellectual 
property. Both Brazil and India introduced their own proposals but 
after they were evaluated by United States associations and business 
organizations and passed their opinions to other developed countries, 
they were criticised and rejected. 
54
    
1.4 DEVELOPING COUNTRIES PERSPECTIVE TO THE TRIPS 
AGREEMENT AND ITS SHAPING 
Developing countries were targeted by developed countries and 
especially by United States in all of the bilateral, regional and 
consequently at international level (GATT/WTO). United States did 
its best to enforce its intellectual property terms through section 301 
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and special 301 of Trade Act 1974. USTR through its power greatly 
influenced and directed the agreements to satisfy United States 
businesses and government. Started with the bilateral agreements, then 
to regional agreements and finally at GATT. This process considered 
to be an economic coercion and the only effective way to enforce 
other states to comply with United States intellectual property 
objectives. The process was supported and assisted by multinational 
corporations and believed that it’s the necessary coercion to limit the 
theft of United States technology and profits.
55
 Transnational 
corporations already controlling almost every aspect of trade in the 
world and through the GATT they wanted to control other areas as 
well.
56
 But in the same time developing countries had different 
opinions regarding intellectual property rights and standards. 
Distinction between developed, developing and least-developing 
countries is necessary while discussing the TRIPS agreement. The 
agreement has given some privileges to developing and least 
developing countries. 
57
 For example, Article 65, 66 and 67 of part VI 
of the TRIPS agreement which regulate the transitional arrangements, 
clearly mentioned the developed, developing and least-developed 
countries, and assigned some privileges and duties on them. 
Therefore, in order for countries to benefit from these privileges, they 
have to be categorized in the developing or least-developing countries. 
Even though the WTO does not have an official list of separating 
countries based on their developments because WTO does not have 
any definition of what constitute the developed, developing and least-
developing countries. Therefore, every country can claim to be a 
developing country so that benefit from the privileges, however, this 
claim can be contested by other members. 
58
    
There are many factors that can be looked at in order to identify 
the developing and least-developing countries. Even though every 
country does continuously develop from one state to another. But as a 
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general rule those countries with limited economic and social 




There are other specific indications which can be relied upon in 
determining the development status of a country. For example United 
Nations Development Programme has a Human Development Index 
(hereinafter the “HDI”), that rely on some factors such as 
Demography, Education, Environmental Sustainability, Gender, 
Health, Human Security, Income/Composition of Resources, 
Inequality, Mobility and Communication, Poverty, Trade and 
Financial Flows, Work, Employment and Vulnerability.
60
 The World 
Bank also stated long list of indications in order to categorize 
countries which they are Agriculture & Rural Development, Aid 
Effectiveness, Climate Change, Economy & Growth, Education, 
Energy & Mining, Environment, External Debt, Financial Sector, 
Gender, Health, Infrastructure, Poverty, Private Sector, Public Sector, 
Science & Technology, Social, Development, Social Protection & 
Labour, Trade and Urban Development.
61
  
However, United Nations’ Development Policy and Analysis 
Division uses three main criteria of income, human assets and 
economic vulnerability, while making recommendations on the 
inclusion and graduation of eligible countries from the list of least 
developed countries.
62
 Therefore when a country claims to be a 
developing or least developing country can rely on these organizations 
and their factors and indications to prove its claim. 
Almost all developed countries in European continent and even 
the United States used patent in the past mainly as a means to 
encourage local development and industrialization. The enactment of 
patent law and its amendments were always done in the light of 
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national economic and social issues. In the same way the developing 
countries such as India and Brazil wished and successfully followed 
the same footstep in order to enhance their local industrializations and 
solve their shortcoming especially in the area of health care. 
Introducing patent to the area of trade was for the first time 
experienced by WTO (GATT) in order to enhance trade. This will be 
great if simultaneously enhance local industrialization and address 
local issues. Another factor that elevated and standardized the patent 
in the developed countries was time. The patent regimes that they are 
practicing today were the process of progressing through time, for 
example patent regime is the United States took almost 300 years to 
be standardized. Enforcing new standard of patent regime for under 
developed countries within a short frame of time will not always 
correlate with national development questions.
63
  
Although majority of countries were of the opinion that 
intellectual property protections are necessary for promotion of further 
innovation, but they differ on what, how and how much to protect. 
Developing countries of the opinion that variation to intellectual 
property law is fundamental for them to stay on the path of 
development.
64
 Due to the economic crises and social situations, for 
example both India and Brazil are suffering from poverty and a high 
incidence of AIDS,
65
 the developing countries in Group Ten could not 
accept all the conditions set forth by developed countries and therefore 
resisted the GATT forum, but United States through its policy of 




During the TRIPS negotiations many groups were established 
which some consisted only the developed countries such as Quad 
Group or only the developing countries such as Andea Group and 
others a mixture of the developed and developing countries such as 
the 10+10 Group and Group 11. The most important groups were 
those groups that included developed countries such as the United 
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States, the European Community, Japan and Canada. The TRIPS 
agreement was the product of the opinions and proposals of those 
groups that consists these developed countries rather than those 
groups that included the developing countries. Least developing 
countries were ignored and not included in any important groups.
67
  
The group of ‘Friends of Intellectual Property’ was another 
important group that formed during Punta del Este and its main 
purpose was to make sure that intellectual property considered as a 
trade related issue. Once the Quad members agreed on an issue and 
reached consensus, Friends Group was used as a path to take the 
consensus forward further. Friends Group was a medium of exercising 
negotiation among developed countries. Negotiators learned from 
each other and developed the idea of what to expect from negotiations 
and what to be negotiated. This led to build a consensus among 
developed countries on intellectual property so that be able to control 
any resistance that comes from developing countries.
68
 
From January 27 to July 31 of 1986 the Preparatory committee 
met formally in nine meetings. A group of ten developing countries 
that consist of India, Brazil, Argentina, Cuba, Egypt, Nicaragua, 
Nigeria, Peru, Tanzania and Yugoslavia, which they were led by India 
and Brazil, insist that comprehensive code on intellectual property 
should not be discussed within GATT. These countries firmly insisted 
that subjects of trade in services, intellectual property rights and 
investment should not be addressed.
69
  
In May 1990 another group of developing countries that included 
Argentina, Brazil, Chile, China, Colombia, Cuba, Egypt, India, 
Nigeria, Tanzania, Uruguay, Pakistan and Zimbabwe started to 
actively participate in the negotiation process of the TRIPS 
Agreement by submitting their own detailed proposal. In their 
proposal they wanted to emphasize on procedures and remedies 
against trade in counterfeit and pirated goods, in the same time tried to 
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minimize the high standards of intellectual property rights that 
developed countries were demanding. The developing countries were 
also focused on the importance of public policy objectives on national 
intellectual property rights and respect and safeguard national legal 
system and traditions on intellectual property rights in light of 
different level of development of each country.
70
  
These countries complained a lot because many comprehensive 
and extensive proposals on intellectual property rights submitted by 
developed countries. Many other documents also submitted by GATT 
Secretariat and WIPO that related to connection between GATT 
norms and intellectual property, intellectual property treaties and 
international standards. India and Brazil as leading countries were put 
on priority watch list and others placed in watch list. Despite all these 
pressures India and Brazil continued on their objections throughout 
the negotiation process. They believed each country is in a different 
state of development and as a sovereign state should be given a 
freedom of setting minimum standards of intellectual property 
accordingly. In fact, the developing country negotiators in an attempt 
to create a strong front line of resistance had met in February 1989 in 
the resort of Talloires in France.  The developing countries knew that 
they cannot individually face the pressures from the developed 
countries and in particular the United States. However, since there was 
no enough cooperation among the developing countries and India as a 
leading country failed to attend informal Third World Group meeting 
in April 1989, the alliance falls apart. Not to forget that the developing 
countries were each individually targeted by the United States through 
its sections of 301 and special 301, and bilateral treaties, especially 
Brazil. United States multinational corporations heavily presented in 
Brazil and by targeting and imposing sanctions on wide range of 
Brazilian goods, showed how United States private sectors serious 
about their goals in reaching the standards of intellectual property 
rights they desire. Also, the GATT Secretariat continuously pressured 
the developing countries through the Green Room process. Group 
discussion in the Green Room grew smaller and key countries were 
participated and exchange consultations. This made the developing 
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countries negotiators call the process the Black Room consultations. 
Eventually, by 1990 onwards the discussions and negotiations were 
focused on how far the final draft of TRIPS agreement deviate from 
the original proposal submitted in 1988 by Pfizer, IBM, DuPont and 
other members of the international business community. Then the 
battle on the language of the TRIPS agreement starts as every country 
wanted the language to be construed in the way that describe the deals 
favours by the country. If a particular issue is not in their favour, the 
negotiators try to construct the article in an ambiguous language so 
that to be able to open a backdoor exit and be able to run away from 
responsibility of that particular issue. But it was a difficult task for 
negotiators as they all entangled in a complex web of relationships. 
Every negotiator was considered insider for some groups and outsider 
for others. Furthermore, some negotiators were fulfilling the wish of 
their countries, which they have other ambitions. For example, South 
Korea did not support India and Brazil fully because South Korea was 
trying to join the Organization for Economic Co-operation and 





From the historical perspective and negotiation process of 
creating the TRIPS Agreement, it can be concluded that the TRIPS 
Agreement as an international agreement did not come into existence 
for the benefits of all countries equally. During the process many 
coercion mechanisms implemented by developed countries and in 
particular the United States of America. The developing countries 
were aware of this fact but accepted the agreement partially because 
they did not have any choice but submit to the will of developed and 
industrialized countries, and also hoping to gain some advantages 
from joining the WTO. 
 
 
                                                 






2 NATURE, SCOPE, OBJECTIVES 
AND PRINCIPLES OF THE 
TRIPS AGREEMENT 
2.1 INTRODUCTION 
The TRIPS Agreement like many other international conventions 
and agreements established for certain purpose and has its own 
specific nature and scope of obligations, objectives and principles. In 
order to understand the nature, purposes, scopes, objectives and 
principles of the TRIPS Agreement, one has to look at the provisions 
and articles of the TRIPS Agreement as they create obligations upon 
the member countries to implement them. Even though there is one 
particular provision in the TRIPS Agreement that dedicated for 
clarifying the objectives of the Agreement, but still there is a debate in 
regard to what is the main objective of the TRIPS Agreement. Critics 
believe that the main objective of the TRIPS Agreement is to enhance 
the protection of intellectual property, however this is considered as a 
common misunderstanding by Nuno Pires de Carvalho. NP de 
Carvalho believes that “the main - if not the only - objective of the 
TRIPS Agreement as well as that of the whole WTO Agreement is to 
promote free international trade”.
72
 Principle of an agreement is 
considered to be a central part of the system by being the spirit of the 
whole agreement and represent the different rules that create one 
single agreement. If not for the principles of the TRIPS Agreement the 
social, environmental and economic aims of the WTO and TRIPS 
Agreement may be jeopardised by the scope of the intellectual 
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 In this part the objectives and principles of the 
TRIPS Agreement will be discussed after looking at the purpose, 
nature and scope of the obligations of the Agreement. 
2.2 PURPOSE, NATURE AND SCOPE OF THE TRIPS AGREEMENT 
The TRIPS Agreement states minimum standard of intellectual 
property rights through rules and principles in order to ensure 
protection of the rights. It is considered to be the most comprehensive 
agreement in the international level compare to other agreement in the 
area of intellectual property rights.
74
 The scope of such rights defined 
through the articles of the agreement by conferring rights to the title 
holders. Rights in the TRIPS Agreement considered to be negative 
rights in the sense that it is required from others not to deal with the 
protected subject matters without permission from the right holders.
75
  
2.2.1 Purposes and Objectives of the TRIPS Agreement 
According to the Preamble 
There are two main purposes and objectives that can be deduced 
from the Preamble which are consistent with the foundation of the 
WTO. First; presenting the intellectual property protection in a better 
way that reduce distortions and impediments to international trade. 
And second; recognition of intellectual property rights as private 




It is not necessary that all international agreements and 
conventions relating to intellectual property have a preamble, for 
example some of those agreements tabled by the United States of 
America and the European Community. Before 1990 having Preamble 
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in the current form was not considered to be useful.
77
 The Preamble 
does not have same legal power as those of the Articles and it is not 
considered to be creating specific rights and obligations. However, it 
can be referred to while interpreting the provisions of the TRIPS 
Agreement.
78
 Not all the Article of the TRIPS Agreement are clear 
enough to avoid interpretation. Some of the articles may carry more 
than one meaning and can be interpreted in more than one ways, 




The TRIPS Agreement in the first sentence of the Preamble states 
that members ‘Desiring to reduce distortions and impediments to 
international trade’ and this is directly connected to the intellectual 
property when the next part of the paragraph of the Preamble states 
that ‘taking into account the need to promote effective and adequate 
protection of intellectual property rights, and to ensure that measures 
and procedures to enforce intellectual property rights do not 
themselves become barriers to legitimate trade’. This proves that 
according to the TRIPS Agreement there is a strong connection 
between intellectual property rights and international trade. The 
existence of such connection was due to the attempts by the United 
States of America and United States’ big corporations to include the 
trade-related aspects of intellectual property rights as one part of 
negotiation in the Uruguay Trade Round which was launched by 
Ministerial Declaration in 1986.
80
 Despite the efforts of developing 
countries or less developed countries to stop this attempt but still 
made it to the Uruguay Round. Even though some analysts are of the 
opinion that the TRIPS Agreement was discussed in wrong place as it 
is not about the free trade but rather creating new domestic rules and 
                                                 
77 Peter-Tobias Stoll, Jan Busche, and Katrin Arend, WTO: Trade-Related Aspects of 
Intellectual Property Rights (BRILL, 2009), p. 65. 
78 Stoll, Busche, and Arend, p. 67. 
79 Resource Book on TRIPS and Development, ed. by United Nations Conference on Trade 
and Development, International Centre for Trade and Sustainable Development, and 
UNCTAD-ICTSD Project on IPRs and Sustainable Development (Cambridge; New York: 
Cambridge University Press, 2005), p. 10. 
80 Drahos, ‘Developing Countries and International Intellectual Property Standard-Setting’, 
p. 769. 
SAMAN ABDULRAHMAN ALI 
84 
regulations, and legal regimes.
81
 However, by relating intellectual 
property rights to free trades, the TRIPS Agreement is recognizing the 
same purpose that stated in the Preamble of the WTO Agreement 
‘substantial reduction of tariffs and other barriers to trade and to the 
elimination of discriminatory treatment in international trade 
relations’. It was the same interest that the GATT of 1947 was 
founded on, which was ‘liberalization of international trade’.
82
 Trade 
in this context refer to both areas of trade of the WTO which they are 
trade in goods and in services.
83
 
The TRIPS Agreement is part of the WTO (GATT) and therefore 
it is concentrated only on those parts of intellectual property rights 
that their protections considered to be distortions and barrier to trade. 
Those areas that the parties to the GATT considered were trade related 
aspects of intellectual property rights such as copyright and trade 
related parts, with some other areas of industrial property that have 
independent Articles within the TRIPS Agreement which are; 
trademarks, geographical indications, industrial designs, patents, and 
layout designs (topographies) of integrated circuits. Some other areas 
that related to industrial protection but not given an independent 
Articles but joint with other areas, and they are protection of 
undisclosed information and plant varieties. Protection of undisclosed 
information though mentioned in Section 7 of Part II of the TRIPS 
Agreement but in Article 39.1 of the TRIPS Agreement it is stated that 
undisclosed information is merely to give ‘effective protection against 
unfair competition as provided in Article 10bis of the Paris 
Convention (1967)’. Plant varieties also mentioned in Article 27.3 (b) 
within Section 5 of Part II of the TRIPS Agreement which dedicated 
for patents. According to the said article plant varieties shall be 
protected by the member countries through patent or an effective sui 
generis system as an alternative patent protection or sui generis 
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system can be combined with patent protection.
84
 Therefore, it 
becomes clear that the reason behind the words of the first paragraph 
of the Preamble of the TRIPS Agreement that international trade 
considered as an important element in the TRIPS Agreement and 
concentration will be on those intellectual property rights that their 
measures and procedures of enforcement will not lead to barrier to 
international trade.    
The first paragraph of the Preamble did not neglect the 
requirement in which the TRIPS Agreement established for 
essentially, in the first paragraph of the Preamble while concentrating 
on trade the members should take ‘into account the need to promote 
effective and adequate protection of intellectual property rights’. This 
is an acknowledgement that effective and adequate protection of 
intellectual property rights is necessary in every individual country in 
order to have free international trade with reduced distortions and 
impediments. In case these effective and adequate protection is absent, 
then it is believed that distortions and impediments subsequently 
occur in international trade and achievements of individuals and 
corporates will be abused as well, while investments will lead astray. 
Therefore, it is not the high standard of intellectual property right or 
its effective and adequate protection that threatens the international 
trade, but the abuse of such rights will do. This is an opinion that 
harmonization of strong intellectual property protection is necessary 
and should be an important objective of the TRIPS Agreement. Other 
abuses of intellectual property rights can be found in other places in 
the TRIPS Agreement such as Article 8.2 and Article 40. Article 8.2 
states that it is necessary to prevent any abuse of intellectual property 
rights by right holders through needed measures by the TRIPS 
Agreement member countries. Such measures can be adopted ‘to 
prevent the abuse of intellectual property rights by right holders or the 
resort to practices which unreasonably restrain trade or adversely 
affect the international transfer of technology’. Article 40 of the 
TRIPS Agreement concentrates on anti-competitive practices that 
relate to intellectual property rights. Therefore, any abuse in practice 
of intellectual property rights that have adverse effect on competition 
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As Article 31.1 of the Vienna Convention in regard of 
interpretation of treaties stated that ‘A treaty shall be interpreted in 
good faith in accordance with the ordinary meaning to be given to the 
terms of the treaty in their context and in the light of its object and 
purpose’, therefore the Preamble serves as a purpose of interpretation 
since the Preamble identifies the object and purpose of the TRIPS 
Agreement. This further strengthened by the Doha Declaration on the 
TRIPS Agreement and public health,
86
 as in paragraph 5 (a) states that 
the provisions of the TRIPS Agreement shall be read with the purpose 
and object of the TRIPS Agreement and especially objectives and 
principles. This clearly refers to the Preamble and Articles of 7 and 8 
of the TRIPS Agreement. Even though its believed that the provisions 
of the TRIPS Agreement cannot be further broadened or narrowed in 
the light of the Preamble and Article 7 and 8, because any alterations 
would mean a new negotiation on what have already agreed on.
87
    
2.2.2 Need for New Rules and Disciplines  
The second paragraph of the Preamble is concerned with passing 
new rules and disciplines that are needed to accomplish the objectives 
of the first paragraph. In the second paragraph five subparagraphs 
numbered in which the new rules and disciplines should be regulated 
for accordingly. The first one is Subparagraph (a) that states ‘the 
applicability of the basic principles of GATT 1994 and of relevant 
international intellectual property agreements or conventions’. There 
are some important principles in the GATT 1994 which they are 
national treatment, most favoured nation, transparency and 
sovereignty,
88
 which the TRIPS Agreement needs to abide by. Since 
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the TRIPS Agreement is integral part of the GATT/WTO, therefore 
it’s understandable that comply with the GATT’s principles. In many 
situations the Panels and Appellate Body have referred to the 
principles and previous GATT jurisprudence in cases of the TRIPS 
Agreement.
89
 Nonetheless, the question to what extent the GATT 
principles apply in the TRIPS Agreement is not clear yet, though these 
principles should not undermine the TRIPS Agreement. However, 
subparagraph (a) goes further than the GATT principles and requires 
the integrity to the applicability of other intellectual property 
agreements and conventions, such as Berne Convention,
90
 Paris 
Convention and the Washington Treaty.
91
 
In subparagraph (b) new rules and disciplines should be regulated 
concerning ‘the provision of adequate standards and principles 
concerning the availability, scope and use of trade-related intellectual 
property rights’. The requirement of adequate standards and principles 
is necessary in order to balance the protection rights of the right 
holders and the interest of public and users in general. It was not the 
intention of the negotiators to impose highly standards form of 
protections, but it was the adequate standards and principles that are 
enough to achieve the objective of the TRIPS Agreement as stated in 
the first paragraph of the Preamble, which is to reduce distortions and 
impediments of international trade.
92
 Then what constitutes adequate 
standards and principles is a matter of opinion, as what may be an 
adequate standards and principles for the developed countries many 
not be the same for less developed countries, and this may change 
through times as well. The developed countries have changed their 
standard of protection through times and during their development 
stages. However, the TRIPS Agreement states minimum standard of 
protection and requires from the member countries to incorporate 
these minimum standards that put forth in the Agreement into their 
national legal system. This has been considered as the highly criticised 
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aspect of the TRIPS Agreement because ‘one size does not fit all’ 
notwithstanding some limited period of transition given by part VI of 
the TRIPS Agreement.
93
     
Subparagraph (c) emphasis on ‘the enforcement of trade-related 
intellectual property rights, taking into account differences in national 
legal systems’. The Preamble wanted to stress on another important 
point as well which is the element of enforcement of the TRIPS 
Agreement that cannot be found in the previous conventions on 
intellectual property rights. This was one of the important point that 
United States of America and other developed countries emphasised 
on during the negotiation because according to them the previous 
conventions such as Paris Convention and Berne Convention lacked 
effective binding enforcement method to deal with non-compliance 
member countries. For this reason, these conventions were called teeth 
less convention by the developed countries.
94
 However, the second 
part of this subparagraph added an important element to the 
enforcement measure which is considering the differences in national 
legal systems. This brings flexibility to the enforcement measure.
95
 
Because this gives an opportunity to the member countries as to how 
implement the obligations required by the TRIPS Agreement.
96
  
In fact, subparagraphs (d) and (e) mention two important and 
necessary points to the developed and developing countries 
respectively. Developed countries were supporting the high standards 
of minimum protection and enforcement provisions, therefore in the 
case of any disputes arising from non-compliance should be resolved 
according to the multilateral procedures of the WTO.
97
 Article 64 of 
the TRIPS Agreement states that ‘The provisions of Articles XXII and 
XXIII of GATT 1994 as elaborated and applied by the Dispute 
Settlement Understanding shall apply to consultations and the 
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settlement of disputes under this Agreement except as otherwise 
specifically provided herein’.    
Since the provisions of the TRIPS Agreement require very 
extensive legislative and administrative measures that are above the 
capacity of less developed countries, hence, it provides for transitional 
arrangements in subparagraph (e) to help those countries in order to be 
able to implement the minimum standard protections of the TRIPS 
Agreement. In two occasions the transitional period extended. The 
first time was on 27 June 2002 when the Council for the TRIPS 
Agreement extended the transitional period until 2016 for least 
developed country members in regard pharmaceutical products. The 
second time was on 19 November 2005 in the same way the 
transitional period was extended for least developed countries until 1 
July 2013 in regard the applicability of the whole TRIPS Agreement.
98
   
There are four more paragraphs in the Preamble that recognize 
important points, such as dealing of international trade in counterfeit 
in paragraph three, as this was the wishes of United States of America 
with the support of EC. Then, the Preamble recognizes the intellectual 
property rights as private rights in the fourth paragraph. This was 
included in order to reaffirm that the matters of intellectual property 
rights should be left for private parties to deal with, though the TRIPS 
Agreement in some occasion allowed the interference of states 
particularly in cases of criminal sanction or balancing the public rights 
and rights of intellectual property right holders.
99
 The importance of 
this paragraph is that it gives rights holders to take burden of their 
rights and be able to defend their rights without necessity of states 
interference and taken action of ex officio.
100
  
The fifth paragraph recognizes an important element which is 
‘Recognizing the underlying public policy objectives of national 
systems for the protection of intellectual property, including 
developmental and technological objectives’. Implementation of high 
standard of intellectual property rights may cause great changes to the 
national systems and policies especially to the less developed 
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countries. In this regard the Preamble recognizes some flexibilities 
and taking into account the public policy objective of national 
systems.
101
 However, others considered this to be more restrictive than 
what applied in many countries, because the public policy objectives 
here limited to ‘national systems for the protection of intellectual 
property’ and not national systems of other areas that may be affected 
by the high standard protection.
102
  
The sixth paragraph recognizes another important element of 
maximum flexibility for the least developed country members. This 
allows the TRIPS Agreement provisions interpreted more flexible in 
favour of least developed countries. In the contract law usually, the 
terms of an agreement are interpreted in the interest of the weaker 
party when circumstances warrant it. This kind of maximum 
flexibility are permitted in the implementation of domestic laws and 
regulation when it serves a sound and viable technological base as 
required the by the sixth paragraph.
103
 
The seventh paragraph emphasizes on the importance of reducing 
tensions and resolving dispute settlement through multilateral 
procedures. This was emphasized on the request of the developing 
countries in order to prevent the developed countries from taken 
bilateral threats and enforcement measure.
104
 Because it is common 
that developed countries use bilateral agreement in order to impose 
their conditions on the developing countries. For example, United 
States of America has done these many times through bilateral 
agreements and using section 301 of the United States Trade Act as a 
weapon against the targeted countries by the USTR to impose what 
United States think a fair practice of intellectual property rights and in 
case of failure of the bilateral agreement imposing sanction is the next 
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The last paragraph of the Preamble desires to establish the 
relationship between the WTO and the WIPO and other relevant 
international organizations. Originally the developing countries were 
resisting the idea of adopting intellectual property rights within the 
GATT forum, because WIPO as part of the United Nation is best 
organization that specialist in the intellectual property rights and not 
the GATT. However, this attempt was not successful, then it was 
requested that the WIPO should be fully associated in activities of 
fields related to intellectual property in the GATT forum. But at the 
end WIPO served as an observer and help the negotiation parties 
during the process of creating the TRIPS Agreement. In 1995 a 
cooperation agreement between WIPO and WTO signed and the 
outcome was stated in Article 63.2 of the TRIPS Agreement which is 
the common registry for notifying laws and regulations. Even though 
the Preamble mentions WIPO by name but does not disregard the role 
of any other relevant international organizations that regulate 
intellectual property rights such as UNESCO.
106
   
2.2.3 Nature and Scope of Obligations 
Article 1 of the TRIPS Agreement mentions nature and scope of 
obligation of the TRIPS Agreement which consists of three clauses. 
The first sentence of Article 1.1 obligates all member countries to give 
effect to the provisions of the TRIPS Agreement through laws and 
regulations. This means that the TRIPS Agreement is not self-
executing, and the minimum standards provided for in the TRIPS 
Agreement have to be given effect by the member countries within 
their jurisdictions,
107
 because there are differences between 
international rights and obligations and their direct applicability. In 
order for international agreements to have domestic validity and apply 
directly, must not include and have any conditions such as 
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requirement of implementation through domestic legislations as it is 
the case of the TRIPS Agreement. Some influential market players 
such as United States of America, the European Community and 
Japan did not accept direct applicability of WTO Agreements and this 
led to other countries to follow the same system. Even though some 
other Member countries such as Australia and Spain accepted direct 
applicability of some provisions of the TRIPS Agreement. Other 
countries if in principles do not accept the direct applicability, then 
has to be done though domestic legislations.
108
  
The TRIPS Agreement does not state any procedures on how the 
process of effective implementation carry out by the member 
countries for the fact that some provisions can be applied directly as 
Article 31 and others only stating minimum standards or offer choices 
between two options as Article 34.1. The important element in the 
first sentence of Article 1.1 of the TRIPS Agreement is that provisions 
of the agreement has to be given an effect that can really operate and 
not only transposing the provisions into national laws and 
regulations.
109
 It does require, however, from the member countries to 
change their national laws and regulations and any other 
administrative procedures that are necessary to give effect to the 
provisions of the TRIPS Agreement and reasonable measure have to 
be taken in order to ensure consistency between national legislations 
and the TRIPS Agreement.
110
 This makes the implementation of the 
TRIPS Agreement very difficult especially for the developing 
countries because the implementation requires reform in many 
domestic legislations, if not all of them, that relate to intellectual 
property laws in a very short period of time.
111
  
The second sentence of Article 1.1 of the TRIPS Agreement gives 
opportunity to member countries to implement more extensive 
protection than the minimum standard which is required in the TRIPS 
Agreement. For example, Article 33 states that the period of 
protection of patent shall not be less than 20 years from the filing date 
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of the application. Therefore, member countries are allowed to 
increase and extend this period. This leads to creating TRIPS plus 
measure which can be implemented through national public policy 
and unilaterally or through bilateral and regional agreements. Since 
the TRIPS Agreement does not prevent TRIPS plus measures by the 
member countries, some developed countries such as the United States 
of America, the European Union and European Free Trade 
Association have signed numerous free trade agreements with 
developing countries especially in the area of patents.
112
  
As of mid-2017 the WTO has received 659 notifications of 
‘Regional Trade Agreements’ and 445 of them are in force.
113
 For 
example, the Community of Andean Nations (hereinafter the “CAN”) 
and the Mercado Comun del Sur (hereinafter the “MERCOSUR”), 
which have been notified to the TRIPS Council. And examples of 
bilateral trade agreements are United States-Jordan and United States-
Chile.
114
 This negative form ‘Members may but shall not be obliged’ 
was originally the idea of United States and European Community 




In the other hand, however, the second part of the second sentence 
of Article 1.1 requires that any implementation of more extensive 
protection should not contravene the provisions of the TRIPS 
Agreement. In other words, implementation of any TRIPS plus laws 
and regulation has to be consistent with actual regulations stipulated in 
the TRIPS Agreement. Strictly reading the words of Article 1.1 may 
lead to the believe that the TRIPS Agreement does not favour of 
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creating TRIPS plus measures through enforcing member countries to 
implement TRIPS plus measures in their national laws. Nevertheless, 
while reading Article 1.1 in conjunction with Article 71.2, it becomes 
clear that multilateral agreements are permitted by the TRIPS 
Agreement that contains higher standards of protection.
116
     
The last sentence of Article 1.1 of the TRIPS Agreement provides 
flexibility to member countries in regard to method of 
implementations as it states that ‘Members shall be free to determine 
the appropriate method of implementing the provisions of this 
Agreement within their own legal system and practice’. Member 
countries are free to choose an appropriate method; however, this can 
be challenged by other member countries in front of a dispute 
settlement panel or the Appellate Body which they can review 
whether it was the best appropriate method within the legal system 
and practice of the member country in question. Then it is the duty of 
the member country to show that it was the best and most suitable 




Article 1.2 of the TRIPS Agreement determines the scope of the 
TRIPS Agreement and defines what the term ‘intellectual property’ 
refers to. Article 1.2 states that all subject of Sections 1 to 7 of Part II 
of the TRIPS Agreement are categorized as intellectual property. 
Those sections are titled according to their type of intellectual 
properties, which they are Copy Right and Related Rights, 
Trademarks, Geographical Indications, Industrial Designs, Patents, 
Layout-Designs (Topographies) of Integrated Circuits, Protection of 
Undisclosed Information and Control of Anti-Competitive Practices in 
Contractual Licences. This is the limitation of the scope of the TRIPS 
Agreement to these categories only and limiting the subject matter 
scope of intellectual property as well. Even within each headings of 
Section 1 to 7 of Part II there may be other subject matters that 
traditionally not considered to be within the headings, such as sui 
generis plant variety protection under section 5 on patents. However, 
since the categories of sections 1 to 7 of Part II are not precise enough 
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and under Article 1.1 the member countries are free to choose the 
method of protection of the subject matters. Therefore, it will be left to 
the member countries to give the subject matters a title, and what title 
will be considered as an intellectual property and to determine the 
scope of intellectual property according to their own legal system.
118
  
2.2.4 Eligibility for Protection under the TRIPS Agreement 
According to Article 1.3 of the TRIPS Agreement nationals of 
other member countries and custom territories should be given same 
treatment as their own nationals, whether it be a natural or legal 
person as stated in footnote number one of Article 1.3. This is the 
same as the principle of non-discrimination in the traditional trade-
based system, which according to this principle foreign national must 
not be given less favourable than its own nationals.
119
 The footnote 
number one further states that even a natural or legal person ‘who 
have a real and effective industrial or commercial establishment in 
that customs territory’ will be treated as nationals of member countries 
of the WTO. The meaning of the word ‘nationals’ is not defined in the 
TRIPS Agreement; therefore, it has to be interpreted in the way that 
accords with the public international laws. In addition to that the 
intellectual property rights are considered private rights as provided 
for by the Preamble of the TRIPS Agreement, therefore such private 
rights can be owned by States or any part or agency of the States as 
long as they hold those intellectual property rights that covered by the 
TRIPS Agreement.
120
 Furthermore, the TRIPS Agreement in the 
second sentence of Article 1.3 states that nationals of Member 
countries of other international conventions that regulate intellectual 
property rights will be considered as nationals of member countries of 
the TRIPS Agreements and will get benefit from the disciplines of the 
TRIPS Agreement.
121
 The international conventions that listed in this 
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provision are the Paris Convention (1967), the Berne Convention 
(1971), the Rome Convention and the Treaty on Intellectual property 
in Respect of Integrated Circuits. It can be concluded that the word 
‘nationals’ has been given very wide meaning in order to protect 
intellectual property rights as private rights of very wide ranges of 
persons, whether at international or domestic levels, or natural or legal 
persons as long as they hold intellectual property rights in those areas 
mentioned in the TRIPS Agreement.   
2.3 OBJECTIVES OF THE TRIPS AGREEMENT 
The TRIPS Agreement contain one article which is titled the 
‘Objectives’ (Article 7 of the TRIPS Agreement) and ordinarily 
should represent the objectives of the whole Agreement. The content 
of the Article was proposed by twelve developing countries to the 
Uruguay Round Negotiating Group, however, the original proposal 
was under the title ‘Article 2 Principles’ of the Anell Draft.
122
 
Paragraphs 1 and 3 of the original proposal of Article 2 of the Anell 
Draft summarised into Article 7 of the TRIPS Agreement. Main 
purpose for the insertion of Article 7 of the TRIPS Agreement was the 
concerns of the developing countries that the TRIPS Agreement and in 
particular the standard protections of patents should be in a manner to 
have positive effect on advancing their technological and economic 
development, and social welfare.
123
 The developing countries were 
worried that the objectives of the TRIPS agreement are directed only 
toward the strong protection of the intellectual property rights by 
developed countries.
124
 To the developing countries the wordings of 
Article 7 of the TRIPS Agreement will balance between rights and 
obligations and their interests will be taking into account, even though 
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it’s mainly concentrated on technology related intellectual property 
rights.
125
 However, the majority of the developed countries’ proposals 
were mainly concentrated on general statement of intent and do not 
coincide with the spirit of the Articles of the TRIPS Agreement. 
Nevertheless, articles of the TRIPS (including Articles 7 and 8) should 
be given greater importance during implementations and 
interpretations.
126
      
Even though the heading of Article 7 particularly states 
‘Objectives’ but the objectives of the TRIPS Agreement cannot be 
limited to Article 7 alone, but rather has to be read with Article 8 and 
the Preamble of the Agreement. For this reason, some scholars such as 
NP de Carvalho are of the opinion that Article 7 is misplaced as it’s 
more accurately related to Patent. Therefore, it should have placed in 
Section 5 (Patents) of the Part II or in the Preamble with the 
Paragraphs 5 and 6 (development objectives).
127
 Article 7 can strongly 
be associated with Patent because the wordings of the Article which 
has some phrases such as ‘technological innovation’, ‘technological 
knowledge’, and the word ‘technology’. All these words indicating 
that the developing countries were mostly concerned with the Patents 
and its impact on their countries.
128
  
Even though the wordings of the Article 7 start with ‘The 
protection and enforcement of intellectual property’ but since it’s 
linked with technical innovation, therefore it applies to those 
provisions of intellectual property rights that involve technical 
innovations only. This means that Article 7 only applies to patents and 
trade secrets as in wider sense may involve technical innovation and 
knowledge even though they cannot be patented. Other areas of 
intellectual property rights such as copyrights and related rights, 
trademarks, geographical indications and industrial designs cannot be 
placed under the umbrella of Article 7 as titled the objectives of the 
TRIPS Agreement. However, it can be argued that the phrase of 
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‘promotion of technical innovation’ is very wide and not necessarily 
limited to the area of patentable inventions. Technical invention is 
considered as only one early stage of the innovation. The innovation 
process may lead to enhancement of existing or creation of new 




Other commentators also are of the opinion that the last two 
phrases of Article 7 of the TRIPS Agreement that read ‘in a manner 
conducive to social and economic welfare’ and ‘to a balance of rights 
and obligations’ have emphasis on wider areas and can apply almost 
to all types of intellectual property rights. Developing countries gave 
up on resisting insertion of protection and enforcement of high 
standards of intellectual property rights in the GATT, which 
apparently all were in favour of developed countries. However, the 
developing countries wanted to make sure that in return the high 
standard of protection, especially in the area of Patent, has some 




This idea of creating link between intellectual property rights’ 
protection and their promotion of social and economic and 
technological development that exist in Article 7, with other ideas in 
the Preamble and Article 8 are originally taken or inspired by those of 
the Draft International Code of Conduct on the Transfer of 
Technology which was negotiated under the umbrella of UNCTAD 
but never became an international instrument.
131
 The wording of 
Article 7 and 8 (objectives and principles) cannot be found in other 
intellectual property international instruments such as Paris 
Convention and Berne Convention.
132
 This becomes clear that this 
idea is not new and the developing countries always wanted some 
benefits in exchange for their compliance to the high standards of 
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protection of intellectual property rights and they wanted this to be 
presented in an international instrument. 
2.3.1 Balance Between Rights and Obligation of Intellectual 
Property Holder 
According to the last part of Article 7, developing countries have 
the right to object the exclusive rights of the right holders if failed to 
use their innovation actively to benefit the social and economic 
welfare of the country or failed to perform their obligations while 
enjoying their rights. However, the developing countries have to be 
careful in balancing between intellectual property right holders’ 
interests in form of fair returning of compensation for their 
innovations and those of the users and public in general. The reason is 
that if the balance tilted towards the interest of users and public, the 
inventors are not spending much efforts of time and money in their 
innovations and this counterproductive process will not be in favour of 
the developing countries and their public.
133
  
It is also well established that enforcement and protection of 
intellectual property rights has a higher purpose of benefiting society 
as a whole and not just protecting the interests of specific individual or 
group rights. Article 7 of the TRIPS Agreement clearly stated that ‘the 
protection and enforcement of intellectual property rights should 
contribute…to the mutual advantage of producers and users of 
technological knowledge’, which means that the protection and 
enforcement should have equal impact and benefit to both of the users 
and producers. All the privileges that contributed to the individuals 
and groups were with the purpose of providing further benefits to 
society in general. This apply to both developed and developing 
societies, but specifically in less developed societies as they are 
considered mostly users of technology and not producers of 
technology. Even though Article 7 of the TRIPS Agreement requested 
and supported by less developed countries, but it fits the spirit of the 
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WTO, as balancing between rights and obligations considered 
superseding objective of the WTO system.
134
  
Even in the previous Intellectual Property conventions (for 
example Article 5A of the Paris Convention) the principle of balance 
of rights and obligations existed between the governments on behalf 
of public interests and intellectual property right holders’ interests.
135
 
This will help the interpreters of the TRIPS Agreement and assist 
courts as well. Usually courts are interested in reasons behind creating 
particular intellectual property rights by national legislators, and in 
this regard, courts can rely on Article 7 that the TRIPS Agreement 
intended to keep balance between interests of right holders and society 
in general. TRIPS negotiators never wanted to abandon the interests of 
user of intellectual property assets and by keeping this balance a 
harmonized atmosphere will be created that promote both social and 
economic welfare.
136
    
GATT’s approach in Intellectual property rights which apparent 
in the TRIPS agreement is permissive approach rather than 
prescriptive approach, in which GATT gives wide freedom to member 
countries to adopt regulations which best suits their unique situation 
with the condition that these regulations should not be inconsistent 
with GATT and their application be far from discriminatory and 
arbitrary manner. Permissive approach to Intellectual Property norms 
comes from the stand that GATT believes intellectual property rights 
may cause trade barriers. This is a special treatment of Intellectual 
Property rights by GATT as the normal approach by GATT to achieve 
trade liberalization was prescriptive approach.
137
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2.4 PRINCIPLES OF THE TRIPS AGREEMENT 
Article 8 of the TRIPS Agreement allocated for specifying the 
principles of the TRIPS Agreement. The origin of Article 8 can be 
traced back to the Anell Draft. In Anell Draft a group of developing 
countries suggested some principles under Article 2 of the B text of 
the Draft. B text is part of the Draft that suggested and supported by 
developing countries. Clause 2 and 4 of Article 2 of the Draft made it 
to the TRIPS Agreement as Article 8 and titled Principles.
138
. Article 8 
of the TRIPS Agreement consists of two paragraphs. Article 8.1 gives 
great powers to member countries in adopting ‘measures necessary to 
protect public health and nutrition, and to promote the public interest 
in sectors of vital importance to their socio-economic and 
technological development’. However, Article 2 of the B text 
contained two extra measures which they were to protect public 
morality and national security, but they did not make it to Article 8. 
Yet still these measures can be found within the other Articles of the 
TRIPS Agreement. Article 27.2 allows members countries to prevent 
patenting inventions if they believe such prevention is necessary to 
protect ordre public and morality, and in the same way Article 73 
provides for security exceptions.
139
      
As we have seen before while discussing Article 7 of the TRIPS 
Agreement, NP de Carvalho believes that Article 8 does not set any 
new principles and exceptions. The important public policies and 
exceptions are already regulated in other articles of the agreement, 
such as exhaustion, compulsory licences, and exclusions from 
patentability or registrability. According to NP de Carvalho, Article 8 
cannot set any new exception or limitation to the rights conferred in 
the TRIPS agreement. However, Article 8 simply offers exceptions 
and limitations to the use of the rights and not on the rights. This 
Article shows how the process of concession of the TRIPS Agreement 
was managed and cleared some doubts that the developing countries 
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had, that they will not be able to adopt measures to stop the effect of 
some of the intellectual property rights on their most important areas 
of public health, nutrition and matters of vital socio-economic 
importance. Hence, Article 8 allows the adoption of some measures by 
member countries with the condition that such measures are consistent 
with the provisions of the TRIPS Agreement.
140
 These measures can 
be intellectual property rights measures that naturally allowed by the 
TRIPS agreement for example exceptions to exclusive rights (Article 
30), compulsory licences (Articles 31 and 31bis) and the disclosure to 
the public of test data (39.3), or other measures like marketing 
approval and price control of medicines, which is considered as a non-
intellectual property rights measures as stated by Correa.
141
 Carlos M. 
Correa gave an example of Canada that as one of the developed 
country put prices of drugs under permanent examination. This 
practice is common in many developing and developed countries 
including many European countries as well.
142
     
The process of such measures can be taken while the member 
countries ‘formulating or amending their laws and regulations’. If the 
term ‘measures’ alone existed in the provision, then it could include 
any rules and decision whether from national authorities or from 
courts. However, since it is stated and encompassed with the terms of 
‘in formulating or amending their laws and regulations’, therefore it 
refers only to ‘binding legislative measures’.
143
 
Originally the developing countries proposed this provision that 
had the words of intellectual property rights to the national laws and 
regulations, however later on it was omitted to include any national 
laws and regulations without been limited to laws and regulations 
related to intellectual property rights. It has to be an official published 
law or regulation; if the measure is stated in an administrative practice 
then it will not be justified under the TRIPS Agreement.
144
   
However, when it comes to measures by Members to promote 
public interest, it is not necessary that those measures in future will 
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achieve their goals, but it’s enough to show that the measure taken is 
suitable for that particular situation. Public interest has a wider 
concept than the ordre public of the Article 27.2. The term ‘public 
interest’ is considered to be more subjective than that of the ‘ordre 
public’ and cannot be measured by any other objective tests. When 
interest of public and an individual collides and face each other, the 
individual should relinquish his rights in favour of that of public, as it 
will benefit the society and common good as a whole.
145
  
Public interest is a domestic issue which covers anything that 
affects the interest of public in general. It cannot be contested by other 
Members with their own view because every country has its own 
priorities and interests base on circumstances of the country in 
question.  The word ‘sector’ also has a wide meaning which can 
include any type of sector of economic activities with different sizes 
even it may include small enterprises. The phrase ‘vital importance to 
their socio-economic and technological development’ may seem to 
limit the scope of the provision, but what constitute an important 
sector is for the Member state to determine within its socio-economic 
and technological development. Furthermore, the phrase ‘socio-
economic and technological development’ is broad enough to include 
any type of activities in different sectors, not limited to matters related 
to economic or technology, but social matters are included as well as 
long as considered socially important.
146
  
Economies of developing countries like Brazil, China, India, and 
South Africa are complex due to their rapid development and cannot 
be compared to that of the European countries and United States of 
America. Sectors of vital importance in China, for example, are very 
different compare to other countries. China may prefer stronger 
intellectual property protection in some specific areas such as 
entertainment, software, semiconductors and certain areas of 
biotechnology. However, in other areas like pharmaceutical, 
chemicals, fertilizers, seeds and foodstuff that China heavily relies on 
due to its massive population for the purpose of agriculture and public 
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health, therefore, in these areas China does not want and resist 
increasing intellectual property protections.
147
 
On the other hand, despite the fact that the origin of this provision 
is from B text of the Anell Draft that included the opinion of the 
developing countries, yet, the current Article 8.1 of the TRIPS 
Agreement contains two phrases that limit the benefits of this 
provision for the developing countries. These phrases in fact were 
added by the developed countries. The first one is the phrase of ‘adopt 
measures necessary’ which allow the member countries to adopt only 
those measures that are necessary and not what they consider 
necessary. In fact, this phrase has affected the abilities of the 
developing countries to adopt any measures which they consider 
necessary. The second phrase that further limit the flexibilities of this 
Article is the requirement that the measures to be ‘consistent with the 
provisions of this Agreement’. Unaware and inexperience of the 
developing countries were the cause of adding these phrases by the 
developed countries during the negotiation process. However, even if 
the developing countries were aware of the side effect of these 
phrases, the belief is that they would not be able to stop the 
modification due to the political pressures of the developed 
countries.
148
           
However, this should also be addressed in the light of Article 7 
and the Preamble, in other words, in the light of the balance of rights 
and obligations, and the social and economic account.
149
 When a 
measure taken by a developing country and found out that the measure 
is inconsistent with one particular standard would not automatically be 
rejected, because it’s the consistency of the measure with the overall 
of the TRIPS Agreement should be taken into account.
150
 Correa is of 
the believe that paragraph four of the Doha Declaration on the TRIPS 
Agreement and Public Health of 2001,
151
 can be understood that when 
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there is a conflict between intellectual property rights and rights to 
protect public health or to promote access to medicines for all, 




2.4.1 Appropriate Measures to be Taken by Member 
Countries 
Again, while NP de Carvalho analysing this provision, he stated 
that this provision does not add any principles to the TRIPS 
Agreement even though the Article named and titled Principles. It 
merely states some conditions that can be taken by member states to 
prevent anticompetitive and abuse practices.
153
 Others believe that 
Article 8.2 is only having a historical and symbolical effects and only 
shows what the developing countries were trying to emphasize during 
the negotiations.
154
 The structure and content of this provision is very 
close to the previous one, as they both provide for measures that can 
be taken by member countries and they also require the consistency 
and necessity as well, though the word necessary is not used in this 
provision but the word ‘’needed’ is used.
155
 In many places the TRIPS 
Agreement used the concept of necessity before one member country 
be able to use measures to limit the intellectual property rights or 
depart from obligations stated in the Agreement. The terms are used 
include ‘necessary, unnecessarily, need and needed’, however these 
terms are synonymous and considered to be requiring same level of 
precaution before a measure to be implemented.
156
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Article 8.2 states that member countries are allowed to use 
appropriate measures that may be needed in order to prevent three 
types of practices by the right holders which they are: 1- abuse of 
intellectual property rights, 2- resort to practices which unreasonably 
restrain trade, 3- adversely affect the international transfer of 
technology. Even though the provision provides that the measures has 
to be within these practices but did not stipulate their content or their 
doctrinal structure.
157
 Therefore, it is open to member countries to 
choose their regulations in order to deal with these practices.    
2.4.1.1 Abuse of Intellectual Property Rights by the Right 
Holders: 
As a general rule there is no absolute rights as can be understood 
from the Latin maxim of ‘summum jus summa injuria’ which means 
‘extreme justice is extreme injustice’.
158
 This means that every right 
should be practiced within limited sphere which rights of society and 
third party be respected.
159
 The word abuse has not been defined in the 
TRIPS Agreement. Therefore, to find the meaning of the word abuse, 
or practices that include within the meaning of the word, some option 
are exists for member countries. As a basic rule no practices that are 
allowed under the TRIPS Agreement can be considered an abuse 
practice. The abuse may refer to, not using the intellectual property 
rights actively or the patent does not work properly. Others connect 
the word abuse with competition law only and do not see it to have 
wider meaning. This opinion is based on the interpretation of Article 
40.2 of the TRIPS Agreement which regulates ‘Control of Anti-
Competitive Practices in Contractual Licences’. This provision states 
that ‘Nothing in this Agreement shall prevent Members from 
specifying in their legislation licensing practices or conditions that 
may in particular cases constitute an abuse of intellectual property 
rights having an adverse effect on competition in the relevant market’, 
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however what can be noticed here is that the word abuse connected 
with practices or conditions that have adverse effect on competition. 
However, this is not the case of Article 8.2, therefore, the word 
‘abuse’ used here is not limited to anti-competitive practices. 
Although all anti-competitive practices considered an abuse of 
intellectual property rights, there are other abuses that cannot be 
categorized within the scope of anti-competitive practices. For that 
reason, the abuse in this context may refer but not limited to: misuse 
of intellectual property, ‘tying agreements, the presupposing of licence 
fees after the expiry of the intellectual property right in question, 
package licences, the charging of licence fees calculated on the total 
turnover of the licence holder and the infringement of non-
competition clauses’.
160
 However, other scholars are of the opinion 
that Article 40 does provide for the elements that exist in this 
provision and its somewhat redundant.
161
         
2.4.1.2 Practices which Unreasonably Restrain Trade  
This phrase commonly interpreted as anti-competitive practices 
and categorised under the competition law. Among those who look at 
it this way is Professor Correa. For this reason, he advises the 
developing countries to regulate competition rules that best suits their 
circumstances. The member countries of the WTO are not required to 
have a competition policy and most of the developing countries either 
don’t have competition policies or they have weak competition policy. 
Nevertheless, such policies have great impact on intellectual property 
rights in developed countries. Therefore, such policies are considered 
as an important aid to legal framework of intellectual property rights. 
Some of the anti-competitive practices that may need an effective 
control by the developing countries are ‘predatory pricing, collusive 
tendering and tied purchases and sales’.
162
 Measures regarding anti-
competitive practices can be regulated within intellectual property 
right’s laws, even though this form is not desirable, or as an 
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independent legislation. In both cases the competition law should be 
an active part of legal frame work of the intellectual property 
system.
163
   
The notion of restrains to trade in this provision according to 
some scholars goes beyond competition law. It is true that restrain of 
competition is one of the principle ways of a restraint of trade, but the 
provision does not lay any limitation to competition forms of restraint. 
Therefore, member countries are allowed to adopt measures to prevent 
any form of trade restraints which occurs as a consequence of using or 
even existing an intellectual property rights by the right holders. 
However, it should be beared in mind that the practices by the right 
holders have to be unreasonably restraint trades, because some 
practices are carried out in order to facilitate the prolific use of the 
intellectual property rights. This means the member countries have to 
create a balance between the unreasonableness with extend benefits 
that has on the intellectual property protection. 
164
       
2.4.1.3 Practices which have Adverse Effect on the 
International Transfer of Technology 
This is an independent form of measure which member countries 
are allowed to take in order to stop any practices by the intellectual 
property right holders which have adverse effect on the international 
transfer of technology. International transfer of technology was one of 
the concerns of the developing countries during all stages of 
negotiation of the TRIPS Agreement especially against one-sided 
restriction by right holders.
165
 This phrase of the provision like the 
ones before it, as discussed in previous sections, does not limited to 
control of anti-competitive practices in contractual licences of Article 
40. Member countries are allowed to regulate laws for transfer of 
technology such as technology pricing. However, still intellectual 
property right holders have freedom of transferring their own 
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technology because in principle they can refuse such transfer but still 




The Preamble, nature and scope of obligation (Article 1), 
objectives (Article 7) and principles (Article 8) of the TRIPS 
Agreement show the facts of the reality of struggles and negotiations 
among developed and developing countries in order to achieve most 
out of the TRIPS Agreement for their own favours and in the same 
time present some important elements of the TRIPS Agreement. The 
TRIPS Agreement in these provisions formalized the idea of 
connection between international trade and intellectual property rights 
and introduced those intellectual property rights that affect 
international trades and tries to reduce distortions and impediments to 
them. In the meantime, the Preamble introduced some flexibilities in 
favour of the developing countries such as ‘taking into account 
differences in national legal system’ while the obligations of the 
TRIPS Agreement implemented. Also, the Preamble recognizes the 
necessity of transitional arrangements or consideration of public 
policy objectives especially development and technological 
objectives.  
Article 1 of the TRIPS Agreement opened the door for TRIPS 
plus measures which has been enforced by developed countries on 
developing countries though bilateral or regional agreements. In the 
same time Article 1 gives freedom of determining method of 
implementation of the TRISP Agreement by member countries which 
give some flexibilities that benefit especially the less developed 
countries. Article 7 is on the objectives of the TRIPS Agreement that 
emphasizes on issues attracted by the developing countries such 
promotion of technological innovation, transfer of technology, balance 
of rights and obligations and giving priority to social and economic 
welfare of the member countries.  
Last but not least, Article 8, which is supported by the developing 
countries as well, presents the important principles of the TRIPS 
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Agreement such as protection of public health and nutrition, and 
promotion of public interest which should be set into priority during 
introducing TRIPS Agreement into local laws, and prevention of 







3 HISTORY OF IRAQI PATENT 
LAW AND ITS AMENDMENTS 
3.1 INTRODUCTION 
The current state of Iraq was established by the Great Britain by 
merging three provinces of Mosul, Baghdad and Basraha which once 
they were part of the Ottoman Empire. The new political entity 
created as one nation consists of many different ethnic and religious 
groups who were inhabiting these provinces for thousands of years.  
The first entry of British Army was in 1914 and by 1918 all the 
three provinces were jointed, and a provisional government was 
established.  In March 1921 Churchill presided a conference in Cairo 
and nominated Faysal I who was son of the Sharif Husayn bin Ali as 
King of Iraq with one condition that a plebiscite to be held in order to 




As a Kingdom Iraq enacted the first patent law according to the 
Law No. 61 of 1935 on Patents.
168
 However, through a revolution the 
political system of Iraq changed, and the monarch overthrown by Abd 
al-Karim Qasim and established the Republic of Iraq in July 1958.
169
  
In the latest constitution of Iraq which was passed by the 
Parliament after the invasion of Iraq by United States of America and 
its Coalition Partners defined the political system of Iraq. The 
Permanent Constitution of Iraq was promulgated in 2005 which is 
considered as the highest law of the country. Article 1 defined The 
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Republic of Iraq, stating that ‘The Republic of Iraq is a single federal, 
independent and fully sovereign state in which the system of 
government is republican, representative, parliamentary, and 
democratic, and this Constitution is a guarantor of the unity of Iraq’.  
After the change of political system from monarchy to republic, in 
1970 the first patent law during the Republic enacted under the title of 
(Patent and Industrial Design) Law No. 65 of 1970,
170
 and replaced 
the old patent law of monarchy reign Law No. 61 of 1935. The Law 
No. 65 of 1970 followed by some instructions, regulations and 
amendments. The most important amendments were through ‘Law 
No. 28 of 1999 First Amendment to Law No. 65 of 1970 on Patents 
and Industrial Designs’,
171
 and Coalition Provisional Authority (CPA) 
Order No. 81 of Patent, Industrial Design, Undisclosed Information, 





3.2 PATENT LAW NO. 61 OF 1935 AND ITS AMENDMENTS  
Patent Law No. 61 of 1935 was a simple and basic law which was 
enacted in a time that invention and industrial development cannot be 
compared to those of current time. The judicial system and capability 
of government in handling and protecting the intellectual property 
rights was at minimal level. For example, in this law the word 
invention under section one defined as ‘producing new thing (matter) 
through information or creating new method and medium for 
producing knowing things or creating new method and medium for 
producing new result in industrial area and that include discovery or 
just improving in the mentioned areas’.
173
  
                                                 
170 ‘Law No. 65 of 1970 on Patent and Industrial Designs’ 
<http://www.wipo.int/wipolex/en/text.jsp?file_id=238400> [accessed 10 October 2017]. 
171 ‘Iraq: Law No. 28 of 1999 First Amendment to Law No. 65 of 1970 on Patents and 
Industrial Designs’ <http://www.wipo.int/wipolex/en/details.jsp?id=10515> [accessed 17 
January 2018]. 
172 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law.’ <http://www.wipo.int/wipolex/en/text.jsp?file_id=181090> [accessed 
10 October 2017]. 
173 ‘Iraq: Law No. 61 of 1935 on Patents’, Section 1. 
History of Iraqi patent law and its amendments 
113 
However, despite the low expectation of outcome of inventions, 
even in this law some important areas were excluded from 
patentability which they were considered vital matters for needs of 
society in general which they were pharmaceutical formulations, 
medicines, and methods used in financial and banking matters.
174
 All 
these exclusions made it to the Law of Patent and Industrial Design 
No. 65 of 1970.  
Under this law (Patent Law No. 61 of 1935) period of protection 
was only 15 years from the filing date, which is considered short 
period by the current standard and without making any differentiating 
among types of inventions. On the other hand, if the patent registered 
outside Iraq, then period of protection would have been same as 
period of protection of that foreign country with the condition that the 
granted period of protection does not exceed 15 years.
175
 This means 
that the law accepted shorter period of protection from foreign 
countries but did not recognize protection longer than 15 years of 
other countries.  
It is also stated under section 21 that the patent will be revoked in 
three circumstances: (A) if the invention was not new, it was granted 
contrary to this law or any other laws, granted by fraud or due to 
infringement of rights of others; (B) the subject of the patent breaches 
public security and its contrary to morality and ethics; and (C) the 
presented information about the invention is not sufficiently 
explaining the subject  or essence of the invention or method of 
application not included in a complete and precise manner.
176
  
Patent Law No. 61 of 1935 clearly stated in section 14 that patent 
will be granted by the registrar according to the provisions of this law 
without making any investigation to the usefulness, correctness, 
truthfulness or correctness of its data or compare it with the invention 
that submitted for patent to make sure it matches the invention, and 
government will not guarantee any of these matters.
177
 Certainly, with 
rules and regulations like this no government in the world will be able 
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to protect intellectual property rights of inventors and right holders in 
a proper way. This certainly will not guarantee the safety of ideas and 
inventions from stealing and copying by others. Even though section 
23 provides for penalties in forms of imprisonment for not more than 
two years or financial penalty and fine not exceeding one thousand 
Iraqi Dinar for those who intentionally deceive, attempt, assist, or 
encourage of doing any of the following acts; (A) manufacture or the 
method of producing which is the subject of the granted patent is 
violating the rights of the original right holder; (B) import, sale, store 
for the purpose of selling or display for selling any manufactured 
product that produced in violation to the rights of the rights holder; 
(C) publish in an announcement, plate (board), stamp or cover that a 
certain thing (invention) was granted a patent but in reality no patent 




From the outset, Patent Law No. 61 of 1935 had undergone three 
amendments prior to its replacement by Patent and Industrial Design 
Law No. 65 of 1970. All these amendments show that the Iraqi 
Government, since its establishment, had tried to provide a patent law 
that best serves the interest of both Iraqi people in general and the 
interest of intellectual property right holders.  
The first amendment was passed by Law No. 64 of 1940 which is 
titled as ‘Amendment to Law No. 61 of 1935 on Patents’.
179
 In this 
amendment two provisions were added to section 22 which is about 
the revocation of patent and all the rights that attached to that patent. 
The original section 22 under subsection 1 provided three situations 
that causes the revocation of the patent; (A) if fees were not paid on 
stipulated time; (B) if the patent holder, without legitimate reasons, 
did not put the invention into work in Iraq within two years of 
granting the patent; (C) if the patent holder brought a foreign product 
similar to the one that he was granted patent for. However, under 
subsection 2 one exception is provided for the above situations, which 
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is the absence of sufficient facilities to industrialize the invention or 
establish a trade base on the invention inside Iraq. But still the 
inventor has to publish the invention to public. In addition to this 
exception, the amendment provided for another two exceptions; (A) in 
case of section 22.1 (A) if the unpaid fee on stipulated time was due to 
war; (B) in case of subsection 2, if patent holder or his representative 
could not publish the invention to public or industrialize and put to 
work the invention was due to war. These exceptions show that the 
amendment to the Patent Law No. 61 of 1935 was in favour of the 
right holders and protecting their rights in better way.  
Another amendment was followed in 1949 by Law No. 27 of 
1949 Second Amendment to Law No. 61 of 1935 on Patents.
180
 This 
amendment added another section that include 2 subsections to Patent 
Law No. 61 of 1935 and according to the new provisions, new patent 
shall not be granted after expiration period of the patent. In another 
word, after expiration of 15 years there will be no extension. 
According to the second provision, after revocation of patent 
according to sections 21 and 22, new patent shall not be granted to the 
invention in which it was subject of the revoked patent.  
The last amendment was during the Republic by the Law No. 210 
of 1968 Amendment to Law No. 61 of 1935 on Patents.
181
 This 
amendment converted the provision of section 14 into section 14.1 
and added section 14.2 and 14.3 as well. According to subsection 2 
the registrar has authority to reject a patent application, transfer its 
ownership, amendment or renew it and eras it from the register if 
found to be contrary to public interest. Subsection 3 gives right of 
appeal to the right holder to the Minister of Economic of the decision 
of the registrar within 30 days, and both party has right to appeal to 
the Council of Ministers and the decision of the Council will be final.  
This amendment is clearly in favour of public in which the 
interest of public is considered to be higher to the interest of the right 
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holders. Right to appeal can be considered as an improvement, but not 
to Minister and Council of Ministers because their decisions are tamed 
by nature because they are executive branch of government in the 
same way of registrar. Therefore, their decisions will be biased toward 
the right holders and they cannot be considered partial. However, the 
perfect place to acquire justice are courts as they are exercising 
judiciary which have judicial power to decide the cases between the 
registrars and the right holders.        
3.3 PATENT AND INDUSTRIAL DESIGN LAW NO. 65 OF 1970 AND 
ITS AMENDMENTS 
Law No. 61 of 1935 was considered to be an outdated law and 
was necessary to be replaced by a new law in order for the Republic of 
Iraq be able to trade with industrialized and developed countries and 
benefit from their technologies and be able to protect the intellectual 
property rights of the inventors and right holders in a better way. This 
can be noticed as explained at the end of the Patent and Industrial 
Design Law No. 65 of 1970 which repealed the Patent Law No. 61 of 
1935, a paragraph written without having any section number and 
titled (Mandating Reasons) which states reasons for replacing the old 
patent law. Under the Mandating Reasons, it is stated that due to the 
economic, industrial and social development of the country that makes 
Patent Law No. 61 of 1935 unable to respond to them in a proper way, 
and for insuring the protection of intellectual property and 
encouraging the inventors and widening the relationship with 
developed countries this law has been enacted. Law No. 65 of 1970 on 
Patent and Industrial Design repealed the Law No. 61 of 1935 on 




Law No. 65 of 1970 has also undergone four amendments which 
two of them are minor amendments and the other two are considered 
major amendments. The first amendment was through ‘Law No. 28 of 
1999 First Amendment to Law No. 65 of 1970 on Patents and 
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 This first amendment includes 13 sections out 
of which the first 12 sections are amendments to the original law No. 
65 of 1970, and the last section simply dedicated for the date of 
enforcement which from date of publishing it in the official Gazette, 
and it include place of writing it down which is Baghdad. Out of these 
12 amendments some of them are minor amendments such as 
changing one word, or one single subsection and others are major 
amendments by changing the whole section, such as section 1, 5, 9, 
13, 29 and 51.  
The first amendment of Law No. 28 of 1999 is considered a huge 
amendment to the original law. However, the second amendment 
which is implemented according to ‘Law No. 5 of 2002 Second 
Amendment to Law No. 65 of 1970 on Patents and Industrial 
Designs’,
184
 has amended only one section. The second amendment 
law includes two sections only and the second section dedicated to 
enforcement date which is from publishing it in the official Gazette. 
The amendment in the first section is about section 22 of the original 
law and replacing it with new section that includes six subsections. 
The original section 22 is about inventions that relate to military and 
defence system in which the registrar has to inform ministry of 
defence. After the amendment section 22 includes more detail on this 
matter and requests forming a special committee that include 
representatives from ministry of defence, military industrialization 
corporation and security services.  
The third amendment can be considered as a major amendment 
because it changes the nature and scope of the original law of Law No. 
65 of 1970 on Patents and Industrial Designs. This amendment 
occurred after the invasion of Iraq by the United States of America 
and its Coalition Partners in 2003 and was made through the Coalition 
Provisional Authority (CPA) Order No. 81 of Patent, Industrial 
                                                 
183 ‘Iraq: Law No. 28 of 1999 First Amendment to Law No. 65 of 1970 on Patents and 
Industrial Designs’ <http://www.wipo.int/wipolex/en/details.jsp?id=10515> [accessed 17 
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Design, Undisclosed Information, Integrated Circuits and Plant 
Variety Law ‘CPA/ORD/26 April 2004/81’. 
Shortly after the invasion of Iraq, the Coalition Provisional 
Authority (hereinafter the “CPA”) was established in order to govern 
the country. On May 6, 2003 Lewis Paul Bremer III named as the new 
director of the CPA, and on May 12 officially took the office. Paul 
Bremer had held many positions in the United States governments 
before taking such position in Iraq, such as assistant to Secretaries of 
State Henry Kissinger and Alexander Haig, ambassador to the 
Netherlands, managing director of Kissinger Associates and 
Homeland Security Advisor Board. On June 28, 2004 the CPA ruling 




Paul Bremer during his directorship and presidency of the CPA 
expected to rebuild a strong Iraq economically and bring justice after 
long run of dictatorship. One of his major work was de-Ba’athification 
program through removing all the Ba’ath party members from their 
ruling authority and prevent them from taking public position ever 
again. In his capacity as chief administrator of the CPA he also 
created the Iraqi Special Tribunal for Crimes against Humanity 
(Special Tribunal) for trying against genocide, crimes against 
humanity and war crimes. He established a property claims 
commission, a central criminal court and a new Iraqi army and civil 
defence corps.
186
 He also issued a series of regulations, orders, 
memoranda and public notices. In his first regulation which named as 
Coalition Provisional Authority Regulation No. 1, he stated that all the 
laws that were in force before the occupation will continue to be in 
force unless they contradict the regulations and orders issued by the 
CPA and until they will be suspended or replaced by the CPA or by 
legislation of any other Iraqi democratic institutions. In section 3 of 
the same Regulation No. 1, it is stated that the regulations and orders 
issued by the CPA will remain enforce unless ‘repealed by the 
                                                 
185 ‘L. Paul Bremer III | American Statesman’, Encyclopedia Britannica 
<https://www.britannica.com/biography/L-Paul-Bremer-III> [accessed 18 January 2018]. 
186 Eric Stover, Hanny Megally, and Hania Mufti, ‘Bremer’s “Gordian Knot”: Transitional 
Justice and the US Occupation of Iraq’, Human Rights Quarterly, 27.3 (2005), 830–57 (pp. 
832–33). 
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Administrator or superseded by legislation issued by democratic 
institutions of Iraq’, it further stated that ‘Regulations and Orders 
issued by the Administrator shall take precedence over all other laws 




The preamble of the CPA Order No. 81 clearly stated that the 
economy of Iraq needs to be changed and modernized in order to 
benefit the whole people of Iraq. For that reason, one of the big 
change to be occurred is by changing the Iraqi intellectual property 
system because the Iraqi Patent and Industrial Design Law No. 65 of 
1970 and other related laws does not meet the international standard 
of protection. It further stated that its necessary to have fair, efficient 
and predictable environment for protection of right holder’s interests 
and privileges whether be a company, lender, entrepreneurs. It also 
refers to the necessity of improving people’s life condition, technical 
skills and fighting unemployment.  It is the interest of the Iraqi 
Governing Council to join the World Trade Organization (WTO) 
therefore its necessary to adopt modern intellectual property 
standards. Also based on the report of Secretary General to the 
Security Council of July 17, 2003, the Preamble states that it is 
necessary to change the economic system from ‘non-transparent 
centrally planned economy to a free market economy characterized by 
sustainable economic growth through the establishment of a dynamic 




Therefore, Paul Bremer gave the right to himself to amend the 
original Patent and Industrial Design Law No. 65 of 1970 through 
Coalition Provisional Authority Order No. 81 of Patent, Industrial 
Design, Undisclosed Information, Integrated Circuits and Plant 
                                                 
187 ‘Coalition Provisional Authority Regulation Number 1’, 2003, p. Section 2 
<http://govinfo.library.unt.edu/cpa-
iraq/regulations/20030516_CPAREG_1_The_Coalition_Provisional_Authority_.pdf> 
[accessed 18 January 2018]; Sean D. Murphy, ‘Coalition Laws and Transition 
Arrangements during Occupation of Iraq’, The American Journal of International Law, 
98.3 (2004), 601–6 (p. 602) <https://doi.org/10.2307/3181659>. 
188 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law.’, The Preamble 
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Variety Law “CPA/ORD/26 April 2004/81”.
189
 Order No. 81 of the 
CPA made 79 amendments to the Law NO. 65 of 1970, out of which 
the first 22 amendments were on Chapter One ‘Patent’ with the first 
amendment dedicated to changing the name of the whole law to 
‘Patent, Industrial Design, Undisclosed Information, Integrated 
Circuits and Plant Variety Law’. The rest of the amendments from 
number 2 to 22 dedicated to amendments of the patent part of the 
original law No. 65 of 1970. The Order No. 81 of CPA added some 
new parts to the original law No. 65 of 1970 as well, such as chapter 
Threebis which titled ‘Protection of Undisclosed Information’, chapter 
Threeter with the title of ‘Protection of Integrated Circuits’, and 
chapter Threequater for the ‘Protection of New Varieties of Plants’.  
However, on 12 May 2013 a new law was enacted under the name 
of Registration, Accreditation and Protection of Agricultural Varieties 
Law No. 15 of 2013 in which repealed chapter Threequater for the 
Protection of New Varieties of Plants. Under this law, section 18 
states that ‘Repeal section 51 to 79 of the CPA Order No. 81 of 2004 
of Law Patent, Industrial Design, Undisclosed Information, Integrated 
Circuits and Plant Variety Law’.
190
 Though this is a mistake by the 
new Law No. 15 of 2013, because CPA had authority to promulgate 
Order No.81 according to the laws and usages of war and Resolution 
1483 and 1511 (2003) of the Security Council,
191
 therefore an 
amendment to the original law becomes part of the law. In its 
capacity, the CPA amended some parts and added some new chapter 
to Law No. 65 of 1970, therefore, the section 18 of Law 15 of 2013 
should have written as follows ‘Repeal chapter Threequater including 
all sections thereunder of the Patent, Industrial Design, Undisclosed 
Information, Integrated Circuits and Plant Variety Law No. 65 of 1970 
Amended’, without any necessity of referring to the CPA Order No. 
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81. This fault can be noticed in Patent, Industrial Design, Undisclosed 
Information, Integrated Circuits and Plant Variety Law No. 65 of 1970 
Amended, under chapter Threequater by referring to the sections of 
the CPA Order No. 81.       
Lastly and for the fourth time Law No. 65 of 1970 on Patent, 
Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law was amended through Law No. 58 of 2015.
192
 
However, the Fourth Amendment did not change much from Law No. 
65 of 1970, because it includes only one minor amendment in Section 
1 which changes the definition of The Ministry from Minister of 
Industry to Minister of Planning, and by this amendment all the 
powers and authorities in the Law No. 65 of 1970 will be shifted from 
the Minister of Industry to the Ministry of Planning. This was the third 
time that the definition of ‘The Ministry’ was amended. The first time 
it was repealed by Law No. 28 of 1999 First Amendment, which 
replaced the word Minister of Economy by The Secretariat and 
defined to mean ‘Secretariat for the Council of Ministers’, then the 
second time this definition repealed by the CPA Order No. 81 and the 
word Minister added again and to be defined as the Minister of 
Industrial.  
3.4 CONCLUSION 
Since the establishment of the first government in the Kingdom of 
Iraq, patent law was enacted as part of encouraging inventions in the 
Kingdom. However, the Patent Law No. 61 of 1935 was 
unpretentiously drafted, and its definition of invention was wide 
enough to include even a simple improvement or a discovery. In this 
law it was clearly stated that the government could not make any 
investigation in the nature of the invention or its data, whether it is 
useful invention or not. It can be perceived that newly established 
country in the Middle East like Iraq a century ago, had little resources 
                                                 
192 ‘Law No. 58 of 2015 Fourth Amendment to Law 65 of 1970 on Patent, Industrial Design, 
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to do all these enquiries, but no legislature should regulate such 
provisions and support executive branch of government from escaping 
its responsibilities. Even though this Law had subsequently seen a 
number of amendments but could not attain international standards, 
therefore, it was a right step to be replaced by the Republic of Iraq and 
enact Patent and Industrial Design Law No. 65 of 1970 instead. 
Patent and Industrial Design Law No. 65 of 1970, also has 
undergone four amendments. The most important amendments were 
the first amendment through Law No. 28 of 1999, and the third 
amendment through CPA Order No. 81. The first amendment included 
13 sections and amended some sections with little alterations and 
repealed some other sections and replaced them with new sections. On 
the other hand, the CPA Order No. 81 which was introduced after the 
invasion of Iraq by the United States of America and its Coalition 
Partners in 2003, altered the Law No. 65 of 19790 with the intention 
of elevate the law to the international standard of protection.  
CPA Order No. 81 changed the title of the Patent and Industrial 
Design Law No. 65 of 1970 to ‘Patent, Industrial Design, Undisclosed 
Information, Integrated Circuits and Plant Variety Law’. Amended 
many sections and added some new chapters to the law. However, on 
12 May 2013 a new law was enacted to and replaced chapter 
Threequater (Plant Variety) of the amended law No. 65 of 1970.  







CHAPTER II: PATENTABLE SUBJECT MATTER 













Patent is a binding contract between the patentee and the public in 
general. According to this agreement the inventor will receive 
exclusive rights for certain period of time in order to benefit from his 
invention. The society will benefit from the invention as well by 
receiving new ideas and after the protection period expired, everyone 
in the society has right to benefit from the invention economically as 
well.  
In this part the terms of patent, invention and criteria of 
patentability and sufficient discretion will be analysed and examined 
according to the TRIPS Agreement and Iraqi patent law No. 65 of 
1970 with reference to the amendments, especially the first 
amendment of law No. 28 of 1999 and the CPA Order No. 81. These 
amendments have repealed those sections that relate to criteria of 
patentability and introduced new sections. However, not all the core 
elements of these terms have changed, nevertheless, the amendments 
have tried to enhance the standard of protection and present clarity.   
1.2 PATENT AND INVENTION UNDER THE IRAQI PATENT LAWS  
1.2.1 Patent  
The original term of patent derived from the words of Letters 
Patent, which means ‘open letter’. It is called open letter because the 
letter is not closed but it meant to be seen by public once sealed by the 
king or administrator to show that the holder of the letter is granted a 
certain offices of state or granted a dignities or any other privileges 
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including monopoly rights in inventions.
193
 The word patent originally 
came from the Latin word of patere (to be open) and the first time as a 
system was practiced in Venice in the fifteenth century and later on 
officially regularized in the Venetian Senate’s 1474 Act. The Act 
referred to some essential features that modern patent law relies on. 
For example, the Act identifies special Office and Board in which new 
and ingenious device to be registered, in condition that the device 
previously was not made in the Commonwealth. The device has to be 
put into practicable work, then forbade everybody else from making 
such device without consent and license from the author for the period 
of ten years. Also provided for punishment in case of infringement 
which was payment of one hundred ductas to the author and the 
device has to be destroyed.
194
    
In England this kind of practice was considered new compare to 
the Venetian Senate’s 1474 Act but had a long history of practice in 
England and the English Crown as they granted many such monopoly 
rights. However, this practice was easy to be abused and in fact 
abused during the reign of Elizabeth I and James I, therefore 
Parliament enacted the Statute of Monopoly, in order to prevent any 
such abuses. The Statute of Monopoly authorise the issuance of letter 
patent, even though the Statute forbade the monopolistic grants by the 
English Crown
195
.   
Patent is considered the strongest of all the other intellectual 
property rights, because it is a binding contract between the inventor 
and the public in general. The patentees will receive limited period of 
exclusive rights to use, make and exploit their inventions, in return the 
inventions will be published, and all the information will be disclosed, 
and then will be available for everyone to study and research on them 
in order to develop them further. However, the patent rights and 
monopoly rights will not be given easily but after a thorough 
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examinations and compliance with strict conditions that must be met. 
This kind of strictness in examination and granted extensive power 
makes the patents the strongest rights.
196
 Since it is an industrialised 
bargain, the government will make sure through protection of the 
inventors’ rights that they will be able to commercialise their 
invention and make money out of their ideas and inventions. For this 
reason, sometimes the patent is called industrial property which 
involve technological inventions that can be used in manufacturing or 
commercial operations, including machines (new machines or 
advancing the existing machines), processes, or other aspects of 
technological inventions.
197
 After the protection period expires the 
public be able to benefit from the disclosure of the new technology 
and innovation, because they will be part of the public domain and 
freely available for everyone to study, use and utilize them.  
The original Iraqi Patent and Industrial Design Law No. 65 of 
1970, in its section 1.8 defines patent as ‘a certificate of registration of 
the invention’, even though section 1 in whole repealed by first 
amendment Law No. 28 of 1999, but the definition of patent stayed in 
same section 1.8 and without altering the definition. CPA Order No. 
81 did not change this definition and therefore remain as it is since the 
first Patent Law during the Republic of Iraq.  
1.2.2 Invention 
Understanding the concept of invention in modern patent law is 
very new which can be traced back to eighteenth century. In modern 
legal system there is difference between invention as an idea and its 
embodiment and has been accepted as an important patent doctrine.
198
 
The term invention in Iraqi Patent Laws has gone through some 
changes since the Law No. 61 of 1935. In this law the word invention 
under section one defined as ‘producing new thing (matter) through 
                                                 
196 Catherine Colston, Principles of Intellectual Property Law, Principles of Law Series 
(London: Cavendish Publ, 1999), p. 37. 
197 Christopher May and Susan K. Sell, Intellectual Property Rights: A Critical History, 
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information or creating new method and medium for producing 
knowing things or creating new method and medium for producing 
new result in industrial area and that include discovery or just 
improving in the mentioned areas’.
199
 This definition shows that the 
word invention had been given the simplest definition because 
according to this definition even discoveries were considered to be 
within the sphere of an invention. According to the basic principle of 
patent laws ‘discovery’ is not patentable. This is because ‘A 
“discovery” is commonly considered to mean the mere recognition of 
what already exists; it is the finding of casual relationships, properties 
on phenomena that objectively existed in nature’.
200
  
One of the important step was taken by the Law No. 65 of 1970 in 
which the term invention in section 1.4 defined is to remove the 
discoveries from the definition. This law defined the invention as 
‘every new innovation that industrially exploitable whether relates to 
new industrial products or innovative methods and means or both of 
them together’.  In the first amendment Law No. 28 of 1999 this 
subsection was amended by adding an extra sentence at the end of the 
subsection to be red as ‘every new innovation that industrially 
exploitable whether relates to new industrial products or innovative 
methods and means or both of them together or achieve some specific 
development in order to be outside of traditional framework’.  
The definition of invention of the original Law No. 65 of 1970 
and including its additional part by the Law No. 28 of 1999 have some 
important elements. Firstly, it has to be a new innovation, secondly, 
industrially exploitable, and third, relates to new industrial products or 
innovative methods and means or both of them, or achieve some 
specific development. The last part (achieve some specific 
development) is the new element which added by Law No. 28 of 1999 
that broaden the concept of invention in the way that even if the new 
innovation which industrially exploitable does not relate to new 
industrial products or methods, still can be considered invention if 
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200 Carlos María Correa, ‘Implementing the Trips Agreement in the Patents Field’, The 
Journal of World Intellectual Property, 1.1 (1998), 75–99 (p. 77) 
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achieve some specific development in order to be outside the 
traditional circle.  
However, the CPA Order No. 81 amended the whole subsection 
and introduced a new definition of the term invention as it is ‘Any 
innovative idea, in any of the fields of technology, which relates to a 
product or a manufacturing process, or both, and practically solves a 
specific problem in any of those fields’. The CPA Order No. 81 
presented some of the elements and criterion of the term invention in a 
clear and more precise form. It exchanged the words of ‘new 
innovation’ to ‘innovative idea’, ‘industrially exploitable’ to ‘field of 
technology’, and ‘achieve some specific development’ to ‘practically 
solves a specific problem in any of those fields’. Even though 
exchanged the words of ‘relates to new industrial products or 
innovative methods and means or both of them’ to ‘relates to a 
product or a manufacturing process, or both’ but both phrases imply 
introduce same conditions. As for the rest will be discussed further in 
the next section. 
On the other hand, the TRIPS Agreement does not define the term 
invention, even though in Article 27.1 clearly states that ‘patents shall 
be available for any inventions’. This will leave the member countries 
to define the term invention in such a way that best suits their legal 
systems. The dominant trend of the member countries is to avoid 
defining the term ‘invention’, because this will give them ‘a certain 
degree of flexibilities in a changing scientific and technological 
context’. Most of the countries simply stating the traditional criteria of 
patentability, in which they are (novelty, inventive step and industrial 
applicability).
201
 However, reference to the word invention has to be 
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1.3 CRITERIA OF PATENTABILITY UNDER THE IRAQI PATENT 
LAWS AND TRIPS AGREEMENT 
Criteria of patentability under the Iraqi patent laws has gone 
through some changes. The original Patent and Industrial Design Law 
No. 65 of 1970 provided for some criteria, and later on the first 
amendment of Law No. 28 of 1999 added some changes. Finally, the 
CPA Order No. 81 changed some of these criteria. In this section, the 
general criteria of patentability of the Iraqi Patent laws will be 
analysed and compared to those of the TRIPS Agreement.  
While section 1.4 of the original law No. 65 of 1970 defined the 
term invention, it provides some important elements which can be 
considered as bases and criteria for granting the patent, because 
nowhere else in the Law No. 65 of 1970 any formal criteria are 
mentioned which can be used as bases of patentability. Section 2 of 
the original Law No. 65 of 1970, however, simply stated that ‘Patents 
of invention shall be granted according to the provisions of this Law’, 
without referring to any criteria of patentability. 
1.3.1  New invention and Novelty  
The invention will be considered new and novel if it is bestowed 
upon the public by the inventor for the first time. However, if the 
invention was taken or created based on the information and 
knowledge that was available in public domain, then the inventor did 




The term new invention was used in section 1.4 of the original 
law No. 65 of 1970 without determining what is meant by new. 
However, section 4 stated two situations in which invention cannot be 
considered new, therefore except for these two situations, every 
invention would have considered to be new invention. This means that 
Iraq has taken restrictive view as to what shall be considered novel 
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and what kind of disclosure affect the criterion of novelty
204
. From 




, it can be observed 
that the Iraqi Legislature gave general ruling to the term ‘New’ and 
restricted novelty to the period of 50 years prior to the patent 
application date. Therefore, any invention that has been practically 
utilised and available for public to benefit from products of the 
invention, prior to the date of the application for patent, then that 
invention considered part of the prior art and cannot be patented 
because it lacks the novelty criterion. Here the priority is given to first 
to file. Even after the amendment by the CPA Order No. 81, priority 
stayed same. May be this is due to the fact the United States of 
America in 2011 amended the US Patent Act and changed the priority 
date from first to invent to first to file.
207
 However, in Germany the 
priority is given to first to invent, the original principle was first to 
file, however this was changed due to the reform in 1936 and replaced 
by first to invent principle.
208
 Even though first to file system is 
considered more efficient and less costly to settle a conflict. In the 
other hand first to invent system is more just and fair, because the 
patent will be given to the person who invented it first.
209
 
Also, even if the invention not utilised but publicized in such a 
way that an expert of the field who is a ‘person having ordinary skill 
in the art (hereinafter the “PHOSITA”)’
210
 can exploit such invention 
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into a practical use, then the invention will not be considered as new 
invention and cannot be granted a patent. However, if the subject 
matter of the invention has been kept secret, then the next invention in 
the same area will be considered novel and the new inventor has right 
to apply for patent as the subject matter invented without relying on 
previous work or publicised information. But according to the United 
States Patent system, secret information considered as part of the 
broader class of prior art, even though it was kept secret from 
public.
211
 However, if an invention was granted a patent or applied for 
a patent by others, then will not be considered a new invention. Same 
principle can be found in Article 87-89 of the European Patent 
Convention (hereinafter the “EPC”). Even prior use by the applicant 
or his predecessor (own publication) also can be considered that it has 
become part of the state of art. If the information has reached the 
public through written or oral sources, I will become part of the state 
of art. Because technical teaching can be described orally, through a 
presentation, lecture, speech … etc. However, only that part of the 
information will become start of art which has been disclosed.
212
 This 
means that if another person applied for patenting the same invention 
or part of it just one day before the new applicant, then the new 
applicant’s invention will not be considered new. It does not matter 
whether all these situations have occurred in Iraq or outside Iraq, 
because section 4 covers inventions whether be inside Iraq or abroad.  
However, section 4 did not refer to verbal disclosure in any way. 
Therefore, if the oral information regarding the subject matter of the 
invention is spread out within community, it will not bar the invention 
from the patentability and the invention will be considered new and 
novel. On the contrary, in United States of America, both forms of 
disclosure whether oral or written will prevent next invention from the 
element of novelty. Though if oral disclosure has occurred outside the 
territory of the United States, then such disclosure will not bar the 
patentability of the subject matter. But this will not apply to written 
disclosure, as like rest of the world if written disclosure has occurred 
inside or outside of the United States, then it will prevent the 
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patentability of the invention on the basis of novelty. However, the 
form of disclosure should not be matter as much as whether the 
information has become part of public domain or not.
213
   
The amendment by the CPA Order No. 81 was considered one of 
the major amendments as it added, suspended and amended many 
provisions of the Original Law No. 65 of 1970. The order amended 
the definition of the Invention and in the new definition the words 
‘every new innovation’ replaced by ‘any innovative idea’. However, 
the CPA Order No. 81 amended section 2 as well by adding some 
more elements and criteria, which states ‘Patents of invention shall be 
granted pursuant to the provisions of this Law for each invention that 
is industrially applicable, novel and involves an inventive step, either 
concerning new industrial products, new industrial methods, or new 
application of known industrial methods’. This new section can be 
seen as positive amendment which states the requirement of 
patentability since it states three criteria of patentability which are 
internationally known and considered to be standard requirements. 
These criteria are: new (novelty), inventiveness (involves an inventive 
step and non-obvious) and industrial applicability (useful) and these 
are the same criteria which is required by the TRIPS Agreement in 
Article 27.1
214
.   
The CPA Order No. 81 also amended section 4 of the Patent and 
Industrial Design Law No. 65 of 1970. First the Order changed the 
numerical of both subsections of 4.1 and 4.2 to subsections 4.a and 
4.b. This is a small technical amendment and does not affect the 
content of the Law and it is unnecessary change. Then it deleted the 
condition of 50 years period in both subsections. Which in fact it will 
bring more legal sense to the subsections, because limiting novelty of 
the inventions to 50 years prior to the date of the application for a 
patent has no logical basis, as to what logic the inventions of 60 years 
prior to the date of the application have not became public knowledge 
and part of public domain but the inventions of past 50 years have 
become part of public domain. The only logic that one may think of is 
that the legislatures were trying to give another chance to inventors to 
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use the old information and produce something out of it, but still more 
provisions should had been included to make this encouragement 
workable in a way that did not affect the legal rights of the owners of 
the original idea and those of their predecessors. However, in general 
time should not matter but the important element is whether the 
information has been available within the community or not, therefore 
by deleting the period restriction, the CPA Order improved the 
original law.  
Furthermore, the CPA Order No. 81 added another provision to 
section 4,
215
 of the Law No. 65 of 1970 which is an exception to the 
previous subsection in which if the disclosure of the information is the 
applicant himself or his predecessor by an action taken in the last 
twelve months before the filing date or priority date, or the disclosure 
occurred due to an abuse by third parties, then such disclosure will not 
bar the element of novelty of the invention. Similar provision can be 
found in the patent acts of other countries, for example in The Patents 
Act 1977 (as amended up to and including 28 January 2018) of the 
United Kingdom
216
, in section 2(4) states the same situations and 
included extras. The United Kingdom Patents Act is very detailed act 
and states all the elements patentability in great detail, and in section 2 
novelty criterion regulated in a satisfactory manner. In section 2(4) 
states that disclosure of subject matter of the patent in six months 
before filing date of the application will not bar the novelty of the 
invention in these situations; disclosure occurred due to the obtaining 
information unlawfully or in breach of confidence or displayed at an 
international exhibition. 
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1.3.2 Inventiveness (involves an inventive step and non-
obvious) 
The primary evidence as to what constitute an inventive step is 
the opinion of a person having ordinary skill and expert as to whether 
the invention is obvious or not and determining such task will ‘involve 
questions of fact and degree’ as well.
217
 This is what the United 
Kingdom Patent Act 1977 confirmed in section 3 by stating ‘An 
invention shall be taken to involve an inventive step if it is not 
obvious to a person skilled in the art, having regard to any matter 
which forms part of the state of the art’. The same regulation and 
interpretation exists in section 103 of the United States Code 35 
Patents, as the question would be whether there is a difference 
between the subject matter and the prior art by a person who have 
ordinary skill in the art.  
However, there is an overlapping between the term invention and 
its criteria of non-obviousness because there is no obvious invention, 
but there can be a degree of inventiveness. For this reason, some has 
suggested that the provision of patentability in the patent laws should 
be read a ‘patents shall be available for any invention provided that it 
is new, involves a sufficient inventive step and is useful’.  Also, it is a 
fact that both novelty and inventive step has to be determined through 
comparison with the prior art.
218
 
The Iraqi original Patent and Industrial Design Law No. 65 of 
1970 does not provide for criteria of patentability in a proper form as 
has been explained previously. However, after the first amendment by 
Law No. 28 of 1999 the definition of invention in section 1.4 provided 
for as ‘every new innovation that industrially exploitable whether 
relates to new industrial products or innovative methods and means or 
both of them together or achieve some specific development in order 
to be outside of traditional framework’. From this definition it can be 
asserted that by the term of ‘new innovation’ the legislature wanted to 
make sure that the invention must have some innovation in it. The last 
sentence of the definition which was added by the first amendment 
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make this objective more perceivable by pointing out that even if the 
invention is not totally new still can be patented if the invention has 
added at least some specific development and addition so that it be 
outside of traditional framework and circle. If the innovation is 
outside the traditional framework, then the invention has added 
something which cannot be found in the prior art. This process can be 
done by comparing the new subject matter to the whole of the prior 
art. But the law failed to mention in a direct manner that it is in the 
perspective of the person with normal skill and expertise that the new 
innovation has been achieved is new to the prior art. Because in 
section 18 of the original Patent and Industrial Design Law No. 65 of 
1970 it is stated that: ‘The Directorate examine the application and its 
annexes to check the following: 1. The application is submitted in 
accordance with section 16 of this Law. 2. The specification and 
drawing illustrate (demonstrate) the invention in a manner that allows 
the owners (employers) of the industry (field) to implement it. 3. The 
innovative elements that the concerned person seeks to protect, should 
be mentioned in the application in a clear and specific manner’.  
Section 16 of the original law also requires that the application for a 
patent should include the detail description of the invention and its 
new elements. Therefore section 18 wants to make sure that the 
directorate will check for these matters in order the owners and 
employers of the industry in that particular field be able to implement 
them. However, Instruction No. 1 of 1990 on implementing Law No. 
65 of 1970 in section 1.1, and Regulation No. 3 of 2001 on the 
classification of Patents and Industrial Designs in section 2(a), state 
that ‘the invention will be considered innovative if it does not look 
obvious (self-evident) to an expert person while taking into 
consideration technical development prior to the application’.
219
 
Indirectly sections 18 and 16 require the invention to have new 
and innovative element in order to be granted a patent and be 
protected. In the other hand, Instruction No. 1of 1990 on 
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implementing Law No. 65 of 1970 and Regulation No. 3 of 2001 on 
the classification of Patents and Industrial Designs clearly stated the 
new invention should have an inventive step. According to section 1.1 
of the instruction and section 2(a) of the regulation if the new 
invention appeared obvious and self-evident to a person skilled in the 
art, then the invention will not be considered innovative. And base on 
section 1.4 of the Law No. 65 of 1970 an invention has considered to 
be a ‘new innovation’. Consequently, an invention according to Patent 
and Industrial Design Law No. 65 of 1970, has to include an inventive 
step in order to be accepted within the definition of invention.    
However, the CPA Order 81 amended section 18.2 in order to 
clear some uncertainties. Section 18.2 as amended by the Order states 
‘That the specification and drawing disclose the invention in a manner 
sufficiently clear and complete for the invention to be carried out by a 
person skilled in the art.’ The wordings of this subsection are very 
close to that of section 16.2 as amended. The difference is that section 
16 demands applicant for a patent to comply with certain conditions 
and section 18 demands the Central Organization for Standardization 
and Quality Control
220
 to make sure the condition has been fulfilled. 
Both of the subsections require the content of the application for 
patent disclose and include enough clear and complete information so 
that can be carried out by a person skilled in the art. And as for the 
inventiveness and non-obviousness of the invention, the CPA Order 
No. 81 when amended section 2 clearly states that the invention in 
order to be patentable should involve an inventive step. Therefore, the 
new Law after all the amendments clearly and undoubtedly include 
the criterion of inventiveness, by requiring that every invention should 
involve an inventive step to a person skilled in the art by comparing to 
the prior art. This is a positive development by enhancing the patent 
law of Iraq to the international standard and clearing some ambiguous 
provisions of the original Law No. 65 of 1970 which did not state the 
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requirements of patentability in an obvious way compare to patent 
laws of developed countries.  
Article 27.1 of the TRIPS Agreement states that the subject matter 
has to involve an inventive step in order to be patented. In the other 
hand, the TRIPS Agreement in footnote 5 gives option to the member 
countries to choose between the terms of ‘inventive step’ and ‘non-
obvious’. Therefore, according the TRIPS Agreement the condition of 
inventiveness will be fulfilled if the subject matter of the invention is 
not obvious to the skilled person in the art while considering the 
technical knowledge and the state of the art.
221
 This shows that the 
non-obviousness is synonymous with the term inventive step as 
explained by the footnote 5 of the TRIPS Agreement. Out of these two 
terms the CPA Order No. 81 chose the term inventive step and it is 
still enforce as part of the Iraqi patent law because it is perfectly 
fulfilling this requirement of the TRIPS Agreement.     
 
1.3.3 Industrial Applicability (Usefulness) 
The general rule is that patent shall not be given to an abstract 
idea even if will lead to an economic revolution. That is why many 
countries in their national statutes require the invention to have 
industrial applicability in order to be patented.
222
 Article 1(4) of the 
Paris Convention provides some example of industrial patents such as 
‘patents of importation, patents of improvement, patents and 
certificates of addition, etc’.
223
 
As to what invention can be covered within the range of ‘capable 
of industrial application’ is left for the countries to decide according to 
their interest. Some has used this term in broader meaning and applied 
to every invention which can be used in any sort of industry, while 
others defined the term more specifically such as those invention that 
can be used in a manufacturing process or produce material 
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 Therefore, generally in order for an invention to be 
patented it has to be used in industrial fields including agriculture.
225
 
This principle can be found in Article 57 of the EPC as it states that 
‘An invention shall be considered as susceptible of industrial 
application if it can be made or used in any kind of industry, including 
agriculture’.  
The Iraqi original Patent and Industrial Design Law No. 65 of 
1970, in section 1.4 while defined the word invention and stated the 
criteria of industrial applicability for patentable invention, that every 
innovation should ‘industrially exploitable whether relates to new 
industrial products or innovative methods and means or both of them 
together’. The words of ‘industrially exploitable’ used by the original 
law have the same meaning as ‘industrially applicable’. The law goes 
further by illustrating the areas in which the invention can relate to 
which are new industrial products or innovative methods and means or 
relate to both products and methods in the same time. Since nowhere 
else in the law the word industrial is defined, therefore the meaning of 
industrial can be taken in a broader meaning to include any kind of 
industry including the agriculture whether be an industrial product or 
method. This kind of understanding can be seen in section 1.2 of the 
Instruction No. 1 of 1990 on implementing Law No. 65 of 1970 and 
section 2(b) of Regulation No. 3 of 2001 on the classification of 
Patents and Industrial Designs, as they state that ‘the invention will be 
considered industrially applicable if it can be applied or used in any 




 After the first amendment by Law No. 28 of 1999 an extra phrase 
added to the definition which was ‘or achieve some specific 
development in order to be outside of traditional framework’, this 
made the meaning of ‘industrially exploitable’ much broader. With 
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this extra phrase it is not necessary that the industrially exploitable 
innovation relate to whole new product or method but will suffice to 
add a specific development so that alter the invention to be 
differentiated from the previous inventions.   
However, the CPA Order No. 81 amended section 1.4 (definition 
of invention) and section 2 (granting of patent). In both of these 
amendments the criterion of ‘industrial applicability’ has changed. In 
section 1.4 the term ‘industrially exploitable’ has been replaced with 
‘in any of the field of technology’. The amendment goes further by 
stating that the innovation has to relate to a product or manufacturing 
process or both, this part is almost same as the original Law No. 65 of 
1970 requirement but with playing around with the words. For 
example, the word ‘new industrial product’ changed to just a 
‘product’, and ‘manufacturing process’ replaced the word of 
‘innovative methods and means’. These all referring to industrial and 
technological innovation which can be seen in the TRIPS Agreement.  
However, the last sentence of the original law which was added 
by the Law No. 28 of 1999 totally changed to ‘and practically solves a 
specific problem in any of those fields’ which this becomes part of the 
‘a product or a manufacturing process or both’ and not an independent 
element, because of the word ‘and’ instead of ‘or’ as it was used in the 
definition of invention of the original law. The definition of invention 
according to the CPA Order No. 81 is mostly relate to technological 
invention, because in the case of the original law, the word industrial 
was used which may carry wider meaning. But this may be due to that 
fact that the CPA Order No. 81 widened section 2 of the original law 
to include all the criteria of the patentability in the same format of all 
the laws and regulations of the developed countries. Section 2 which 
is amended by the CPA Order No. 81 clearly stated the invention in 
order to be patented should be ‘industrially applicable’ whether 
‘concerning the new industrial products, new industrial methods, or 
new application of known industrial methods’. Article 1(3) of the 
Paris Convention
227
 gave the widest definition to what should include 
within the meaning of industrial property by stating that ‘Industrial 
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property shall be understood in the broadest sense and shall apply not 
only to industry and commerce proper, but likewise to agricultural and 
extractive industries and to all manufactured or natural products, for 
example, wines, grain, tobacco leaf, fruit, cattle, minerals, mineral 
waters, beer, flowers, and flour’. 
CPA Order No. 81 when amended section 1.4 introduce another 
sentence which is ‘in any of the fields of technology’, this part has 
been taken from ‘in all fields of technology’ of the TRIPS Agreement. 
This means that the range of patentability can be extended to all fields 
of technology, including pharmaceuticals
228
 which in many countries 
were excluded from patentability including Iraq. In the original Law 
No. 65 of 1970, section 3 which state the situations and areas in which 
patent shall not be granted and in section 3.2 stated the ‘medical and 
pharmaceutical formulations’. Nevertheless, CPA Order No. 81 
suspended section 3.2, in order to clear any doubts whether 
pharmaceutical products and methods included within the scope of 
fields of technology and prevent Iraq from excluding such inventions 
from patentability.       
The TRIPS Agreement require the invention to be capable of 
industrial application. And in footnote 5 states that the term ‘capable 
of industrial application’ is synonymous with the term of ‘useful’. 
However, the term ‘useful’ seems to be broader than the industrial 
capability. Because there are some inventions which are not applicable 
industrially but still offer some benefits to society and humanity. For 
example, United States of America allows purely experimental 
invention to be patented, which cannot be used in industry, such as 
methods of doing business. Because United States uses the term 
utility, therefore it is not necessary all inventions have technical effect 
in order to be patented. But since the TRIPS Agreement provides for 
minimum standard, member countries are allowed to implement 
higher standard than what required by the TRIPS Agreement, 
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therefore this practice of United States is justifiable.
229
 As long as the 
invention can be proved to be useful for a particular purpose.
230
  
1.4 SUFFICIENT DESCRIPTION AND DISCLOSURE UNDER IRAQI 
PATENT LAW AND TRIPS AGREEMENT  
According to section 16.1 of the original Law No. 65 of 1970 that 
the application for the patent should be submitted to the registrar and 
should not include more than one invention. In section 16.2 it is stated 
that the application shall include a detailed description of the 
invention and the method of its exploitation so that it can be 
executable. The description shall include the new elements that the 
applicant (inventor) request to be protected in a clear manner and shall 
be accompanied by the drawing of the invention.  
The CPA Order No. 81 amended section 16.2 and added 16.2bis. 
Section 16.2 as amended states that the invention should be disclosed 
in a sufficiently clear manner and complete so that can be carried out 
by a person skilled in the art. In fact, this amendment by the CPA 
Order is exactly similar to the first part of Article 29.1 of the TRIPS 
Agreement. Article 29.1 of the TRIPS Agreement also demand 
member countries to require from the applicant for a patent to 
‘disclose the invention in a manner sufficiently clear and complete for 
the invention to be carried out by a person skilled in the art’. Since 
Iraq desires to join the WTO and by extension to TRIPS Agreement, 
the amendment by the CPA Order No. 81 brings the Iraqi patent law 
aligned with TRIPS Agreement and a step closer to fulfil the 
accession requirements. During the negotiation period of the TRIPS 
Agreement the developing countries wanted the patentee to be 
enforced to bring the patented invention into work, but the attempt 
was rejected by the industrialized countries. In the same way the 
developing countries proposed of using ‘person versed in the technical 
field’ instead of ‘person skilled in the art’ but it was turned down.
231
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The developing countries were trying to take every chance to focus on 
the technical field as it was what they were looking for to gain out of 
the TRIPS Agreement.  
However, the second part of Article 29.1 of the TRIPS Agreement 
which is an optional request in which the member countries ‘may 
require the applicant to indicate the best mode for carrying out the 
invention known to the inventor’, this part cannot be seen in the 
amendment by the CPA Order. Even though the words of ‘sufficiently 
clear and complete’ gives the sense of very high disclosure of the 
invention. In such a way that it is not just enough for the person 
skilled in the art to understand but rather he will be able, based on his 
skill and the clear and complete disclosure, to carry out the invention 
without going through the reverse engineering. However, the member 
countries may request from the inventor to reveal what was the best 
mode for carrying out the invention. This was not mandated by the 
TRIPS Agreement because there may not necessarily the specific 
technicalities have been developed for carrying out the invention at 
the time of filing the application, or the best mode may change after 
filing the application
232
. However, some areas such as 
biotechnological invention which by nature cannot be described 
properly enough, therefore member countries are allowed to ask for 
deposit of such material to assist written description, or other methods 
that can help third parties understand them properly. And the 
indicating the best mode for carrying out the invention will certainly 
help in using the invention after expiry date of the patent or during the 
lifetime of the patent in case of compulsory licence.
233
  Certainly, this 
optional provision is very useful for developing countries which 
always trying to get benefit from foreign technology and be able to 
use them locally through the patentees directly or indirectly through 
compulsory licences. Nevertheless, the CPA Order No. 81 decided not 
to include such provision into the Iraqi patent law through its 
amendments, which in fact having such provision enhance the Iraqi 
patent law by benefiting from foreign technology to the maximum 
extend. In fact, surprisingly same provision can be found in the United 
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States of American’s patent law as it states, in section 35 U.S.C. 112 
Specification, that ‘shall set forth the best mode contemplated by the 
inventor or joint inventor of carrying out the invention’.
234
      
Section 16.2bis which is added by the CPA Order 81 provides 
that ‘An applicant for a patent shall provide information concerning 
the applicant’s corresponding foreign applications and grants’. The 
exact same provision can be found in the TRIPS Agreement as well 
but as an optional provision in which member countries are allowed to 
include it in their local laws or opt it out. However, having such 
provision will help the developing countries as they have limited 
human resources and infrastructure, therefore this provision will 
facilitate their examination and decision in regard of the application 
by contacting foreign patent offices and coordinate as to their process 
of examinations and decisions.
235
    
This shows that the CPA Order No. 81 has included some good 
provisions for Iraq as a developing country and to bring up the 
regulation standard to that of the international communities and 
TRIPS Agreement. But failed in some situations to include provisions 
like second part of Article 29.1, which would have been very helpful 
for Iraqi patent law, especially Iraq could have benefited from such 
provisions in regard to the foreign technological invention which they 
want to apply for patent in Iraq, and it is part of international standard 
and TRIPS Agreement also provided for as an optional provision.   
1.5 CONCLUSION 
In the definition of the term invention and criteria of patentability, 
the CPA Order No. 81 had altered the original law No. 65 of 1970 to a 
great extent. Since TRIPS Agreement does not provide for definition 
of invention, therefore it has been left for member countries to define 
the term in their best interest. However, CPA Order No. 81 changes 
the definition to include every kind of technical invention. As for the 
requirement of new invention, the CPA Order No. 81 has improved 
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both section of 1.4 and 2 by clearly presenting and requesting that the 
invention has to be new and novel in order to be patentable. It has also 
improved the Iraqi patent law so that it could reach the same level of 
that of international communities and TRIPS Agreement. However, 
failed to include optional requirement of the TRIPS Agreement in 
Article 29.1 of requesting the inventor to reveal the best mode for 
carrying out the invention. 
The CPA Order No. 81 enhanced the original law by clearing the 
doubt and ambiguity of the criterion that the invention should ‘involve 
an inventive step’, as its required by the TRIPS Agreement. Because 
the original law did not mention the inventive step requirement in an 
obvious way. Since it is the one of the essential and important criteria 
of patentability in the modern patent system, therefore the amendment 
in this regard by the CPA Order No. 81 is positive improvement.  
The CPA Order No. 81 has successfully aligned the ‘industrial 
applicability’ requirement with that of the TRIPS Agreement like the 
previous two requirements. Choosing the ‘industrial applicability’ 
instead of ‘usefulness’, will be much better for Iraq as a developing 
country that want to receive all technology to develop itself as the 
term usefulness is much wider and allows patenting of broader fields. 
However, the CPA Order No. 81 by asserting ‘in any of the fields of 
technology’ and suspending the exception of ‘medical and 
pharmaceutical formulation’, has burdened Iraq to a responsibility 
which is not obliged to take while still not a WTO member. This step 
is not in favour of Iraq because it has not yet recovered from the 
severe aftereffect of the invasion and still in war with terror. Many 
Iraqi people still living in shelter and not have access to basic living 
requirements including medicine. Therefore, this amendment can be 
considered as a premature move by the CPA and the Iraqi interest was 
not in mind while the original law amended as much as trying to 
higher the standard of intellectual property protection to that of the 









2 EXCLUSIONS FROM 
PATENTABILITY 
2.1 INTRODUCTION 
Article 27.1 of the TRIPS Agreement generalized granting patent 
for all types of inventions in all the fields of technology without 
excluding any areas and without discrimination as to the place of 
invention. However, Article 27.2 and 27.3 of the TRIPS Agreement 
limited the first provision by excluding some types of invention from 
patentability. For example, Article 27.2 gives freedom and choice to 
member countries to exclude from patentability of invention if the 
commercial exploitation of such invention in the territory of a member 
country goes against ordre public and morality. Hence, this chapter 
discusses Article 27.2 of the TRIPS Agreement first, then will be 
followed by the position of Iraqi patent law.  
Similarly, Article 27.3 provides for two different types of 
exclusions which are also optional for member countries to implement 
or not. The first type is related to methods of treatment of humans or 
animals whether be a diagnostic, therapeutic and surgical. In this 
chapter detail of this provision is discussed with reference to those 
countries that provide for protection of method of treatment through 
patent such as United States of America, New Zealand and Australia. 
Then the position of Iraqi patent law and its amendments will be 
discussed. The second part of Article 27.3 provides for exclusions 
from patentability of plants and animal. However, this provision 
requests the member countries to provide for protection whether be in 
a form of patent or sui generis system or combination of both of them. 
Due to the significance of this provision, it will not be discussed in 
this chapter, but will be analysed in a broader context independently in 
the next chapter.    
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Lastly, this chapter will examine the access to medicines and 
public health. Due to importance of this topic, this chapter will focus 
on the Doha Declaration on the TRIPS Agreement and Public Health 
as well. Some of the paragraphs of the Doha Declaration deal with 
flexibilities and options of the member countries to handle their 
domestic issues concerning public health. The position of developing 
countries and how they can access to medicines to fulfil their public 
needs will be discussed. Then the position of Iraqi patent law and its 
amendments will be discussed.   
2.2 ORDRE PUBLIC AND MORALITY 
2.2.1 Ordre public and Morality Under TRIPS Agreement 
Article 27.2 of the TRIPS Agreement allows member countries to 
exclude inventions from patentability if the commercial exploitation 
of the inventions endanger ordre public and morality in territory of the 
country concerned.
236
 This is based on the proposals submitted by (the 









  The concept of ordre public and 
morality is not new as many countries used these concepts to prevent 
inventions from patenting long time even before the TRIPS 
Agreement was born. For example, in the United States of America, 
these concepts referred to in 1817 as ‘frivolous or injurious to the 
well-being, good policy, or sound morals of a society’. In European 
countries’ laws and many other civil law countries the practice of 
exclusion from patentability similar to the wordings of Article 27.2 of 
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the TRIPS Agreement, were provided for. Such as Article 53(a)
241
 of 
the European Patent Convention.
242
  
The notion of ‘ordre public’ is taken from the French word of 
public order and it is used because it gives much narrower meaning 
than the English notions of ‘public order’ and ‘public interest’. The 
European Patent Office has related ordre public to cases such as riots 
and public disorder, or those inventions that leads to criminal or 
offensive behaviour. Every invention has to be taken individually in 
order to be decided whether it is against ordre public. However, since 
there are no exact cases and situations that can be limited to ordre 
public, therefore, member countries are free to apply the ordre public 
to those situations that have no prior cases nor well known at 
international level. This in fact gives a flexibility to member countries 
to evaluate their conditions and decide on those principles if are 
breached will tantamount breaching ordre public.
243
 Ordre public can 
be related to public policy, which is directly affecting the institutions 
of a particular society. Without such ordre public, society will tear 
apart, and the structure of civil society will be endangered.
244
 It is also 
related to the notion of security, whether collective or individual, such 
as physical damage or anything can put the normal life of society in 
general into risk, or simply disharmonize the livelihood of individuals 
to live in peace and security.
245
     
In the same way of the ordre public, the term morality is not 
defined in the TRIPS Agreement. Likewise, a unanimous definition of 
the term morality was not achieved so far at the international law.
246
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However, Article XX(a) of GATT of 1947
247
 which appeared also in 
GATT of 1994 was dedicated for the ‘General Exceptions’ in which 
‘public morals’ which was considered as one of the bases of excluding 
invention from patentability. Here, the law clearly states that its public 
morals and not individual morals or private morals that leads to 
exceptions.
248
 Therefore, if the commercial exploitation of the 
invention in the territory of a member country caused collective 
immorality or has negative effect on the morality of the community at 
large, then this member country is allowed to exclude such invention 
from patentability.  
Though originally there is a jurisprudential debate as the positivist 
school of law believes that law should be based on logic and reason 
only without considering morality. On the other hand, the school of 
natural law believes that law should reflect the morals of society.
249
 In 
line with this principle, the majority of countries in the world 
considered morality in regulating their laws. For this reason, the 
draftsmen of TRIPS Agreement and GATT were cogitating on this 
principle. That is why we can clearly see that the TRIPS Agreement 
did not ignore the issue of morality in intellectual property protection. 
Furthermore, what constitutes a morality is dependent on the 
understanding of a country or cultural group to a particular conduct. 
Because some conducts and behaviours are considered normal and 
correct in some countries and societies, while in some other societies 
and countries the same conducts and behaviours are seen utterly 
different. Hence, the evaluation has to be done on case by case basis. 
In this regard religious, social and moral values of every society have 
to be considered. Therefore, in evaluating the outcome of industrial 
exploitation of an invention, whether it will affect the morality of the 
society, it has to be looked at from the realizations of fair and 
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reasonable persons. Needless to mention that the principle of good 
faith has to be observed as well.
250
    
Article 27.2 of the TRIPS Agreement includes the term 
‘necessary’ and this looked at as requirement from the member 
countries. It has to be proven that it is necessary to exclude the 
invention from patentability because its commercial exploitation 
endangers the ordre public and morality of the member country. This 
needs to be shown that there is a real connection between the 
safeguarding of the ordre public and morality and the outcome of the 
measure that has been taken by the member country.
251
 The member 
country also has to prove that other measures were not available that 
are consistent with the principles of the WTO, in order to be taken by 
them to protect ordre public and morality. This means that the 
member country has to use this measure as the last resort, after 
ensuring that there was no other justifiable and reasonable alternative 
that is less consistent with the WTO.
252
  
To elaborate more on ordre public, Article 27.2 of the TRIPS 
Agreement provides some examples that may be considered as a basis 
for ordre public and morality which they are protection of ‘human, 
animal or plant life or health or to avoid serious prejudice to the 
environment’. However, ordre public and morality are not limited to 
these situations or cases related to these situations. But still the focus 
is on the commercial exploitation of the invention and not the 
invention itself. The TRIPS Agreement allows member countries to 
exclude from patentability the invention that its commercial 
exploitation goes against the principles of ordre public. Therefore, if 
the invention is not applied in the member country, then the member 
country cannot exclude its patentability. The TRIPS Agreement 
clearly states that such exploitation has to be practically occurred in 
specific territory of the member country. In other words, the invention 
has to be industrially applied and exploited in territory of a particular 
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member country, and then this member country will be allowed to 
exclude its patentability base on the principles of ordre public.  
The last proviso of Article 27.2 states that it’s not allowed for a 
member country to exclude patentability merely because the industrial 
exploitation of the invention is prohibited by domestic law. Therefore, 
in order for any invention to be excluded from patentability has to be 
based on real grounds as mentioned in Article 27.2.
253
 This is 
influenced by Article 4quater of the Paris Convention for the 
Protection of Industrial Property, in which the Article states that ‘The 
grant of a patent shall not be refused and a patent shall not be 
invalidated on the ground that the sale of the patented product or of a 
product obtained by means of a patented process is subject to 
restrictions or limitations resulting from the domestic law’.
254
 
According to this Article of the Paris Convention restrictions and 
limitations by domestic laws and regulations that are not part of the 
patent system, should not be imported into the system.
255
 However, 
Article 27.2 of the TRIPS Agreement goes further than sale of 
products or products itself, by generalizing the concept of exclusion to 
every kind of commercial exploitations that the right holder obtained 
by the TRIPS Agreement. Since commercial exploitation is not 
defined in the TRIPS Agreement, therefore, one can apply the 
definition of The Panel in the case of Canada-Pharmaceutical 
Patents, which states that exploitation include every commercial 
activity that the patent holder performing on his patent in order to gain 
economic benefits.
256
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2.2.2 Ordre public and Morality Under Iraqi Patent Law 
Section 3 of the Patent and Industrial Designs Law No. 65 of 
1970 states that ‘Patent shall not be granted in the following 
circumstances; 1. Inventions in which their exploitations cause 
breaches of public moral or ordre public or contradict the public 
interest’. Here the law clearly refers to the exploitation of an 
invention. In fact, the Law No. 65 of 1970 is different from Article 
27.2 of the TRIPS Agreement because the word commercial does not 
exist within section 3.1 of the Law No. 65 of 1970. However, the 
explanation in section 1.2 of the Instruction No. 1 of 1990 on 
implementing Law No. 65 of 1970 and Regulation No. 3 of 2001 on 
the classification of Patents and Industrial Designs in section 2(b), 
made it clear that the word exploitation or industrial exploitation 
(application) ‘can be applied or used in any fields of work related to 
industry, agriculture, profession, and services in broader 
understanding’.
257
 Therefore, the term exploitation has general 
meaning and can be referred to any kind of commercial use, in which 
the patent holder uses his patent to gain benefits.  
When it comes to the issue of morality, under the Iraqi Patent 
Law the word public moral is used, hence, clearly eliminate any 
doubts that may arise whether morality is meant to be public or 
individual moral as in the case of Article 27.2 of the TRIPS 
Agreement as has been discussed in the previous section.  
Iraq is one of the most multicultural and socially diverse countries 
in the Middle East. Therefore, the meaning of the term public moral 
needs to carry the broadest sense as much possible. Because what is 
moral according to Iraqi Muslims may not be the same for Iraqi 
Christians, Yazidis or Sabians )Mandaean) or other minority religions, 
and vice versa. Iraq has some ethnics as well, apart from Arab, such as 
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Kurds which is the second largest population, and other ethnic 
minorities like Assyrians, Syriac, Turkmen, Armenian and Yazidi 
which is considered as a different ethnic as well. With all this 
diversity, it will be difficult to define public morality in Iraq, because 
each of these religious and ethnic groups are living in separate areas. 
Even though in the big cities such as Baghdad, all these groups can be 
found creating one big community with shared perspective of morals. 
However, one can find a village or a group of villages, or even a city 
that have only one of these religious or ethnic groups. That is why in 
the early beginning the Iraqi patent law referred to public moral and 
still it’s a big task to define exact conducts of public moral in Iraq. 
After all, in the end, balance has to be created between public and 
individual interests. And every moral in question should be evaluated 
by a reasonable person in a good faith. 
Section 3 of the Patent and Industrial Designs Law No. 65 of 
1970 refers to two more reasons beside public morality, which 
member countries can exclude patentability of an invention base on 
them which they are ‘ordre public and public interest’. If the 
exploitation of an invention breaches ordre public or contradict public 
interest, then Iraq is allowed to refuse patenting such invention no 
matter how innovative and novel it is. As for the term ‘ordre public’, 
it has same meaning as and will cover all those areas that covered by 
the TRIPS Agreement. However, the Law No. 65 of 1970 does not 
refer to ‘protect human, animal or plant life or health or to avoid 
serious prejudice to the environment’ and CPA Order No. 81 also did 
not amend this subsection, therefore it is enforced as it is without 
referring to ‘protect human, animal or plant life or health or to avoid 
serious prejudice to the environment’. Nevertheless, as it is explained 
previously these are simply some examples and the words ‘ordre 
public and morality’ cannot be limited to these issues only.  However, 
the Law No. 65 of 1970 has an extra term which is ‘public interest’. 
Public interest is very general term which can include the above issues 
and more. Because if its limited and can only be invoked in the most 
serious issues of public order such as ‘where a genuine and 
sufficiently serious threat is posed to one of the fundamental interests 




 then why public interest mentioned in the same 
subsection with ordre public.  
Public interest can be invoked when if the exploitation of the 
invention goes against the interest of the public. However, the same 
precautions of ordre public and morality has to be taken into 
consideration while invoking the issue of public interest, such as 
weighing and balancing all the factors.
259
  
Lastly, the question then will be whether section 3.1 of the Law 
No. 65 of 1970 comply with the TRIPS Agreement. Despite the CPA 
Order No. 81 ordered with the intention to bring intellectual property 
law of Iraq up to the international standard and joining Iraq to WTO 
(TRIPS Agreement) was in mind while the CPA Order No. 81 was 
regulated.
260
 Therefore, by not adding or deleting any words in this 
subsection, one can conclude that the CPA was of the opinion that this 
subsection was in fact is in compliance with the TRIPS Agreement. 
Nevertheless, the extra term ‘public interest’ is wide enough to 
include ordre public and public morals, and other areas. As Nicolas F. 
Diebold, while analysing the public order and public morals, states 
that all the exceptions under Article XIV of General Agreement on 
Trade in Services (hereinafter the “GATS”) and Article XX GATT are 
public interests which can be used member countries to justify their 
actions.
261
 Therefore, the term ‘public interest’ is an extra exception 
that cannot be found in Article 27.2 of the TRIPS Agreement. 
Nevertheless, under Article 8.1 of the TRIPS Agreement, member 
countries are allowed to take measures to promote their ‘public 
interest in sectors of vital importance to their socio-economic and 
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 Therefore, it can be concluded that 
section 3.1 of the Law No. 65 of 1970 is in compliance with the 
provisions of the TRIPS Agreement by following the general 
principles that stated in Article 8.1.   
2.3 DIAGNOSTIC, THERAPEUTIC AND SURGICAL METHODS FOR THE 
TREATMENT OF HUMANS OR ANIMALS 
2.3.1 Diagnostic, therapeutic and surgical methods for the 





 of the TRIPS Agreement provides for some 
exclusions from patentability by member countries, such as (a) 
diagnostic, therapeutic and surgical methods for the treatment of 
humans or animals, (b) plants and animal. Even though in 
subparagraph (b) member countries required to provide protection of 
plant varieties in form of a patent system or an effective sui generis 
system or both.  
Based on the developing countries’ proposal, Article 27.3(a) 
introduced a provision that relate to medical care. However, the 
proposal by the developing countries
264
 were much wider than what is 
stated in this provision. The exception in this clause is limited to those 
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categories that are mentioned.
265
 This provision is dealing with 
methods of treatment of humans and animals, which cannot be used 
for excluding products and process that are part of human and animal 
treatments. Therefore, only those methods that are used in medical 
treatment of humans and animals can be excluded from 
patentability.
266
 Other methods which are not used for animal 
treatment, such as those methods used for enhancing the quality of 
animal meat or used for enhancing other beneficial properties of 
animals, cannot be excluded from patentability according to Article 
27.3(a). Likewise, cosmetic methods are not subject to this provision 
because they are not considered to be an essentially importance for 
public health and are not under ethical scrutiny, unlike other methods 
of treatment.
267
     
This provision is limited to diagnostic, therapeutic and surgical 
methods that are used in treating humans or animals. Many countries 
around the world exclude these methods from patentability. Even 
though some of them do not have included specifically in their laws 
but still exclude them on the base of lack of industrial applicability.
268
 
However, under TRIPS Agreement these methods excluded from 
patentability as an exception and not on lack of patentability 
requirements.
269
 And TRIPS Agreement does not enforce member 
countries to implement this provision because it is an optional 
provision. However, a country like United Kingdom clearly in The 
Patents Act of 1977 in section 4A of Methods of treatment or 
diagnosis, states that ‘(1) A patent shall not be granted for the 
invention of- (a) a method of treatment of the human or animal body 
by surgery or therapy, or (b) a method of diagnosis practised on the 
human or animal body’.
270
 Similar provisions can be found in other 
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international conventions, for example in European Patent Convention 
(EPC 1973) in both Article of 52(4) and 53(c).
271
  
 Nevertheless, in some developed countries like Australia, New 
Zealand and United States of America these methods are patentable if 
they satisfy the criteria of patentability. In United States of America, 
the criterion of utility is used instead of industrial applicability, hence 
the scope of patentability is broader in such a way that methods of 
treatment can be patented. Though in 1996 the United States Patent 
law (United States Code Title 35 - Patents) was amended
272
 to give 
immunity to medical practitioners from infringement suits for using 
patented surgical procedures.
273
 In New Zealand, the method of 
treatment of humans and animals are patented. However, the 
patentability of these methods is not unlimited. There is an exception 
to this type of patents. If the method used to surgery on humans or to 
treat or prevent diseases in humans, then the method will not be 
patented. On the other hand, patentability of these methods in 
Australia are much broader. The general position in Australia is that 
the methods of medical treatment are patentable.
274
  
Granting patents to methods of treatment are rare in countries 
where they allow patenting such methods. A possible reason behind 
this may be the difficulties in enforcing such patents. It is very 
problematic for patent owners to check and monitor activities of a 
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large number of doctors and surgeons while practicing and applying 
these methods in their own private offices whereas strict privacy rules 
apply between them and patients.
275
       
Reasons for excluding these methods may be different from one 
country to another but generally can be related to ethical and moral 
issues in the developed countries.
276
 However, most of the developing 
countries are excluding methods of treatment on the basis of necessity 
of their countries to have such methods available for free.
277
 Some 
other justifications for not patenting these methods may include; First, 
Patients may be denied to have access to a method of treatment while 
no other alternative is available; Second, The right holder may refuse 
the patented method; Third, Compulsory licence may not be the right 
toll to make the patented information available for all; Fourth, 
Patenting these methods will prevent flow of ideas between scientists 
and medical profession; Fifth, Conflicts of interest between the doctor 
and patient if the doctor is the right holder of the patented method of 
treatment; Lastly, Disclosure of patient’s record for the purpose of 
royalty payment by the patentee.
278
       
However, generally it is an accepted idea among the profession 
that such invention should be dealt with by peer review and other 
colleagues be able to benefit from the invention. Such practices are 
considered to be part of professional ethics; therefore, these methods 
are not dealt with by the patent office. However, Nuno Pires de 
Carvalho compares these methods to culinary recipes and believes that 
both of them are generally not patented because their exact application 
will depend on individual skills. He believes that even if cooking 
recipes can be patented, but usually are not applied for. Because the 
application of the recipes depend on a skilled cook and his reward will 
be through becoming popular chef and gains through having more 
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clients and put higher prices on his menu. In the same way the skilled 
doctor or surgeon will be able to apply the methods. Also, such 
methods have very limited markets because they are usually applied 
on very limited cases. Therefore, rewards can be received by applying 
them skilfully and gain professional prestige.
279
       
Generally, Article 27.3(a) of the TRIPS Agreement does not 
affect patentability of equipment and instruments that will be used for 
executing these methods that are mentioned in the provision. But in 
case these methods can be performed without using the patented 
apparatus and instruments, then according to Article 27.3(a) the user 
has to get permission from the right holder of such apparatus in order 
to execute such methods. Nevertheless, the governments have other 
options to bypass the permission of the rights holder of this apparatus 
such as compulsory licences, because such apparatus made the non-
patented methods a de facto monopolization.
280
 Even though one may 
argue that pharmaceutical products are considered methods of 
treatment for humans and animals, then according to Article 27.3(a) 
can be excluded from patentability. Because patent claims relating to a 
particular substance that can be used for medical treatment and 
therapeutic methods are almost same without any real difference 
between them. In both situations a medical activity is going to be 
applied for a patent.
281
 However, Article 70.8
282
 of the TRIPS 
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Agreement clearly stated that member countries have to provide 
patent protection for pharmaceutical and agricultural chemical 
products.
283
   
 
2.3.2 Iraq’s Patent Law Position to Diagnostic, therapeutic 
and surgical methods for the treatment of humans or 
animals 
The Patent and Industrial Design Law No. 65 of 1970 does not 
contain any provision to regulate protection of diagnostic, therapeutic 
and surgical methods for the treatment of humans or animals or to 
exclude such methods from patentability. The only provision in regard 
of patenting medical activity is section 3.2 which stated that patent 
shall not be granted to medical and pharmaceutical formulations, and 
without stating any rules in regard of methods of treatment of humans 
and animals. Since the law is silent about patenting methods of 
treatment, therefore, it can be considered that these methods are 
patentable.  
The most important amendments to the Law No. 65 of 1970, were 
passed through Law No. 28 of 1999 and CPA Order No. 81. However, 
none of these two amendments touch the issue of patenting or 
excluding from patentability the methods of treatment of humans or 
animals. Surprisingly both of them suspended section 3.2 of the Law 
No. 65 of 1970 which excluded medical and pharmaceutical 
formulations from patentability. In addition to that, the amendment 
Law No. 28 of 1999 may be justified as to why does not have added 
(or remained silent) any regulation with respect to methods of 
treatment. The reason was that this amendment was passed in 1999 
before the invasion of Iraq and there was no intention from Iraqi 
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government to join WTO as Iraq was under sanction by United 
Nations Security Council Resolution 661 of 6 August 1990.
284
  
However, the CPA Order No. 81 was passed after the invasion of 
Iraq, and in the preamble of the Order, it clearly states that 
‘Recognizing the demonstrated interest of the Iraqi Governing Council 
for Iraq to become a full member in the international trading system, 
known as the World Trade Organization, and the desirability of 
adopting modern intellectual property standards’. Therefore, there is 
no excuse for the CPA not to pass any regulation regarding the 
methods of treatment of humans and animals. Does this silence from 
the CPA is because United States of America is allowing patentability 
of methods of treatment of humans and animals? However, since this 
issue is debatable even in United States to the extent that the law in 
this regard was amended in 1996 to provide immunity to medical 
practitioner or a related health care entity against any suits that arises 
from using patented surgical procedures.
285
 Therefore, the CPA should 
have considered this issue more carefully and added a provision 
similar to Article 27.3 (a) of the TRIPS Agreement, because the CPA 
and the United States Government created some ‘cells’ for reforming 
Iraqi Commercial Law. Each of these cells chaired by a senior United 
States National Security Council and included representatives of 
several United States agencies such as Department of Commerce, 
Defense, State, and the Treasury. Then for deciding on every matter, 
the CPA coordinated with the governing Council in Iraq, Iraqi 
ministries, and the Iraqi civil society groups and coalition partners as 
well.
286
 Hence, surely the CPA was aware how less developed Iraq is 
and what will benefit the country in future especially in the area of 
intellectual property rights. All the amendments to the intellectual 
property rights (laws on trademarks, patents and copyrights) were 
passed by the CPA with help of attorneys for the United States Patent 
and Trademark Office, as they worked closely together. Therefore, the 
                                                 
284 ‘United Nations Official Document -Security Council Resolutions - 1990’ 
<http://www.un.org/Docs/scres/1990/scres90.htm> [accessed 22 February 2018]. 
285 ‘United States Code Title 35 - Patents’, Section 287 (c) (1). 
286 Theodore W. Kassinger and Dylan J. Williams, ‘Commercial Law Reform Issues in the 
Reconstruction of Iraq’, Georgia Journal of International and Comparative Law, 33 
(2004), 217 (pp. 219–20). 
Exclusions from patentability 
163 




Since this provision added basis on the proposal of the developing 
countries and Iraq as one of the developing countries have great 
necessity for provision like this to help develop its medical profession 
and infrastructure. In addition to that, excluding methods of treatment 
from patentability is also popular in developed countries and 
international convention as well. Likewise, many countries around the 
world are preventing methods of medical treatment to be patented, 
including countries from European community, Asia, Africa, North 
America, South America and Central America.
288
 Therefore, the CPA 
by being well aware of the TRIPS Agreement and Iraqi situation, 
should have added a provision to section 3 of the Law No. 65 of 1970 
to ‘exclude from patentability: diagnostic, therapeutic and surgical 
methods for the treatment of humans or animals’ as stated by Article 
27.3(a) of the TRIPS Agreement.                
2.4 ACCESS TO MEDICINES AND PUBLIC HEALTH   
2.4.1 General Considerations  
Usually prices of health-related materials and pharmaceuticals are 
very high and the excuse for such high prices is the cost of their 
research and development. Therefore, if level of protection of 
intellectual property rights of pharmaceuticals and other health related 
materials and equipment increase, this will automatically increase 
their prices on the national market as well. The sources of these 
formulations and materials are the developed countries. However, 
public health sectors and normal people in less developed countries 
are economically under pressure and cannot cope with such higher 
prices. Thus, any increase of intellectual property protection of health 
materials will directly affect general population of the developing 
countries. However, Abbott and Correa argued that some developing 
                                                 
287 Kassinger and Williams, p. 224. 
288 O. Mitnovetski and D. Nicol, ‘Are Patents for Methods of Medical Treatment Contrary to 
the Ordre public and Morality or “generally Inconvenient”?’, Journal of Medical Ethics, 
30.5 (2004), 470–75 (p. 470) <https://doi.org/10.1136/jme.2002.000786>. 
SAMAN ABDULRAHMAN ALI 
164 
countries like Saudi Arabia that have high level of petroleum 
revenues, increasing intellectual property protection of 
pharmaceuticals and other health related materials may not affect the 
country’s public health sector.
 289
  
The countries spending on drugs within the public health sector 
are in different situations. For example, the developed countries 
expenditures on drugs is around 10 to 20 percent of total health 
spending, while this percentage goes much higher up to 50 percent in 
the least developed countries. The problem is that the TRIPS 
Agreement does not make any distinction between the lifesaving 




The TRIPS Agreement has been blamed for preventing countries 
from accessing to inexpensive copies of patented medicines (generic 
drugs) and raising prices of medicines through patent monopolies. The 
higher cost of patented drugs was the reason of inaccessibility of 
AIDS treatment in the developing and least developed countries and 
subsequently thousands of people lost their lives in Africa.
291
      
Pharmaceutical enterprises claiming that strong patent protection 
of their products will lead to good incomes that automatically 
encourage them to conduct expensive research and development. On 
the other hand, lesser standards of protection will lead to low income 
streams and lower incentives to invent. According to this argument, 
the higher the standard of protection and the higher cost of payment 
by consumers will eventually benefit the society by encouraging 
pharmaceutical companies to do long term researches and 
developments. However, it has been argued by the developing 
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countries that in cases of crises of diseases like HIV/AIDS, long term 
research and development will not benefit the patents while they are 
dead. As for other diseases if the price of medicines and other 
products are very high, then only limited numbers of individuals will 
be able to buy them. The rest of the public in developing and least 
developed countries will not be able to buy them in the first place. 
Therefore, the pharmaceutical enterprises will not be able to receive 
incomes that guarantee their survivals.
292
  
However, the profits of pharmaceutical companies are very low in 
developing countries as it represents only 5 to 7 percent of total profit 
of the companies since 90 percent of their sales are within the territory 
of the developed countries. Therefore, it will not be a huge loss to the 
pharmaceutical companies to reduce their profit percentage in the 
developing countries. Rather they should look at it as a humanitarian 
assistance by giving up portion of their profit. Another general 
argument for unreasonably higher prices of pharmaceutical products 
and medicines is the cost of research and development. However, data 
shows that only 10 to 20 percent of pharmaceutical companies’ 
budgets are spent on research and development. The substantial 
amount of their expenses is spent on advertising and promotion, and 
other administrative expenditures. Nonetheless, after all these 
expenses their profits and earnings are very high.
293
     
One may wonder why the developing countries rely on generic 
drugs. One of the main reasons may be due to the response of 
developed countries to public health crises in the developing countries 
as has been described as poor. Even when the World Bank and 
International Monetary Fund interfere to help, their aid will not be so 
much beneficial because their help will be in the form of loans and not 
grants. The loan has to be paid back eventually with addition to 
interest. Hence, overall this aid will weaken the economic 
development of developing and least developed countries. In some 
cases, also, while a country refused to comply or delay 
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implementation of health reform legislation, such as the Republic of 
South Africa, received threating of imposing trade and economic 
sanctions. Therefore, in crises situations, developing countries cannot 
rely on developed countries or international community to response to 
their problems. The developing and least developed countries must 
prepare themselves to respond to any public health crises. The 
principal self-help and solutions for them may be the generic drugs 
that are patented by pharmaceutical enterprises.
294
    
The drug prices vary substantially between patented drugs and 
off-patent drugs, especially when there is more than one company 
produces the drugs. For example, in the United States, the price of off-
patent drugs will reduce by 60 percent, however, when the same drug 
produced by ten companies the price falls to 25 percent of the 
wholesale price of the original patented drug.
295
    
2.4.2 The Doha Declaration on the TRIPS Agreement and 
Public Health 
Even after the enforcement of the TRIPS Agreement, the 
developing and least developed countries did not stop from their 
attempt to protect and advance their essential interests. They 
understood that by working together and creating coalition, they will 
be able to protect themselves from being outplayed by the EU-US 
block. The result of their attempt was the adoption of the Doha 
Declaration on the TRIPS Agreement and Public Health (14 
November 2001) (hereinafter the “Doha Declaration”).
296
 This is the 
clear signal that the developing countries want to remedy the 
unbalanced result of the Uruguay Round.
297
 However, it cannot be 
said that the Doha Declaration will resolve all concerns of the 
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developing countries in regard to medicines and TRIPS Agreement, 
but still it is a significant improvement.
298
 
Initially the Doha Declaration negotiated by member countries of 
the WTO through TRIPS council which made recommendations to the 
General Council and finally to report submitted to the Ministerial 
Conference. Since the Ministerial Conference has ‘the authority to 
take on decisions on all matters under any of the Multilateral Trade 
Agreement’.
299
 Therefore, it can be said that the Doha Declaration is 
the result of WTO decision making framework.
300
 In this capacity, the 
Doha Declaration has legal effect on the WTO bodies, especially the 
Dispute Settlement Body and the Council for TRIPS Agreement as 
well as all the member countries. The Doha Declaration represents a 
political statement that the developing and least developed countries 
rely on in the area of public health in order to have access to 
medicines without fear of legal battle. The Doha Declaration interprets 
the TRIPS Agreement, instructs the council for TRIPS Agreement and 
decide on transitional provisions of the TRIPS Agreement.
301
 
The Doha Declaration generally addresses the issues of public 
health and not limited to some specific issues as the developed 
countries wanted to, such as AIDS. Nevertheless, it finally 
implemented the style that mostly mirrors the drafts of the developing 
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countries. The core point of the draft of the developing countries was 
the notion of that ‘nothing in the TRIPS Agreement shall prevent 
Member from taking measures to protect public health’.
302
 The Doha 
Declaration introduced a major alteration that is not in favour of the 
pharmaceutical companies. Because the developing countries are 
allowed to break patent protections for every kind of illnesses that 
became the national health issue and includes variety of illness such as 
cancer, diabetes, asthma, and etc.
303
 Generally, the Doha Declaration 
modified TRIPS Agreement to the extent that member countries are 




The Doha Declaration consists of 7 paragraphs and the first three 
paragraphs are considered to be preambles and the rest of paragraphs 
are considered to be the operative paragraphs.
305
 In the first paragraph 
of the Doha Declaration it is stated that ‘We recognize the gravity of 
the public health problems afflicting many developing and least-
developed countries, especially those resulting from HIV/AIDS, 
tuberculosis, malaria and other epidemics’.
306
 The ministers clearly 
admitted that there is massive public health problem affecting the 
developing and least developing countries and some examples are 
stated. However, these are just some examples of illnesses that were 
recognised as the major issues during the Doha Ministerial 
Conference. Because as it is clear from the end of the sentence, it 
mentions ‘other epidemics’, which can be related to any other major 
health issues that might face developing and least developed countries 
in future.  
The second paragraph of the Doha Declaration states that ‘We 
stress the need for the WTO Agreement on Trade-Related Aspects of 
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Intellectual Property Rights (TRIPS Agreement) to be part of the 
wider national and international action to address these problems’.
307
 
This paragraph emphasizes that the TRIPS Agreement should not be 
an obstacle in solving issues related to public health concerns by being 
part of the bigger action whether at national or international level in 
order to solve the addressed issues. This might be addressed to some 
of the WTO members which they dismissed the participation of an 
important organization such as World Health Organization in formal 
meeting while discussing the issues of accessing to medicines. Thus, 
one can see that this paragraph obliquely recognizes the role of the 
World Health Organization in preventing and treatment of diseases.
308
        
The third paragraph of the Doha Declaration states that ‘We 
recognize that intellectual property protection is important for the 
development of new medicines. We also recognize the concerns about 
its effects on prices’.
309
 This paragraph attempts to reconcile between 
the position of developed and developing countries by addressing their 
concerns in one paragraph. In the first sentence of the paragraph the 
opinion of the developed countries stressed on by indicating that 
indeed the intellectual property protection is promoting the 
development of new medicines. This came after the developing 
countries presented their doubts that high standard of intellectual 
property protection does not encourage research and development of 
pharmaceutical drugs that particularly relevant to them. The second 
sentence in an inadequate and weak manner admits that higher 
standard of intellectual property protection will have negative 
consequences in which increase the price of patented drugs. This 
automatically will affect the poor people in the developing and least 
developed countries by having difficulty in accessing such medicines. 
This paragraph acknowledges two contradicting opinions. In one side 
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it acknowledges the importance of intellectual property protection for 
research and development of drugs while in the other side it admits 
this is actually a concern and have negative effect on their prices.
310
 
However, this is considered as a big political victory for the 
developing and least developed countries that they achieved consensus 
among all member countries that patent protections have impact on 
drug prices. By nature, the patent system encourages the right holder 
to put higher prices on patented materials than those off patented or 
normal products that are subject to competitive market.
311
    
The fourth Paragraph of the Doha Declaration is an important one 
as it states that: 
  ‘We agree that the TRIPS Agreement does not and should not 
prevent members from taking measures to protect public health. 
Accordingly, while reiterating our commitment to the TRIPS 
Agreement, we affirm that the Agreement can and should be 
interpreted and implemented in a manner supportive of WTO 
members' right to protect public health and, in particular, to promote 
access to medicines for all.  
In this connection, we reaffirm the right of WTO members to use, 
to the full, the provisions in the TRIPS Agreement, which provide 
flexibility for this purpose’.
312 
    
This paragraph was one of the most controversial provisions of 
the Doha Declaration and gone through intensive negotiations because 
the target of the developing countries was to acquire recognition that 
the TRIPS Agreement should not be interpreted to prevent member 
countries to adopt measures that are necessary to protect public health. 
However, the developed countries and pharmaceutical companies used 
pressure and opposed the attempt of the developing countries. The 
developing countries wanted to emphasize on some measures and 
flexibilities such as compulsory licence and parallel importation to 
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enhance public health protection. However, the developed countries 
were of the opinion that reference of public health in Article 8 of the 
TRIPS Agreement should only be applied in consistency with other 
provisions of the TRIPS Agreement. They argued that TRIPS 
Agreement cannot be seen as a barrier of public health’s protection 
and provisions of the TRIPS Agreement should not be undermined. 
Furthermore, the European Union countries are of the opinion that the 
TRIPS Agreement should not be blamed for the health crises that exist 
within the territory of the developing and least developed countries 
and at the same time it should not be a barrier in combating the health 
crises of the developing countries. The European Union’s position was 
more understandable to the situation of the developing countries and 
was ready to negotiate concerns on the interpretation of the provisions 
of the TRIPS Agreement.
313
    
One of the important points of paragraph four is that it started 
with the term of ‘we agree’, which represents the Doha Declaration as 
an agreement by the member countries. And since it is decided by the 
member countries of the WTO, therefore, this agreement can have 
interpretative authority of the TRIPS Agreement according to Article 
31.3
314
 of the Vienna Convention on the Law of Treaties of 1969. 
According to Article 31.3 of the Vienna Convention, in the process of 
interpretation of any treaty or application of its provisions, the 
subsequent agreement among members of the treaty shall be taken 
into account. Not just agreement between members but any 
subsequent practice or any relevant rules of international law has to be 
taken into consideration.
315
 Therefore, the Doha Declaration in 
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paragraph four emphasizes that this declaration is an agreement and 
shall be taken into account in the process of interpretation of the 
TRIPS Agreement or in the process of implementation of the 
provisions of the TRIPS Agreement.   
In the first sentence of paragraph four, the Doha Declaration 
emphasizes that the TRIPS Agreement does not prevent the member 
countries to take measures in order to protect public health and should 
not be interpreted as such. This indicates that a conflict may arise 
between intellectual property rights protection and measures to protect 
public health. Therefore, in such case when a conflict exists between 
the intellectual property rights and public health, the acts of 
intellectual protection should not be an obstacle in front of member 
countries to take necessary measures to protect public health. This can 
be read with Article 8.1
316
 of the TRIPS Agreement which allows 
member countries to adopt measures necessary to protect public 
health, and this provision provides for a proviso that such measure 
have to be consistent with the provisions of the TRIPS Agreement. 
However, when combining Article 8.1 with paragraph four, it can be 
argued that member countries may be able to derogate from some 
obligations under the TRIPS Agreement if it is necessary to protect 
public health.
317
       
The second sentence of paragraph four confirms commitment of 
member countries to the TRIPS Agreement and guides panels and the 
Appellate Body on how to interpret the provisions of the TRIPS 
Agreement on issues relating to public health, as it states, ‘we affirm 
that the Agreement can and should be interpreted and implemented in 
a manner supportive of WTO members' right to protect public health 
and, in particular, to promote access to medicines for all’. Therefore, 
when there is ambiguity, or more than one interpretation is possible in 
a case, the panel or the Appellate Body should choose the 
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interpretation that is supportive the member countries’ right to protect 
public health and particularly to access to medicines.
318
     
In the second part of paragraph four, the Doha Declaration 
emphasizes on another important point which is flexibilities in the 
TRIPS Agreement. This part as states in the Doha Declaration that ‘In 
this connection, we reaffirm the right of WTO members to use, to the 
full, the provisions in the TRIPS Agreement, which provide flexibility 
for this purpose’, affirms that the member countries have full right to 
benefit from all the flexibilities available in the TRIPS Agreement in 
all the areas and especially in the area of protection of public health 
and taking necessary measures in this regard.      
Developing countries and least developed countries also can take 
advantage of Article 8 of the TRIPS Agreement in order to optimize 
the protection of their public health. This can be achieved by taking 
advantage of all the flexibilities and safeguards and incorporate them 
into their legislation. This eventually makes them have better access to 
medicines.
319
 This was confirmed by the former WTO Director-
General Mike Moore, during the discussion of the Doha Declaration, 
as he stated that this meeting is an opportunity for member countries 
to feel that they have right to use the flexibilities in the TRIPS 
Agreement such as parallel imports and compulsory licensing.
320
  
Paragraph five of the Doha Declaration includes four 
subparagraphs. In subparagraph 5 (a) it states that ‘In applying the 
customary rules of interpretation of public international law, each 
provision of the TRIPS Agreement shall be read in the light of the 
object and purpose of the Agreement as expressed, in particular, in its 
objectives and principles’. Here, the Declaration emphasizes on 
customary rules of interpretation according to Article 31 of the Vienna 
Convention as has been discussed within the content of previous 
paragraph four. It also refers to Article 7 and 8 of the TRIPS 
Agreement by stating that each provision of the TRIPS Agreement 
should be read with its objectives and principles, as they are the titles 
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of Article 7 and 8 of the TRIPS Agreement. This indicates that these 
Articles are more than preamble Articles and has to be referred for the 
interpretative purposes.
321
 This clearly has political impact beside its 
legal impact, as combining customary rules of interpretation of public 
international law and objectives and principles of the TRIPS 
Agreement. Therefore, the member countries have the right to take all 




Subparagraph 5.b. states that ‘Each member has the right to grant 
compulsory licences and the freedom to determine the grounds upon 
which such licences are granted’. This subparagraph affirms rights of 
the member countries to use compulsory licence as one of the main 
legal instrument to limit the exclusive rights of the patent owner in 
order to fulfil their public policy objectives including supply of 
medicines according to domestic needs. Article 31 of the TRIPS 
Agreement provides for compulsory licence, but this Article states 
some conditions that has to be followed such as it has to be 
determined case by case, prior negotiation, remuneration … etc. 
Article 31 states some possible grounds which can be used for 
granting compulsory licence, such as national emergency, public non-
commercial use, and anti-competitive. Nevertheless, these grounds are 
not exhaustive, as member countries are free to stipulate other grounds 
as well. This subparagraph of 5.b. just reaffirm that member countries 
have rights of using compulsory licences to fulfil their public health 
needs and meet other objectives as well.
323
      
Subparagraph 5.c. of the Doha Declaration states that ‘Each 
member has the right to determine what constitutes a national 
emergency or other circumstances of extreme urgency, it being 
understood that public health crises, including those relating to 
HIV/AIDS, tuberculosis, malaria and other epidemics, can represent a 
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national emergency or other circumstances of extreme urgency’. This 
subparagraph gives explicit freedom to member countries to determine 
what constitute a national emergency or other circumstances of 
extreme urgency. This is to allow them, to grant compulsory licence 
according to their own circumstances. Combining this subparagraph 
with the previous one is helping the member countries to deal with 
public health more freely without fear of legal battle from the 
pharmaceutical industries.
324
     
The last subparagraph of 5.d. states that ‘The effect of the 
provisions in the TRIPS Agreement that are relevant to the exhaustion 
of intellectual property rights is to leave each member free to establish 
its own regime for such exhaustion without challenge, subject to the 
MFN and national treatment provisions of Articles 3 and 4’. This is 
the clearest evidence and unequivocal recognition that member 
countries of the TRIPS Agreement have right to allow parallel 
importation (exhaustion of intellectual property rights) of medicines. 
When a product has been put onto market by the patent holder, then 
the buyers have right to sale and transfer, and subsequently the patent 
holder’s right to stop such action by buyers is extinguished and 
exhausted by his first sale. In the same way when the patented product 
is licensed whether voluntarily or involuntarily through a compulsory 
licence, and the licensee put the product onto the market, it has the 
same consequences as though the patent holder has put the product 
onto market. There are two provisions in the TRIPS Agreement which 
allow the principle of exhaustion and parallel importation, which they 
are Article 6 and 31 lit. (f). Article 6
325
 states that exhaustion is not 
subject to dispute settlement without defining the term of exhaustion. 
This indicates that member countries are permitted to define this 
principle according to reasonableness and needs. They may define in 
such a way that exhaustion occur by first sale through a licensee in the 
same manner as it happens by first sale through a patent holder. 
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Article 31 lit. (f)
326
 also states that the compulsory licence should be 
granted predominantly for fulfilling the needs of domestic market. 
Hence, the non-predominant portion can be exported by the licensee 
and imported by another without the consent of the patent holder.
327
  
This subparagraph gives an opportunity to those member 
countries that want to legitimately apply for an international 
exhaustion principle according to the TRIPS Agreement. However, 
such member countries should incorporate such permissions in their 
domestic legislations in order be able to benefit from this flexibility or 
others that allowed under the TRIPS Agreement and confirmed by the 
Doha Declaration. Such flexibilities do not automatically become part 
of the laws of member countries, hence the member countries will not 
be protected from legal actions of the patent holders. This is 
unfortunate fact that most of developing countries’ patent laws have 
not used (or partially used) these flexibility in their favour which 
clearly allowed by the TRIPS Agreement.
328
    
Paragraph six of the Doha Declaration states that ‘We recognize 
that WTO members with insufficient or no manufacturing capacities 
in the pharmaceutical sector could face difficulties in making effective 
use of compulsory licensing under the TRIPS Agreement. We instruct 
the Council for TRIPS to find an expeditious solution to this problem 
and to report to the General Council before the end of 2002’.
329
 This 
paragraph acknowledges the fact that some member countries are 
uncapable of utilising the compulsory licence as an effective tool to 
handle their public health crises because of insufficient or no 
manufacturing capacities. At the same time these member countries 
cannot import sufficient quantities of generic medicines from other 
member countries that used the compulsory licence to produce 
medicines. This is due to the restriction imposed by Article 31 lit. (f) 
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that compulsory licence should be granted in order to supply 
predominantly the requirement of domestic market of the member 
country that granted such licence. Though non-predominant portion 
can be exported but the amount may not be sufficient as many 
developing countries may want to import such products in large 
quantities to meet their needs. Therefore, those member countries with 
manufacturing capacities such as India, the United Kingdom and 
United States of America, are able to grant compulsory licence and 
produce the quantities they need for their public health crises. On the 
other hand, those countries that do not have sufficient manufacturing 
capacities to produce medicines will not be able benefit from 
compulsory licence, even though they have massive health crises such 
as AIDS in the African countries. In fact, this is the problem of most 
of the developing countries for the fact that production capacities of 
pharmaceutical products in the world is unbalanced.
330
  
Some developing countries have limited capacity to produce 
certain types of medicines, but not all types that are necessary for their 
public health. However, in general the developing countries have not 
used the compulsory licence as a tool to solve their health care 
problems. This may be due to some reasons; first, increasing incidence 
of patent protection is a recent phenomenon by the TRIPS Agreement; 
second, developing countries facing strong opposition from developed 
countries and their big pharmaceutical companies to use the 
compulsory licences, and such opposition require strong political 
commitment from the developing countries part; third, some 
developing countries have concern over reaction of foreign direct 
investors; forth, it is better for companies and enterprises in 
developing countries to deal directly with foreign patent holders than 
compete against them through compulsory licences; finally, granting 
and implementing compulsory licences require some prior conditions 
that relate to administrative, financial, and technical capacities, which 
are usually absent in developing countries.
331
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Out of this concern the Doha Declaration in the second sentence 
of paragraph six instructed the TRIPS Council to find a solution and 
report back to the General Council before the end of 2002 as a matter 
of urgency. Base on this, a legal situation had to be found so as to 
enable the member countries to authorize compulsory licensing for 
export.
332
 This is clear that the Doha Declaration left this problem 
unresolved and passed the responsibilities onto the Council to find a 
solution. Looking for solution for the problem in the paragraph 6 was 
not easy. It took almost two years of negotiations among member 
countries in order to arrive at a solution that satisfies both of the 
industrialised and developing countries. At the end, and after a 
compromise from both sides a solution achieved and adopted as a 
decision of the General Council.
333
 The decision titled 
‘Implementation of Paragraph 6 of the Doha Declaration on the 





This Decision was considered as a significant step in respond to 
the problem initiated by paragraph 6. According to paragraph 11 of 
the Decision of 30 August 2003, the TRIPS Council has to prepare an 
amendment to the TRIPS Agreement that replace the provisions of the 
Decision by the end of 2003. The amendment was finalized and 
proposed to be adopted by the member countries under the title of 
‘Amendment of the TRIPS Agreement’ Decision of 6 December 
2005.
335
 Article 31bis and the Annex of the TRIPS Agreement, which 
                                                 
332 Bartelt Sandra, ‘Compulsory Licences Pursuant to Trips Article 31 in the Light of the 
Doha Declaration on the Trips Agreement and Public Health’, The Journal of World 
Intellectual Property, 6.2 (2005), 283–310 (p. 296) <https://doi.org/10.1111/j.1747-
1796.2003.tb00202.x>. 
333 Frederick M. Abbott and Rudolf V. Van Puymbroeck, Compulsory Licensing for Public 
Health: A Guide and Model Documents for Implementation of the Doha Declaration 
Paragraph 6 Decision (World Bank Publications, 2005), p. 9 
<http://siteresources.worldbank.org/INTSAREGTOPHIVAIDS/Resources/DohaGuideJun
e22005.pdf>. 
334 ‘WT/L/540 - WTO | Intellectual Property (TRIPS) - Implementation of Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’ 
<https://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm> [accessed 7 April 
2018]. 
335 ‘WTO | Intellectual Property (TRIPS) - Amendment of the TRIPS Agreement - Decision 
of 6 December 2005’ <https://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm> 
[accessed 7 April 2018]. 
Exclusions from patentability 
179 
were the content of the Decision of December 2005 are almost 
identical to the wording of the provisions of the Decision of August 
2003.
336
 The amendment includes waiver of two important provisions 
of Article 31 which are an obstacle of transporting medicines 
produced under compulsory licence to those developing countries with 
insufficient or no manufacturing capacities. First, exporting member 
countries are relinquished from the obligation that they have to 
produce medicines under the compulsory licence predominantly for 
their domestic market. Second, importing member countries of 
medicines produced under compulsory licence are relinquished from 
responsibilities of paying remuneration to the right holder.
337
 These 
are an important and significant improvement in favour of the 
developing countries in order to fulfil their needs through acquiring 
enough medicines for their public health crises.       
The last paragraph of the Doha Declaration, which is paragraph 
seven which states that 
‘We reaffirm the commitment of developed-country 
members to provide incentives to their enterprises and 
institutions to promote and encourage technology transfer to 
least-developed country members pursuant to Article 66.2. 
We also agree that the least-developed country members 
will not be obliged, with respect to pharmaceutical products, 
to implement or apply Sections 5 and 7 of Part II of the 
TRIPS Agreement or to enforce rights provided for under 
these Sections until 1 January 2016, without prejudice to the 
right of least-developed country members to seek other 
extensions of the transition periods as provided for in 
Article 66.1 of the TRIPS Agreement. We instruct the 
Council for TRIPS to take the necessary action to give 
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The least developed countries have repeatedly complained that 
the developed countries are not doing their part of the deal within the 
TRIPS Agreement which is transfer of technology as required by 
Article 66.2.
339
 This article of the TRIPS Agreement requires from the 
developed countries do their best in motivating and encouraging their 
domestic enterprises and institutions for the purpose of transferring 
technology to least developed countries so that they be able to build a 
viable technological base for themselves. Paragraph 7 in the first 
sentence reaffirm this obligation of the developed countries that 
imposed by the TRIPS Agreement. Besides this, a Working Group
340
 
under the umbrella of the General Council established in order to 
make recommendation to help easy transfer of technology to least 
developed countries and examine the relationship between trade and 
transfer of technology.
341
        
The second sentence of paragraph seven provides for extension of 
transitional period for the least developed countries. The extension 
period is in regard of section 5 (Patents) and 7 (Protection of 
Undisclosed Information) and in relation to pharmaceutical products 
only and until 1 January 2016. Though this date is passed right now, 
however, it was a great opportunity for the least developed countries 
to take the advantage of this period because it was an extension over 
the period which is provided for by Article 66.1 of the TRIPS 
Agreement. The least developed countries did not have to follow the 
procedures stated in Article 66.1 in order to benefit from this new 
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extension. As this extension is without prejudice to other rights that 
provided for under Article 66.1, therefore, the least developed 
countries still had rights to apply for extra transitional period for other 
matters under Article 66.1.
342
    
2.4.3 Access to Medicine and Iraqi Patent Law 
The original Iraqi Patent and Industrial Designs Law No. 65 of 
1970 clearly excluded patentability of medicines. Section 3.2 states 
that patent shall not be granted in the cases of medical and 
pharmaceutical formulations. Therefore, according to this subsection, 
Iraq did not give intellectual property right to protect medicines and 
drugs. In this situation Iraq was having access to all medicines 
whether to buy generic drugs or produce medicines by public 
company to fulfil the needs of the people without having permission 
from right owners. According to this subsection even if Iraq was not 
in public health crises such as having epidemics in the country, 
companies and enterprises were allowed to import and export any 
types of drugs without fear of facing legal action by the right holders.     
However, the exclusion of medical and pharmaceutical 
formulations from patentability did not last, as it was repealed by both 
of the major amendment that passed over the original Law No. 65 of 
1970. First the Law No. 28 of 1999 in section 3 states that ‘subsection 
(2) of section 3 of the Law is repealed’. Then for second time the 
same subsection repealed by the CPA Order No. 81. The CPA Order 
No. 81 in Article 6 states that ‘Article 3.2 is suspended’. The CPA 
Order No. 81 refers to the provisions of the Law No. 65 of 1970 as 
Articles and not sections. It is unclear why the Order No. 81 
suspended this subsection from the original Law No. 65 of 1970 while 
it was repealed by the amendment Law No. 28 of 1999. The only 
logical explanation has to be that the CPA was not aware of existing 
amendment Law No. 28 of 1999, otherwise, suspending a repealed 
subsection will not add any legal value to the original Law No. 65 of 
1970. 
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Neither of the amendments of Law No. 28 of 1999 nor the CPA 
Order No. 81 added any new provisions to substitute such suspension. 
Many countries have included some sort of exceptions of patenting 
medicines. For example, Law No. 9.279 of May 14, 1996 (Law on 
Industrial Property) of Brazil in section 43 states some exception to 
exclusive rights of the titleholder and in subsection III states that ‘to 
the preparation of a medicine in accordance with a medical 
prescription for individual cases, carried out by a qualified 
professional, as well as to the medicine so prepared’.
343
 Also Indian 
Patent Act 1970 in section 47 provided that patent shall be granted 
with subject to certain condition and in subsection (4)  states: 
‘in the case of a patent in respect of any medicine or drug, the 
medicine or drug may be imported by the Government for the purpose 
merely of its own use or for distribution in any dispensary, hospital or 
other medical institution maintained by or on behalf of the 
Government or any other dispensary, hospital or other medical 
institution which the Central Government may, having regard to the 
public service that such dispensary, hospital or medical institution 




These examples show that member countries
345
 of the WTO and 
TRIPS Agreement are included in their laws exceptions to exclusive 
rights of patenting medicines whether be in a simple way in case of 
Brazil or in a more advance way as in case of idea in which the 
exception may benefit the country in many situations. Therefore, the 
CPA Order No. 81 should have taken advantage of the Doha 
Declaration by including a new provision in regard of access to 
medicines and drugs to benefit the public health of Iraq. Excluding 
pharmaceutical and medical formulations from patentability may be 
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very extreme for current position of Iraq which intends to join the 
WTO and TRIPS Agreement. But taken into consideration of Iraqi 
situation as a developing country that still in war with terror, the CPA 
Order No. 81 should have included a provision so as to enable Iraq to 
handle public health crises whenever arise.  
 
2.5 CONCLUSION 
Ordre public and morality are two important principles that were 
introduced to TRIPS Agreement in Article 27.2. Though, meaning of 
these terms can be taken from laws of other countries such as United 
States of America and France or other international institutions such 
as European Patent Office, but neither terms defined by the TRIPS 
Agreement. This gives flexibility to member countries to apply these 
terms in their own situations and decide on each case individually. 
Some examples are provided by the TRIPS Agreement that can be 
used as basis for using ordre public and morality by member countries 
to protect them such as ‘human, animal or plant life or health or to 
avoid serious prejudice to the environment’. However, these are just 
samples and ordre public and morality can be extended to other areas 
if necessity requires that. In Patent and Industrial Designs Law No. 65 
of 1970 these concepts are used in a wider context to include public 
moral, ordre public (public policy) and public interest. Clearly these 
terms cover wider areas due to diversity in ethnic, cultural and 
religious sects of Iraq. Therefore, these exclusions can be taken 
advantage of by Iraq since none of the amendments altered them.  
Article 27.3 (a) introduced another important and optional 
exclusion from patentability which is diagnostic, therapeutic and 
surgical methods of treatment of humans and animals. Excluding these 
methods from patentability is very popular around the world and even 
some countries exclude them on the base of lack of industrial 
applicability. However, this provision cannot be found in the Law No. 
65 of 1970. Despite the importance of this exclusion due to the health 
crises in Iraq, the amendments that passed on the Law did not add any 
similar provision. Latest amendment was through CPA Order No. 81. 
The CPA was well aware of the provisions of the TRIPS Agreement, 
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and in the same time the CPA was running Iraq, therefore, through its 
full knowledge of the situation should have added a provision to the 
Law No. 65 of 1970 similar to Article 27.3 (a) of the TRIPS 
Agreement.    
Access to medicines and protection of public health is an 
important issue to the developing and least developed countries. Due 
to the vital of this issue the Doha Declaration on the TRIPS 
Agreement and Public health was adopted in Ministerial Conference 
in 2001. Even though this declaration did not solve all the problems of 
the developing and least developed countries, but it mirrored their 
interest to a great extent. The Doha Declaration gives a great 
opportunity to these countries to have access to medicine to solve their 
public health issues in any epidemic cases without fear of facing legal 
battle from big pharmaceutical companies and developed countries. 
The reason is that the Doha Declaration clearly admits the fact that 
strong intellectual property rights will increases prices of medicines. 
Furthermore, the declaration stresses that the TRIPS Agreement 
should be interpreted and implemented in a manner to fulfil the needs 
of the member countries to protect their public health and have access 
to medicines. Though the Law No. 65 of 1970 excluded 
pharmaceutical and medical formulations from patentability, but this 
exclusion suspended by both of the amendments of Law No. 28 of 
1999 and CPA Order No. 81. In return both amendments were silent 
as how the country resolves the epidemic crises and how the country 
access to medicines in such crises. They should have introduced a 
provision in this regard like most of the developing countries have 
such as Brazil and India.          







3 SAVING SEED, PLANTS AND 
PLANT VARIETIES UNDER 
TRIPS AGREEMENT AND 
IRAQI PATENT LAW 
3.1 INTRODUCTION 
 
Saving seed can be defined as ‘the practice of saving seed yield 
from one harvest for future crop use’. Also, the Brown Bag Sale has 
been explained as it ‘occurs when farmers purchase seed from seed 
companies, plant the seed in their own field, harvest the crop, and then 
sell the reproduced seed to other farmers for them to plant as crop-
seed on their own farms’.
346
 Traditionally farmers in both developed 
and developing countries replanted, exchanged or sold seed from 
previous year production. However, under the patent system farmers 
are not allowed to sell grown seed as its common especially in the 
developed countries that crops annual purchase is a rule. But this 
practice still rare in the developing countries, instead of informal 
reuse, exchange or sell is a normal practice.
347
 
There are some international treaties and organizations that 
govern the patents of plants and seeds. The important ones are The 
International Convention for the Protection of New Varieties of Plants 
(hereinafter the “UPOV Convention”) (Act of 1991), The World 
Trade Organization’s Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS Agreement) (1995), The World 
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Intellectual Property Organization (WIPO), International Treaty on 
Plant Genetic Resources for Food and Agriculture by Food and 
Agricultural Organization of the United Nations (hereinafter the 
“Plant Treaty”) (2001),
348
 and The Convention on Biological 
Diversity (hereinafter the “CBD”). Out of these international treaties, 
Iraq is a member of WIPO,
349
 and most recently on accessed and 
became one of the contracting parties of the Treaty on 27 November 
2017.
350
 and is currently in the process of conceding TRIPS 
Agreement as well. The process of accession of Iraq to the TRIPS 
Agreement first initiated on 13 December 2004 and the working party 
met again for the second time in April 2008.
351
   
Iraqi patent law is still in the process of evolution and not 
finalized yet. The first patent law in the Republic of Iraq was passed 
under the title of (The Patent Law and Industrial Design) Law No. 65 
of 1970, which subsequently undergone many amendments. The first 
amendment was by Law No. 28 of 1999 and the second amendment 
implemented by Law No. 5 of 2002. However, after the invasion of 
Iraq by United States of America and Coalition partners, the Coalition 
Provisional Authority (CPA) under the ruler of Paul Bremer rewrote 
some of the laws of Iraq especially in the areas related to trade in 
general including the patent law. The CPA introduced the Order 81/26 
on April 2004 under the title of (Patents, industrial design, undisclosed 
information, integrated circuits and plant variety Law).
352
 Then, this 
title became the new amended title to the Law No. 65 of 1970 (The 
Patent Law and Industrial Design) and introduced 22 amendments to 
the patent section. Order 81/26 also made some amendments in regard 
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to plant variety by adding chapter Threequater of Protection of New 
Plant Varieties which consists of 28 Articles. However, the Law No. 
65 of 1970 amended in 2013 and chapter Threequater removed 
entirely and was replaced by a new law under the name of Law No. 15 
of 2013 on Registration, Accreditation and Protection of Agricultural 
Varieties.
353
 The study will examine amendments in intellectual 
property laws of Iraq on saving seeds (plant varieties) whether they 
are compatible with international treaties or there are further steps 
necessary to take.   
3.2 INTERNATIONAL TREATIES THAT REGULATE THE PROTECTION 
OF VARIETIES AND PLANTS BY MEANS OF INDUSTRIAL 
PROPERTY RIGHTS 
3.2.1 The World Intellectual Property Organization 
WIPO as an international organization always tried to create an 
international patent system and to provide some minimum protection 
standards. However, as an agent of United Nations, the influence of 
developing countries on WIPO has been great. The developing 
countries were continuously tried to increase the standard of transfer 
of technology in one hand, but when it comes to the scope of 
patentable subject matters, WIPO has not been favoured for the 
inclusion of plant varieties.
354
  The Paris Convention in which Iraq is a 
member country does not have any provision regarding the plant 
varieties.
355
 However, in Patent Law Treaty,
356
 which was passed by 
WIPO ‘with the aim of harmonizing and streamlining formal 
procedures with respect to national and regional patent applications 
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and patents and making such procedures more user friendly’,
357
 
Article 3 (1) (a) states that the provisions of Patent Law Treaty ‘shall 
apply to national and regional applications for patents for invention 
and for patents of addition’. In the Explanatory Notes on The Patent 
Law Treaty and Regulations Under The Patent Law Treaty, which are 
prepared by the International Bureau of the WIPO stated that if a plant 
is the result of a genetic engineering, then application for patents of 
such plants are allowed under the Patent Treaty Law.
358
 Even though 
Iraq is a member state of WIPO, but Iraq is not a contracting party to 
the Patent Treaty Law,
359
 therefore, not bound by the provisions of the 
Patent Treaty Law.    
3.2.2 International Treaty on Plant Genetic Resources for 
Food and Agriculture by Food and Agricultural 
Organization of the United Nations (Plant Treaty) 
The origin of the Plant Treaty goes back to the voluntary 
International Undertaking on the Plant Genetic Resources adopted by 
the Commission on Genetic Resources for Food and Agriculture in 
1983. The international Undertaking’s objective was to ‘make plant 
genetic resources available for plant breeding, recognizing that they 
were a “heritage of mankind” and available to all’.
360
 Later on in 1996 
the Global Plan of Action at the Leipzig International Technical 
Conference on Plant Genetic Resources adopted. All these works then 
adopted by the Commission on Genetic Resources for Food and 
Agriculture in 2001 as a legally binding international treaty and 
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entered into force on 29 June 2004.
 361
 The objectives of the Plant 
Teary as stated in Article 1 are ‘the conservation and sustainable use 
of plant genetic resources for food and agriculture and the fair and 
equitable sharing of the benefits arising out of their use’. Farmers’ 
rights were considered key element during the adoption in 2001 of the 
Plant Treaty and entering into force of the Treaty in 2004.
362
 Article 9 
of the Plant Treaty dedicated to the Farmers’ Rights and recognizes 
and justifies the rights that farmers have due to the ‘enormous 
contribution that the local and indigenous communities and farmers of 
all regions of the world, particularly those in the centres of origin and 
crop diversity, have made and will continue to make for the 
conservation and development of plant genetic resources which 
constitute the basis of food and agriculture production throughout the 
world.’ 
363
 The Plant Treaty further stated that nothing in Article 9 
under Farmers’ Rights shall be interpreted in such a way as to limit 
the farmers’ rights to save, use, exchange and sell farm-
saved/propagating materials.
364
 It is clear that the Treaty doesn’t want 
any contracting party to limit the farmers’ rights which help and 
develop plant genetic resources as a production basis of foods and 
agriculture. However, it has to be taken into account that FAO does 
not address all the rights of the farmers, for example the rights of 
those farmers in regard of those plant varieties commercialised from 
their farm germ plasm.
365
 The Plant Treaty also does not provide for 
intellectual property rights.
366
 Currently Iraq is one of the contracting 
parties as accessed the Treaty on 29 August 2014 and entered into 
force on 27 November 2014.
367
 The entry into force of the Treaty is 
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one year after the last amendment of the Law No. 65 of 1970 in 2013 
and enacting Law No. 15 of 2013 on Registration, Accreditation and 
Protection of Agricultural Varieties.  
However, as stated in the preamble of the Plant Treaty that 
‘Affirming that nothing in this Treaty shall be interpreted as implying 
in any way a change in the rights and obligations of the Contracting 
Parties under other international agreements; Understanding that the 
above recital is not intended to create a hierarchy between this Treaty 
and other international agreements’. The language of the preamble is 
clear enough that contracting parties cannot escape any obligations 
they have under other international agreements, even though they have 
joined them later than the Plant Treaty.
368
 This means that even if Iraq 
in the future will join the TRIPS Agreement, yet it still has to comply 
with the high standard of intellectual property rights that the TRIPS 
Agreement provided for, especially in the area of patent and breeders’ 
rights, even though Iraq is one of the contracting parties of the Pant 
Treaty. 
3.2.3 Convention on Biological Diversity (CBD) 
The United Nations Environment Programme (hereinafter 
“UNEP”) responded to the wide spread acknowledgment of 
importance of biological diversity to present and future generations, 
and to threats to species and ecosystems caused by human activities, 
by establishing some Ad Hoc Working Groups that started from 1988 
to 1991, and by 1992 they agreed on the final version of the text 
which they have provided, and the CBD came into existence. The Ad 
Hoc Working Group while discussing the creation of a legal text, they 
had to take into consideration ‘the need to share costs and benefits 
between developed and developing countries as well as ways and 
means to support innovation by local people.’
369
 The CBD is an 
attempt for creating an international regulation for the purpose of 
conservation and utilization of biological resources. The CBD 
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recognizing that the genetic resources and crop diversities are centred 
in less developed countries. However, the language of the CBD is 
considered vague language because the CBD tried to satisfy the needs 
of all. For that reason, the CBD contains provisions for the protection 
of Intellectual Property rights, transfer of technology, and accesses to 
genetic resources and results and benefits that arise from 
biotechnologies, which should all be based on mutually greed terms 
by both developed and developing countries. These are the outcome of 
the political deal that brought the CBD into existence.
370
  
Genetic resources are defined as ‘genetic materials of actual or 
potential value’ which refers to any ‘any material of plant, animal, 
microbiological or other origin containing functional units if heredity’ 
as defined by Article 2 of the CBD. Therefore, seeds, cuttings and 
even DNA of the plants are all covered within the scope of the CBD. 
In principle the CBD is a convention mainly concerned with the 
farmers’ rights. Hence many developing countries tried to incorporate 
as many provisions as possible into the TRIPS Agreement. Because 
TRIPS Agreement is part of the package of WTO and any country 
(whether it is a developed or less developed) wishes to join the WTO 
has to incorporate the TRIPS Agreement and comply with all its 
provisions. As some developed countries like the United States of 
America not ratified the CBD. The important provisions of the CBD 
that of the farmers’ rights inserted into the TRIPS Agreement are only 
those apparent in Article 27 of the TRIPS Agreement which is related 
to patents and in particular Article 27 (3) which every member 
country has to provide some sort of protection of plant varieties 
whether through a patent or sui generis  system or both.
 371
 
Enforcement of other provisions of the CBD through the TRIPS 
Agreement is opposed by some developed countries such as United 
States of America, Japan and Switzerland.
372
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Iraq has acceded to the CBD in 2009.
373
 However, 
implementation of the CBD has considered by some policy makers 
and members of civil society to cause some conflicts with 
implementation of the TRIPS Agreement when in future Iraq becomes 
party to the TRIPS Agreement. According to them in the TRIPS 
Agreement interest of private commerce is placed above the interest of 
public and reduced other objectives of public policy.
374
 On the 
contrary to that opinion some others are of the belief that contracting 
parties can implement both of the CBD and TRIPS Agreement 
without any conflict and in fact it is what expected from them to do. 
Since this is the normal principle of international law that countries 
are members of different bilateral and multilateral agreements and 
they are in fact implementing all these agreements in the same time, in 
a manner that does not cause any conflict and they considered to 
perform their obligations.
375
     
3.2.4 The International Convention for the Protection of 
New Varieties of Plants (UPOV Convention) (Act of 
1991) 
The UPOV Convention was first drafted in 1961 and came into 
force in 1968 when the United Kingdom, the Netherlands and 
Germany, as first countries ratified the UPOV Convention. The 
UPOV Convention has undergone three revisions in 1972, 1978 and 
1991.
376
 These revisions were not in favour of seed users and farmers 
but were in favour of the corporate breeders. Initially the UPOV 
Convention of 1991 had limited members, but after the TRIPS 
Agreement obliged that every member country should have an 
intellectual property rights for the protection of plant varieties, and 
also through the trade agreements between some developed and non-
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The UPOV Convention is considered as a sui generis  form of 
intellectual property protection
378
 that includes the rights of plant 
breeders and intellectual property rights of plant varieties.
379
 Even 
though Article 27 (3) (b) of the TRIPS Agreement only mentioned the 
word ‘sui generis ’ without anything about the UPOV Convention, 
however majority member countries of the TRIPS Agreement, while 
implementing the requirement of having intellectual property 
protection of plant varieties, they incorporate the UPOV Convention 
into their legal system.
380
    
Although the rights of the farmers and seed savers after every 
revision of the UPOV Convention were narrowed and the rights of the 
corporate breeders strengthened further.
381
 After every revision, 
duration of protection increased as well. In the previous Act of 1978 
the duration of protection was 18 for trees and vines, and 15 for other 
plants. However, in the current UPOV Convention of 1991 the 
minimum duration of protection as stated in Article 19 is 25 years for 
trees and vines, and 20 years for other plants from the date of granting 
protection. However, the UPOV Convention of 1991 provides for 
some exceptions to the Breeder’s right, which some of them 
categorised as compulsory exceptions under Article 15 (1) and the 
other as optional exception which provided in Article 15 (2) of Act 
1991 of the UPOV Convention. The optional exception is new and 
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allows farmers to save seeds under certain conditions in such a way 
that interest of the breeder is not undermined.
382
  
3.2.4.1 Compulsory Exception 
Article 15 (1) of the UPOV Convention of 1991 provided some 
compulsory exception and the first of such exceptions is ‘acts done 
privately and for non-commercial purposes.’ This means that the act 
has to be done for private purposes and at the same time for non-
commercial purposes. If one of these two elements is not available the 
exception does not apply. For example, if seeds of protected variety 
are saved by a farmer in his own farm but used for commercial 
purposes, then the exception does not apply and authorisation from the 
breeder is required. However, if the same seeds are to be used in his 
own gardens without sharing them with others or the farmer use the 
production of the protected seeds only for consumption by himself, his 
families and those dependents on him for living such as subsistence 
farming, then these acts will fall within the scope of Article 15 (1) (i) 
in which breeder’s authorisation is not required.
383
       
The second compulsory exception is provided for under Article 
15 (1) (ii) are ‘acts done for experimental purposes’. This simply 
includes all acts done by any one for the experimental purposes, and 
it’s called ‘research exemption’
384
.  The third and last compulsory 
exceptions to the breeder’s right is ‘acts done for the purpose of 
breeding other varieties’ unless it is ‘essentially derived from the 
protected varieties, not clearly distinguishable from the protected 
variety or its production requires the repeated use of the protected 
variety’, as stated in Article 14(5). The second part of the third 
compulsory exception is ‘acts referred to in Article 14 (1) to (4) in 
respect of such other varieties’, which they are (multiplication, 
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conditioning, offering, marketing, etc). The third compulsory 
exception also called ‘breeder’s exemption’.
385
  
3.2.4.2 Optional Exception 
The UPOV Convention of 1991 named Article 15 (2) an optional 
exception, and also the text of the provision with the phrase of ‘each 
Contracting Party may’ clearly suggests that it is an optional 
provision. Therefore, the contracting parties have choice to implement 
it or not, and if decided to adopt the optional exception, then farmers 
are allowed to use the product (seed) of their harvest for propagating 
purposes. However, the product has to be obtained by planting on 
their own holding (Article 15 (2)). The Diplomatic Conference of 
1991 of the UPOV Convention limited the saving seed practice to 
those seeds that only considered as a common practice on the land of 
the Contracting Party. In the Diplomatic Conference was of the 
opinion that this provision cannot be presented as a ‘farmer’s 
privilege’ and cannot be extended to areas of agricultural or 
horticultural production in which replanting saving seeds are not 
common practice. This means that other areas in which the production 
of the harvest is not used for replanting as a common practice such as 
production of fruits, ornamentals and vegetables, cannot be covered 
by the optional exception of the UPOV Convention.
386
         
The phrase of ‘within reasonable limits and subject to the 
safeguard of the legitimate interests of the breeder’ is a requirement 
that all member countries have to take into consideration while 
implementing the optional exception. Even though inclusion of the 
optional exception into the UPOC Convention of 1991 is recognition 
of saving seed practice by some countries, but the process has to be 
applied on a crop by crop basis according to the member country in 
such a way that does not prejudice the legitimate interests of the 
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breeder and does not weaken the objectives and incentives that 
provided by the UPOV Convention.
387
 The purpose of all these 
exceptions in general is creating a balance between rewarding 
innovations in plant varieties and use of these protected innovations 
for benefits of society as a whole.
388
 This will certainly depend on 
each member state individually and during implementing this 
provision the concerned member state has to consider all relevant 
factors in order to arrive to such balanced legislation of plant variety 
protection. Iraq currently is not one of the Members of UPOV, 
however when expressed an interest of becoming Member of UPOV 
and participate in the sessions of the Council, Iraq accepted by the 
Office of the Union to be an observer of the Council of the UPOV.
389
  
3.2.5 Saving Seeds under TRIPS Agreement 
TRIPS Agreement is considered unique in nature as it includes 
minimum standard of patentable objects. Before TRIPS Agreement 
patent principles regulated by Paris Convention, as it allowed states 
liberally to exclude from patentability. Article 27 of the TRIPS 
Agreement is considered one of the important Articles of the TRIPS 
Agreement as it regulates the patent. The subject of patent is a 
commercial subject and highly affecting the livelihood of all the 
members and in particular the less developed countries. In general, 
Article 27 of the agreement requires the Member countries to grant 
patent if the conditions of paragraph 1 met and not lawfully excluded 
from patentability according to paragraphs 2 and 3 of Article 27. Even 
though Article 27 should provide for minimum standard of protection 
rights but paragraph 1 stated that ‘patents shall be available for any 
inventions, whether products or processes’, which is considered as a 
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very high standard of protection. This part of paragraph 1 directed to 
the developing countries as it was practice of many of them to exclude 
patentability of many areas though the general conditions of being 
‘new, involve an inventive step and are capable of industrial 
application’ were available. Therefore, developing countries should 
provide for patents for all the areas unless it’s provided for exclusions 
under paragraphs of 2 and 3.
390
    
The generality of Article 27.1 of the TRIPS Agreement caused 
some disagreement among member countries. One of the controversial 
areas that includes in Article 27.1 is biotechnology related inventions. 
TRIPS Agreement does not provide any rules to regulate 
biotechnology related inventions. However, Article 27.3 (b) which is 
an exception clause stated that the members are allowed to exclude 
from patentability plants and animals. Also, Article 27.2 provides for 
very general exceptions on the ground of ordre public and morality, 
which can be relied on in cases where members could not avoid 
patentability on bases of Article 27.3.
391
     
3.2.5.1 Article 27.3 (b) of the TRIPS Agreement 
The provision of Article 27.3 (b) is a complex provision and it 
reflects the position of most of the developing countries and some 
developed countries as well. The developing countries during the time 
of Uruguay Round (during the negotiation of the TRIPS Agreement) 
were not experienced enough to evaluate any provisions related to the 
field of biotechnology. Furthermore, some developed countries such 
as Canada was reluctant to submit to full patentability according to 
Article 27.3 (b), as there was a debate at national level whether to 
accept the patentability of higher life forms. Therefore, during the 
Uruguay Round Canada was reluctant to accept the patentability of 
higher life forms in Article 27.3 (b).
392
 Since the TRIPS Agreement 
has come into existence the differences among developed countries 
reduced but not eliminated as to what should be patented and excluded 
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from patentability. In the United States of America plant varieties and 
animal races are subject to protection while in Europe they are not.
393
 
The origin of patentability of living things is relatively new in 
developed countries, as it traces back to 1930s in the United States of 
America and as for the plant varieties and breeders’ rights it started to 
exist in second half of the twentieth century.
394
  
Article 27.3 (b) allows the patentability of micro-organism, 
micro-biological processes for the production of plants and animals, 
and non-biological processes for the productions of plants and 
animals. However, members are allowed to exclude from patentability 
‘whole animal (including, obviously, human beings), animal varieties 
and parts of animals (including parts of human beings); whole plants 
and plant varieties (provided an alternative system of protection is 
provided) and parts of plants; and essentially biological process.’
395
 
Article 27.3 (b) gives some flexibilities for protection of plant 
varieties, however, the provision enforces the member countries to 
provide some form of protection through patent or any form of sui 
generis . This causes problems to the developing countries as most of 
them never have any form of protection to the plant varieties and this 
caused concern for them as any form of protection will have huge 
impact on their farming practices especially in the area of seed saving 
and exchanging, genetic diversity and food security. For that reason, 
during the negotiations most of the developing countries backed up by 
European Community countries rejected the proposal forwarded by 
the United States, Japan, the Nordic countries and Switzerland. They 
proposed that plants and living organisms to be widely covered and 
protected by patent.
 396 
A question may arise here: what is Plant variety? Since the TRIPS 
Agreement does not provide a definition for it. However, in order to 
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understand what Plant Variety is, one can look at other conventions 
such as the UPOV convention and also more clear definition can be 
found in a ruling of European Patent Office in 1995 of (Greenpeace v 
Plant Genetic Systems NV) by refereeing to the UPOV Convention as 
well. The Technical Board of Appeal of the European Patent Office in 
the Reasons for the Decision stated that plant varieties as a concept 
refers to:  
‘any plant grouping within a single botanical taxon of the lowest-
known rank which, irrespective of whether it would be eligible for 
protection under the UPOV Convention, is characterised by at least 
one single transmissible characteristic distinguishing it from other 
plant groupings and which is sufficiently homogeneous and stable in 
its relevant characteristics’
397
    
Even though Article 27.3 (b) permits member countries to 
exclude from patentability plant varieties including hybrids, plant 
cells, seeds and other plant materials, but they should provide some 
type of protection through patents, sui generis or a combination of 
both. Under this provision it is stated that the sui generis has to be an 
effective sui generis system in protecting the plant varieties, therefore 
the content and scope of the system is left to the discretion of the 
member countries to choose. Again, this flexibilities and choices is 
due to the disagreement among the industrialized countries, as in 
USA, Japan and Australia patenting of plant varieties were allowed 
but this is not the case in Europe.
398
  
3.2.5.2 Sui generis System    
The system of sui generis for protecting the plant varieties is not 
new. During 1920s and 1930s some countries introduced a protection 
system different from patent protection for the purpose of breeders’ 
rights and called it sui generis system. Breeders’ rights also rely on 
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features such as new, distinct, uniform and stable in order to protect 
the plant varieties. Under the breeders’ rights the specific and existing 
plant variety will be protected and allows the farmers to re-use the 
seeds obtained by their own and the protected variety can be used in 
extra breeding without permission from the title holder and this called 
the (Breeders’ exemption). The sui generis system spread around 
world and adopted by many countries especially when the UPOV 
Convention adopted during 1960s.
399
 The UPOV Convention 
described as an inbuilt balance which not only allows farmers to save 
seeds for future uses, but farmers allowed to use new varieties a 
couple of times on his own farm for the purpose of multiplication. The 
UPOV Convention is very useful for the researchers as it allows the 
protected varieties to be used for new selections.
400
 Article 15 (1) (ii) 
of the UPOV Convention of 1991 is dedicated for one of the 
compulsory exceptions to the Breeder’s Right, in which stated that 
breeder’s right shall not extend to ‘acts done for experimental 
purposes’. 
Although the developed countries possess most of the industrial 
technologies in the area of biotechnology, the vast majority of the 
biodiversity exists in the developing countries, which can be 
considered as the source of current developments. However, only the 
developing countries mostly affected (negatively) by the strong patent 
system. Usually developing countries’ fears arise when the patent or 
any intellectual property right system prevent small scale and medium 
scale farmers and breeders from re-using the saved seeds as their 
traditional practice in developing countries. Also relying on small 
numbers of protected seeds may eliminate the varieties of existing 
seeds and affect the biodiversity of the land. Patenting some types of 
genes and plant varieties that are necessary for surviving some 
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developing countries, reduce the chances of further research and 
breeding when necessity required doing so.
401
        
3.3 SAVING SEED UNDER INTELLECTUAL PROPERTY LAWS OF 
IRAQ   
3.3.1 Law No. 50 of 2012 on Seeds and Seed Tubers 
The Iraqi government recognized the importance of seed to the 
country since 1927, the year in which legislation was passed by in 
order to enhance the production of cotton through improved seed. The 
latest attempt by Saddam’s Regime was in 1995 when National Seed 
Board (hereinafter the “NSB”) was established and chaired by the 
Ministry of Agriculture. Under the NSB many research centres 
established for the purpose of seed production and supply among 
others.
402
 The current governing system which is considered a 
democratic system of government tries its best to align its laws with 
international laws. Therefore it has passed some laws such as Law No. 
50 of 2012 on Seeds and Seed Tubers, which is a new attempt to 
organize and encourage seed production in both public and private 
sectors.
403
 Under this law, section 2 states the aims of the Law and in 
subsection two states that the second aim of this law is to ‘guarantee 
the registration, accreditation and protection of new agricultural 
varieties that bred by researcher of Republic of Iraq, including those 
varieties that previously registered and accredited, and to provide 
enough quantities to be given to farmers in suitable times, prices and 
locations, and to ensure special procedures to authenticate the seeds 
and related matters’. The Law guarantees the registration, 
accreditation and protection of new agricultural varieties bred by Iraqi 
researchers including those varieties that previously registered and 
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accredited. Section 2 of the Law states the aim of the Law which 
primarily emphasizes on the varieties and seeds bred by Iraqi 
researchers and breeders without reference to varieties propagated 
outside Iraq as stated in Section 2.   
However, chapter five of the Law deals with Trade of Seeds and 
Seed Tubers, consists of sections of 18 to 30, regulate trade and 
exchange of seeds and seed tubers that are produced, imported or 
exported. These sections give rights to producers, importers and 
exporters of seeds and seed tubers to apply for licence to produce, 
import or export seeds and seed tubers. This clearly gives rights of 
foreign and outside seeds and seed tubers to be registered, accredited 
and protected by Iraqi government. In the final step, the National Seed 
Board after getting recommendation from the competent authority
404
 
will grant approval to licence and can be renewed every three years.
405
 
This shows that this law encourages exchange of seeds and seed 
tubers and allow introducing foreign seeds into Iraqi market, without 
stating the protection duration. However, there are some conditions 
that have to be met before granting the licence of importing and 
releasing foreign seeds into Iraq. Section 18 of the Law No. 50 of 
2012 on Seeds and Seed Tubers, states that application has to be made 
to the competent authority to get a licence, and sample has to be 
submitted for lab inspection before NSB grants permission. There is a 
book guidance of official varieties that all accredited and registered 
varieties recorded in order to be qualified to the program of seed 
authentication (verification).
406
 The importer and imported foreign 
seeds and seed tubers has to comply with the conditions stated by the 
law No. 50 of 2012. For example, the importer should have a valid 
licence in order to import. The type, varieties and country of origin 
has to be fixed on the licence or permission papers that issued from 
official authority that recognized by the competent authority. The 
importer has to notify the NSB on any genetic alteration and the 
nature of the alteration. The imported seeds and seed tubers should 
                                                 
404 The Competent Authority is defined by sec. 1 (14) of the Law No. 50 of 2012 on Seeds 
and Seed Tubers, as General Commission for Seed Inspection and Authentication.  
405 ‘Law No. 50 of 2012 on Seeds and Seed Tubers’, sec. 20 (1). 
406 ‘Law No. 50 of 2012 on Seeds and Seed Tubers’, sec. 8. 
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have been tested by the International Seed Testing Association 
(hereinafter the ‘ISTA’) or other international testing rules that verify 
the seeds authentication according to the laws of the country of origin, 
however, the system of authentication of the country of origin has 
been recognized by the Ministry (Ministry of Agriculture).
407
 Also, 
the imported seeds and seed tubers have to be from varieties available 
and relied on in Iraq. Even though the Minister of Agriculture has 
authority in emergency situations and on suggestion by the NSB to 
allow the importation of limited seeds for limited period from varieties 
that are not relied nor accredited in Iraq but has been accredited in the 
country of origin with the condition that has similar agricultural 
environment to Iraq. If these conditions are not met the imported seeds 
and seed tubers have to be returned or destroyed, with exception to 
small quantities that can be kept for research purposes.
408
           
The Law No. 50 of 2012 on Seeds and Seed Tubers regulate and 
encourage trades of local and foreign seeds. However, it does not 
protect the seeds and seed varieties in the sense of intellectual 
property protections that exist within patents and other sui generis 
systems. Therefore, it cannot be considered as an active sui generis 
system that required by Article 27.3 (b) of the TRIPS agreement.  
3.3.2 The Intellectual Property Legislations 
3.3.2.1 The situation before the Coalition Invasion 
According to the document published by the Food and 
Agriculture Organization of the United Nations (hereinafter the 
“FAO”) in 2015, Iraq as a whole is going through series of political, 
infrastructural and economic crises. These crises affected many areas 
of Iraqis’ livelihoods including the agricultural sector and food 
production. After the 2003 invasion, FAO realised the disasters that 
happened to Iraq’s bank seed, therefore started helping government in 
rebuilding seed industry.
409
 Focusing on Iraq’s agriculture is essential 
                                                 
407 ‘Law No. 50 of 2012 on Seeds and Seed Tubers’, sec. 1 (1). 
408 ‘Law No. 50 of 2012 on Seeds and Seed Tubers’, secs 24–27. 
409 FAO, ‘Iraq and FAO, Advancing Agricultural Technologies for Food Security and 
Resilience’ (FAO, 2015), pp. 1–2 <www.fao.org/3/a-au080e.pdf>. 
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for the Iraqi people as it is one thing that they can always rely on in 
this uncertainty of the political future of the country. Flourishing the 




Historically, Iraq is considered as a land of agriculture by virtue 
of the rivers of Tigris and Euphrates and their tributaries. This fertile 
soil made Iraq cradle land of some of the oldest great civilizations, 
and ‘Iraq is an important primary and secondary centre of 
domestication for many crops such as wheat, barley, lentil, chickpea 
and medics… Cereal production occupies about 95% of the arable 
land.’
411
 However, the original un-amended Patent Law which was 
introduced in 1970 (Law No. 65 of 1970) did not contain any rules to 
regulate the plant varieties. To illustrate that, section 3 of this law was 
allocated to subject matters or areas which cannot be patented did not 
contain any regulations in regard to livings whether animals, plants or 
anything related to them. This shows that before the invasion of Iraq, 
the Iraqi Government did not want to patent any living matters or 
process in this regard. Even after the 2003 invasion when CPA Order 
No. 81/26 April 2004 was introduced by the CPA (which amended the 
first Patent law of 1970), yet section 3 does not contain any regulation 
in this regard. However, the CPA Order No. 81 inserted a new chapter 
for protecting the plant varieties. After the invasion ended and after a 
few set of elections, the new parliament and the new government 
decided that the chapter for plant varieties protection should be 
repealed and replaced by a new Law No. 15 of 2013 on Registration, 
Accreditation and Protection of Agricultural Varieties.    
3.3.2.2 The amendments of the CPA Order No. 81 
CPA took upon itself the responsibilities to rebuild Iraq in every 
way including the legal system. The CPA administrator L. Paul 
Bremer III, through a series of Orders introduced many new rules and 
regulations to many areas of Iraqi Laws, including the intellectual 
property laws of Iraq. Through these changes the CPA wanted to 
                                                 
410 Crosby, p. 527. 
411 Abbas, p. 1. 
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elevate the position of Iraq to the required international standard both 
economically and politically.
412
 One of the Orders was the Order No. 
81 of the CPA which added chapter Threequater (consists of 28 
Articles) of Protection of New Plant Varieties and revolutionised the 
intellectual property protection as it is the first of kind in Iraq’s 
Intellectual Property Laws. In its preamble the Order stated that the 
CPA to enhance the economic condition of the people of Iraq through 
important changes to the Iraqi intellectual property system. One of the 
significant changes was an addition and for the first time explicitly 
new plant varieties (livings) protected with a specific duration of time 
and the law provides punishment for its infringement. Article 1of the 
Order defined the word variety as:  
‘Any plant grouping within a single botanical taxon of the 
lowest known rank, which grouping, irrespective of whether 
the conditions for the grant of a breeder’s right are fully 
met, can be defined by the expression of the characteristics 
resulting from a given genotype or combination of 
genotypes, distinguished from any other plant grouping by 
the expression of at least one of the said characteristics and 
considered as a unit with regard to its suitability for being 
propagated unchanged’
413
        
However, when comparing this definition with the one provided 
by the UPOV Convention of 1991 in its Article 1 (vi) it shows that 
both of the definitions are same. This means that the Order copied the 
definition of variety from the UPOV Convention word by word. When 
it comes to the criteria of registration, the Order required the same 
criteria as those of the UPOV Convention of 1991. The plant variety 
has to be novel, distinctive, uniform and stable, in order to be 
registered and protected by the Order.
414
    
                                                 
412 Elizabeth Mirza Al-Dajani, ‘Post Saddam Restructuring of Intellectual Property Rights in 
Iraq Through a Case Study of Current Intellectual Property Practices in Lebanon, Egypt, 
and Jordan.’, The John Marshall Review of Intellectual Property Law, 6.2 (2007), 250–71 
(pp. 250–51). 
413 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law.’, Article 1 <http://www.wipo.int/wipolex/en/text.jsp?file_id=181090> 
[accessed 10 October 2017]. 
414 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law.’, Chapter Threequarter, Article 4. 
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 Novelty:  3.3.2.2.1
The criterion of novelty as requested by the Order require that the 
variety propagating and harvesting has not being sold or transferred 
with the consent of the breeder for more than one year inside Iraq and 
for more than four years outside Iraq, but six years outside Iraq if 
related to trees and vines, at the date of filing the registration or at the 
date of priority provided for in Article 8 (A) of chapter threequater. 
According to Article 8 (A) of chapter threequater the applicant 
permitted to apply for right of priority within twelve months following 
the first registration. This right of priority is valid in all member 
countries of the WTO or other international agreement in this area in 
which Iraq is a member. This right of priority is also taken from 
Article 11 of the UPOV Convention of 1991. However, as mentioned 
earlier the fact is that Iraq up to this moment is not a member country 
of WTO. Thus, there was no reason for CPA to grand this favour to an 
organization (Member States) that cannot return back the favour in the 
same way. This was particularly right when Iraq was under occupation 
and was in need of favour from developed and even stabled 
developing countries.  
 Distinctness:  3.3.2.2.2
The requirement of distinctness of the variety is considered as a 
second criterion for granting protection to the new variety by Article 4 
(B) of the Order. The new variety has to be clearly distinguishable 
from any other variety which considered a common knowledge. Any 
variety has been applied for granting intellectual property protection 
or for entering in the Register, will be considered as common 
knowledge if this process occurred before filing the application for 
new variety.
415
 This article again is the exactly worded as written in 
Article 7 of the UPOV Convention of 1991 and has the same criterion 
of distinctness.  
                                                 
415 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits And 
Plant Variety Law.’, chap. Threequater, 4 (B). 
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 Uniformity:  3.3.2.2.3
The third criterion for a variety to be considered as a new variety 
is uniformity. Article 4 (C) of the Order requires the new variety has 
possessed adequate uniformity in its relevant characteristics. The 
Order stated that new variety acquire the uniformity criterion ‘if it is 
uniform subject to the variation that may be expected from the 
particular features of its propagation’.  
 Stability:  3.3.2.2.4
The fourth requirement of new variety is stability as stated by 
Article 4 (D) of the Order. The stability acquired when the relevant 
characteristics of the new variety remain unchanged after repeated 
propagation or in the case of a particular cycle of propagation, at the 
end of each such cycle. The third and fourth criteria are also taken 
from the Articles of 8 and 9 of the UPOV Convention of 1991. 
Another important element from the Order which is exactly taken 
from the UPOV Convention of 1991 is the duration of the breeder’s 
right. Article 17 of chapter threequater of the Order stated that 
duration for protecting the new variety shall be twenty years from the 
date of filing the application. However, the protection period of trees 
and vines shall be twenty-five years.      
3.3.2.3 The Law No. 15 of 2013 
Sui generis system has a strong point in which provides for rights 
of both breeders and farmers in well balanced and equitable system. 
The Order also provides for the rights of breeder as it is stated in the 
UPOV Convention of 1991. However, one of the crucial area for 
every country is the farmer’s right, especially for the developing 
countries. The UPOV Convention of 1991 provides some exceptions 
to the breeder’s right in uses of new and protected variety for private 
and non-commercial purposes, experimental purposes and breeding 
other varieties with some exceptions. Another important exception to 
the breeder’s right which is in favour of farmers in the way that 
developing countries, those countries in which their economy heavily 
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rely on small farmers can benefit from this optional exception as 
stated by the UPOV Convention of 1991:   
‘[Optional exception] Notwithstanding Article14, each 
Contracting Party may, within reasonable limits and subject 
to the safeguarding of the legitimate interests of the breeder, 
restrict the breeder’s right in relation to any variety in order 
to permit farmers to use for propagating purposes, on their 
own holdings, the product of the harvest which they have 
obtained by planting, on their own holdings, the protected 
variety or a variety covered by Article14 (5)(a)(i) or (ii).’
416
 
This exception was not taken into consideration by the CPA in 
Iraq while they had seen the situation of the fields and seed bank of 
Iraq which was destroyed by the invasion war.
417
 Contrary to that the 
Order completely prohibited the farmers from ‘re-using seeds of 
protected varieties or any varieties mentioned in items 1 and 2 of 
paragraph (C) of Article 14 of this Chapter.’
418
 This provision was in 
fact taken from the United States of American Patent Act, as the 
courts in USA interpreted the Act in companies’ interest and prevent 
farmers from saving, reuse, or resale protected seeds.
419
 This shows 
that in some situations the Order failed to follow the UPOV 
Convention of 1991 and regulate laws that are in best interest of Iraqi 
farmers.  
It is worth mentioning that the Law No. 15 of 2013 on 
Registration, Accreditation and Protection of Agricultural Varieties 
replaced the CPA Order No. 81 and regulated the protection of new 
varieties in different way. The Law No. 15 of 2013 consists of 20 
sections only and without giving details on some issues. The criteria 
of protection of new varieties stated in section 3 are without 
dedicating any special subsection to each criterion and without 
                                                 
416 ‘International Convention For The Protection Of New Varieties Of Plants. Act of 1991’, 
Article 12 (2) 
<http://www.upov.int/export/sites/upov/upovlex/en/conventions/1991/pdf/act1991.pdf> 
[accessed 9 October 2017]. 
417 Elizabeth Finkel, ‘Scientists Seek Easier Access to Seed Banks’, Science, 324.5933 
(2009), 1376–1376 (p. 1376) <https://doi.org/10.1126/science.324_1376>. 
418 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits and 
Plant Variety Law.’, Chapter Threequater, Article 15 (B). 
419 Crosby, p. 511. 
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defining them. Section 3 (3) of the Law stated that new variety, hybrid 
or progeny in order to be registered or accredited should have the 
stability, uniformity, distinctiveness characteristics, and have high 
genetic value and agricultural addition or new industrial application. 
These criteria should have been explained and defined as any other 
important legal terms. Every important legal term needs to be clarified 
in order to avoid misinterpretations. The rest of the section which 
consists of nine subsections is merely technical requirements for 
registration and accreditation.   
Apart from that the Law No. 15 of 2013 provides for the breeder’s 
rights in detail as well. However, the Law provides extra exception 
than the one provided by the Order. Section 12 (1) of the law states 
that the breeder’s right shall not include acts by individual or 
companies whether private or public, or other public-sector bodies for 
personal un-commercial purposes or for experimental purposes or for 
breeding another new variety or hybrid. Section 16 (1) authorising 
minister on recommendation from the committee
420
 to grant licence to 
others with the permission of the breeder of using the protected 
variety, hybrid or progeny if public interest required that. In this case 
the breeder will be awarded equitable monetary compensation in 
which the financial value of the licence has been taken into 
consideration by the neutral committee established for this purpose. 
Section 14 also reduced the protection period of the variety, hybrid or 
progeny to ten years from the date of filing the application, except 
varieties of trees and vines that shall be protected for twenty years.  
3.4 CONCLUSION: 
After the invasion of Iraq, the bank seed and seeds reserved in 
other ways were affected severely by the war and the invasion. War 
affected human resources as well, especially the scientists who 
migrated to outside of Iraq either because of poverty, unemployment 
or fear on their own lives. There was no need in what so ever to enact 
law for protection of biological varieties to the level of that of 
                                                 
420 Section 1 (1) defined The Committee as the national committee for registration, 
accreditation, and protection of agricultural varieties.  
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developed countries as the CPA did. It becomes clear that the new 
Law is not regulated in such a better way than the Order was but 
provides for licences and shorter period of protection. However, by 
replacing the Order, it shows that the current Iraqi government 
believes that it is not yet in a situation and condition to enact a law 
equivalent to the international conventions but tries to fulfil the 
requirements of TRIPS Agreement by providing a protection to plant 
varieties in a form of sui generis system. Iraq should amend the Law 
No. 15 of 2013 so that get benefit from other international laws that 
Iraq recently became party such as International Treaty on Plant 
Genetic Resources for Food and Agriculture by Food and Agricultural 
Organization of the United Nations. Also comply in better way to 
international laws by increasing the duration of protection and best 
serve the interests of the Iraqi community by taking the advantage of 
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1 PATENT AND  
RIGHTS CONFERRED  
1.1 INTRODUCTION 
The basic principle of granting patent is that the patent owner 
should have certain rights over his patented invention whether be a 
product or a process. In this regard the TRIPS Agreement has included 
special provision that confers certain rights to the patent owner. In this 
section the Article 28 of the TRIPS Agreement will be analysed in 
detail in order to find out the rights that are conferred to the patent 
owners. Article 33 and 34 of the TRIPS Agreement will also be 
analysed that regulate terms of protection and special circumstances of 
reversing burden of proof in cases that relate to process patents.  
In line with this analysis, this section will turn into analysing the 
Iraq’s position on how patent and rights conferred by the original law 
No. 65 of 1970 with reference to amendments especially the first 
amendment law No. 28 of 1999 and CPA Order No. 81. The relevant 
sections of the law and its amendments will be compared to the 
provisions of the TRIPS Agreement in order to find out the degree of 
compliance.  
1.2 RIGHTS CONFERRED ACCORDING TO THE TRIPS AGREEMENT 
The basic principle of the patent rights is to exclude others from 
exploiting the patented invention and to say ‘no’ to others. This means 
that patent is emphasizing on excluding others rather than the right to 
use by the patent owner, as the right to use emerges from economic 
freedom.
421
 Therefore, the exclusivity confers negative rights, which 
is a legal tool in the hand of the patent owner to prevent others from 
utilising and performing some specific acts in regard of the invention, 
                                                 
421 Carvalho, The TRIPS Regime of Patents and Test Data, p. 356. 
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rather than positive rights which gives the patent owner rights over his 
products and processes. The principle of exclusivity is inherent to 
patent grants, which allows the title holder to enjoy the invention 
exclusively in order to obtain economic gains during the lifetime of 
the patent which is 20 years from the filing date.
422
  
Article 33 of the TRIPS Agreement
423
 provides the minimum 
protection period of 20 years from the filing date and not from the 
grant of the patent. Therefore, member countries are not under 
obligation to provide for minimum effective protection, as there may 
be some lost of time between filing date and granting date of the 
patent, due to delay in examination process or marketing approval.
424
    
Article 28.1 of the TRIPS Agreement states that ‘A patent shall 
confer on its owner the following exclusive rights:’, and states two 
situations according to the subject matter of the patent whether be a 
product or process. The content of Article 28.1 was inspired by Article 
19 of the draft Patent Law Treaty as it was existed in 1990, as it was 




1.2.1 Where the subject matter of a patent is a product.  
Article 28.1 lit. (a) of the TRIPS Agreement states that ‘where the 
subject matter of a patent is a product’ the patent owner has exclusive 
rights ‘to prevent third parties not having the owner’s consent from 
the acts of: making, using, offering for sale, selling, or importing for 
these purposes that product’. The enumeration of acts that are 
mentioned in Article 28 in which the patent owner has power to 
prevent others is exhaustive, therefore, should be narrowly 
interpreted.
426
 Footnote 6 of the TRIPS Agreement which provides 
elaboration on this point states that ‘This right, like all other rights 
                                                 
422 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 414. 
423 Article 33 of the TRIPS Agreement states that ‘The term of protection available shall not 
end before the expiration of a period of twenty years counted from the filing date’. 
424 Correa, Trade Related Aspects of Intellectual Property Rights, p. 343. 
425 Gervais, p. 374. 
426 Correa, Trade Related Aspects of Intellectual Property Rights, p. 296. 
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conferred under this Agreement in respect of the use, sale, importation 
or other distribution of goods, is subject to the provisions of Article 6’.  
The definition of these terms in Article 28 have not been 
elaborated by the TRIPS Agreement, therefore, they have to be 
defined by the member countries according to their legal systems and 
practices, in accordance of Article 1.1 of the TRIPS Agreement.
427
 
The terms ‘offering for sale’ and ‘selling’ are legal terms and their 
meaning have to coincide with the system of the member country in 




The term ‘making’ literally refers to ‘constructing, framing, 
creating, from parts or other substances’. However, if a different 
process was used in making the same product then the patent rights 
have not been infringed and it does not matter whether large or small 
quantities are produced. Since this provision does not elaborate on 
what include within the term of making, therefore, special 
consideration has to be given for acts of repair or modification of 
patented product. Nevertheless, the infringement in these cases will 
depend on the extent of such acts and the circumstances of the case.
429
  
Recent developments have allowed some exception within the 
scope of Article 31bis of the TRIPS Agreement, in which 
manufacturing and making for purpose of exporting is not considered 
infringement if the conditions of compulsory licence under Article 
31bis are met. Also, some member countries have considered some 
acts of making not infringement of exclusive rights within the 
meaning of Article 28.1 lit. (a) such as ‘preparation in a pharmacy or 
by a medical doctor, of a medicine in accordance with a medical 
                                                 
427 Article 1.1 of the TRIPS Agreement states that ‘Members shall give effect to the 
provisions of this Agreement. Members may, but shall not be obliged to, implement in 
their law more extensive protection than is required by this Agreement, provided that such 
protection does not contravene the provisions of this Agreement. Members shall be free to 
determine the appropriate method of implementing the provisions of this Agreement 
within their own legal system and practice.’ 
428 Carvalho, The TRIPS Regime of Patents and Test Data, p. 356. 
429 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 419. 
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prescription and for individual use’,
430
 within the scope of Article 30 
of the TRIPS Agreement.   
The term ‘using’ here refers to using in the commercial 
transaction. Using product for private or domestic purposes will not 
infringe the rights of the patent holder. Some uses have been 
considered not infringing the rights of the patent holders within the 
scope of Article 30, such as for the purpose of scientific research and 
experiment or uses under voluntary or compulsory licences.
431
  
Evidently, uses of patented product which marketed by the patent 
owner or with his consent whether be domestically or internationally 
(exhaustion of rights has to be considered) will not be within the range 
of exclusive rights of the patent owner. The patent owner may prevent 
those uses that ‘include for example activities of commercialization 
but not entailing sale, like renting, leasing or sales demonstrations’.
432
  
Nevertheless, mere position or display of the patented product is 
within the scope of ‘using’ of the provision. On the other hand, 
utilization of patented products as parts of vehicles, aircraft or vessel, 
may be covered by this provision and the right holder has right to 
prevent such uses. Even though many countries have provided for 




Article 5ter of the Paris Convention
434
 provides for exception of 
patented devices that forming part of vessels, aircraft or land vehicles, 
as from the title of the Article. This is the only exception that deals 
                                                 
430 Correa, Trade Related Aspects of Intellectual Property Rights, p. 296. 
431 Michael Blakeney, Trade Related Aspects of Intellectual Property Rights: A Concise 
Guide to the TRIPs Agreement, Intellectual Property in Practice (London: Sweet & 
Maxwell, 1996), p. 87. 
432 Stoll, Busche, and Arend, pp. 515–16. 
433 Correa, Trade Related Aspects of Intellectual Property Rights, p. 297. 
434 Article 5ter of the Paris Convention states that ‘In any country of the Union the following 
shall not be considered as infringements of the rights of a patentee: 1. the use on board 
vessels of other countries of the Union of devices forming the subject of his patent in the 
body of the vessel, in the machinery, tackle, gear and other accessories, when such vessels 
temporarily or accidentally enter the waters of the said country, provided that such devices 
are used there exclusively for the needs of the vessel; 2. the use of devices forming the 
subject of the patent in the construction or operation of aircraft or land vehicles of other 
countries of the Union, or of accessories of such aircraft or land vehicles, when those 
aircraft or land vehicles temporarily or accidentally enter the said country’. 
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with infringement of patents. This exception was added on the basis of 
the French proposal at the Hague Revision of Conference in 1925 and 
stayed as it is since then. The main purpose of this exception is to 
limit the rights of the patent owner to protect the freedom of transport 
for the interest of public from the exclusive rights of the patent owner 
that may cause prejudice.    
The term ‘offering for sale’, this include any activity with the aim 
of selling the patented product such as commercialization of the 
product. This has been differentiated from the term ‘selling’ in the 
provision because some member countries such as United States of 
America offering for sale is not considered an offence and there is no 
penalty for such act.
435
 Also, offers to licence or lease will not be 
covered by this right, as it is explicitly states that include only offering 
for sale.
436
   
The term ‘selling’ has to be interpreted narrower than the term of 
‘commercializing’. Because the patent owner has rights to prevent 
others from sale or resale of the infringing products only, and not 
those products that legitimately available in market whether the patent 
owner has put it in market, or available in market through a 
voluntarily or compulsory licences.
437
     
The term ‘importing’ is very general which empowers the patent 
owner to prevent others from importing his patented product in all 
circumstances even if for non-commercial purposes or for free.
438
 
Nevertheless, the principle of exhaustion of rights under Article 6 has 
to be taken into consideration, as required by Footnote 6, while 
implementing the exclusive right to import. However, Article 31bis of 
the TRIPS Agreement, has recently provided for some exceptions 
under special compulsory licence for the purpose importing 
pharmaceutical products.   
                                                 
435 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 420. 
436 Stoll, Busche, and Arend, p. 516. 
437 Correa, Trade Related Aspects of Intellectual Property Rights, p. 297. 
438 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 420. 
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1.2.2 Where the subject matter of a patent is a process 
Article 28.1 lit. (b) states that ‘where the subject matter of a 
patent is a process’ the patent owner has exclusive right ‘to prevent 
third parties not having the owner’s consent from the act of using the 
process, and from the acts of: using, offering for sale, selling, or 
importing for these purposes at least the product obtained directly by 
that process’.  
Here according to the first part of the provision the patent owner 
has right to prevent the others from using his process to make 
products, and the process here refers to the method of making the 
product. Though in some member countries such as the United States 
of America beside the method of making, also method of use of the 
product can be protected if it is not suggested by the prior art, but 
Article 28.1 lit. (b) does not provide for such protection.
439
 
According to the second part of Article 28.1 lit. (b) the protection 
is not limited to the process but rather extended to the acts of using, 
offering for sale, selling and importing of products that obtained 
directly by the patented process. This is an extra step that was not 
available in the majority of the member countries at the time of 
adoption of the TRIPS Agreement.
440
 Almost all the developing 
countries did not protect the direct product of the patented process. On 
the other hand, in developed countries such as Germany this type of 
protection was provided for since 1891.
441
 Article 5quater of the Paris 
Convention,
442
 also provides that when a member of the Union 
provides protection to the production of the patented process, then this 
                                                 
439 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 420. 
440 Correa, Trade Related Aspects of Intellectual Property Rights, p. 298. 
441 Stoll, Busche, and Arend, p. 517. 
442 Article 5quater of the Paris Convention states that ‘When a product is imported into a 
country of the Union where there exists a patent protecting a process of manufacture of the 
said product, the patentee shall have all the rights, with regard to the imported product, that 
are accorded to him by the legislation of the country of importation, on the basis of the 
process patent, with respect to products manufactured in that country’ 
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protection has to be extended to the imported products that have been 
made abroad by that process.
443
  
Nevertheless, Article 28.1 lit. (b) is protecting those products that 
directly obtained by the protected process. The reason is that there are 
many products that can be obtained from different processes, 
therefore, simply proving that the product can be obtained by the 
protected process is not enough to be covered by this provision. In 
order to be covered by this protection, evidence has to be produced 
that the patented process was used in making the product. Though the 
term ‘at least’ indicates that the member countries may, but not under 
obligation, extend the protection to similar products that are not 
manufactured by the patented process.
444
  
Differentiating between processes that make same product is 
important, because in the chemical sector similar products can be 
obtained through different processes. Therefore, in order for the 
extended protection apply to the products, it has to be proved that it 
was manufactured by the patented process. However, sometimes it is 
complicated, as the process of making the product involves some steps 
and not all these steps are patented. In this case in order for the 
product to be protected it has to be proved that no material or 
important steps outside the patented process were use in 
manufacturing the product.
445
   
Article 34 of the TRIPS Agreement
446
 is dedicated for burden of 
proof in cases (of civil proceedings) that concern the process patents, 
                                                 
443 Ricketson, pp. 415–16. 
444 Correa, Trade Related Aspects of Intellectual Property Rights, pp. 298–99. 
445 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 421. 
446 Article 34 of the TRIPS Agreement states that ‘1. For the purposes of civil proceedings in 
respect of the infringement of the rights of the owner referred to in paragraph 1(b) of 
Article 28, if the subject matter of a patent is a process for obtaining a product, the judicial 
authorities shall have the authority to order the defendant to prove that the process to 
obtain an identical product is different from the patented process. Therefore, Members 
shall provide, in at least one of the following circumstances, that any identical product 
when produced without the consent of the patent owner shall, in the absence of proof to the 
contrary, be deemed to have been obtained by the patented process: (a) if the product 
obtained by the patented process is new; (b) if there is a substantial likelihood that the 
identical product was made by the process and the owner of the patent has been unable 
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where direct evidence of using the patented process in manufacturing 
is not available. Contrary to the normal standard of rules of evidence, 
Article 34.1 allows the judicial authority to reverse the procedural 
principles and put the burden of proof on the infringer to demonstrate 
that the patented process is not infringed.
447
 This is based on the 
‘probatio diabolica’, as it is very difficult for the patent owner of the 
process to prove that his patented process was used by the infringer to 
manufacture the products that are similar to the products that can be 
produced by his patented process, except in cases that he can access 
the process that made similar products.
448
       
There are some conditions that have to be met in order for the 
judicial authority of the member countries to reverse the burden of 
proof. It has to be proved that the product is similar and identical to 
the product that can be produced by the patented process. Then, the 
member country has to implement a prima facie presumption that the 
product obtained by the patented process in two situations as states in 
Article 34.1 ‘(a) if the product obtained by the patented process is 
new, or (b) if there is a substantial likelihood that the identical product 
was made by the process and the owner of the patent has been unable 
through reasonable efforts to determine the process actually used’. 
Therefore, it has to be shown that the product for the first time 
manufactured by the patented process and such product is new, and 
that the patent owner has to show that he has taken every necessary 
step in his capacity to determine what process was used but was 
unsuccessful. The term ‘substantial likelihood’ has been defined as ‘a 
                                                                                                                   
through reasonable efforts to determine the process actually used. 2. Any Member shall be 
free to provide that the burden of proof indicated in paragraph 1 shall be on the alleged 
infringer only if the condition referred to in subparagraph (a) is fulfilled or only if the 
condition referred to in subparagraph (b) is fulfilled. 3. In the adduction of proof to the 
contrary, the legitimate interests of defendants in protecting their manufacturing and 
business secrets shall be taken into account’. 
447 Gervais, pp. 408–9. 
448 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, pp. 496–97. 
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strong possibility based on the facts of the case and the available 
evidence’.
449
     
Paragraph 2 of Article 34 of the TRIPS Agreement emphasizes 
that the member countries are free to reverse the burden of proof in 
only one of the above situations. These two cases exist because of 
disagreement between the European Commission and the United 
States of America. During the negotiation of the TRIPS Agreement, 
the European Commission preferred reversing burden of proof only in 
the first situation, while the United States of America favoured the 
second option.
450
       
Paragraph 3 of Article 34 of the TRIPS Agreement is an effort to 
protect the interest of the alleged infringer by protecting his process in 
confidentiality, because there is a chance that the product 
manufactured by a different process than the patented process. 
Therefore, the alleged infringer has right to keep his process secret 
and the member countries have to take this into consideration while 
revering the burden of proof. This can be done by appointing an 
expert as a mediator, who has to keep the received information of the 
alleged infringer as confidential and during the court proceedings he 
can only disclose whether the process is the patented process or not.
451
      
1.2.3 Rights to assign, transfer and licence 
Article 28.2 of the TRIPS Agreement states that ‘Patent owners 
shall also have the right to assign, or transfer by succession, the patent 
and to conclude licensing contracts’. This indicates that patents are 
assignable without any limitation, and they are transferable by 
succession as well. Nevertheless, the right of member countries of 
registration of the assignment and transfer are not precluded by this 
provision. The right of registration is within the power of member 
countries in order to protect the rights of third parties from the effects 
of the process of assignment and transfer.
452
     
                                                 
449 Gervais, p. 409. 
450 Gervais, p. 409. 
451 Stoll, Busche, and Arend, p. 613. 
452 Correa, Trade Related Aspects of Intellectual Property Rights, p. 299. 
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This provision also confers the right to conclude licensing 
contracts. Therefore, the patent owner has rights to enter into 
agreements for the purpose of licencing the patent. However, this 
provision does not refer to cases in which the member countries are 
allowed to grant compulsory licence without or against the consent of 
the patent owner. According to Article 31 and 31bis of the TRIPS 
Agreement, member countries are allowed to grant compulsory 
licence. Therefore, the rights of the patent owner to conclude licensing 
contracts does not prevent the rights of the member countries of the 
TRIPS Agreement to impose the compulsory licence according to 
Article 31 and 31bis.
453
 
According to Article 28.2 the patent owner has rights to grant 
licence and stipulate conditions of such contracts. Nevertheless, this 
provision does not prevent the member countries to practice their 
rights according to Article 40.2 of the TRIPS Agreement.
454
 Thus, 
member countries have rights to insert in their domestic legislations 
licensing practices and conditions in order to control abuses of 
licensing agreements.
455
      
1.3 IRAQ’S POSITION TO PATENT AND RIGHTS CONFERRED 
Once patent granted, the right holder has legal monopoly over his 
invention and outcome of his invention whether be a process or a 
product. Section 12 of the original Patent and Industrial Designs Law 
No. 65 of 1970 clearly states that ‘the patent shall confer upon owner 
of the invention exclusive right to exploit the invention by all legal 
means’. This is a direct grant of monopoly right to the inventor to use 
                                                 
453 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 422. 
454 Article 40.2 of the TRIPS Agreement states that ‘Nothing in this Agreement shall prevent 
Members from specifying in their legislation licensing practices or conditions that may in 
particular cases constitute an abuse of intellectual property rights having an adverse effect 
on competition in the relevant market. As provided above, a Member may adopt, 
consistently with the other provisions of this Agreement, appropriate measures to prevent 
or control such practices, which may include for example exclusive grant back conditions, 
conditions preventing challenges to validity and coercive package licensing, in the light of 
the relevant laws and regulations of that Member.’ 
455 Correa, Trade Related Aspects of Intellectual Property Rights, p. 300. 
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his invention whether be a process or product in all possible ways that 
law allows it. Nevertheless, this Section was amended by the CPA 
Order No. 81. Section 12 after the amended has two subsections,
456
 
one specified for patented product and the other for industrial process.  
Section 12 lit. (a) provides that the patent shall prevent any person 
from using the patented product without licence whether for the 
purpose of making, exploiting, using, offering for sale, selling or 
importing that product. In the same way Section 12 lit. (b) states that 
no one allowed without authorisation of the patent owner to use the 
patented process or any product directly made by the patented process, 
offering for sale, selling, or importing the product. Noticeably, the 
amended Section 12 is more detailed because it has been taken from 
provisions of the TRIPS Agreement. These two subsections are almost 
the same as Article 28. 1. lits. (a) and (b).  
However, Article 28 of the TRIPS Agreement has another 
provision which states that ‘Patent owners shall also have the right to 
assign, or transfer by succession, the patent and to conclude licensing 
contracts’. However, the CPA Order No. 81 did not state this 
provision with the other two subparagraphs. Yet, in the original patent 
law No. 65 of 1970 some references can be found in Section 25 which 
has not been amended since then. Section 25 states that ‘It is 
permissible to utilize the patent in all legal means possible, and to 
transfer its ownership including all rights attached to it through a 
succession. The patent right cannot be used against others except after 
its registration by the registrar, and the utilisation, mortgaging and 
transfer of its ownership will be announced accordingly’. However, 
over all the CPA Order No. 81 improved the exclusivity right of the 
patent owner by monopolising some specific acts which can be 
                                                 
456 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits And 
Plant Variety Law.’  Section 12 amended to read as ' “A patent shall grant its owner the 
following rights: a) Where the subject of the patent is a product, the right to prevent any 
person who has not obtained the owner's authorization from making, exploiting, using, 
offering for sale, selling or importing that product. b) Where the subject of the patent is an 
industrial process, the rights to prevent any person who has not obtained the owner's 
authorization from using the process or the product directly made by the process, offering 
for sale, selling or importing the 
product.'<http://www.wipo.int/wipolex/en/text.jsp?file_id=181090> [accessed 10 October 
2017]. 
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performed by the patent owner, compare to the general statement of 
the original patent law No. 65 of 1970.  
In neither the original Iraqi patent law No. 65 of 1970 nor the 
amendments that followed including the CPA Order No. 81, include 
any provision that regulate the burden of proof similar to Article 34 of 
the TRIPS Agreement. As it has been explained before, it is very 
difficult for the patent owner to prove whether his patented process 
was used to produce similar product that can be manufactured by his 
process. For this reason, Article 34 authorised the member countries to 
reverse the burden of proof and request the alleged infringer to prove 
that different process was used. CPA Order No. 81 should have added 
similar provision in order the owner of patented process enjoy better 
protection. 
Section 13 of the original Law No. 65 of 1970 consisted of two 
paragraphs that regulate the protection period of patents. In the first 
paragraph it states that ‘the protection period of patent is 15 years 
from the date of applying for patent or from the date of completion of 
documentations, and annually will be renewed by paying the fee as 
required by law’. The second paragraph was dedicated for protection 
of foreign patents within the territory of Iraq.  As it is stated that ‘the 
protection period of patents that have been registered outside Iraq will 
be the exact period that were granted in the foreign country, but the 
registration period inside Iraq shall not exceed 15 years, and the 
certified copy should be placed with the registration office and 
renewed annually according to the above paragraph’.  
Nevertheless, this section repealed by the first amendment Law 
No. 28 of 1999 and replaced by new provision which stated that 
‘protection period is 20 years starts from the date of applying for 
patent, except for patents of medical and pharmaceutical formulations 
in which the protection period will be 10 years and can be extended 
twice for the period of 5 years each time, and all required documents 
have to be completed within 6 months from the application date, and 
annually will be renewed by paying the fee as required by law’. This 
clearly can be considered as a progress to the previous section by 
extending the protection period from 15 years to 20 years. However, 
provided for protection of medical and pharmaceutical formulations 
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which is not provided for by the TRIPS Agreement as the minimum 
protection period required by Article 33 of the TRIPS Agreement is 
20 years from the filing date without any reference to medicines.  
For this reason, the CPA Order No. 81 has tried to correct this 
situation and brings the Iraqi patent law in compliance with the TRIPS 
Agreement, by repealed section 13 for the second time and replace it 
with new provision as states that ‘The term of duration of the patent 
shall not end before the expiration of a period of twenty years for 
registration under the provisions of this Law as from the date of the 
filing of the application for registration under the provisions of this 
Law.’  
1.4 CONCLUSION 
From Article 28 of the TRIPS Agreement it can be concluded that 
the nature of rights conferred to the patent owner is negative rights 
that exclude others from utilising the patented invention whether be a 
product or process for a certain period. Article 33 states that the patent 
owner has rights to exclude others from utilising his patented 
invention for at least 20 years from the filing date. Article 28.1 lits. (a) 
and (b) confer rights to exclude others from making, using, offering 
for sale, selling or importing patented products or products directly 
manufactured by patented process, and also prevent third parties to 
use the patented process without authorisation of the patented owner. 
The patent owner also has the right to assign, transfer and to conclude 
licensing contracts. Article 34 of the TRIPS Agreement provides for 
reverse of burden of proof in cases where similar products of patented 
process have been manufactured. In these cases, it is very difficult for 
the owner of the patented process to prove that the products are not 
manufactured by his patented process, therefore, the judicial authority 
of the member countries has the right to order the alleged infringer to 
prove that his products are not manufactured by the patented process. 
Nevertheless, his interests of keeping his process as a secret have to be 
considered by the member countries.  
Section 12 of the original Iraqi patent law No. 65 of 1970 
provided for rights conferred but the provision did not separate the 
patented product from patented process and did not mention anything 
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about the products that are directly manufactured by the patented 
process. Therefore, the CPA Order No. 81 rightfully repealed this 
section and replaced by another that provides for the rights conferred 
in detail and similar to Article 28.1 lits. (a) and (b) of the TRIPS 
Agreement. However, Article 28.2 is not included in the amendment 
of the CPA Order No. 81, therefore, for the purpose of more clarity 
and better compliance with the TRIPS Agreement, it should have 
added such provision within section 12, instead of section 25. The 
patent law No. 65 of 1970 lacks provision similar to Article 34 of the 
TRIPS Agreement that provide for reverse of burden of proof, and all 
the amendments did not touch this issue. CPA Oder should have 
added this provision to the law No. 65 of 1970 in order the owner of 




2 EXCEPTIONS AND 
LIMITATIONS TO PATENT 
RIGHTS IN THE TRIPS 
AGREEMENT AND IRAQI 
PATENT LAW 
2.1 INTRODUCTION 
Intellectual property rights in general and in particular the 
protection of patent rights have expanded the power of exclusive 
rights of the patent holder to the extent that the developing countries 
could not hide their concerns. The concerns mostly are about the high 
standard of protection of individual interests of the patent holder over 




Normally patent offers exclusive rights in which others are not 
allowed to use patent holders’ inventions without their authorization. 
Patent offers an important market benefit to the patent holder through 
monopoly. However, patent laws around the world have limited these 
exclusive rights of use in some circumstances and they call it 
‘exceptions to exclusive rights’. The purposes of these exceptions 
vary, they may be for non-commercial (such as private use and 
scientific research) or commercial use. They also can serve as the 




                                                 
457 Carlos María Correa, Intellectual Property Rights And The Use of Compulsory Licenses: 
Options for Developing Countries (South Centre, October 1999), p. 1 
<https://www.iatp.org/files/Intellectual_Property_Rights_and_the_Use_of_Co.pdf> 
[accessed 21 March 2018]. 
458 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 430. 
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This chapter discusses the exceptions that the TRIPS Agreement 
provides pursuant to its Article 30. This Article states the conditions 
and criteria that has to be followed when a member country needs to 
put exceptions to the rights conferred by the TRIPS Agreement which 
is exclusive rights of the patent holders. These criteria are going to be 
analysed and discussed in detail. There are many different exceptions, 
but since Article 30 does not mention any exception by name, 
therefore, this chapter will analyse some possible exceptions that can 
be categorised under the umbrella of this Article. 
Next, the TRIPS Agreement provides for another exception that 
limits the exclusive rights of the patent holders, which is called 
‘compulsory licence’. To clarify that, Article 31 provides for some 
unexclusive grounds of grating the compulsory licence and conditions 
that have to be followed by a member country so that to grant 
compulsory licence or as Article 31 refers to it as ‘other use without 
authorization of the right holder’. This chapter will also analyse all the 
subparagraphs of Article 31 in detail in order to examine their effects 
on granting compulsory licence and how to be applied by the member 
countries.   
This chapter will further discuss and analyse Article 31bis of the 
TRIPS Agreement, as it is newly added Article to the Agreement that 
provides further limitation to the exclusive rights of the patent holder. 
Article 31bis provides for a particular compulsory licence in regard of 
pharmaceutical products. This Article will be discussed and analysed 
in detail with reference to the Annex of the TRIPS Agreement, and 
how can be applied in order to enable member countries to use it so 
that their public health needs are fulfilled.  
The last section of this chapter will be dedicated for discussing 
and analysing the exceptions and limitations to the exclusive rights of 
the patent owner that provided by the Iraqi Patent and Industrial 
Designs Law No. 65 of 1970. In the first-place the position of the Iraqi 
patent law before the amendment will be discussed and analysed. 
Then, the amendments passed by the CPA Order No. 81 will be 
analysed while comparing to the original law before amendment and 
its suitability and improvements will also be analysed. 
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2.2 EXCEPTIONS TO RIGHTS CONFERRED UNDER THE TRIPS 
AGREEMENT (ARTICLE 30) 
Article 30 of the TRIPS Agreement under the title of ‘Exceptions 
to Rights Conferred’, states that ‘Members may provide limited 
exceptions to the exclusive rights conferred by a patent, provided that 
such exceptions do not unreasonably conflict with a normal 
exploitation of the patent and do not unreasonably prejudice the 
legitimate interests of the patent owner, taking account of the 
legitimate interests of third parties’.  
Different countries adopted different exceptions to exclusive 
rights of the patent holder. Some of the long established exceptions 
that are used by the countries all over the world at the time of 
negotiations of the TRIPS Agreement are; private and non-
commercial use, experimental and scientific use, prior use, 
extemporaneous preparation of a medicine in a pharmacy, foreign 
vessels, aircraft or land vehicles, international civil aviation (chicago), 
regulatory review (bolar)
459
, exhaustion of patent rights (national 
exhaustion and regional or international exhaustion),
460
 and parallel 
imports (importation of products from a country where the product 
legally marketed). During the negotiation some of these exceptions 
proposed by developing countries to be included in the TRIPS 
Agreement, but it was rejected by the developed countries. The 
developed countries proposed a general language similar to that of 
Article 9 (2) of the Berne Convention, without stating any specific 
acts that could be exempted.
461
   
                                                 
459 Named after a United States case of ‘Roche Products, Inc. Appellant, v. Bolar 
Pharmaceutical Co., Inc., Appellee, 733 F.2d 858 (Fed. Cir. 1984)’, Justia Law 
<https://law.justia.com/cases/federal/appellate-courts/F2/733/858/459501/> [accessed 11 
March 2018]. 
460 Christopher Garrison, Exceptions to Patent Rights in Developing Countries ‘United 
Nations Conference on Trade and Development (UNCTAD), International Centre for 
Trade and Sustainable Development (ICTSD)’ (International Centre for Trade and 
Sustainable Development (ICTSD), 2006), pp. 2–15. 
461 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 431-432. 
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Some other developed countries including the United States 
supported the idea that the member countries should have the right to 
restrict exclusive rights of the patent holder through compulsory 
licence only. However, at the end the TRIPS Agreement adopted the 
general formulation without stating any particular exceptions. This 
shows that there was a difference between the developed and 
developing countries, and even among the developed countries as 
well, which finally gave birth to Article 30 out of compromise. Article 
30 is very similar to Article 9.2 of the Berne Convention. Article 
9.2
462
 of the Berne Convention has become a model for some other 
Article of the TRIPS Agreement such as Article 13 (Limitations and 
Exceptions to Copyright and Related Rights), Article 17 (Exceptions 
to Trademarks), and Article 26.2 (Protection of Industrial Designs).
463
    
Nuno Pires de Carvalho is of the opinion that this article should 
be considered as a deviation from the general rule of the TRIPS 
Agreement that patent rights are exclusive. The general rule is stated 
in Article 28
464
 of the TRIPS Agreement that the patent holder has 
exclusive right whether to protect the product or process of his 
invention and prevent other benefits from the invention without his 
consent. Therefore, Article 30 is an exception to the general rule and 
always should be dealt with in an exceptional way and its language 
                                                 
462 ‘WIPO-Administered Treaties: Berne Convention for the Protection of Literary and 
Artistic Works’ Article 9 Right of Reproduction: 2. Possible Exceptions 'It shall be a 
matter for legislation in the countries of the Union to permit the reproduction of such 
works in certain special cases, provided that such reproduction does not conflict with a 
normal exploitation of the work and does not unreasonably prejudice the legitimate 
interests of the author.' <http://www.wipo.int/treaties/en/text.jsp> [accessed 11 March 
2018]. 
463 Stoll, Busche, and Arend, pp. 536–37. 
464 Article 28 of the TRIPS Agreement, Right Conferred 1. A patent shall confer on its owner 
the following exclusive rights: 
(a) where the subject matter of a patent is a product, to prevent third parties not having the 
owner’s consent from the acts of: making, using, offering for sale, selling, or importing for 
these purposes that product; 
(b) where the subject matter of a patent is a process, to prevent third parties not having the 
owner’s consent from the act of using the process, and from the acts of: using, offering for 
sale, selling, or importing for these purposes at least the product obtained directly by that 
process. 
2. Patent owners shall also have the right to assign, or transfer by succession, the patent and to 
conclude licensing contracts. 
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with a restrictive manner. For de Carvalho, this Article is introduced 
in order to create a balance between rights and obligations as required 
by Article 7 of the TRIPS Agreement. Out of this member countries 
are not allowed to request further derogation from the general rule of 
exclusive rights of Article 28.
465
      
However, others are of the opinion that member countries have 
more freedom while adopting the exceptions under Article 30 into 
their domestic patent legislation, especially in determining what act 
can be permitted with the nature and extent of the permitted act.
466
  
2.2.1 The Criteria for the Application of Article 30  
The moment TRIPS Agreement adopted by a member country, all 
the exceptions to the exclusive rights of the patent holder that exist 
under the domestic laws and future regulations in this regard have to 
be coincided with the tests and provisos of Article 30.
467
 There are 
three criteria that should be met in order for exceptions successfully 
implemented under Article 30. The WTO Panel in Canada-
Pharmaceutical Patents,
468
 intensively analysed and interpreted the 
scope of exceptions under Article 30. Therefore, in analysing and 
discussing terms of this Article, the opinion of the Panel cannot be 
ignored and will be an important source of interpretation.
469
 In the 
case of Canada-Pharmaceutical Patents it was held by the Panel that 
there are three criteria in Article 30 that have to be met in order for the 
                                                 
465 Carvalho, The TRIPS Regime of Patents and Test Data, p. 377. 
466 Stoll, Busche, and Arend, p. 537. 
467 Garrison, p. 19. 
468 ‘WTO | Dispute Settlement - the Disputes - DS114 Canada-Pharmaceutical Patents’ '
 ' 
<https://www.wto.org/english/tratop_e/dispu_e/cases_e/ds114_e.htm> [accessed 3 May 
2018]. 
469 Rodrigues Jr and Edson Beas, p. 90. 
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member countries be able to adopt the exception. The criteria are; 
firstly, the exception must be limited, secondly, the exception does not 
unreasonably conflict with a normal exploitation of the patent, and 
thirdly, do not unreasonably prejudice the legitimate interests of the 
patent owner, taking account of the legitimate interests of third 
parties.
470
       
Each criterion should be looked as related to each other and 
interpreted accordingly. However, each carries different meaning and 
must be complied to each of them separately. The Panel further 
explained that if an exception complies with the first condition but 
still there is chance to fail with other two conditions, or complies with 
the first two conditions, may still fail with the third conditions. 
Therefore, in order for an exception under Article 30 of the TRIPS 
Agreement to be permitted to limit the exclusive rights of the patent 
holder has to fulfil all the three conditions that are required by the 
Article.
471
 The first condition is of a legal nature, while the other two 
conditions are related to economic influence of the exception.
472
  
2.2.1.1 The Limited Exception 
For the definition of ‘limited’ the Panel in the case of Canada-
Pharmaceutical Patents referred to the interpretation of European 
Communities. According to the EC the word ‘limited’ can be 
described by words such as ‘narrow, small, minor, insignificant or 
restricted’.
473
 These words actually relate to measurement. Therefore, 
it can be said that this condition refers to some sort of 
quantification.
474
 The Panel agreed with the opinion of the EC to give 
the word ‘limited’ a narrow connotation instead of broad meaning 
cited by the Canada. Even the Panel admitted that the word ‘limited’ 
may carry both of the narrow and broad meaning but in this context 
                                                 
470 Canada – Patent Protection of Pharmaceutical Products - Report of the Panel, 
WT/DS114/R ON 17 MARCH 2000. 
471 Canada – Patent Protection of Pharmaceutical Products - Report of the Panel, 
WT/DS114/R ON 17 MARCH 2000, Paragraph 7.21. 
472 Carvalho, The TRIPS Regime of Patents and Test Data, p. 379. 
473 Canada – Patent Protection of Pharmaceutical Products - Report of the Panel, 
WT/DS114/R ON 17 MARCH 2000, Paragraph 7.28. 
474 Carvalho, The TRIPS Regime of Patents and Test Data, p. 379. 
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while combined with the word ‘exception’, it connotes a narrow 
meaning. The reason is that the word exception also refers to a limited 
derogation. Therefore, the phrase ‘limited exception’ connotes a 
narrow exception. An example is given by the Panel to explain the 
meaning of ‘limited’ which is ‘a mail train taking only a limited 
number of passengers’.
475
 Also the Panel was of the opinion that 
‘limited exception’ can be determined by the extension of curtailment 




However, the Panel report in the case of Canada-Pharmaceutical 
Patents does not create any binding precedents and this report was not 
subject to appeal. Therefore, future panels and Appellate Body may 
change their mind in this regard and adopt the broader meaning that 
was proposed by Canada.
477
   
2.2.1.2 The Exception Does Not Unreasonably Conflict 
with A Normal Exploitation  
This condition requires that the exception does not unreasonably 
conflict with a normal exploitation of the patent. Therefore, it has to 
be determined what is unreasonable in particular circumstances and in 
what situation does it conflict with the normal exploitation of the 
patent.
478
 The Panel in the case of Canada-Pharmaceutical Patents 
did not define the terms of unreasonable and conflict. Therefore, the 
member countries have flexibility in determining what does 
unreasonably conflict mean. However, the Doha Declaration on the 
TRIPS Agreement and Public Health states that in accordance with the 
customary rules of interpretation of public international law, the 
                                                 
475 Canada – Patent Protection of Pharmaceutical Products - Report of the Panel, 
WT/DS114/R ON 17 MARCH 2000, Paragraph 7.30. 
476 Canada – Patent Protection of Pharmaceutical Products - Report of the Panel, 
WT/DS114/R ON 17 MARCH 2000, Paragraph 7.32. 
477 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 434. 
478 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, p. 434. 
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provisions of the TRIPS Agreement have to be interpreted in the light 
of the objectives and principles of the TRIPS Agreement. Therefore, 
the provisions of the TRIPS Agreement including Article 30, should 
be interpreted according to the principles of Articles 7 and 8. Hence, 
the protection of intellectual property rights should be best presented 
so that public and society’s interests are protected, not only the 
interest of individual rights. This is how all the developing countries 
look at the principles of Article 7 and 8.
479
 
In order to find out whether the regulated exception unreasonably 
conflicts with normal exploitation of the patent, not only the regulated 
exception has to be examined, but also its application has to be 
examined as well.
480
     
In the case of Canada-Pharmaceutical Patents both parties 
(Canada and EC) were of the opinion that the word ‘exploitation’ 
refers to the extraction of commercial value whether by working the 
patent, licensing the patent to others, or selling the patent rights to 
others. However, they disagree on the meaning of ‘normal’.
481
 Yet, the 
Panel held that the word ‘normal defines the kind of commercial 
activity Article 30 seeks to protect’. Because the word ‘normal’ in 
dictionary defined to be something ‘regular, usual, typical, ordinary, 
conventional’. Therefore, the Panel concluded that the normal 
exploitation by any patent owner is the right to exclude all forms of 
competition that may reduce the economic benefit expected to be 
gained through a monopoly rights granted by the patent.
482
 
However, Nuno Pires de Carvalho is of the opinion that the Panel 
has errored because according to him exclusive right of the patent 
holder excludes the illegal competition only. It is usual in market that 
the patented products face competition from other patented products 
or even un-patented products. Therefore, ‘normal exploitation’ should 
not be linked with competition. According to NP de Carvalho ‘normal 
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exploitation’ is the type of exploitation that follows the general 
standards and objectives of the law.
483
          
2.2.1.3 The Exception Do Not Unreasonably Prejudice the 
Legitimate Interests of the Patent Owner, Taking 
Account of the Legitimate Interests of Third Parties 
The last requirement and condition of Article 30 of the TRIPS 
Agreement is that the regulated exception by the member countries 
should not unreasonably prejudice the legitimate interest of the patent 
owner and in the same time the legitimate interest of third parties has 
to be taken into consideration. Even though this condition is 
complicated as it requires proving a negative action, but still the 
member countries that asserted the exception have the burden of proof 
on them. Because no one can know whether legitimate interest of the 
patent owner is prejudiced or not until knowing what legitimate 
interest the patent owner claims. The same logic applies to the 
legitimate interest of the third parties. Because it is difficult to 
apprehend the legitimate interest of the third parties without 
determining the legitimate interest of the patent owner.
484
   
In order to find out the real meaning of ‘legitimate interest’ the 
Panel in the case of Canada-Pharmaceutical Patents, first tried to find 
out the literal meaning of the word ‘legitimate’ in normal dictionary in 
which the Panel stated that ‘The word "legitimate" is commonly 
defined as follows: (a) Conformable to, sanctioned or authorized by, 
law or principle: lawful; justifiable; proper; (b) Normal, regular, 
conformable to a recognized standard type’. Base on this, the Panel 
rejected the proposal by the EC that the ‘legitimate interest’ refers to 
‘legal interest’.
485
 However, the Panel preferred to look at ‘legitimate 
interest’ in this context as ‘a normative claim calling for protection of 
interests that are "justifiable" in the sense that they are supported by 
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relevant public policies or other social norms’.
486
 In this sense 
‘legitimate interest’ is much broader than the ‘legal interest’.
487
  
However, a problem may arise in dealing with legitimate interest 
of the patent owner and that of the third parties. The underlying public 
policy may be equal in regard of protection of intellectual property 
rights of private entity in return for creating the invention and 
transferring it to society for the benefit of all. Nevertheless, the 
legitimate interest of patent owner and legitimate interest of third 
parties are different. Normally the legitimate interest of the patent 
owner is to exclude others (third parties) from utilization of the 
invention or prevent competitors from competing his invention in 
order to gain maximum economic profit. On the other hand, may be 
the legitimate interest of the third parties to be able to utilize the 
invention without getting the authorization from the patent owner.
488
 
However, as has been mentioned before, Article 30 should be 
interpreted in the light of Articles 7 and 8 which are on objectives and 
principles respectively. Accordingly, member countries have to keep 
balance between protecting the rights of patent owners and social and 
economic welfare of society. In order to solve the conflict of interests, 
it is best to introduce an exception that best keep the balance of rights 
and obligations.        
2.2.2 Exceptions That Can Be Categorised Under Article 30 
According to Article 30, member countries have rights to 
introduce exception with some conditions as discussed in previous 
section. However, providing exceptions under this Article is optional 
and not mandatory. Therefore, member countries have rights to 
introduce one or more exceptions according to their needs and ability 
to fulfil the conditions. There are some exceptions that are adopted in 
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the legislations of many member countries.
489
 Here are some of those 
permitted exception: 
2.2.2.1 Research and Experimentation Exception 
One of the exceptions that are widely used by the international 
community and one of the most popular one is research use and 
experimentation. Even though the scope of applicability of this 
exception may vary from one-member country to another, but they 
usually allow the use of the patented invention for the purpose of 
scientific experiments without needs of authorisation of the patent 
holder. The widely use of this exception shows that there is an 
international agreement that the development of scientific research 
and technology should not be monopolized by the patent holders.
490
 
The exemptions can include those researches and experiments that are 
performed on the patented inventions with the intention of commercial 
purposes. For example, to improve the patented invention, for the 
purpose of evaluation of the patented invention so that request a 
licence, or simply to check whether the patented invention really 
works, and the patent granted is valid.
491
 The Panel in the case of 
Canada-Pharmaceutical Patents while analysing the term of 
‘legitimate interest’ states that ‘under the policy of the patent laws, 
both society and the scientist have a "legitimate interest" in using the 
patent disclosure to support the advance of science and technology’. 
The public policy purpose of granting patent is to facilitate the transfer 
and advancement of knowledge in the area of patent. Therefore, if 
granting patent is for the purpose of preventing others from 
experimental use, then this will go also against the requirement of 
disclosure to the public. Nevertheless, at the end the Panel did not 
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decide whether adopting this exception by the member countries falls 
within the terms of Article 30.
492
     
2.2.2.2 Early Working, Regulatory Review or Bolar 
Exception 
This is another important exception that can be allowed under 
Article 30. Even though this exception is new compared to the use of 
other exception, but it was known at the time of negotiations of the 
TRIPS Agreement. This exception is useful in the area of 
pharmaceutical products. Granting patent to a new medicine requires a 
very difficult and long process of tests, trials and collecting data in 
order to prove that the medicines are safe and effective.
493
 
Nevertheless, under this exception the manufacturers of generic drugs 
are allowed to use and test the invention during the protection period 
without requirement to apply to get authorisation from the patent 
owner. The logic behind this exception is that the products of generic 
drugs be available to consumers to buy the moment the patent 
expires.
494
 This is in the benefit of members of society to get 
medicines at lower prices.
495
   
This exception has been named as ‘Bolar Exception’ after the 
United States case of ‘Roche Products Inc. v. Bolar Pharmaceutical 
Co.’ (Fed. Cir. 1984).
 
The subject matter and core issue of this case 
was early working on patented drugs. Even though the outcome of the 
case was negative, in the sense that the Court of Appeals for the 
Federal Circuit did not allow the early work on the patented drug.
496
 
However, this case became the reason that the United States Patent 
Act was amended in order to include such exception in Section 217.e 
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 Then many countries around the world included this exception 
into their legislations, among them countries of the European Unions. 
Some of these countries are Canada, Australia, Argentina, France, 
England, Israel and Thailand.
498
  
  European Directive 2001/83/EC of the European parliament and 
of the Council of 6 November 2001 on the community code relating to 
Medicinal products for human use, in Article 10.6 states that 
‘Conducting the necessary studies and trials with a view to the 
application of paragraphs 1, 2, 3 and 4 and the consequential practical 
requirements shall not be regarded as contrary to patent rights or to 
supplementary protection certificates for medicinal products’.
499
 
Article 27 (d) of the Notices From European Union Institutions, 
Bodies, Offices and Agencies  states that the rights conferred by a 
patent shall not extend to ‘the acts allowed pursuant to Article 13(6) of 
Directive 2001/82/EC (1) or Article 10(6) of Directive 2001/83/EC (2) 
in respect of any patent covering the product within the meaning of 
either of those Directives’.
500
 Therefore, the bolar exception officially 
considered as an exception to the exclusive rights of the patent 
owners.  
The Panel in the case of Canada-Pharmaceutical Patents referred 
to this exception as regulatory review and confirmed that this type of 
exception is consistent with Article 30 of the TRIPS Agreement.
501
 
There can be no conflict with Article 30, since this exception allows 
the marketing of generic drugs only after expiry of the protection 
period of the patent.
502
  
                                                 
497 ‘United States Code Title 35 - Patents’. 
498 Stoll, Busche, and Arend, p. 549. 
499 ‘Directive 2001/83/EC of the European Parliament and of the Council of 6 November 
2001 on the Community Code Relating to Medicinal Products for Human Use, Official 
Journal L – 311, 28/11/2004, P. 67 – 128 as Amended by Directive 2002/98/EC, 
2004/24/EC and 2004/27/EC’ 
<http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_g
uideline/2009/10/WC500004481.pdf> [accessed 3 May 2018]. 
500 ‘Notices from European Union Institutions, Bodies, Offices and Agencies’ <http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:175:0001:0040:EN:PDF> 
[accessed 3 May 2018]. 
501 Canada – Patent Protection of Pharmaceutical Products - Report of the Panel, 
WT/DS114/R ON 17 MARCH 2000, Paragraphs 7.47, 7.50, 7.59, 7.73, 7.83 and 7.84. 
502 Stoll, Busche, and Arend, p. 550. 
SAMAN ABDULRAHMAN ALI 
240 
2.2.2.3 Individual Prescriptions Exception 
Nowadays many member countries have included this exception 
in their legislation in which manual preparation of medicines and 
medical products in a pharmacy by pharmacists or by a medical 
professional and doctors are allowed on the request of individual 
prescription.
503
 This exception is limited to individual cases; therefore, 
manufacturing of large quantities are not allowed.
504
 In the case of 
Canada-Pharmaceutical Patents, the Panel held that a pharmacist is 
allowed to use a patented pharmaceutical invention while preparing 
and dispensing a medical compound. The Panel listed some countries 
that have this exception in their legislations.
505
   
2.2.2.4 Prior Use Exception 
It is normal that more than one research centres or institutions 
carrying out research on the same issue and trying to reach solution to 
the same problem. It is possible that a third party independently has 
been carrying out actions and activities that relates to the invention but 
in secret. That is why usually the research centres are in race to invent 
first and apply for patent as soon as possible. Once patent granted, the 
patent owner has right of monopoly and prevent others from using his 
invention without prior authorization. However, its well-recognized 
principle that it is also not fair to prevent third parties to complete 
their work that they have started before the patent was granted. 
Similarly, prior users are allowed to continue manufacture whatever 
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they were producing. Therefore, the right of protection of the patent 
owner should be limited in this regard.
506
 This right of prior use does 
not create any direct legal relationship between the patent holder and 
the prior user. It only asserts the rights of the bona fide use of 
invention by third parties before filing the patent and granting the 
patent.
507
    
In the WIPO draft treaty for harmonization of patent law prior use 
was recognized as a legitimate ground of exception. Some member 
countries of the European Patent Convention recognized the prior use 
as an exception such as Section 64 of the United Kingdom Patents Act 
1977.
508
 Since this exception under the United Kingdom Patents Act 
1977 has been considered to be consistent with the European Patent 
Convention, therefore, it has to be considered to be compatible with 
the TRIPS Agreement as well.
509
  
2.2.2.5 Parallel Imports 
The term of ‘Parallel Imports’ has been defined as ‘Products 
imported into a country without the authorization of the right holder in 
that country, which have been put on the market in another country by 
that person or with his consent (Article 6)’. According to Article 6 of 
the TRIPS Agreement,
510
 when a state or a group of states regulating 
the principle of exhaustion (international exhaustion) in their domestic 
legislations, the patent owner losses the exclusive rights of 
importation of the protected products and parallel importation is 
authorised within the states.
511
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Insertion of international exhaustion under Article 6 was the wish 
of the developing countries in order to permit parallel imports, so that 
their consumers are able to access to products at lower prices. 
However, this idea was not accepted by the developed countries. 
Nevertheless, eventually Article 6 adopted a liberal view in which the 
member countries are at liberty to adopt the most suitable system 
according to their needs whether be a national or international 
exhaustion. On other hand, the developed countries have rights under 
Article 6 to adopt national exhaustion so that they prevent access by 
other countries to import patented products.
512
 The reason is that 
according to national exhaustion only exclusive right to use, offer for 
sale and sell are extinguished. The logic is that the patent owner has 
gained full benefit from his patent rights when he has made the first 
sale of a particular product. However, other exclusive rights of making 
and importing of that particular product are still within the exclusive 
rights of the patent holder.
513
   
This concept has great economic benefits, because the same 
product can be sold at a much lower price in one country than 
others.
514
 This is due to differences in economic growth and 
development of the countries. Least developed countries have much 
lower GDP per capita income; hence price of products is much lower 
than developed countries. Another fact that affect the price of product 
is that in least developed and developing countries the cost of 
production is much lower and standard of living is much lower than 
developed countries. If the price of products to be equal in developed 
and least developed countries, then rate of sale and gain of profit will 
be much lesser in the least developed countries. That is why once the 
patent holder imported or licenced for his products to be imported to a 
least developed country, then he has to agree to sell the products in 
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lower prices in that country. Then other countries can benefit from this 
reduction prices and buy it through a parallel importation.  
Article 30 of the TRIPS Agreement also, in principle, has enough 
flexibility to allow derogation to the exclusive rights to import in 
cases where the patented product legally commercialised or imported 
in a foreign country. According to Article 28 of the TRIPS Agreement 
the exclusive right of importing patented products is belong to the 
patent owner. Article 28.1 states that patent owner has some exclusive 
rights and in lit. (a) states that ‘where the subject matter of a patent is 
a product, to prevent third parties not having the owner’s consent from 
the acts of: making, using, offering for sale, selling, or importing for 
these purposes that product;’. However, an explanation is given in the 
footnote 6 that right of importation of products like all the other rights 
are subject to exhaustion as it states that ‘This right, like all other 
rights conferred under this Agreement in respect of the use, sale, 
importation or other distribution of goods, is subject to the provisions 
of Article 6’.
515
   
2.3 OTHER USE WITHOUT AUTHORIZATION OF THE RIGHT 
HOLDER (COMPULSORY LICENCE)  
Developed countries in general do not have problem with the high 
standard of protection of patent rights. This is due to their historical 
backgrounds and experiences with patent rights. Their solid traditions 
and laws in the area of competition and consumer protections are well 
legislated. In contrast, this type of high standard of protection that 
exists in the TRIPS Agreement is new to the least developed and 
developing countries. They are unprepared and unable to deal with the 
high standard of protection. This high standard of protection directly 
affects the general population which they have lower income. The 
majority of people have problem in accessing the patented products 
which some of them may be necessary for their livelihood, such as 
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medicines. That is why the use of compulsory licences for the 
developing countries is receiving growing attention.
516
      
Compulsory licences are tools created for keeping balances 
between patent holder’s rights and need of society for the patented 
product, and usually it is operated where the balance is tilted toward 
the interest of society over the interest of patent holder. Compulsory 
licence can be defined as ‘involuntary contract[s] between a willing 
buyer and an unwilling seller imposed and enforced by the state’.
517
 
For this reason the compulsory licences are considered to be very 
powerful rights granted to authorities, therefore, it has to be used 
extremely carefully, otherwise they will cause great injustice. Thus, 
compulsory licences are restricting the legal rights of the patent 
owners unwillingly by authorising third parties to commercialise the 
patented products by making, using, and selling them.
518
      
Compulsory licence limiting the exclusive rights of the patent 
owners. The basic principle of granting patent is that the patent holder 
should enjoy some exclusive rights and should have monopoly over 
his invention, to sell, produce, make, use and import in the best way of 
his wish to gain economic benefit in return for his creative activity. 
However, once the compulsory licence enforced on him without his 
permission, it is considered to be a direct interference with his ‘private 
power’ that he has due to his patent. Thus, this process of compulsory 
licence discourages others to invest in research and development and 
may kill desires of creating and inventing new products.
519
 Therefore, 
it has to be used carefully in order to keep balance between interests 
of both patent owner and general public.    
Nowadays many developing countries have adopted the principle 
of compulsory licence in their domestic laws. Those countries that 
recently provided for compulsory licence stated a comprehensive list 
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of reasons that may cause granting compulsory licence. However, 
generally compulsory licence is granted for lack or insufficiently 
working, and to remedy the situations that occur due to anti-
competitive practices. It is usually granted for the sake of public 
interest in cases of emergency or governmental use. The World Health 
Organization stated that the compulsory licence can also be granted in 
cases of abuse of patents in order to reduce the price of medicine so 
that be people be able to buy it.
520
    
2.3.1 Historical Background 
For the first time in history the concept of compulsory licence was 
introduced in the United Kingdome through the Statute of Monopolies 
in 1623. Then the same concept was introduced by other countries 
during nineteenth century so that apply it on their local patented 
inventions. Prior to the application of the principle of compulsory 
licence in some countries such as France, the drastic measure of 
forfeiture for non-working was applied. Then it was replaced by 




However, for the first time under patent act the concept of 
compulsory licence was introduced under United Kingdom’s Patent, 
Designs and Trade Marks Act 1883. Section 22 of the Act empowered 
the Board of Trade to order the grant of a compulsory licence where: 
‘(a) The patent is not being worked in the United Kingdom; or (b) The 
reasonable requirements of the public with respect to the invention 
cannot be supplied; or (c) Any person is prevented from working or 
using to the best advantage an invention of which he is possessed’.
522
 
The content of this Section became the base for the United Kingdom’s 
subsequent adopted patent acts of 1902, 1907, 1919, 1949 and 1977, 
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 This provision had influenced the patent 
acts of other countries. To the extent that having compulsory licence 
provision in the patent law around the world became a typical feature. 
As of the beginning of the 1990s recognition of this principle by 
countries reach one hundred countries. Furthermore, it had great role 
in developing international conventions as well, such as Paris 




The Paris Convention as one of the leading conventions in the 
area of patents, provides for compulsory licence in order to ‘prevent 
the abuses which might result from the exercise of the exclusive rights 
conferred by the patent, for example, failure to work’, as states in 
Article 5. A. (2). This provision deals with compulsory licence only in 
order to prevent abuses that resulted from the exercises of the 
exclusive rights of the patent owner. The word abuse is not elaborated 
here except for cases of ‘failure to work’.
525
   
The Paris Convention does not allow granting compulsory licence 
in the early period of granting the patent, but applicant to compulsory 
licence has to wait three to four years before he is allowed to apply for 
the licence. At the same time, this Convention does not provide for 
any limitation on the granting of the licence and does not provide for 
compensation. These reasons contributed the negotiation of having 
compulsory licence in the TRIPS Agreement.
526
  
2.3.2 Compulsory Licence and Article 31 of the TRIPS 
Agreement 
Article 31 of the TRIPS Agreement regulated an important 
principle which is granting the so-called compulsory licence. 
However, the terms of compulsory licence, non-voluntary licence, 
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licences of right or obligatory licence are not used in the TRIPS 
Agreement. Instead, Article 31 refers to this principle as ‘other use 
without authorization of the right holder’.
527
 Therefore, it is 
permissible that member countries use any terms they prefer as long 
as it indicates of other use of subject matter of a patent without 




The term compulsory licence was not used in the TRIPS 
Agreement because many member countries of the GATT did not use 
this term. In many of those counties, already the governments were 
allowed to use private property for the benefit of public without 
authorisation of the owner as long as the just compensation is 
provided for. Another reason is that the word ‘licence’ indicates of 
having voluntary permission from the right holder but in fact the 
granting of compulsory licence is enforced on the right owner of the 
subject matter of the patent without having any choice of refusal 
through a governmental authority whether be an executive branch or 
judicial branch. In the case of compulsory licence, the right holder is 
not part of the deal, because he refused licencing others to use his 
invention. He is a third party to a negotiation between the authority 
that grants the compulsory licence and an entity that granted the 
authority to utilise the invention. Therefore, one can argue that using 
the word ‘licence’ in this situation is misleading.
529
     
Footnote 7 of the TRIPS Agreement further illustrates the 
meaning of ‘other use’ by stating that it ‘refers to use other than that 
allowed under Article 30’. This is in order to distinguish between 
‘limited exceptions’ that are allowed under Article 30 with three 
conditions (have been discussed in previous Section in detail) and 
compulsory licence under Article 31. Article 30 may provide for 
limited exceptions through legislation that have general effect on 
parties involved. On the other hand, Article 31 directly affect interests 
of an individual right holder and authorised party. Article 31 states the 
procedures that the member countries should follow when granting a 
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licence and it include some terms that should be embodied in the 
licence. These procedures and terms may vary from one compulsory 
licence to another depend on the context in which the licence granted. 




Since Article 31 does not provide for specific grounds of granting 
the compulsory licence and it was left for the member countries to 
decide. Nevertheless, the member countries can find some grounds in 
the provisions of the Article. The only ground mentioned specifically 
is semiconductor technology in Article 31 (c). Nevertheless, within 
Article 31 references can be found to some grounds, albeit these 
grounds are not exhausted, such grounds are national emergency, anti-
competitive practices, public non-commercial use and dependent 
patents.
531
   
For using other grounds, the member countries can use 
interpretation of Article 8 of the TRIPS Agreement, in which gives the 
member countries some options, such as in Article 8.1 to ‘adopt 
measures necessary to protect public health and nutrition, and to 
promote the public interest in sectors of vital importance to their 
socio-economic and technological development’. Also, based on 
Article 8.2 the member countries have the choice to provide measures 
in their laws and regulations that are ‘Appropriate measures, provided 
that they are consistent with the provisions of this Agreement, may be 
needed to prevent the abuse of intellectual property rights by right 
holders or the resort to practices which unreasonably restrain trade or 
adversely affect the international transfer of technology’. Combination 
of these provisions of Article 8 with Article 31, they provide great 
deal of flexibilities to member countries to grant compulsory licence 
on grounds of their choice. However, it has to be taken into 
consideration that the member countries are not allowed to grant 
compulsory licence on frivolous grounds or on no grounds.
532
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Article 31 of the TRIPS Agreement states two types of ‘other use’ 
as it states in the introductory note ‘Where the law of a Member 
allows for other use of the subject matter of a patent without the 
authorization of the right holder, including use by the government or 
third parties authorized by the government’. Therefore, it allows to 
grant compulsory licence, firstly for use by the government and 
secondly for use by third parties authorized by the government. 
However, Article 31 states a list of conditions that have to be followed 




2.3.2.1 Individual Merits 
The first principle that must be followed in order to grant a 
compulsory licence is that it has to be granted on a case by case 
basis.
534
 This principle can be found in Article 31 lit. (a) which states 
that ‘authorization of such use shall be considered on its individual 
merits’. This clearly prevents member countries to approve granting 
compulsory licence in advance, such as for patents in a specified field 
of technology or involving certain patentees.
535
 This provision states 
so that member countries do not provide ‘blanket licensing clause’ in 
their national laws in order to grant compulsory licence automatically 
in some areas. It is allowed that a member country to legislate that an 
area of health and nutrition area considered as inherently public 
interest, but such law should not lead to automatic compulsory 
licenses.
536
 Rather the compulsory licence has to be applied 
exceptionally, therefore, every individual application for granting such 
licence should be dealt with separately and considered duly.
537
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2.3.2.2 Prior Negotiations and protection of the right holder  
Article 31 lit. (b) of the TRIPS Agreement
538
 states some 
important conditions and principles that member countries have to 
follow before granting compulsory licence. First, it requires that the 
proposed user whether be a government or third parties have contacted 
the right holder to negotiate acquiring the voluntary licence before 
applying for compulsory licence. This means that the TRIPS 
Agreement prefer voluntary licence. Nevertheless, this Article is 
flexible because it requires that the negotiation has to be carried on 
reasonable terms within reasonable period of times. The word 
‘reasonable’ is not defined in the Article, therefore, its left for the 
member countries to decide. Generally, the negotiation is around the 
amount of royalty that has to be paid to the patent owner. The royalty 
amount may differ base on many things, such as on the number of 
products made or sold, or base on the licensee’s net income, or it can 
be a fixed amount at periodic intervals. Nonetheless, the royalty 
payment differs from one industry to another, and sometimes within 
the same industry the royalty payment may be different from one 
technology to another. However, the negotiation may include other 
elements such as, duration of the licence terms, additional technology, 
grant-back, tying arrangements and export restrictions.
539
 The 
condition of ‘reasonable commercial terms and reasonable period of 
time’ has to be complied by the prospective licensee.
540
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Next, Article 31 lit. (b) in its second sentence provided for three 
exceptions to prior negotiation. This means that the member countries 
are allowed not to follow the previous requirement of prior negotiation 
‘in case of a national emergency or other circumstances of extreme 
urgency or in cases of public non-commercial use’. These terms are 
very general, and they may carry a variety of interpretation. What 
constitute emergency has not been defined in the TRIPS Agreement, 
therefore it is left for member countries to decide. The member 
countries can in their legislations and through official decrees name 
situations and circumstances that may constitute an emergency. 
However, when one look at the second waiver of the prior negotiation 
‘other circumstances of extreme urgency’, which provide for much 
wider flexibility for the member countries, it becomes clear that 
declaring urgency does not need official declaration of national 
emergency. Though the word ‘extreme’ is used here that refers to the 
ultimate urgency, but there isn’t any general rule that can be used to 
differentiate between extreme urgency and moderate urgency.
541
      
The next exception that does not require prior negotiation is 
‘public non-commercial use’. This term is much wider than the 
emergency and extreme urgency use, because it does not require any 
emergency or extreme circumstances. Therefore, the member 
countries have right to use this exception whenever they desire to 
serve their citizens. This exception is very important for the 
developing and least developed countries, as it allows them to avoid 
costly patents that serve public interests especially those related to 
public health care. The significance of this exception can be noticed in 
Article 31 lit. (b) fourth sentence as it does not require advance 
notification of the patent owner prior to use.
542
  
However, meaning of both of the words of ‘public’ and ‘non-
commercial’ to be taken into consideration and defined in good faith. 
The word public normally refers to government and official authority 
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that carry the activity of using the patent invention. The word public 
also in this context gives the meaning that the patent invention should 
be used for public benefits. Thus, in order to invoke this exception, the 
subject matter of the patent should be used by official authority and 
for the benefit of the public. As of the word of ‘non-commercial’, it 
should be understood as to mean ‘not for profit’. Therefore, the patent 
invention should not be used for gaining profits as it is usually done 
by commercial enterprises and it should be used for public institutions 
such as a public hospital that does not run for the purpose of economic 
gain.
543
          
Third, the third sentence of Article 31 lit. (b) states that in cases of 
national emergency or extreme urgency the government is under 
obligation to inform the patent owner as soon as reasonably 
practicable. Even though in these two circumstances the prior 
negotiation is waived but nevertheless the licensee bears the parallel 
obligation to give notification to the patent owner of the granting the 
compulsory licence. However, the time of notification is not 
determined but the term of ‘reasonably practicable’ is used. This gives 
flexibility and ample time to the licensee to inform the patent owner, 
and it is not necessary to be prior to the grant of the licence.
544
   
In the fourth sentence of Article 31 lit (b), it is stated that public 
non-commercial use is not under obligation to notify the patent owner 
as it is the case for national emergency and extreme urgency. The 
fourth sentence reads as ‘In the case of public non-commercial use, 
where the government or contractor, without making a patent search, 
knows or has demonstrable grounds to know that a valid patent is or 
will be used by or for the government, the right holder shall be 
informed promptly’. This sentence indicates that the governments or 
contractors has to notify the patent owner only if they know or have 
reasonable grounds to know that the subject matter of the licence is 
patented. It further instructs that the user whether the government or 
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the contractor is not under obligation to do a patent search to find out 
whether the subject matter of the licence is patented or not.
545
 It 
cannot be presumed that the government or the contractor knew that 
the invention was patented, and public knowledge presumption is not 
acceptable here. The patent owner is the one has to prove that the 
licensee had knowledge of the existence of the patent. The 
government can also benefit from the domestic legislations which can 
provide for use of privately owned inventions without authorisation. 
In fact, such legislations are allowed under Article 44.2 of the TRIPS 
Agreement,
546
 which allow governments to use such invention with 
the condition of just remuneration according to Article 31 lit. (h).
547
          
2.3.2.3 The Scope and Duration of the Compulsory licence 
Article 31 lit. (c) of the TRIPS Agreement clearly stated the scope 
and duration of the compulsory licence as it states that ‘the scope and 
duration of such use shall be limited to the purpose for which it was 
authorized, and in the case of semi-conductor technology shall only be 
for public non-commercial use or to remedy a practice determined 
after judicial or administrative process to be anti-competitive’.  
In the first part this provision limits the scope and duration of a 
licence to the purpose of which it was authorised.
548
 This imply that 
the grant of compulsory licence should not be unrestricted to any field 
of application, but rather it has to be limited for the purpose it was 
granted for. For example, if a compulsory licence granted for some 
parts of military aircraft, then the same patented parts cannot be used 
for civil aircrafts. In the same way the duration of the licence has to be 
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limited as well. Nevertheless, this does not mean that the compulsory 
licence has to be given to a certain period only, but the licence 
duration has to be long enough to fulfil the purpose it was granted for. 
Or else, Article 31 will not fulfil the purpose it was designed for.
549
   
Article 31 does not limit the grounds for which the compulsory 
licence can be applied, instead it states conditions that should be 
followed when the compulsory licence is granted. Even though this 
provision can be seen as encouraging granting of compulsory licence, 
but it has been argued by Nuno Pires de Carvalho that the conditions 
set by Article 31 with the intention of protecting the private rights of 
the patent holders.
550
 Thus Article 31 lit. (b) restricts the purpose 
(grounds) of granting compulsory licence in regard of semi-conductor 
technology which shall be only for the purpose of public non-




Article 31 lit. (d) clearly states that ‘such use shall be non-
exclusive’. This means that the granting of a compulsory licence to a 
particular patented invention does not exclude the patent owner from 
using his product. The patent owner still has the right to 
commercialise his invention and licensing it to third parties. This is to 
make sure that granting compulsory licence is not first choice of the 
licensee and this also encourage voluntary licensing.  
According to this provision the patent owner has rights to 
compete with the licensee whether directly by himself or license the 
invention to third parties. The patent owner is under no obligation to 
share his commercial strategy with the licensee. This eventually create 
a commercial risk for the licensee, as exploitation of the patented 
invention necessitate good amount of investment. This eventually 
leads to decrease of application of granting compulsory licence. 
However, the purpose of Article 31 ‘is not to facilitate granting 
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compulsory licences, but rather to submit them to conditions of 




Article 31 lit. (e) of the TRIPS Agreement states that ‘such use 
shall be non-assignable, except with that part of the enterprise or 
goodwill which enjoys such use’. This is to ensure that the licensee 
does not obtain a stronger position than what the compulsory licence 
has already granted him. The licensee is not allowed to create a 
trading system for the compulsory licence that was granted to him.
553
  
Looking at this subparagraph, one question may arise as to 
whether it allows sub-licensing or not as Article 5. A. (4) of the Paris 
Convention
554
 clearly states that sub-licensing is not allowed under 
compulsory licences. However, Article 31 lit. (e) of the TRIPS 
Agreement does not mention the word sub-licensing. Nevertheless, in 
this regard the compulsory licence can be compared to voluntary 
licence. As in voluntary licence when the licence is non-exclusive, the 
licensee does not have authority to sub-licence the patent. In the same 
way Article 31 lit. (d) clearly states that the compulsory licence has to 
be non-exclusive, and subsequently it cannot be sub-licensed again. 
Thus, it was not necessary for Article 31 lit. (e) state again that sub-
licencing is not allowed as it is the case with Article 5. A. (4) of the 
Paris Convention.
555
     
Exception has been given to the goodwill, which does not 
constitute any tangible assets of the subject matter of the compulsory 
licence. This in fact create a flexibility against the non-assignment. 
Thus, according to part of the Article 31 lit. (e), if the entire assets of 
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the compulsory licence is in the form of goodwill, then it can be 
assigned and transferred as part of the market transaction.
556
    
2.3.2.6 Predominantly for The Supply of The Domestic 
Market 
Article 31 lit. (f) of the TRIPS Agreement states that ‘any such 
use shall be authorized predominantly for the supply of the domestic 
market of the Member authorizing such use’. This means that the 
compulsory licence should be ‘predominantly’ used for the domestic 
market. This indicate that the intention of the granting such licence 
should be for fulfilling the domestic market and not for exporting. 
Even though the term ‘predominantly’ may carry the meaning that 
small part of the subject matter of the compulsory licence can be 
exported but should not exceed more than fifty percent of the total 
production. Prior to the existence of the TRIPS Agreement, many 
countries legislated the principle of compulsory licence with the 
intention of exporting it to foreign markets. The Paris Convention did 
not prevent such practices. However, once the TRIPS Agreement 
implemented such practice should not be allowed. Because the 
principle of compulsory licence under Article 31 is considered as an 
exception to the general rule of exclusive rights of the patent owner, 
therefore, it should be kept as an exception. Thus, this subparagraph is 
introducing another limitation to the Paris Union Members that are 
member of the WTO (TRIPS Agreement) in the same time.
557
  
This subparagraph, according to the previous argument, prevents 
a country that have no technological capabilities to produce under the 
patented invention, to be able to buy such products for lesser money 
from another country that produce them under compulsory licence.
558
 
For this reason, some other authors claim that if the intention of a 
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member country of granting the compulsory licence is principally to 
fulfil the need of domestic market, then it has complied with the term 
‘predominantly’.
559
 Thus it does not make any different how many 
percentage of the compulsory licence’s products will be exported to 
foreign market.            
 However, under Article 31 lit. (k) when the compulsory licence 
granted by judicial or administrative process of a member country to 
remedy an anti-competitive practice, then that member country is not 
obliged to comply with Article 31 lit. (f). In another word, in this 
situation the member country is allowed to export majority of the 
products to foreign market.
560
     
Furthermore, recent developments have added some more 
exceptions to this subparagraph. At the Doha Ministerial Conference 
in 2001, the Doha Declaration on the TRIPS Agreement and Public 
Health was adopted. On the recommendation of Paragraph 6 of the 
Doha Declaration
561
 which was intended to create a path to the 
member countries so that they can easily access to medicines.
562
  
Eventually this followed by a Decision of the General Council of 30 
August 2003. Part of this decision became Article 31bis and other 
became an Annex to the TRIPS Agreement. This was adopted by the 
General Council under the name of Amendment of the TRIPS 
Agreement (Decision of 6 December 2005)
563
 and submitted to the 
member countries in order to be accepted.
564
 Article 31bis 1 provides 
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2.3.2.7 Termination 
Article 31 lit. (g) of the TRIPS Agreement states that 
‘authorization for such use shall be liable, subject to adequate 
protection of the legitimate interests of the persons so authorized, to 
be terminated if and when the circumstances which led to it cease to 
exist and are unlikely to recur. The competent authority shall have the 
authority to review, upon motivated request, the continued existence 
of these circumstances’. This subparagraph provides for termination 
of the compulsory licence while the legitimate interest of the licensee 




This subparagraph requires that the compulsory licence formally 
be terminated by the authority (executive or judicial) after taking all 
circumstances into consideration. Automatic termination is not 
allowed in this situation though the situations that causes its grant 
disappear, because it create a great risk to the licensee and this will 
cause injustice.
567
 Some mechanism can be adopted in order to 
terminate the compulsory licence in such a way that the legitimate 
interest of the licensee is adequately protected. For example, in the 
terms of granting the compulsory licence a sufficient time can be 
stipulated so that the licensee recover the costs he has spent and earn 
reasonable profit. Also, during the normal period of the compulsory 
licence, it cannot be terminated so that to protect the licensee’s 
interest. However, if the patent holder requested such termination, 
then he has to compensate the licensee for rest of the licence’s value 
and in the same time he has to fulfil the needs of the market instead of 
the licensee.
568
 Therefore, in deciding to terminate the compulsory 
licence balance has to be kept between the legitimate interest of the 
licensee and that of the patent owner.
569
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When a member country legislates rules of compulsory licence 
into their laws, it has to be bear in mind to include some mechanism in 
order the patent owner be able to petition for a review to prove that the 
circumstance lead to granting the licence are not existence anymore 
and are unlikely to recur, as stated by this subparagraph. Nonetheless, 
the licensee has the right to appeal and present its own justification 
and evidence so that the licence be continued or renewed.
570
 
2.3.2.8 Adequate Remuneration 
Article 31 lit. (h) of the TRIPS Agreement states that ‘the right 
holder shall be paid adequate remuneration in the circumstances of 
each case, taking into account the economic value of the 
authorization’. This is an improvement by the TRIPS Agreement as 
the Paris Convention does not provide for any regulations as to 
adequate compensation of the patent owner, whether the licensee is a 
government or private party.
571
 This is because TRIPS Agreement in 
its preamble
572
 has considered intellectual property rights as private 




During the negotiation process in Brussels, the negotiators were 
hesitating whether to choose the term ‘adequate’ as it was proposed by 
the United States of America, or ‘fair and equitable’ which was 
supported by several members. This subparagraph is considered to be 
one of the most controversial provisions of the TRIPS Agreement.
574
 
However, this subparagraph does not illustrate the meaning of 
‘adequate remuneration’. Nevertheless, one can get a hint of the 
meaning of this term by looking at Article 44 and 45 of the TRIPS 
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Agreement. Article 44 provides for injunctions, but the second 
paragraph
575
 states that when the use is by government or third parties 
authorised by government, then the only remedy is the one provided 
by subparagraph (h) Article 31 instead of damage according to Article 
45
576
. Since the judicial authority is the one which has to assess the 
adequate damage and in the above cases the adequate damage is 
replaced by adequate remuneration, therefore, the same criteria can be 
used to assess the ‘adequate remuneration’. Which can be determined 
in the same way as damage, by calculating the amount that the patent 
owner would have made if he was the one utilising the patented 
invention instead of the licensee.
577
  
Adequate remuneration is different from one case to another 
according to their circumstances as it is stated in the subparagraph. 
Therefore, adequate remuneration cannot be standardized in which a 
uniform fee to be paid by the compulsory licensee in the same sector 
of industry. A uniform and average fee can be taken into consideration 
and used only as one of the factors of determining the adequate 
remuneration. Also, when trying to determine the adequate 
remuneration, the subparagraph requires that the economic value of 
the authorization has to be taken into account. But the provision is 
unclear whether it refer to the economic value according to the 
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patentee or the licensee. Economic value according to the 
authorization of the patentee would be the fee that he asks for 
licencing his patented invention in a voluntary licence. On the other 
hand, according the licensee the economic value of the compulsory 
licence would be the potential profit that the licensee is expecting.
578
 
Therefore, member countries are free to select factors that may 
determine the adequate remuneration, but they have to be careful 
because if they enforce inadequate remuneration, then they will 
violate Article 31 lit. (h).
579
  
2.3.2.9 Judicial Review    
Article 31 in both subparagraphs of (i) and (j) provides for 
judicial review or independent review by a distinct higher authority in 
that member country. However, in the first subparagraph of (i) it is 
states that ‘the legal validity of any decision relating to the 
authorization of such use shall be subject to judicial review or other 
independent review by a distinct higher authority in that Member’, 
which is requesting review of a decision of granting compulsory 
licence. This refers to legal validity of the decision only, without 
dealing with any other interlocutory issues. On the other hand, 
subparagraph (j) states that ‘any decision relating to the remuneration 
provided in respect of such use shall be subject to judicial review or 
other independent review by a distinct higher authority in that 
Member’, which is requesting review of a decision relating to the 
remuneration. Here the review is not limited to validity of the 
decision, but all other decisions that have influence the decision 
should be reviewed. Beside the amount of the remuneration, other 
issues such as methods of payment, currency, liquidity and insurance 
can be subject to review.
580
 
Due to the fact that the legal systems of the member countries are 
different from one another, therefore, these subparagraphs are only 
stating general terms and give some discretion during 
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implementations. Both of the subparagraphs state that the review can 
be carried out by the judicial review, which is clear enough by the 
patentee and the licensee to follow the procedures. However, the 
second part which is an independent review by a distinct higher 
authority in that member country, is not clear enough as the 
subparagraphs do not define the nature of that authority. But the word 
‘independent’ means that the reviewing person or body should not be 
under control the authority that granted the licence or determined the 
remuneration. The term ‘distinct’ indicates that there should be 
adequate separation between the person or body reviewing and the one 
granting or determining the remuneration in function even though they 
are under same agency. This is reinforcing the idea of independent 
review. The term ‘higher authority’ refers to the notion that the 
reviewing authority should be higher in raking and level than the one 
granted the licence or determined the remuneration, so that be out of 
their influence in making the decision.
581
 This option of ‘independent 
review by a distinct higher authority’ was added to these 
subparagraphs by Australia during the negotiations.
582
 This seems to 
be a good choice as usually the judicial process may consume very 
long time and cost a lot, however, the process of administrative review 
is faster and less costly. If the procedures laid down in this provision 
followed carefully, the decision will be as just as the one reviewed by 
judicial authority.   
2.3.2.10 Remedies for Anticompetitive practices 
Anti-competitive practice was one of the main concerns of TRIPS 
Agreement negotiators, which had increased due to the monopolies 
arise from the exclusive rights granted to patent owners by the 
intellectual property rights. Other articles and provisions of the TRIPS 
Agreement has allowed member countries to take measures and 
control such practices, such as Article 8.1 and 40 of the TRIPS 
                                                 
581 United Nations Conference on Trade and Development, International Centre for Trade and 
Sustainable Development, and UNCTAD-ICTSD Project on IPRs and Sustainable 
Development, pp. 477–78. 
582 Stoll, Busche, and Arend, p. 576. 




 Beside these provisions, also Article 31 lit. (k) states 
that ‘Members are not obliged to apply the conditions set forth in 
subparagraphs (b) and (f) where such use is permitted to remedy a 
practice determined after judicial or administrative process to be anti-
competitive. The need to correct anti-competitive practices may be 
taken into account in determining the amount of remuneration in such 
cases. Competent authorities shall have the authority to refuse 
termination of authorization if and when the conditions which led to 
such authorization are likely to recur’.  
This provision gives authority to member countries to bypass the 
conditions in Article 31 lits. (b) and (f), which are notifying and prior 
negotiation with the patent owner, and the licence should be 
predominantly used for supplying the domestic market, when the 
compulsory licence granted in order ‘to remedy a practice determined 
after judicial or administrative process to be anti-competitive’. 
However, in this situation the government should not deprive the 
patent owner from receiving adequate remuneration, nevertheless this 
situation can be taken into consideration while determining the 
adequate remuneration. This provision can be interpreted as allowing 
the national authorities to reduce the remuneration or even a ‘royalty 
free’ licence. The final sentence gives further authority to the member 
countries’ competent authority to refuse termination of the 
compulsory licence if and when the anti-competitive conditions which 
led to granting the licence are likely to recur.
584
   
2.3.2.11 Dependent Patents 
Article 31 lit. (l) of the TRIPS Agreement,
585
 provides for three 
more conditions beside other conditions of this Article, in cases that 
                                                 
583 Blakeney, Trade Related Aspects of Intellectual Property Rights, p. 92. 
584 Stoll, Busche, and Arend, p. 577; United Nations Conference on Trade and Development, 
International Centre for Trade and Sustainable Development, and UNCTAD-ICTSD 
Project on IPRs and Sustainable Development, p. 479. 
585 Article 31 lit. (l) of the TRIPS Agreement states that ‘where such use is authorized to 
permit the exploitation of a patent ("the second patent") which cannot be exploited without 
infringing another patent ("the first patent"), the following additional conditions shall 
apply: 
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concern the dependent patents. The dependent patent (second patent) 
is a patented invention which cannot be worked without exploiting the 
original patent (first patent). Generally, the dependent patent owner 
requests a voluntary licence over the original patent. However, if it is 
not granted, the dependent patent owner may apply for authorisation 
of using the original patent through a compulsory licence.
586
  
In Article 31 lit. (l) of the TRIPS Agreement it is stated that when 
compulsory licence granted in order to permit the second patent which 
cannot be exploited without infringing the first patent, three additional 
conditions has to be followed.  
Firstly; it is required that the second patent involve an important 
technical advancement, and such technical advancement should have 
considerable economic significance. However, the term ‘economic 
significance’ is not precise concept and may carry many 
interpretations. It is possible that the second patent have technically 
advanced the original patent but may have little application with great 
economic significance and vice versa.
587
 Determining important 
technical advancement of an invention is matter of subjective 
judgment that carry a wide range of discretion.
588
 However, this 
condition introduced by the TRIPS Agreement because some 
countries had very generous policy in granting compulsory licence in 
these cases. Therefore, it was introduced in order to limit granting 
such licences only after following this stringent condition.
589
       
Secondly, the first patent owner, shall be given a cross-licence on 
reasonable terms so that to be able to benefit from the invention of the 
                                                                                                                   
(i) the invention claimed in the second patent shall involve an important technical advance of 
considerable economic significance in relation to the invention claimed in the first patent; 
(ii) the owner of the first patent shall be entitled to a cross-licence on reasonable terms to use 
the invention claimed in the second patent; and 
(iii) the use authorized in respect of the first patent shall be non-assignable except with the 
assignment of the second patent’.   
586 Anonymous, ‘Genes and Ingenuity: Gene Patenting and Human Health (ALRC Report 99), 
27. Compulsory Licensing, Dependent Patents’, 2010 
<https://www.alrc.gov.au/publications/27-compulsory-licensing/dependent-patents> 
[accessed 5 April 2018]. 
587 Carvalho, The TRIPS Regime of Patents and Test Data, p. 471. 
588 Stoll, Busche, and Arend, p. 578. 
589 Gervais, p. 394. 
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second patent. This condition stipulated here in order to keep balance 
and both patent owners benefit from each other’s inventions and not 
one of them only. However, it is required that there should be a 
negotiation process on reasonable terms. This indicate there the cross-
licence will not be without compensation. It is presumed that the first 
patent owner already received adequate compensation after the 
compulsory licence granted to the second patent owner. Therefore, 
when the first patent owner acquires the cross-licence, it is logic that 
he should compensate the second patent owner as well. Or the 
economic value of both patented inventions can be evaluated and the 
most valuable receive an adequate compensation.
590
       
The final and third condition is related to non-assignability of the 
first patent except with the assignment of the second patent. However, 
the condition of non-assignment already covered by Article 31 lit. (e). 
Therefore, one can perceive that the third condition of Article 31 lit. 
(l) replacing Article 31 lit. (e), with one addition which is the 
exception of non-assignability to the second patent only. For this 
reason, it has been suggested by Nuno Pires de Carvalho, that this 
condition should read as ‘the compulsory licence granted under 
subparagraph (l) shall be assigned only with the patent that enjoys 
such use’.
591
     
2.4 ARTICLE 31BIS AND COMPULSORY LICENCE FOR PUBLIC 
HEALTH 
Article 31bis is the first amendment to the TRIPS Agreement. It 
was amended by the General Council’s Decision of 6 December 
2005,
592
 and submitted to member countries to be accepted. However, 
in order for any amendment to take effect, two thirds of the member 
countries have to accept it. Paragraph 3 of Article X of the WTO 
Agreement states that an amendment ‘shall take effect for the 
                                                 
590 Carvalho, The TRIPS Regime of Patents and Test Data, p. 471; Stoll, Busche, and Arend, 
p. 578. 
591 Carvalho, The TRIPS Regime of Patents and Test Data, p. 472; Stoll, Busche, and Arend, 
p. 578. 
592 ‘WTO | Intellectual Property (TRIPS) - Amendment of the TRIPS Agreement - Decision 
of 6 December 2005’. 
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Members that have accepted them upon acceptance by two thirds of 
the Members and thereafter for each other Member upon acceptance 
by it’.
593
  For this reason the amendment entered into force only on 23 
January 2017. Beside Article 31bis, the amendment also inserted an 
Annex and Appendix to the TRIPS Agreement. Basically, the 
provisions that inserted through this amendment are to give a legal 
basis to the member countries to be able to grant special compulsory 
licences in regard of producing and exporting generic medicines to 
those member countries that don’t have domestic capabilities to 




However, the original idea of having a special Article in the 
TRIPS Agreement in regard of compulsory licence for health products 
emerged from the Paragraph 6 of the Doha Declaration.
595
 This 
paragraph admits that some member countries have insufficient or no 
manufacturing capacities thus cannot effectively use the compulsory 
licence tools to produce medicines. Therefore, the TRIPS Council 
should find a solution as soon as possible and report back to the 
General Council by the end of 2002. For this purpose, TRIPS Council 
conducted several meetings, and some solutions discussed, such as 
amendment to Article 31 lit. (f) in a manner to allow for granting 
compulsory licence for the purpose of exporting only.
596
 Meetings 
took place throughout 2002 and 2003 and the final compromised 
agreement by the member countries within the TRIPS Council 
                                                 
593 ‘WTO | Legal Texts - Uruguay Round Agreement - Marrakesh Agreement Establishing the 
World Trade Organization’ <https://www.wto.org/english/docs_e/legal_e/04-
wto_e.htm#articleX> [accessed 8 April 2018]. 
594 ‘WTO | Intellectual Property (TRIPS) - (as Amended on 23 January 2017)’ 
<https://www.wto.org/english/docs_e/legal_e/31bis_trips_01_e.htm> [accessed 7 April 
2018]. 
595 ‘WT/MIN(01)/DEC/2 -WTO | Ministerial Conferences - Doha 4th Ministerial - 
Declaration on the TRIPS Agreement and Public Health - Adopted 14 November 2001’, 
Paragraph 6 states that ' We recognize that WTO members with insufficient or no 
manufacturing capacities in the pharmaceutical sector could face difficulties in making 
effective use of compulsory licensing under the TRIPS Agreement. We instruct the 
Council for TRIPS to find an expeditious solution to this problem and to report to the 
General Council before the end of 2002’'. 
596 Peter Rott, ‘The Doha Declaration: Good News for Public Health?’, Intellectual Property 
Quarterly, 3 (2003), 284–311 (p. 295). 
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submitted to the General Council of the WTO and endorsed as 
‘Implementation of Paragraph 6 of the Doha Declaration on the 
TRIPS Agreement and Public Health’
597
 on 30 August 2003.
598
 
Eventually this adopted and presented as an amendment of the TRIPS 
Agreement by the decision of the General Council on 6 December 
2005, and finally took effect as part of the TRIPS Agreement’s Article 
31bis, Annex and Appendix on 23 January 2017. 
The first paragraph of Article 31bis states that ‘The obligations of 
an exporting Member under Article 31(f) shall not apply with respect 
to the grant by it of a compulsory licence to the extent necessary for 
the purposes of production of a pharmaceutical product(s) and its 
export to an eligible importing Member(s) in accordance with the 
terms set out in paragraph 2 of the Annex to this Agreement’. This 
paragraph is almost identical to paragraph 2 of the Decision of the 
General Council which was prepared under the title of 
‘Implementation of Paragraph 6 of the Doha Declaration on the 
TRIPS Agreement and Public Health’ on 30 August 2003’.
599
  
This paragraph exempted an exporting member country from 
obligation stated under Article 31 lit. (f), which is granting a 
compulsory licence predominantly for the supply of domestic market. 
Therefore, exporting members are allowed to grant a compulsory 
licence so that majority or all of the productions under such licence be 
exported to outside the country. Even though this provision does not 
clarify which member countries can be an exporting country, but in 
                                                 
597 ‘WT/L/540 - WTO | Intellectual Property (TRIPS) - Implementation of Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’. 
598 Duncan Matthews, ‘WTO Decision on Implementation of Paragraph 6 of The Doha 
Declaration on The TRIPS Agreement and Public Health: A Solution To The Access To 
Essential Medicines Problem?’, Journal of International Economic Law, 7.1 (2004), 73–
107 (p. 9) <https://doi.org/10.1093/jiel/7.1.73>. 
599 ‘WT/L/540 - WTO | Intellectual Property (TRIPS) - Implementation of Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’, Paragraph 2 ' The 
obligations of an exporting Member under Article 31(f) of the TRIPS Agreement shall be 
waived with respect to the grant by it of a compulsory licence to the extent necessary for 
the purposes of production of a pharmaceutical product(s) and its export to an eligible 
importing Member(s) in accordance with the terms set out below in this paragraph'. 
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the Annex to the TRIPS Agreement under paragraph 1 lit. (c)
600
 all 
member countries are eligible to be an export member country.
601
 
However, Article 31bis 1 states that the exporting country must under 
the compulsory licence produce and export pharmaceutical products 
and exporting them to an eligible importing member.  
‘Pharmaceutical product’ is defined by the paragraph 1 lit. (a) of 
the Annex of the TRIPS Agreement.
602
 The pharmaceutical products 
are not limited to medicines, but they can be any patented products, or 
any products produced in the patented process within the 
pharmaceutical sector. Paragraph 1 lit. (a) of the Annex also states that 
it includes any ‘active ingredients necessary for its manufacture and 
diagnostic kits needed for its use would be included’. Therefore, it 
may include vaccines as well because normally they are produced by 
pharmaceutical sectors as other medicines.
603
 It can include other 
patented products such pharmaceutical salts, isomers, polymorphs, 
combinations, manufacturing processes, etc, as long as these 
pharmaceutical products are required to be patented in the exporting 
countries.
604
     
‘Eligible importing member’ is also defined in the paragraph 1 lit. 
(b) of the Annex.
605
 All the least developed countries are 
                                                 
600 Paragraph 1 lit. (c) of the Annex to the TRIPS Agreement states that ‘"exporting Member" 
means a Member using the system to produce pharmaceutical products for, and export 
them to, an eligible importing Member’ 
601 Stoll, Busche, and Arend, p. 585. 
602 Paragraph 1 lit. (a) of the Annex of the TRIPS Agreement states that ‘"pharmaceutical 
product" means any patented product, or product manufactured through a patented process, 
of the pharmaceutical sector needed to address the public health problems as recognized in 
paragraph 1 of the Declaration on the TRIPS Agreement and Public Health 
(WT/MIN(01)/DEC/2). It is understood that active ingredients necessary for its 
manufacture and diagnostic kits needed for its use would be included’.  
603 Vandoren Paul and Eeckhaute Jean Charles, ‘The Wto Decision on Paragraph 6 of the 
Doha Declaration on the Trips Agreement and Public Health’, The Journal of World 
Intellectual Property, 6.6 (2005), 779–93 (p. 784) <https://doi.org/10.1111/j.1747-
1796.2003.tb00242.x>. 
604 Carlos María Correa, ‘Implementation of the WTO General Council Decision on 
Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health’, World 
Health Organization, 2004, p. 9 <http://bases.bireme.br/cgi-
bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=google&base=REPIDISCA&lang
=p&nextAction=lnk&exprSearch=181527&indexSearch=ID> [accessed 10 April 2018]. 
605 Paragraph 1 lit. (b) of the Annex of the TRIPS Agreement states that ‘"eligible importing 
Member" means any least-developed country Member, and any other Member that has 
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automatically eligible importing members without performing any 
obligations.
606
 Nevertheless, all the other member countries of the 
TRIPS Agreement whether be a developing or developed countries, 
can be categorised as the eligible member countries as long as they 
inform the TRIPS Council that they are using the system in whole or 
partially. This notification can be done at any time. The system can be 
used only for national emergency, other circumstances of urgency or 
in case of non-commercial use or for all of them, as it is stated by this 
paragraph of the Annex. This notification is just routine procedures 
and only for the purpose of transparency.
607
 As the footnote 1 of the 
Annex clarifies that this notification does not need to be approved by a 
WTO body in order for the member to use the system.  
This paragraph of the Annex further states that some member 
countries have decided not to use this system as importing member 
and in footnote 3 the name of these members are mentioned which 
they are ‘Australia, Canada, the European Communities with, for the 
purposes of Article 31bis and this Annex, its member States, Iceland, 
Japan, New Zealand, Norway, Switzerland, and the United States’. 
The Annex states also that some other member countries (names of 
these countries are not mentioned in the Annex) are decided to use the 
system only in cases of national emergency and other circumstances 
of extreme urgency. 
The last part of Article 31bis 1, states that paragraph 2 of the 
Annex has to be taken into consideration while applying Article 31bis 
1. Paragraph 2 lit. (a) of the Annex states three conditions that have to 
                                                                                                                   
made a notification to the Council for TRIPS of its intention to use the system set out in 
Article 31bis and this Annex ("system") as an importer, it being understood that a Member 
may notify at any time that it will use the system in whole or in a limited way, for example 
only in the case of a national emergency or other circumstances of extreme urgency or in 
cases of public non-commercial use. It is noted that some Members will not use the system 
as importing Members and that some other Members have stated that, if they use the 
system, it would be in no more than situations of national emergency or other 
circumstances of extreme urgency’.  
606 Correa, ‘Implementation of the WTO General Council Decision on Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’, p. 15. 
607 Frederick M. Abbott, ‘The WTO Medicines Decision: World Pharmaceutical Trade and 
the Protection of Public Health’, American Journal of International Law, 99.2 (2005), 
317–58 (p. 345) <https://doi.org/10.2307/1562501>. 
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be followed by eligible importing member while making a notification 
to the TRIPS Council. First, name and quantities of the product(s) has 
to be specifies. Second, the least developed countries are presumed to 
have no manufacturing capacities. However, other eligible importing 
members have to prove that they have no manufacturing capacities, or 
they have insufficient capacities in the pharmaceutical sector to 
produce the products that they are intending to import, according to 
the Appendix to the Annex of the TRIPS Agreement. Third, if the 
pharmaceutical product is patented in its territory, the member country 
has to state in its notification, that it has granted or intending to grant 
compulsory licence to that product according to Article 31 and 31bis 
of the TRIPS Agreement and provisions of the Annex.  
Paragraph 2 lit (b) and (c) of the Annex states four obligations on 
the exporting member countries when they grant a compulsory licence 
for the purpose of exporting. Firstly, according to paragraph 2 lit. (b) 
(i) of the Annex, it has to produce only the amount necessary in order 
to meet the needs of eligible importing member country and has to 
import all of the amount to that member country only. Secondly, 
according to paragraph 2 lit. (b) (ii) of the Annex, the products have to 
be labelled through a special packaging, colouring or any other way so 
that easily be differentiated in order not to have significant impact on 
the price of the product elsewhere or prevent transferring them to 
different market. Thirdly, according to paragraph 2 lit. (b) (iii) of the 
Annex, before transferring the products, in the website of the licensee 
or WTO website, information about the quantities and special features 
of the product should be posted. Lastly, according to paragraph 2 lit. 
(c) of the Annex, the exporting member should notify the TRIPS 
Council about the transaction including, the conditions of the licence 
and its duration, name and address of the licensee, type of the product 
and its quantities, information about the importing member country, 
and other details that posted on the website, according to previous 
requirement.  
Even though, these requirements suggest that a compulsory 
licence for the purpose of export should be granted for a limited 
quantity, however, there is nothing to prevent the exporting country in 
a single compulsory licence export to more than one country. In fact, 
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several importing countries can arrange among themselves for 
importing same pharmaceutical products in one exporting country in 
order to obtain much suitable prices.
608
  
The second paragraph of Article 31bis of the TRIPS Agreement
609
 
states some important regulation in regard of payment of adequate 
remuneration to the patent holder. Previously according to Article 31 
lit. (h) of the TRIPS Agreement when both importing and exporting 
countries grant a compulsory licence, both of them should have paid 
an adequate remuneration to the patent owner. However, under Article 
31bis 2 prevents this double payment when both importing and 
exporting granting compulsory licence for the same pharmaceutical 
products. This paragraph provides that in such cases only the 
exporting country is required to pay the adequate remuneration 
according to the patent owner taking into account economic value and 
circumstances of the importing country. This is considered to be a 
reasonable solution to prevent double payment of remuneration and 
this will not lead to any difficulties.
610
 In order for the importing 
member country to be exempted from payment of the remuneration is 
that the importing country grant compulsory licence corresponds to 
similar licence in the exporting member and the exporting member has 
paid the remuneration.
611
    
The third paragraph of Article 31bis of the TRIPS Agreement,
612
 
provides for another important exemption to the principle of Article 
                                                 
608 Correa, ‘Implementation of the WTO General Council Decision on Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’, p. 25. 
609 Article 31bis 2 of the TRIPS Agreement states that ‘Where a compulsory licence is 
granted by an exporting Member under the system set out in this Article and the Annex to 
this Agreement, adequate remuneration pursuant to Article 31(h) shall be paid in that 
Member taking into account the economic value to the importing Member of the use that 
has been authorized in the exporting Member. Where a compulsory licence is granted for 
the same products in the eligible importing Member, the obligation of that Member under 
Article 31(h) shall not apply in respect of those products for which remuneration in 
accordance with the first sentence of this paragraph is paid in the exporting Member’.  
610 Frederick M. Abbott and Jerome H. Reichman, ‘The Doha Round’s Public Health Legacy: 
Strategies for the Production and Diffusion of Patented Medicines under the Amended 
TRIPS Provisions’, Journal of International Economic Law, 10.4 (2007), 921–87 (p. 944) 
<https://doi.org/10.1093/jiel/jgm040>. 
611 Stoll, Busche, and Arend, p. 588. 
612 Article 31bis 3 of the TRIPS Agreement states that ‘With a view to harnessing economies 
of scale for the purposes of enhancing purchasing power for, and facilitating the local 
SAMAN ABDULRAHMAN ALI 
272 
31 lit. (f) in regard of granting compulsory licence predominantly for 
supplying the domestic market. Article 31bis 3 allows for re-export of 
imported pharmaceutical products.
613
 However, this waiver applies 
when the member countries of the TRIPS Agreement are least 
developed and developing countries that they are members of the 
same regional trade agreement. Furthermore, the member countries of 
that regional trade agreement are at least half of them are from the list 
of United Nations least developed countries. Therefore, this condition 
only applies on the African regional groupings, as it was their specific 




The main advantage of this exemption which created by Article 
31bis 3 is that it applies to all the member countries of the regional 
trade agreement and notification to the TRIPS Council is not 
necessary whenever an exportation is made. However, this provision 
does not allow the same exporter to supply to all or some of the 
member countries of the same regional trade agreement, but rather the 
waiver is in regard of re-exporting from the importing member 
country of the trade agreement to other members.
615
 Nevertheless, the 
last sentence of this provision provides for the principle of 
territoriality as it states that ‘It is understood that this will not 
prejudice the territorial nature of the patent rights in question’. 
Therefore, according to this principle when the pharmaceutical 
                                                                                                                   
production of, pharmaceutical products: where a developing or least-developed country 
WTO Member is a party to a regional trade agreement within the meaning of Article 
XXIV of the GATT 1994 and the Decision of 28 November 1979 on Differential and More 
Favourable Treatment Reciprocity and Fuller Participation of Developing Countries 
(L/4903), at least half of the current membership of which is made up of countries 
presently on the United Nations list of least-developed countries, the obligation of that 
Member under Article 31(f) shall not apply to the extent necessary to enable a 
pharmaceutical product produced or imported under a compulsory licence in that Member 
to be exported to the markets of those other developing or least-developed country parties 
to the regional trade agreement that share the health problem in question. It is understood 
that this will not prejudice the territorial nature of the patent rights in question’. 
613 Abbott and Reichman, pp. 944–45. 
614 Vandoren Paul and Eeckhaute Jean Charles, p. 790. 
615 Correa, ‘Implementation of the WTO General Council Decision on Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’, p. 25. 
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product is patented in an importing member country, such patent is 
valid and has legal effect only in that member country. It is 
independent from any other patent granted for the same product in 
other member countries. Thus, a compulsory licence granted for a 
patent in one-member country does not have any effect on another 
patent granted for the same product in other member countries. This 
principle of territoriality obliges every member wishes to import from 
the original exporter or from another importing member country, it 
has to apply for compulsory licence.
616
        
The purpose of this waiver as stated by both Article 31bis 3 and 
paragraph 5 of the Annex, is to promote economies of scale as it was 
an existing concern during the negotiation on the Decision of 30 
August 2003, especially for the developing countries.
617
 Therefore, 
paragraph 5 of the Annex states that this kind of exporting and 
importing should be promoted. Further this paragraph provides that 
the developed member countries should take responsibility to provide 
technical cooperation in accordance with Article 67 of the TRIPS 
Agreement and also with other intergovernmental organization.
618
  
Paragraph four of Article 31bis of the TRIPS Agreement states 
that ‘Members shall not challenge any measures taken in conformity 
with the provisions of this Article and the Annex to this Agreement 
under subparagraphs 1(b) and 1(c) of Article XXIII of GATT 1994’. 
This paragraph expressly prevents nonviolation nullification or 
impairment under subparagraphs 1(b) and 1(c) of Article XXIII of 
GATT 1994.
619
 Therefore, member countries are not allowed to bring 
                                                 
616 Vandoren Paul and Eeckhaute Jean Charles, p. 790. 
617 Stoll, Busche, and Arend, p. 588. 
618 Article 67 of the TRIPS Agreement, under the title ‘Technical Cooperation’ states that ‘In 
order to facilitate the implementation of this Agreement, developed country Members shall 
provide, on request and on mutually agreed terms and conditions, technical and financial 
cooperation in favour of developing and least-developed country Members. Such 
cooperation shall include assistance in the preparation of laws and regulations on the 
protection and enforcement of intellectual property rights as well as on the prevention of 
their abuse, and shall include support regarding the establishment or reinforcement of 
domestic offices and agencies relevant to these matters, including the training of 
personnel’.  
619 ‘WTO | Disputes - Dispute Settlement CBT - Legal Basis for a Dispute - Types of 
Complaints and Required Allegations in GATT 1994 - Article XXIII of GATT 1994 
Subparagraph 1 Lits (B) and (C). ‘If any contracting party should consider that any benefit 
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actions under these two subparagraphs which relates to dispute 
settlement in cases of nonviolation and situation. This prohibition is 
important because it will bring substantial insecurity to those countries 
that are ready to use the system.
620
   
The last paragraph is Article 31bis 5 of the TRIPS Agreement 
which states that ‘This Article and the Annex to this Agreement are 
without prejudice to the rights, obligations and flexibilities that 
Members have under the provisions of this Agreement other than 
paragraphs (f) and (h) of Article 31, including those reaffirmed by the 
Declaration on the TRIPS Agreement and Public Health 
(WT/MIN(01)/DEC/2), and to their interpretation. They are also 
without prejudice to the extent to which pharmaceutical products 
produced under a compulsory licence can be exported under the 
provisions of Article 31(f)’. 
In the first sentence this provision confirms that Article 31bis and 
the Annex do not interfere with the rights, flexibilities and obligations 
of the member countries under the TRIPS Agreement and the Doha 
Declaration the TRIPS Agreement and Public Health. However, 
Article 31bis 5 reaffirms the exceptions that provided by this Article 
under paragraphs of Article 31bis 1 and 3, which they are exceptions 
to obligations under Article 31 lits. (f) and (h).
621
 Therefore, during 
implementation of this provision the member countries still can 
benefit from the flexibilities and limitations to the principle of 
exclusivity of rights of the patent owner. In the same time, 
implementation of this provision should not permit the member 
                                                                                                                   
accruing to it directly or indirectly under this Agreement is being nullified or impaired or 
that the attainment of any objective of the Agreement is being impeded as the result of, 
(b) the application by another contracting party of any measure, whether or not it conflicts 
with the provisions of this Agreement, or (c) the existence of any other situation’.’ 
<https://www.wto.org/english/tratop_e/dispu_e/disp_settlement_cbt_e/c4s2p1_e.htm> 
[accessed 14 April 2018]. 
620 Abbott and Reichman, p. 945. 
621 Article 31 lits. (f) and (h) of the TRIPS Agreement, ‘(f) any such use shall be authorized 
predominantly for the supply of the domestic market of the Member authorizing such use; 
(h) the right holder shall be paid adequate remuneration in the circumstances of each case, 
taking into account the economic value of the authorization’.  
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countries to escape from the obligations provided for in the TRIPS 
Agreement and Doha Declaration. 
The EC Regulation No. 816/2006 also provides for compulsory 
licence for the purpose of manufacturing pharmaceuticals and 
exporting them to countries with public health issues. This regulation 
is considered to be an action by the EU in order to solve public health 
problems especially in the least developed and developing countries 
that do not have access to safe and affordable medicines. 
Nevertheless, even the developed countries that informed the WTO 
about their intention to import such medicines, can be eligible to 
benefit from this scheme.
622
  
The term ‘their interpretation’ refers to the interpretation of the 
TRIPS Agreement and Doha Declaration. Paragraph 5 lit. (a) of the 
Doha Declaration,
623
 states while interpreting the provisions of the 
TRIPS Agreement according to Article 31 of the Vienna Convention, 
the objectives and principles of the TRIPS Agreement have to be 
taken into consideration. Those objectives and principles stated in 
Article 7 and 8 of the TRIPS Agreement with other principles that are 
laid down in the Preamble and Part I of the TRIPS Agreement.
624
       
The last sentence of Article 31bis 5 of the TRIPS Agreement 
emphasizes that Article 31bis and the Annex shall not affect the rights 
of the member countries to export pharmaceutical products in which 
produced under compulsory licence and fulfilled the requirement of 
Article 31 lit. (f). Basically, Article 31 lit. (f) requires the member 
countries to grant the compulsory licence predominantly for supplying 
the domestic market. Therefore, the non-predominant portion can be 
exported to another member country.
625
     
                                                 
622 ‘Regulation (EC) No. 816/2006 - Export of Generic Medicines to Developing Countries: 
Compulsory Licences’ <http://eur-lex.europa.eu/legal-
content/EN/TXT/HTML/?uri=LEGISSUM:l21172&from=ES> [accessed 4 May 2018]. 
623 ‘WT/MIN(01)/DEC/2 -WTO | Ministerial Conferences - Doha 4th Ministerial - 
Declaration on the TRIPS Agreement and Public Health - Adopted 14 November 2001’, 
‘In applying the customary rules of interpretation of public international law, each 
provision of the TRIPS Agreement shall be read in the light of the object and purpose of 
the Agreement as expressed, in particular, in its objectives and principles’. 
624 Stoll, Busche, and Arend, p. 590. 
625 Abbott, ‘The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a 
Dark Corner at the WTO’, p. 495. 
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2.5 IRAQ’S POSITION TO COMPULSORY LICENCE 
One of the important principles of patent is granting exclusive 
right to the patent owner. However, countries around the world 
specify some circumstances in which they limit the exclusive right of 
the patent owner. These limitations are called exceptions as it is stated 
in Article 30 of the TRIPS Agreement as ‘Exceptions to Rights 
Conferred’. Different countries have stated different exceptions, 
however, in the previous part some examples have been discussed that 
can be allowed under Article 30 of the TRIPS Agreement, such as 
Research and Experimentation Exception, Early Working, Regulatory 
Review or Bolar Exception, Individual Prescriptions Exception, Prior 
Use Exception and Parallel Imports. However, the patent law No. 65 
of 1970 does not state any such exceptions and neither the CPA Order 
No. 81. The CPA was well aware of the provisions of the TRIPS 
Agreement, therefore, should have taken advantage of Article 30 of 
the TRIPS Agreement and included some of these exceptions in the 
amendment. As these exceptions are important for the fulfilment of 
the needs of society and its development.   
2.5.1 Compulsory Licence Under the Original Law No. 65 of 
1970 
There is another type of exception which limit the exclusive rights 
of the patent owners, which is called compulsory licence exception. 
However, this exception has to be applied for and granted by 
executive or judicial authority. The Iraqi patent law No. 65 of 1970 
provides regulation in regard of compulsory licence in sections of 27, 
28 and 29.
626
 Nevertheless, all these Section were amended by CPA 
Order No. 81.
627
 However, before the amendment Section 27 was 
consisted of two provisions. In the first provision the patent owner 
was required to inform the Registrar of the exploitation date of the 
invention within 30 days of the commencement of the exploitation. 
The second provision provided for three circumstances in which the 
                                                 
626 ‘Law No. 65 of 1970 on Patent and Industrial Designs’. 
627 ‘Order No. 81 Patent, Industrial Design, Undisclosed Information, Integrated Circuits And 
Plant Variety Law.’ 
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Registrar authorised to grant compulsory licence to whom applied for 
it. According to this provision the Registrar was the executive 
authority that empowered to grant compulsory licences in the 
following circumstances. First, if the right holder did not exploit the 
invention in Iraq within three years of granting the patent. Second, if 
the exploitation by the patent owner did not correspond to the needs of 
the country. Three, if the patent owner stopped exploiting the 
invention for at least two years. However, the provision stated a 
condition on the applicant that he should be able to exploit the 
invention in a serious manner. The provision also stated that the patent 
owner has legal right to apply in the registry in order to receiving an 
adequate remuneration within ninety days of granting the compulsory 
licence. This suggest that if the patent owner did not apply for 
remuneration within specified period he will loss his legal right to 
receive remuneration. The provision also provided that the patent 
owner has right appeal against the decision of the Registrar before the 
Minister within thirty days of receiving notification of the grant of the 
compulsory licence, and the decision of the Minister is final and 
irreversible. According to Section 1.1 of the original patent law No. 65 
of 1970 the Minister is Minister of Industry. 
Section 28 of the original patent law No. 65 of 1970 before the 
amendment provided for another circumstance in which the 
compulsory licence can be granted accordingly. In this case 
compulsory licence can be granted to a dependent patent. Section 28 
stated that when the exploitation of the patented invention (second 
patent/dependent patent) has great industrial significance and its 
exploitation require using another previously patented invention (first 
patent), then the Registrar has the authority to grant compulsory 
licence to the second patent owner. However, the provision of this 
Article required that the second patent owner approached the first 
patent owner to obtain voluntarily licence on reasonable conditions 
and the first patent owner refused to grant him the voluntarily licence. 
According to this provision what constitute reasonable conditions in 
this context can be determined by the Registrar.  
Section 28 provided for granting compulsory licence in the vice 
versa situation as well. In circumstances when the first patent is a 
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dependent patent, and it has great importance that requires using 
subsequent patented invention (second patent). In the same condition 
the first patent owner has to request voluntarily licence from the 
second patent owner on reasonable conditions. If his request is 
refused, then the Registrar will be allowed to grant compulsory 
licence. In both circumstances adequate remuneration should be 
provided according to the stipulations stated in Section 27. 
Section 29 of the original law No. 65 of 1970 stated that ‘the 
Registrar may revoke the patent granted and anyone who has interest 
may request the Registrar to revoke it if the invention was not 
exploited in Iraq within two years of granting the compulsory licence’. 
This Section obviously did not make any sense as to why the patent 
would be revoked if the invention was not exploited during granting 
the compulsory licence. But Iraqi legislature spotted the mistake and 
amended this Section through the Law No. 28 of 1999 First 
Amendment to Law No. 65 of 1970.
628
 Therefore, Section 29 to be 
read as ‘the Registrar may revoke the compulsory licence granted and 
anyone who has interest may request the Registrar to revoke it if the 
invention was not exploited in Iraq within two years of granting the 
compulsory licence’.  
In all the previous circumstances of granting compulsory licences 
according to Section 27 and 28, the Registrar was authorised to revoke 
the compulsory licence pursuant to Section 29. According to Section 
29 everyone who had an interest could request for revocation of the 
compulsory licence if the invention was not exploited in Iraq within 
two years of granting the compulsory licence.        
2.5.2 Compulsory Licence After the Amendment made by 
the CPA Order No. 81. 
The CPA Order No. 81 amended all the three sections that 
regulated the compulsory licence under the Iraqi patent law No. 65 of 
1970. The amended Section 27 consists of three paragraphs in which 
they provide for different circumstances in which the compulsory 
                                                 
628 ‘Iraq: Law No. 28 of 1999 First Amendment to Law No. 65 of 1970 on Patents and 
Industrial Designs’. 
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licence can be provided for exclusively. First, Section 27. A. states 
that when the use of the subject matter of the patent necessary for 
national defence or emergency or for non-commercial public good. In 
these circumstances the compulsory licence can be granted to states 
authorities or third parties. The only condition stated in the paragraph 
A. is that the patentee has to be notified as soon as possible. 
Circumstances referred in this paragraph are close to Article 31 lit. (b) 
of the TRIPS Agreement. In the TRIPS Agreement the terms of 
‘national emergency or other circumstances of extreme urgency or in 
cases of public non-commercial use’ are used. The term emergency in 
Section 27. A clearly refers to national emergency, which obviously 
include necessities in circumstances of national defences. Therefore, it 
was not necessary to include this circumstance within Section 27. A.  
On the other hand, the original patent law No. 65 of 1970 before 
the amendments, in its Section 30 stated that the Minister may issue 
an order to confiscate (expropriate) the ownership of the invention if 
public interest of the country or national defence requires it. This 
expropriation includes all rights gained through the patent. 
Nevertheless, Section 30 provided for adequate remuneration and 
right to appeal to the President of the Republic of Iraq. However, this 
Section has nothing to do with compulsory licence, because in 
compulsory licence the patent owner is not deprived totally from his 
right over the invention, it is simply an authorisation of using his 
invention without his consent. Meanwhile, according to this section, 
the patent owner permanently loses right over the invention and not 
allowed to exploit it any more. Hence the CPA Order No. 81 amended 
Section 30 to be read as ‘The Registrar's compulsory license decision 
shall be appealable to the Minister within 60 days of its notification’. 
Therefore, it seems that the CPA wanted to replace this total 
deprivation of the rights of the patent owner to granting licence over 
the invention without his consent in circumstances of necessity for 
national defence. However, it would have been more beneficial for 
Iraq, if the CPA had copied the three circumstances of Article 31 lit. 
(b) of the TRIPS Agreement ‘national emergency or other 
circumstances of extreme urgency or in cases of public non-
commercial use’. The term ‘other circumstances of extreme urgency’ 
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would have been much more beneficial instead of national defence, as 
will include wider range of circumstances that can be determined by 
Iraq to grant compulsory licence. 
Next, Section 27. B. 1 provides for another circumstance in which 
the Registrar can grant a compulsory licence; that is if the patent 
owner does not exploit the invention or exploits insufficiently. 
However, some durations have been stipulated before the compulsory 
licence granted. Either four years have passed from the application 
date or three years from granting date, and the applied date is the one 
that elapses later. Therefore, the Registrar cannot grant licence even 
though the invention has not been exploited unless the latest date of 
these two periods has elapsed. The Section has authorised the registrar 
to extend this period if found out that reasons beyond control of the 
patent owner, prevented him to exploit the invention.  
The new amended Section 27. B. 1 has restricted granting 
compulsory licence compared to the old Section 27. In the old Section 
27. 2 compulsory licence could be granted in three situations related to 
exploitation. Firstly, patented invention was not exploited within three 
years of granting the licence. Secondly, exploitation did not 
correspond to the needs of Iraq. Thirdly, stopped exploitation at any 
time for two years. However, the new Section 27. B. 1 removed the 
second and third circumstances and extended the period of the first 
one. This is clearly being in the benefit of patent owners, and while 
considered as a great disadvantage for a developing country like Iraq, 
because having variety of options to grant compulsory licence 
certainly help the country to fulfil its needs of products and 
technologies in considerable low prices. Furthermore, according to the 
new Section 27. B. 2 any importation of subject matter of the patent to 
Iraq will be considered an exploitation of the patent.  
The last circumstance of granting compulsory licence according 
to Section 27. C. is to remedy unfair competition. This is a new 
circumstance that was not existed in the original Iraqi patent law. 
Therefore, it benefits the country to balance between exclusive right of 
the patent owner and fair competition. This provision is inspired by 
Article 31 lit. (k) of the TRIPS Agreement. However, it is failed to 
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include all the exceptions that stated in Article 31 lit. (k) such as 
exception to prior negotiation and notification.  
Section 28 of the original patent law before amendment provided 
compulsory licence in cases of dependent patents. However, this type 
of compulsory licence is removed after the amendment by the CPA 
Order No. 81. The current section 28 provides for conditions and 
requirements of granting compulsory licence. The conditions are, A. 
Each application shall be considered on its merits, B. Prior negotiation 
on reasonable remuneration and conditions failed during a reasonable 
period of time between the parties, C. ‘The scope and duration of the 
license shall be limited to the purpose for which it is granted. If the 
license application relates to semiconductor technology, then it shall 
only be granted for non-commercial public good or to rectify practices 
deemed by the competent judicial or administrative authority to be 
anticompetitive’, D. Shall not be exclusive, E, shall not be assignable, 
F. should be for meeting the demand of the domestic market except in 
cases of anticompetitive, and G. patent owner shall receive equitable 
remuneration.  
All these conditions can be found in Article 31 of the TRIPS 
Agreement, some of them rephrased and others exactly copied. 
However, some conditions such as judicial review of the licence was 
not included within Section 28, instead an independent section was 
added which is Section 30bis that states ‘The Registrar's compulsory 
license decision shall be appealable to the Minister within 60 days of 
its notification’. But this section does not include judicial review of 
adequate remuneration as it is the case in Article 31 lit. (j) of the 
TRIPS Agreement. Also, the CPA Order No. 81 did not include in its 
amendment any special provisions in regard of ‘Remedies for 
Anticompetitive practices’ like Article 31 lit. (k) and ‘Dependent 
Patent’ like Article 31 lit. (l). Since the CPA Order No. 81 was 
ordered to inline the Iraqi patent law with the TRIPS Agreement, it 
should have included all the conditions and paragraphs of Article 31 
of the TRIPS Agreement, including compulsory licence in cases of 
dependent patents.  
Section 29 also amended to read as ‘The Registrar may cancel the 
compulsory license sua sponte or on the strength of an application 
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from the patentee if the reasons for its grant lapsed. This license 
cancellation shall, however, preserve the rights of those involved in 
the compulsory license’. This restricts the right to apply for 
cancelation to patent owners only. In the old Section 29 whoever had 
an interest in the licence could apply for revocation if it was not 
exploited within two years of granting it. However, in the new section, 
the patent owner has to apply for cancellation and state that the 
reasons for its grant are no longer exist.  
The CPA Order No. 81 did not add any special regulation in 
regard of compulsory licence for medical products and drugs. The 
Doha Declaration on the TRIPS Agreement and Public Health (14 
November 2001),
629
 in paragraph 6 states that solution has to be found 
in regard of problem of the public health that the developing countries 
facing. Then the General Council of the WTO endorsed a solution 
under the title of ‘Implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health’
630
 on 30 
August 2003, on which eventually becomes Article 31bis and the 
Annex of the TRIPS Agreement. Therefore, since the CPA amended 
the Iraqi patent law No. 65 of 1970, should have taken some points 
from these attempts of the TRIPS Council to include special 
regulation in regard of compulsory licences for medicines, because 
Iraq as one of the developing countries cannot produce and obtain 
enough medicines to fulfil the needs of the country. Even though the 
CPA Order No. 81 has improved and aligned the Iraqi patent law 
closer to the TRIPS Agreement but could have done better.    
2.6 CONCLUSION 
The TRIPS Agreement has provided for exceptions and limitation 
to the exclusive rights of the patent owners. These exceptions can be 
found mainly in three Articles of the TRIPS Agreement. The first is 
Article 30 which is titled ‘Exceptions to Rights Conferred’. Iraq as 
one of the developing countries can benefit from the exception 
                                                 
629 ‘WT/MIN(01)/DEC/2 -WTO | Ministerial Conferences - Doha 4th Ministerial - 
Declaration on the TRIPS Agreement and Public Health - Adopted 14 November 2001’. 
630 ‘WT/L/540 - WTO | Intellectual Property (TRIPS) - Implementation of Paragraph 6 of the 
Doha Declaration on the TRIPS Agreement and Public Health’. 
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provided under Article 30 if it becomes member of the TRIPS 
Agreement. Member countries have right to determine the type of 
exception to implement that best serve the needs of their countries. 
Options are not restricted whether be for a non-commercial purpose or 
for commercial purpose because Article 30 does not mention any 
exception by name and it is left for member countries to decide. For 
example, it can be for private use, experimental and scientific use, 
prior use, extemporaneous preparation of a medicine in a pharmacy, 
regulatory review (“bolar”), individual prescriptions, exhaustion of 
patent rights (national exhaustion and regional or international 
exhaustion), and parallel imports (importation of products from a 
country where the product legally marketed). However, Article 30 
states some conditions that have to be followed. Once these conditions 
fulfilled then the member countries have the right to choose the 
exceptions that satisfy their requirements without fear of legal actions 
from the patent owners.  
The original Iraqi patent law No. 65 of 19790 does not include 
any exceptions that have been allowed under Article 30 even though 
Iraq is still not a member of the TRIPS Agreement. Series of 
amendments have passed on this law including the major one by the 
CPA Order No. 81. Nonetheless, none of them inserted any provision 
that provide for exceptions which legally allowed under Article 30 of 
the TRIPS Agreement. The majority of the blame is on the CPA Order 
No. 81 because it was regulated with the intention of preparing Iraq to 
join the WTO in which include the TRIPS Agreement. The CPA was 
well aware of the situation of Iraq after the invasion and the detailed 
provisions of the TRIPS Agreement as well. Therefore, the CPA 
should have included some of the above exceptions to boost Iraq’s 
economy for rebuilding again after the invasion.  
Another important exception is the so-called compulsory licence, 
which is provided by the TRIPS Agreement and calls it ‘Other use 
Without Authorization of the Right Holder’. Article 31 and 31bis 
provide for compulsory licence with substantial detail. Article 31 
allows compulsory licence to be granted in cases of ‘national 
emergency or other circumstances of extreme urgency or in cases of 
public non-commercial use’, ‘to correct anti-competitive practices’ 
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and dependent patent. However, Article 31 states some condition and 
requirements that have to be followed by the member countries before 
being able to grant compulsory licence. Since some of these 
conditions have made obstacles for the developing and least 
developed countries that have insufficient or no manufacturing 
capacities so that be able to use compulsory licence to produce and 
access important products for their needs especially in the area of 
public health.  
In order to rectify this situation, the TRIPS Agreement was 
amended and Article 31bis with an Annex and Appendix were 
inserted. These newly added provisions provide for easy access to 
medicines by allowing member countries export and import medicines 
produced under compulsory licence. The provisions also provide for 
some exceptions to the conditions that are stated in Article 31 lits. (f) 
and (h).  
The original patent law No. 65 of 1970 provided for compulsory 
licence in a limited number of situations such as, if the invention was 
not exploited within three years of granting the licence, exploitation 
did not correspond to the needs of Iraq, stopped exploitation at any 
time for two years and dependent patent. However, the CPA Order 
No. 81 repealed all these situations except for not exploiting within 
three from granting the licence or four years from the application date. 
The CPA Order No. 81 provides for some new exception but not for 
all the situations and cases that are stated in the TRIPS Agreement, 
especially in relation to medical products. Therefore, the CPA Order 
No. 81 should have included all the exceptions available in the TRIPS 






5 CONCLUSION  
In the first section of chapter one it has been established that the 
TRIPS Agreement is one of the most significant international 
agreement that regulates the intellectual property rights. Most of the 
countries around the world are either became members or are in the 
process of becoming member to the TRIPS Agreement. However, 
before this agreement many other agreements have existed that 
regulate the intellectual property rights such as Paris Convention and 
Berne Convention. Most of the developed and developing countries 
were unsatisfied with them. Developing countries were unsatisfied 
because originally these conventions were endorsed and agreed upon 
by the developed countries, and the developing countries could not 
find their interest in them. On the other hand, some developed 
countries were unsatisfied because they could not sanction the non-
compliance parties properly.  
Eventually, due to the efforts and pressures from the United States 
of America and its big businesses the intellectual property rights 
issues inserted into the GATT (WTO) and TRIPS Agreement came 
into existence. Both of the United States Trade Representative 
(USTR), Intellectual Property Committee (IPC) and United States 
International Trade Commission (ITC) played great roles in enforcing 
the United States’ legislative and executive to persuade countries 
around the world for creating the TRIPS Agreement. Some of the 
attempts were through dialogue and other through threat of unilateral 
retaliation and imposing trade sanctions.  
The least developed and developing countries were all aware of 
the fact that the TRIPS Agreement is going to be in favour of the 
developed countries. They were aware of that fact and also that these 
developed countries used the patent as a tool for encouraging domestic 
development and industrialization. Now the developed countries are 
well industrialized, and they need high standard of protection of 
intellectual property rights. Nonetheless, the least developed countries 
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and developing countries accepted the TRIPS Agreement with few 
privileges and benefits for them, but with the hope that they will be 
getting some advantages of receiving technologies while joining the 




In section two the researcher established that in the TRIPS 
Agreement international trade is connected to the intellectual property 
rights and by not having effective and adequate protection of 
intellectual property rights by member countries will negatively affect 
the free international trade by causing impediments and distortions. To 
avoid this situation the negotiators of the TRIPS Agreement intended 
to regulate adequate standards and principles, not to impose highly 
standard form of protection. However, these principles have to be 
given effect through domestic legislations of member countries, as the 
TRIPS Agreement is not self-executing. The TRIPS Agreement, 
however, does not specify how these principles should be 
implemented, but rather the method of implementation is left for 
member countries to choose according to their own legal system and 
practice.          
Even though the TRIPS Agreement provisions are considered to 
be high standard of protection for the developing countries. However, 
Article 7 will take the interest of the developing countries into account 
and establishes a balance between rights and obligations. The content 
of this Article which is titled objectives, were taken from the 
proposals of the developing countries, so that the TRIPS Agreement 
will not operate only in the interest of the developed countries. This 
Article reflects on the interests of the developing countries in which 
concentrated on promotion of technical innovation in such a manner 
that conducive to social and economic welfare. This requirement of 
the developing countries is not something new because it can be found 
in other international conventions such as Paris Convention and Berne 
Convention. Therefore, they wanted this to be fixed in the TRIPS 
Agreement in exchange of their compliance to the high standards of 
protection of intellectual property rights that exists in the TRIPS 
Conclusion 
287 
Agreement. Otherwise, the developing countries have legal rights to 
object to the exclusive rights that granted by the Agreement. 
It can be concluded from the first part of Article 8 that the 
member countries have the right to take measures necessary to protect 
their public health, nutrition and other public interest of vital socio-
economic importance. These measures can be taken from the TRIPS 
Agreement such as the exceptions and limitations or the member 
countries can take measures not stated within the TRIPS Agreement 
such as marketing approval and price control of medicines. Therefore, 
these measures are not limited to intellectual property rights’ measures 
but can include measures from any national laws and regulations that 
have been officially published as laws and regulations. 
The second provision of Article 8 provides for further measures 
by the member countries that help them to prevent or stop the right 
holders from using their exclusive rights abusively. The word ‘abuse’ 
used in this provision is not limited to anti-competitive practices but 
can include any type of abuse that infringe the rights of third party and 
society in general. Furthermore, the member countries are allowed to 
adopt measures to prevent the right holder to use their intellectual 
property rights if such use caused any form of trade restraints. In 
addition to the abovementioned, this provision empowers the member 
countries especially the developing countries to achieve their aim of 
receiving technology in return of compliance with the high standard of 
protection. The provision states that if the right holders’ practices have 
adverse effect on the international transfer of technology to the 
member country, then this member country has right to adopt 
measures to prevent such practices.    
III 
 
In section three the history of Iraqi patent law and its amendments 
were examined and analysed with references to important terms such 
as patent and invention. Next, the criteria of patentability in both Iraqi 
patent law and TRIPS Agreement have been discussed and examined. 
The Iraqi patent law was passed through some stages since 
establishment of Iraq as a country in 1920s. During the Monarchy 
period, Iraq enacted its first patent law, which was Law No. 61 of 
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1935 on Patents. This law amended few times until finally repealed by 
Patent and Industrial Design Law No. 65 of 1970 during the republic 
era because it was considered to be an outdated law. Law No. 65 of 
1970 has also undergone four amendments, in which only two of them 
have made significant amendments, which they are first amendment 




In section one of chapter two the definition of the term ‘invention’ 
was discussed, in which under Law No. 61 of 1935 the term had a 
simple definition i.e. considered discovery as invention that can be 
patentable. However, this term was changed from such a simple 
definition to a more modern definition by Law No. 65 of 1970, and 
even further developed by the amendment under Law No. 28 of 1999. 
Nevertheless, this definition was repealed and replaced by another one 
which was introduced by the amendment provided by the CPA Order 
No. 81. Even though the latest definition is included with the precise 
criteria of patentability, but the TRIPS Agreement does not define the 
term ‘invention’ as it is left for member countries to define according 
to their own legal systems.  
All the criteria of patentability could be found within the 
definition of the term ‘invention’ in the Law No. 65 of 1970 before the 
amendment by the CPA Order No. 81. However, after the amendment 
the same criteria can be found in the definition, and the CPA Order 
No. 81 also specified another section for including all the criteria of 
patentability that are mentioned in the TRIPS Agreement. This way 
the CPA Order NO. 81 has improved the Iraqi patent law by clearly 





In section two and three it has been established that the member 
countries of the TRIPS Agreement are allowed to exclude some areas 
from patentability. Therefore, according to the TRIPS Agreement 
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right of granting patent is limited base on some principles. Article 
27.2 states that if the commercial exploitation of an invention 
endanger ordre public and morality. None of these terms are defined 
by the TRIPS Agreement, which is in favour of the member countries 
to define them according to their domestic understanding. However, 
generally speaking any invention jeopardises the structure of civil 
society and institutions of the society, then will be excluded from 
patentability base on breaching ordre public and morality. 
Interestingly, section 3.1 of the Iraqi patent law No. 65 of 1970 
provides that if exploitation of an invention breaches the principle of 
ordre public, public moral and public interest, will be excluded from 
patentability. All the amendments including the CPA Order No. 81 did 
not amend this provision. Therefore, this provision is in compliance 
with the TRIPS Agreement even though the term public interest is not 
mentioned in Article 27.2 of the TRIPS Agreement, but member 
countries are allowed to protect their public interest according to 
Article 8 of the TRIPS Agreement.  
Article 27.3 (a) of the TRIPS Agreement also provides for another 
important exclusion from patentability which is ‘diagnostic, 
therapeutic and surgical methods for the treatment of humans or 
animals’. This provision is optional provision as all the exclusion 
provisions in the TRIPS Agreement are optional. Therefore, some 
member countries do not exclude method of treatment form 
patentability such as Australia, New Zealand and United States of 
America. Nonetheless, majority of member countries are excluding 
method of treatment from patentability.  
It is noticeable that such provision cannot be found in the Iraqi 
patent law No. 65 of 1970 and none of the amendments added any 
provision in this regard. Since Iraq is one of the developing countries 
and in need of exclusion from patentability as much as possible to 
cope with the current situation that Iraq is going through sectarian 
wars and war with terror. Iraq is underdeveloped country in many 
areas especially in the areas that related to medicines and method of 
treatments. Therefore, this thesis is recommending adding a provision 
similar to that of the TRIPS Agreement to the Law No. 65 of 1970 in 
section 3.2 to be read as ‘patent shall not be granted in diagnostic, 
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therapeutic and surgical methods for the treatment of humans or 
animals’.  
Furthermore, the Doha Declaration on the TRIPS Agreement and 
Public Health admitted that there is massive public health problem 
that affects the developing counties. In this regard the ministers, 
through the Doha Declaration emphasized that the TRIPS Agreement 
should not be an obstacle in solving the public health issues of the 
developing countries but instead should be part of the solution. In 
addition, the it has been admitted that high standard of protection is 
having negative impact on drug prices. Therefore, the provisions of 
the TRIPS Agreement should be interpreted in a manner supportive to 
member countries to protect their public health and access medicines 
through flexibilities that available within the TRIPS Agreement. Doha 
Declaration further stated that the member countries should have right 
to determine ground of granting compulsory licence in this regard and 
determine what constitutes the national emergency and other 
circumstances of emergency.  
The original Iraqi patent law No. 65 of 1970 had a provision that 
excluded medical and pharmaceutical formulations from patentability. 
However, this provision repealed and suspended by both amendments 
of No. 28 of 1999 and CPA Order No. 81 without substituting it with 
another provision related to access to medicine. The CPA Order No. 
81 ordered in 2004 which is 3 years after endorsement of the Doha 
Declaration, therefore the CPA Order No. 81 should have taken 
advantage of the Doha Declaration and added a new provision to 
make easy for Iraq to access to medicines for needs of the public 
health, like other member countries have done it. This shows that the 
CPA Order No. 81 was legislated within the intention of solving the 
problems of Iraqi people. Therefore, the law No. 65 of 1970 should be 
amended in this regard to include some situations that Iraq can access 
medicines without authorisation of the patent holders as an exception 
to their exclusive rights, such as in cases of ‘preparation of a medicine 
in accordance with a medical prescription for individual cases, carried 







Article 27.3 (b) of the TRIPS Agreement excludes from 
patentability of plants and animals, however, it requires that member 
countries to provide for protection of plant varieties through a patent 
or an effective sui generis system or a combination of both of them. 
The original Iraqi patent law No. 65 of 1970 does not have any 
regulation in this regard. However, the CPA Order No. 81 added a 
new chapter for the protection of plant varieties. All the essential 
provisions of this chapter such as the definition of plant varieties and 
requirement of registration and protection, have been taken from the 
UPOV Convention of 1991. However, the CPA Order No. 81 failed to 
take the optional exception from the UPOV Convention of 1991 
which gives limited right of re-using seed. But instead in this regard 
the CPA Order No. 81 has followed the United States of America’s 
style of prohibiting saving, re-suing or resale protected seed. This 
showed that the CPA Order No. 81 was not regulated in best interest 
of Iraq, as the CPA was well aware of the bad situation of Iraqi fields 
and seed bank.  
However, Law No. 15 of 2013 on Registration, Accreditation and 
Protection of Agricultural Varieties has replaced the CPA Order No. 
81. The new law regulated the protection of new varieties in different 
way and provides for breeder’s rights and in the same time provides 
for some extra exceptions than the CPA Order No. 81. Nevertheless, 
Law No. 15 of 2013 reduced the period of protection. Therefore, this 
thesis recommends this law to be amended so that Iraq can have a 
better sui generis system for protection of plant varieties that comply 
with the TRIPS Agreement and in the same time take advantage of the 
UPOV Convention that offered better rights to farmers in regard of 




In section one of chapter three, it has been concluded that Article 
28 of the TRIPS Agreement has conferred certain exclusive rights to 
the patent owners in a form of negative rights. Some of these rights 
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are over the patented products, patented processes and direct products 
of patented processes, and other rights are related to rights to assign, 
transfer by succession and conclude licensing contracts. Nevertheless, 
these exclusive rights are subject to some exceptions that referred to in 
Articles of 30, 31 and 31bis the TRIPS Agreement. The TRIPS 
Agreement in Article 34 also provides for reversing the burden of 
proof in civil proceeding of cases involve identical products of the 
patented process. 
The original Iraqi patent law No. 65 of 1970 referred to these 
rights in section 12 in a general term that the patent owner has 
exclusive right to exploit the invention by all legal means. However, 
the CPA Order NO. 81 repealed this section and replaced with the 
new one while it failed to follow the Article 28 of the TRIPS 
Agreement by not stating the rights to assign, transfer and concluding 
licensing contracts. Even though section 25 of the original law No. 65 
of 1970 states some of them but not similar to the TRIPS Agreement 
especially in the rights to conclude licensing contracts. Therefore, this 
thesis recommends that an amendment in section 12 in order to 
include all the exclusive rights that are stated by the TRIPS 
Agreement will be necessary. Since the original Iraqi patent law does 
not contain any provision similar to Article 34 of the TRIPS 
Agreement, and none of the amendments including the CPA Order 
No. 81 added any similar provision, therefore, this thesis also 
recommends that similar provision should be inserted to the Iraqi 




Section two was dedicated to the exceptions to exclusive rights of 
patent owners. It has been concluded that Article 30 of the TRIPS 
Agreement can be used to grant many types of exceptions to the 
exclusive rights of the patent owners by following the criteria in 
Article 30. There are three general criteria, the exception must be 
limited, the exception should not unreasonably conflict with a normal 
exploitation of the patent, and do not unreasonably prejudice the 
legitimate interests of the patent owner, taking account of the 
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legitimate interests of third parties. Therefore, the member countries 
are allowed to place exceptions to exclusive rights as long as they 
follow the criteria.  
Next this section has discussed and analysed the compulsory 
licence. compulsory licence is another important tool that keeps 
balance between patent owner’s rights and need of society for 
patented products, through limiting the exclusive rights of the patent 
owners. Article 31 of the TRIPS Agreement provides for ‘other use 
without authorization of the right holder’, and the term ‘other use’ 
refers to other exceptions to the exclusive rights of the patent holders 
than what allowed under Article 30. Grounds of granting compulsory 
licence is left for the member countries to determine according to their 
circumstances. Nevertheless, some conditions and requirements are 
stated in other for member countries to follow before granting the 
compulsory licence either to government or third parties authorised by 
government.  
The thesis has discussed in detail these conditions and 
requirements and concluded despite the importance of the compulsory 
licence exception to the member countries so that use it for fulfilling 
their needs, however, some of the conditions have created obstacles in 
front of least developed and developing countries to use this 
exception. Article 31 lit. (f) is one of the major obstacles for the least 
developed and developing countries, as it requires the compulsory 
licence should be granted predominantly for the supply of the 
domestic market. The fact is that many of those countries do not 
possess enough technology to produce most of the patented products 
locally. This eventually lead to amendment of the TRIPS Agreement 
and Article 31bis was added.  
Article 31bis submitted to member countries to be accepted by the 
General Council on 6 December 2005 and entered into force only on 
23 January 2017 in addition to an Annex and Appendix. This article 
was added to remedy the obstacles that Article 31 caused to the least 
developed and developing countries. Therefore, Article 31bis permits 
the member countries to grant compulsory licence so that majority of 
the pharmaceutical products under the licence can be exported to other 
member countries. Furthermore, Article 31bis exempts the importing 
SAMAN ABDULRAHMAN ALI 
294 
member country from adequate remuneration. This thesis has 
concluded that this Article can help the member countries to fulfil 
their needs of medicines for their public health. 
 Following the above discussion, the thesis has discussed and 
analysed the position of Iraqi patent law to exception to exclusive 
rights of the patent owners. In fact, neither the original law No. 65 of 
1970 nor the CPA Order No. 81 contain any regulations allowing 
exceptions within the scope of Article 30 of the TRIPS Agreement. 
Since the CPA Order No. 81 ordered with the intention of inline the 
Iraqi intellectual property laws with that of the TRIPS Agreement, and 
if the CPA acted in favour of Iraq should have included some 
important exceptions that are allowed with the scope of Article 30 
such as parallel imports.  
Nevertheless, the original law No. 65 of 1970 provided for 
compulsory licence in a few cases such as, if the right holder did not 
exploit the invention in Iraq within three years of granting the patent, 
if the exploitation by the patent owner did not correspond to the needs 
of the country, if the patent owner stopped exploiting the invention for 
at least two years and in cases of dependent patent. However, the CPA 
Order No. 81 amended all the provisions that related to compulsory 
licence by extending the period of not exploiting the invention in Iraq 
in the first situation and removing all the other three situations, even 
though compulsory licence in cases of dependent patent is provided 
for by the TRIPS Agreement. The CPA Order No. 81 added some new 
provisions to the Law No. 65 of 1970 in regard of compulsory licence 
that have taken them from Article 31 of the TRIPS Agreement. In this 
the CPA Order NO. 81 has brought the original law closer to the 
TRIPS Agreement but failed to mention any circumstances that stated 
in Article 31bis of the TRIPS Agreement.  
Last but not least, Article 31bis took effect only in 2017 but the 
Doha Declaration and Implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health took place 
between 2001 and 2003, therefore, the CPA was well aware of the 
problem of developing countries in regard of supplying medicines for 
their public health crises. For this reason, the CPA should have added 
the exceptions in Article 31bis, which basically has been taken from 
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provisions of the Implementation of Paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and Public Health. Again, in 
this regard the CPA did not acted in interest of Iraq. Therefore, this 
thesis recommends that all the exceptions to exclusive rights of the 
patent holders exist within the TRIPS Agreement should be 
implemented by the Iraqi patent law so that be able to fulfil the needs 
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